CA3155930A1 - Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof - Google Patents
Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereofInfo
- Publication number
- CA3155930A1 CA3155930A1 CA3155930A CA3155930A CA3155930A1 CA 3155930 A1 CA3155930 A1 CA 3155930A1 CA 3155930 A CA3155930 A CA 3155930A CA 3155930 A CA3155930 A CA 3155930A CA 3155930 A1 CA3155930 A1 CA 3155930A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- binding domain
- dpp4
- hcvr
- dep1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 title claims abstract description 1076
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 382
- 239000000427 antigen Substances 0.000 title claims description 390
- 108091007433 antigens Proteins 0.000 title claims description 387
- 102000036639 antigens Human genes 0.000 title claims description 387
- 102100039808 Receptor-type tyrosine-protein phosphatase eta Human genes 0.000 claims abstract description 297
- 101000606506 Homo sapiens Receptor-type tyrosine-protein phosphatase eta Proteins 0.000 claims abstract description 296
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims abstract description 162
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 81
- 201000010099 disease Diseases 0.000 claims abstract description 51
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 claims abstract description 44
- 208000035475 disorder Diseases 0.000 claims abstract description 29
- 230000009758 senescence Effects 0.000 claims abstract description 26
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims abstract description 21
- 230000000779 depleting effect Effects 0.000 claims abstract description 7
- 230000002147 killing effect Effects 0.000 claims abstract description 6
- 239000012634 fragment Substances 0.000 claims description 282
- 210000004027 cell Anatomy 0.000 claims description 250
- 210000002865 immune cell Anatomy 0.000 claims description 131
- 239000000203 mixture Substances 0.000 claims description 62
- 239000003814 drug Substances 0.000 claims description 31
- 230000004068 intracellular signaling Effects 0.000 claims description 28
- 230000000139 costimulatory effect Effects 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 125000006850 spacer group Chemical group 0.000 claims description 18
- 230000003176 fibrotic effect Effects 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 230000002685 pulmonary effect Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 abstract description 81
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 120
- 150000007523 nucleic acids Chemical class 0.000 description 104
- 108090000623 proteins and genes Proteins 0.000 description 93
- 102000039446 nucleic acids Human genes 0.000 description 84
- 108020004707 nucleic acids Proteins 0.000 description 84
- 239000013598 vector Substances 0.000 description 64
- 102000004169 proteins and genes Human genes 0.000 description 61
- 235000018102 proteins Nutrition 0.000 description 58
- 210000001744 T-lymphocyte Anatomy 0.000 description 47
- 230000001105 regulatory effect Effects 0.000 description 33
- 239000013604 expression vector Substances 0.000 description 32
- 230000014509 gene expression Effects 0.000 description 32
- 125000000539 amino acid group Chemical group 0.000 description 30
- 125000003275 alpha amino acid group Chemical group 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 27
- 108060003951 Immunoglobulin Proteins 0.000 description 26
- 150000001413 amino acids Chemical class 0.000 description 26
- 102000018358 immunoglobulin Human genes 0.000 description 26
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 25
- 102000045598 human DPP4 Human genes 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- -1 i.e. Substances 0.000 description 21
- 210000001539 phagocyte Anatomy 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 239000002537 cosmetic Substances 0.000 description 13
- 239000003623 enhancer Substances 0.000 description 13
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 230000011664 signaling Effects 0.000 description 13
- 241000894007 species Species 0.000 description 13
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 12
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 241001529936 Murinae Species 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 102000002090 Fibronectin type III Human genes 0.000 description 10
- 108050009401 Fibronectin type III Proteins 0.000 description 10
- 108091008874 T cell receptors Proteins 0.000 description 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 10
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 8
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 8
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 208000026935 allergic disease Diseases 0.000 description 8
- 230000001086 cytosolic effect Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 229940072221 immunoglobulins Drugs 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 230000008030 elimination Effects 0.000 description 7
- 238000003379 elimination reaction Methods 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 102000016904 Armadillo Domain Proteins Human genes 0.000 description 6
- 108010014223 Armadillo Domain Proteins Proteins 0.000 description 6
- 108010087819 Fc receptors Proteins 0.000 description 6
- 102000009109 Fc receptors Human genes 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 6
- 206010057249 Phagocytosis Diseases 0.000 description 6
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 6
- 206010052779 Transplant rejections Diseases 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000010094 cellular senescence Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 230000002998 immunogenetic effect Effects 0.000 description 6
- 229940027941 immunoglobulin g Drugs 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 230000008782 phagocytosis Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 230000003362 replicative effect Effects 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- 241000289632 Dasypodidae Species 0.000 description 4
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 4
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 102100022339 Integrin alpha-L Human genes 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101100332184 Rattus norvegicus Dpp4 gene Proteins 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000009327 senolytic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 208000004804 Adenomatous Polyps Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 102100024263 CD160 antigen Human genes 0.000 description 3
- 102100027207 CD27 antigen Human genes 0.000 description 3
- 102000053028 CD36 Antigens Human genes 0.000 description 3
- 108010045374 CD36 Antigens Proteins 0.000 description 3
- 102000000311 Cytosine Deaminase Human genes 0.000 description 3
- 108010080611 Cytosine Deaminase Proteins 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
- 101000746783 Homo sapiens Cytochrome b-c1 complex subunit 6, mitochondrial Proteins 0.000 description 3
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 3
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 3
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 3
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 description 3
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 3
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 3
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102100025323 Integrin alpha-1 Human genes 0.000 description 3
- 102100032816 Integrin alpha-6 Human genes 0.000 description 3
- 102100025390 Integrin beta-2 Human genes 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 102100029197 SLAM family member 6 Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 3
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 3
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 206010064930 age-related macular degeneration Diseases 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 102000048638 human UQCRH Human genes 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 210000003411 telomere Anatomy 0.000 description 3
- 102000055501 telomere Human genes 0.000 description 3
- 108091035539 telomere Proteins 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 102100036184 5'-3' exonuclease PLD3 Human genes 0.000 description 2
- 101710142108 5'-3' exonuclease PLD3 Proteins 0.000 description 2
- 102100040038 Amyloid beta precursor like protein 2 Human genes 0.000 description 2
- 241000384062 Armadillo Species 0.000 description 2
- 102100034304 Armadillo repeat-containing X-linked protein 3 Human genes 0.000 description 2
- 101710127380 Armadillo repeat-containing X-linked protein 3 Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000023514 Barrett esophagus Diseases 0.000 description 2
- 208000023665 Barrett oesophagus Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 102000004225 Cathepsin B Human genes 0.000 description 2
- 108090000712 Cathepsin B Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 2
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 2
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 229920003360 EVASIN® Polymers 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101150064015 FAS gene Proteins 0.000 description 2
- 102100034722 Glutathione S-transferase LANCL1 Human genes 0.000 description 2
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical group NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 2
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 2
- 101000824104 Homo sapiens High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 2
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 description 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 2
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 description 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 2
- 102100035571 Integral membrane protein GPR137B Human genes 0.000 description 2
- 102100032818 Integrin alpha-4 Human genes 0.000 description 2
- 102100039904 Integrin alpha-D Human genes 0.000 description 2
- 102100022341 Integrin alpha-E Human genes 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 102100020789 Interleukin-15 receptor subunit alpha Human genes 0.000 description 2
- 101710107699 Interleukin-15 receptor subunit alpha Proteins 0.000 description 2
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 2
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 2
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 2
- 101710116771 Lysosome-associated membrane glycoprotein 2 Proteins 0.000 description 2
- 102100038884 Major vault protein Human genes 0.000 description 2
- 101710094960 Major vault protein Proteins 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 102100039373 Membrane cofactor protein Human genes 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 101100226902 Mus musculus Fcrlb gene Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 102100022158 Neuferricin Human genes 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102100040769 Olfactory receptor 1F1 Human genes 0.000 description 2
- 101710140990 Olfactory receptor 1F1 Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000007932 Progeria Diseases 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102000015799 Qa-SNARE Proteins Human genes 0.000 description 2
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 2
- 102100026085 RNA-binding region-containing protein 3 Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 102100033909 Retinoic acid receptor beta Human genes 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 102100032780 Semaphorin-5B Human genes 0.000 description 2
- 101710199399 Semaphorin-5B Proteins 0.000 description 2
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 2
- 102100032829 Sorting nexin-3 Human genes 0.000 description 2
- 101710103902 Sorting nexin-3 Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 102100021813 Stress-associated endoplasmic reticulum protein 1 Human genes 0.000 description 2
- 101710084859 Stress-associated endoplasmic reticulum protein 1 Proteins 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 102100036827 Tubulin gamma-2 chain Human genes 0.000 description 2
- 101710100139 Tubulin gamma-2 chain Proteins 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 2
- 108091005956 Type II transmembrane proteins Proteins 0.000 description 2
- 102100029827 Unconventional myosin-X Human genes 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 102100040566 V-type proton ATPase subunit d 2 Human genes 0.000 description 2
- 102100038398 Vacuolar protein sorting-associated protein 26A Human genes 0.000 description 2
- 101710187769 Vacuolar protein sorting-associated protein 26A Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 102000004604 Vesicle-Associated Membrane Protein 3 Human genes 0.000 description 2
- 108010017749 Vesicle-Associated Membrane Protein 3 Proteins 0.000 description 2
- 102100023560 Zinc finger protein 419 Human genes 0.000 description 2
- 101710145282 Zinc finger protein 419 Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 208000032625 disorder of ear Diseases 0.000 description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 2
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000012246 gene addition Methods 0.000 description 2
- 238000003197 gene knockdown Methods 0.000 description 2
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 208000030613 peripheral artery disease Diseases 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108020003519 protein disulfide isomerase Proteins 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- CNJLMVZFWLNOEP-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[4.1.0]heptan-5-one Chemical compound O=C1C(C)CCC2C(C)(C)C12 CNJLMVZFWLNOEP-UHFFFAOYSA-N 0.000 description 1
- HHDUMDVQUCBCEY-UHFFFAOYSA-N 4-[10,15,20-tris(4-carboxyphenyl)-21,23-dihydroporphyrin-5-yl]benzoic acid Chemical compound OC(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)C(O)=O)c2ccc([nH]2)c(-c2ccc(cc2)C(O)=O)c2ccc(n2)c(-c2ccc(cc2)C(O)=O)c2ccc1[nH]2 HHDUMDVQUCBCEY-UHFFFAOYSA-N 0.000 description 1
- 108091005667 ADAMTS7 Proteins 0.000 description 1
- 208000010400 APUDoma Diseases 0.000 description 1
- 101710140955 ATP synthase subunit alpha Proteins 0.000 description 1
- 102100027573 ATP synthase subunit alpha, mitochondrial Human genes 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010066728 Acute interstitial pneumonitis Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010058285 Allergy to arthropod bite Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710168921 Amyloid beta precursor like protein 2 Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 101000978560 Arabidopsis thaliana F-box protein MAX2 Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100032435 BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 2 Human genes 0.000 description 1
- 101710108256 BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 2 Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006045 Boutonneuse fever Diseases 0.000 description 1
- 108010056102 CD100 antigen Proteins 0.000 description 1
- 108010017009 CD11b Antigen Proteins 0.000 description 1
- 102100038077 CD226 antigen Human genes 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 101710139831 CD82 antigen Proteins 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100067721 Caenorhabditis elegans gly-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102100032404 Cholinesterase Human genes 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- AMRLSQGGERHDHJ-FXQIFTODSA-N Cys-Ala-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMRLSQGGERHDHJ-FXQIFTODSA-N 0.000 description 1
- WVWRADGCZPIJJR-IHRRRGAJSA-N Cys-Val-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CS)N WVWRADGCZPIJJR-IHRRRGAJSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 206010060902 Diffuse alveolar damage Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000275449 Diplectrum formosum Species 0.000 description 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
- 102100029952 Double-strand-break repair protein rad21 homolog Human genes 0.000 description 1
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100037067 Electron transfer flavoprotein beta subunit lysine methyltransferase Human genes 0.000 description 1
- 101710189425 Electron transfer flavoprotein beta subunit lysine methyltransferase Proteins 0.000 description 1
- 102100027262 Electron transfer flavoprotein subunit beta Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101710198774 Envelope protein US9 Proteins 0.000 description 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102100037317 F-box/LRR-repeat protein 7 Human genes 0.000 description 1
- 102000036354 FBXLs Human genes 0.000 description 1
- 108091007025 FBXLs Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710081488 Glutathione S-transferase LANCL1 Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 101150090209 HCST gene Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 208000031071 Hamman-Rich Syndrome Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000936262 Homo sapiens ATP synthase subunit alpha, mitochondrial Proteins 0.000 description 1
- 101000890401 Homo sapiens Amyloid beta precursor like protein 2 Proteins 0.000 description 1
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 1
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000584942 Homo sapiens Double-strand-break repair protein rad21 homolog Proteins 0.000 description 1
- 101001057122 Homo sapiens Electron transfer flavoprotein subunit beta Proteins 0.000 description 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 1
- 101001090483 Homo sapiens Glutathione S-transferase LANCL1 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101001000801 Homo sapiens Integral membrane protein GPR137B Proteins 0.000 description 1
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 description 1
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 description 1
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 description 1
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000637179 Homo sapiens NHS-like protein 2 Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 101000973264 Homo sapiens Neuferricin Proteins 0.000 description 1
- 101000634537 Homo sapiens Neuronal PAS domain-containing protein 2 Proteins 0.000 description 1
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
- 101000692148 Homo sapiens RNA-binding region-containing protein 3 Proteins 0.000 description 1
- 101001132698 Homo sapiens Retinoic acid receptor beta Proteins 0.000 description 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000585623 Homo sapiens Unconventional myosin-X Proteins 0.000 description 1
- 101150003028 Hprt1 gene Proteins 0.000 description 1
- 238000012450 HuMAb Mouse Methods 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- UWBDLNOCIDGPQE-GUBZILKMSA-N Ile-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN UWBDLNOCIDGPQE-GUBZILKMSA-N 0.000 description 1
- WMDZARSFSMZOQO-DRZSPHRISA-N Ile-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 WMDZARSFSMZOQO-DRZSPHRISA-N 0.000 description 1
- MUFXDFWAJSPHIQ-XDTLVQLUSA-N Ile-Tyr Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 MUFXDFWAJSPHIQ-XDTLVQLUSA-N 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 101710194133 Integral membrane protein GPR137B Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 1
- 102100033016 Integrin beta-7 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 101710150988 Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000007811 Latex Hypersensitivity Diseases 0.000 description 1
- 101150028321 Lck gene Proteins 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 201000009324 Loeffler syndrome Diseases 0.000 description 1
- 101001043810 Macaca fascicularis Interleukin-7 receptor subunit alpha Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 101710146216 Membrane cofactor protein Proteins 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 241001590997 Moolgarda engeli Species 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 102100031816 NHS-like protein 2 Human genes 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101710128043 Neuferricin Proteins 0.000 description 1
- 102100029045 Neuronal PAS domain-containing protein 2 Human genes 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102000001760 Notch3 Receptor Human genes 0.000 description 1
- 108010029756 Notch3 Receptor Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
- 102000002131 PAS domains Human genes 0.000 description 1
- 108050009469 PAS domains Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- KLAONOISLHWJEE-QWRGUYRKSA-N Phe-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KLAONOISLHWJEE-QWRGUYRKSA-N 0.000 description 1
- 102000004422 Phospholipase C gamma Human genes 0.000 description 1
- 108010056751 Phospholipase C gamma Proteins 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108030003971 Protein adenylyltransferases Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 101710165423 RNA-binding region-containing protein 3 Proteins 0.000 description 1
- 102100031522 Ras-related protein Rab-23 Human genes 0.000 description 1
- 108050002327 Ras-related protein Rab-23 Proteins 0.000 description 1
- 101710138747 Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 102100028516 Receptor-type tyrosine-protein phosphatase U Human genes 0.000 description 1
- 101710162078 Receptor-type tyrosine-protein phosphatase eta Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
- 206010039251 Rubber sensitivity Diseases 0.000 description 1
- 102100029216 SLAM family member 5 Human genes 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- 108091006656 SLC9A7 Proteins 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 102000018636 Selenoprotein T Human genes 0.000 description 1
- 108050007799 Selenoprotein T Proteins 0.000 description 1
- 102100027744 Semaphorin-4D Human genes 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 108010091769 Shiga Toxin 1 Proteins 0.000 description 1
- 102100028760 Sialidase-1 Human genes 0.000 description 1
- 101710128612 Sialidase-1 Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102100029971 Sodium/hydrogen exchanger 7 Human genes 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000204903 Sweet potato virus G Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101710107477 TBC1 domain family member 1 Proteins 0.000 description 1
- 102100040238 TBC1 domain family member 1 Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102100037549 Thioredoxin reductase-like selenoprotein T Human genes 0.000 description 1
- 101710143749 Thioredoxin reductase-like selenoprotein T Proteins 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 101150009046 Tnfrsf1a gene Proteins 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 101710096653 Transcription elongation factor A N-terminal and central domain-containing protein Proteins 0.000 description 1
- 102100035160 Transcription elongation factor A N-terminal and central domain-containing protein Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100036078 Transforming growth factor beta regulator 1 Human genes 0.000 description 1
- 101710194537 Transforming growth factor beta regulator 1 Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- OHGNSVACHBZKSS-KWQFWETISA-N Trp-Ala Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)N[C@@H](C)C([O-])=O)=CNC2=C1 OHGNSVACHBZKSS-KWQFWETISA-N 0.000 description 1
- PITVQFJBUFDJDD-XEGUGMAKSA-N Trp-Ile Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)=CNC2=C1 PITVQFJBUFDJDD-XEGUGMAKSA-N 0.000 description 1
- YVXIAOOYAKBAAI-SZMVWBNQSA-N Trp-Leu-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 YVXIAOOYAKBAAI-SZMVWBNQSA-N 0.000 description 1
- DZHDVYLBNKMLMB-ZFWWWQNUSA-N Trp-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 DZHDVYLBNKMLMB-ZFWWWQNUSA-N 0.000 description 1
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 1
- DVLHKUWLNKDINO-PMVMPFDFSA-N Trp-Tyr-Leu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O DVLHKUWLNKDINO-PMVMPFDFSA-N 0.000 description 1
- LWFWZRANSFAJDR-JSGCOSHPSA-N Trp-Val Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O)=CNC2=C1 LWFWZRANSFAJDR-JSGCOSHPSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 108091005966 Type III transmembrane proteins Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102100020726 Ubl carboxyl-terminal hydrolase 18 Human genes 0.000 description 1
- 101710153383 Ubl carboxyl-terminal hydrolase 18 Proteins 0.000 description 1
- 101710119006 Uncharacterized protein C Proteins 0.000 description 1
- 101710109000 Unconventional myosin-X Proteins 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 101710192373 V-type proton ATPase subunit d2 Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 238000012452 Xenomouse strains Methods 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 208000024340 acute graft versus host disease Diseases 0.000 description 1
- 201000004073 acute interstitial pneumonia Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 208000021096 adenomatous colon polyp Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 208000010029 ameloblastoma Diseases 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 206010002895 aortic dissection Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 201000005476 astroblastoma Diseases 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 102000027005 chemokine binding proteins Human genes 0.000 description 1
- 108091008503 chemokine binding proteins Proteins 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 108091007930 cytoplasmic receptors Proteins 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 description 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 208000019993 erythroplakia Diseases 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 208000013397 idiopathic acute eosinophilic pneumonia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000012309 immunohistochemistry technique Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000026585 laminopathy Diseases 0.000 description 1
- 201000005391 latex allergy Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000032646 lung growth Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000006508 oncogene activation Effects 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 206010030983 oral lichen planus Diseases 0.000 description 1
- 208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000008789 oxidative DNA damage Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000036178 pleiotropy Effects 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001469 poly(aryloxy)thionylphosphazene Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000013608 rAAV vector Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 108091008761 retinoic acid receptors β Proteins 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 229940125381 senolytic agent Drugs 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000034280 venom allergy Diseases 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464458—Proteinases
- A61K39/46446—Serine proteases, e.g. kallikrein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464463—Phosphatases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to DEP1-binding domains and DPP4-binding domains, as well as antibodies and chimeric antigen receptors (CAR) comprising the same. Also disclosed are uses and methods for treating, preventing or alleviating senescence-related diseases or disorders, or for depleting and/or killing senescent cells.
Description
DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTCCBIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THE
SAME, AND USES THEREOF
FIELD OF INVENTION
The invention relates to DEP1-binding domains and DPP4-binding domains, as well as antibodies and chimeric antigen receptors (CAR) comprising the same. Also disclosed are uses and methods for treating, preventing or alleviating senescence-related diseases or disorders, or for depleting and/or killing senescent cells.
BACKGROUND OF INVENTION
Cellular senescence is an evolutionarily conserved state of stable replicative arrest induced by several pro-ageing stressors, including telomere attrition, oxidative stress, DNA damage and oncogene activation. Cellular senescence is associated with apoptosis resistance, and results in secretion of a broad repertoire of cytokines, chemokines, growth factors, matrix remodeling proteases: the so-called senescence-associated secretory phenotype (SASP). This cellular state also promotes proliferation and tissue deterioration.
Conversely, senescence is also anti-proliferative, and may be requisite for optimal cutaneous wound healing. Therefore, cellular senescence is an example of antagonistic pleiotropy in which natural selection favors processes that are beneficial early in life, even if they cause harmful effects later in post-reproduction life.
Since its discovery, senescence, once defined as the limited replicative capacity of primary human fibroblasts, now serves as a key player driving organismal aging via exhaustion of tissue repair capacity. Several human pathologies have been associated with detrimental effects of senescence such as lung fibrosis, type 2 diabetes, obesity, osteoarthritis, ocular diseases, Alzheimer's and Parkinson's disease (Munoz-Espin and Serrano, 2014. Nat Rev Mol Cell Biol. 2014 Jul; 15(7):482-96). Therapeutic strategies so far to balance these pathologies related to accumulation of senescent cells are dependent
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTCCBIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THE
SAME, AND USES THEREOF
FIELD OF INVENTION
The invention relates to DEP1-binding domains and DPP4-binding domains, as well as antibodies and chimeric antigen receptors (CAR) comprising the same. Also disclosed are uses and methods for treating, preventing or alleviating senescence-related diseases or disorders, or for depleting and/or killing senescent cells.
BACKGROUND OF INVENTION
Cellular senescence is an evolutionarily conserved state of stable replicative arrest induced by several pro-ageing stressors, including telomere attrition, oxidative stress, DNA damage and oncogene activation. Cellular senescence is associated with apoptosis resistance, and results in secretion of a broad repertoire of cytokines, chemokines, growth factors, matrix remodeling proteases: the so-called senescence-associated secretory phenotype (SASP). This cellular state also promotes proliferation and tissue deterioration.
Conversely, senescence is also anti-proliferative, and may be requisite for optimal cutaneous wound healing. Therefore, cellular senescence is an example of antagonistic pleiotropy in which natural selection favors processes that are beneficial early in life, even if they cause harmful effects later in post-reproduction life.
Since its discovery, senescence, once defined as the limited replicative capacity of primary human fibroblasts, now serves as a key player driving organismal aging via exhaustion of tissue repair capacity. Several human pathologies have been associated with detrimental effects of senescence such as lung fibrosis, type 2 diabetes, obesity, osteoarthritis, ocular diseases, Alzheimer's and Parkinson's disease (Munoz-Espin and Serrano, 2014. Nat Rev Mol Cell Biol. 2014 Jul; 15(7):482-96). Therapeutic strategies so far to balance these pathologies related to accumulation of senescent cells are dependent
2 on direct elimination of senescent cells based on their intrinsic properties (e.g., their apoptotic resistance or P53 dependence) (Yosef et al., 2016. Nat Commun.
7:11190;
Chang et al., 2016. Nat Med. 22(1):78-83; Baar et al., 2017. Cell. 169(1):132-147).
Although these first-generation senolytic approaches serve as a proof-of-principle for drug discovery targeting senescence, they are limited by their observed toxic side effects.
While the role of senescence and the contribution of senescent cells are increasingly recognized in the context of aging and a variety of disease states, relatively little is known regarding the influences of senescent cells in normal lung growth and agingper se, or in the induction or progression of lung diseases across the age spectrum, such as bronchopulmonary dysplasia, asthma, chronic obstructive pulmonary disease, or pulmonary fibrosis. However, crucial evidences have been recently provided by several groups that cellular senescence contributes to lung ageing (Hashimoto et al., 2016. JCI
Insight. 1(12):e87732; Lehmann et al., 2017. Eur Respir J. 50(2):1602367;
Schafer et al., 2017. Nat Commun. 8:14532).
Among lung diseases, idiopathic pulmonary fibrosis (IPF) is a typical example of an ageing disease characterized by a progressive destruction of lung parenchyma and interstitial remodeling, leading to IPF symptoms (i.e., chronic shortness of breath, cough, fatigue and weight loss) and resulting in dramatic truncation of healthspan and lifespan.
The potential to blunt lung disease by targeting senescent cells using a novel class of drugs called "senolytics" is currently discussed. Indeed, two studies by Lehmann et al.
and Schafer et al. suggest that cellular senescence is a salient feature of lung fibrosis, and that targeting/elimination of these cells could be beneficial. In particular, they show that cellular senescence markers such as SAPG, P21, P16INK4a and DNA damage response are detectable within IPF patients, as well as in experimental models of lung fibrosis.
They further demonstrate that senescent cell elimination rejuvenates pulmonary health in aged mice. However, it is unclear whether and how senescent cells regulate IPF
in humans or if their removal may be an efficacious intervention strategy.
Although promising, it cannot be excluded that senolytic drugs could be detrimental in IPF patients. Indeed, senolytic drug treatment may result in massive epithelial cell
7:11190;
Chang et al., 2016. Nat Med. 22(1):78-83; Baar et al., 2017. Cell. 169(1):132-147).
Although these first-generation senolytic approaches serve as a proof-of-principle for drug discovery targeting senescence, they are limited by their observed toxic side effects.
While the role of senescence and the contribution of senescent cells are increasingly recognized in the context of aging and a variety of disease states, relatively little is known regarding the influences of senescent cells in normal lung growth and agingper se, or in the induction or progression of lung diseases across the age spectrum, such as bronchopulmonary dysplasia, asthma, chronic obstructive pulmonary disease, or pulmonary fibrosis. However, crucial evidences have been recently provided by several groups that cellular senescence contributes to lung ageing (Hashimoto et al., 2016. JCI
Insight. 1(12):e87732; Lehmann et al., 2017. Eur Respir J. 50(2):1602367;
Schafer et al., 2017. Nat Commun. 8:14532).
Among lung diseases, idiopathic pulmonary fibrosis (IPF) is a typical example of an ageing disease characterized by a progressive destruction of lung parenchyma and interstitial remodeling, leading to IPF symptoms (i.e., chronic shortness of breath, cough, fatigue and weight loss) and resulting in dramatic truncation of healthspan and lifespan.
The potential to blunt lung disease by targeting senescent cells using a novel class of drugs called "senolytics" is currently discussed. Indeed, two studies by Lehmann et al.
and Schafer et al. suggest that cellular senescence is a salient feature of lung fibrosis, and that targeting/elimination of these cells could be beneficial. In particular, they show that cellular senescence markers such as SAPG, P21, P16INK4a and DNA damage response are detectable within IPF patients, as well as in experimental models of lung fibrosis.
They further demonstrate that senescent cell elimination rejuvenates pulmonary health in aged mice. However, it is unclear whether and how senescent cells regulate IPF
in humans or if their removal may be an efficacious intervention strategy.
Although promising, it cannot be excluded that senolytic drugs could be detrimental in IPF patients. Indeed, senolytic drug treatment may result in massive epithelial cell
3 depletion by apoptosis, which could trigger diffuse alveolar damage and acute exacerbation, since the regenerative capacity of epithelial cells in IPF
patients is impaired.
There remains thus a need for alternative strategies for depleting senescent cells and improving health and lung functions of IPF patients.
The Inventors have developed such alternative strategy, by potentiating an immune response against senescent cells in a way that would lead to their clearance from lung tissue. They provide herein a new association of two cell surface markers, DPP4 and DEP1, which are targeted to detect and deplete senescent cells in the lung.
Senescent cells are immunogenic in nature and are subject to immune surveillance mechanisms.
Dipeptidyl peptidase 4 (DPP4, also named CD26) is a cell surface protease with a wide range of biological functions. As a serine-type protease, DPP4 preferentially cleaves off substrates with proline and alanine at the penultimate position. Expression of DPP4 is widespread throughout the body. Interestingly, DPP4 has been identified as a senescent cell surface targetable protein, functionally required for fibroblast activation and tissue fibrosis (Kyoung et al., 2017. Genes Dev. 31(15):1529-1534).
Density Enhanced Protein Tyrosine Phosphatase (DEP1, also named CD148, HPTP-eta, or PTP receptor type J (PTPRJ)) is an enzyme that removes phosphate groups covalently attached to tyrosine residues in proteins. DEP1 is highly expressed on both hematopoietic and nonhematopoietic cells, including lung cells. It has been shown that DEP1 can directly interact with and dephosphorylate the regulatory subunit of PI3K
(p85) (Tsuboi et al., 2008. Biochem J. 413(1):193-200) and that hyperactivation of PI3K/Akt plays an important role in the profibrotic phenotype of IPF-derived lung fibroblasts by promoting cell proliferation and migration and myofibroblast differentiation (Kral et al., 2016. Sci Rep. 6:23034; Nho et al., 2014. PLoS One. 9(4):e94616).
The Inventors herein provide antibodies, bispecific antibodies, chimeric antigen receptors (CARs) and bispecific CARs, including immune cell populations expressing said CARs directed specifically against senescent cells for treatment and prophylaxis of age-related diseases and disorders, and other diseases and disorders associated or exacerbated by the presence of senescent cells, such as, for example, pulmonary fibrosis. The antibodies and
patients is impaired.
There remains thus a need for alternative strategies for depleting senescent cells and improving health and lung functions of IPF patients.
The Inventors have developed such alternative strategy, by potentiating an immune response against senescent cells in a way that would lead to their clearance from lung tissue. They provide herein a new association of two cell surface markers, DPP4 and DEP1, which are targeted to detect and deplete senescent cells in the lung.
Senescent cells are immunogenic in nature and are subject to immune surveillance mechanisms.
Dipeptidyl peptidase 4 (DPP4, also named CD26) is a cell surface protease with a wide range of biological functions. As a serine-type protease, DPP4 preferentially cleaves off substrates with proline and alanine at the penultimate position. Expression of DPP4 is widespread throughout the body. Interestingly, DPP4 has been identified as a senescent cell surface targetable protein, functionally required for fibroblast activation and tissue fibrosis (Kyoung et al., 2017. Genes Dev. 31(15):1529-1534).
Density Enhanced Protein Tyrosine Phosphatase (DEP1, also named CD148, HPTP-eta, or PTP receptor type J (PTPRJ)) is an enzyme that removes phosphate groups covalently attached to tyrosine residues in proteins. DEP1 is highly expressed on both hematopoietic and nonhematopoietic cells, including lung cells. It has been shown that DEP1 can directly interact with and dephosphorylate the regulatory subunit of PI3K
(p85) (Tsuboi et al., 2008. Biochem J. 413(1):193-200) and that hyperactivation of PI3K/Akt plays an important role in the profibrotic phenotype of IPF-derived lung fibroblasts by promoting cell proliferation and migration and myofibroblast differentiation (Kral et al., 2016. Sci Rep. 6:23034; Nho et al., 2014. PLoS One. 9(4):e94616).
The Inventors herein provide antibodies, bispecific antibodies, chimeric antigen receptors (CARs) and bispecific CARs, including immune cell populations expressing said CARs directed specifically against senescent cells for treatment and prophylaxis of age-related diseases and disorders, and other diseases and disorders associated or exacerbated by the presence of senescent cells, such as, for example, pulmonary fibrosis. The antibodies and
4 CARs described herein are specific for at least one senescent cell-associated antigen (e.g., DEP1 and/or DPP4), and induce the clearance (i.e., removal, elimination, destruction) of senescent cells. Said clearance may, for example, be mediated by antibody-dependent cell cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) or both.
SUMMARY
The present invention relates to a DPP4-binding domain, comprising a combination of three heavy chain variable region (HCVR)'s complementary-determining regions (CDRs) and three light chain variable region (LCVR)'s CDRs, said combination being as defined in Table 3.
In one embodiment, the DPP4-binding domain comprises:
a) a HCVR which comprises the following three CDRs:
VH-CDR1 selected from the group consisting of SEQ ID NO: 109 and 108;
VH-CDR2 selected from the group consisting of SEQ ID NO: 122 and 127;
VH-CDR3 selected from the group consisting of SEQ ID NO: 139 and 138;
b) a LCVR which comprises the following three CDRs:
VL-CDR1 selected from the group consisting of SEQ ID NO: 148 and 147;
VL-CDR2 selected from the group consisting of SEQ ID NO: 160 and 159;
VL-CDR3 selected from the group consisting of SEQ ID NO: 172 and 171.
In one embodiment, the DPP4-binding domain is selected from the group consisting of:
i. a DPP4-binding domain comprising a VH-CDR1 with SEQ ID NO: 109, a VH-CDR2 with SEQ ID NO: 122, a VH-CDR3 with SEQ ID NO: 139, a VL-CDR1 with SEQ ID NO: 148, a VL-CDR2 with SEQ ID NO: 160 and a VL-CDR3 with SEQ ID NO: 172; and ii. a DPP4-binding domain comprising a VH-CDR1 with SEQ ID NO: 108, a VH-CDR2 with SEQ ID NO: 127, a VH-CDR3 with SEQ ID NO: 138, a VL-CDR1 with SEQ ID NO: 147, a VL-CDR2 with SEQ ID NO: 159 and a VL-CDR3 with SEQ ID NO: 171.
In one embodiment, the DPP4-binding domain is selected from the group consisting of:
SUMMARY
The present invention relates to a DPP4-binding domain, comprising a combination of three heavy chain variable region (HCVR)'s complementary-determining regions (CDRs) and three light chain variable region (LCVR)'s CDRs, said combination being as defined in Table 3.
In one embodiment, the DPP4-binding domain comprises:
a) a HCVR which comprises the following three CDRs:
VH-CDR1 selected from the group consisting of SEQ ID NO: 109 and 108;
VH-CDR2 selected from the group consisting of SEQ ID NO: 122 and 127;
VH-CDR3 selected from the group consisting of SEQ ID NO: 139 and 138;
b) a LCVR which comprises the following three CDRs:
VL-CDR1 selected from the group consisting of SEQ ID NO: 148 and 147;
VL-CDR2 selected from the group consisting of SEQ ID NO: 160 and 159;
VL-CDR3 selected from the group consisting of SEQ ID NO: 172 and 171.
In one embodiment, the DPP4-binding domain is selected from the group consisting of:
i. a DPP4-binding domain comprising a VH-CDR1 with SEQ ID NO: 109, a VH-CDR2 with SEQ ID NO: 122, a VH-CDR3 with SEQ ID NO: 139, a VL-CDR1 with SEQ ID NO: 148, a VL-CDR2 with SEQ ID NO: 160 and a VL-CDR3 with SEQ ID NO: 172; and ii. a DPP4-binding domain comprising a VH-CDR1 with SEQ ID NO: 108, a VH-CDR2 with SEQ ID NO: 127, a VH-CDR3 with SEQ ID NO: 138, a VL-CDR1 with SEQ ID NO: 147, a VL-CDR2 with SEQ ID NO: 159 and a VL-CDR3 with SEQ ID NO: 171.
In one embodiment, the DPP4-binding domain is selected from the group consisting of:
5 PCT/EP2020/076995 i. a DPP4-binding domain comprising a HCVR with a sequence sharing at least 80%
of sequence identity with the non-CDR regions of SEQ ID NO: 185 and a LCVR
with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 213; and 5 ii. a DPP4-binding domain comprising a HCVR with a sequence sharing at least 80%
of sequence identity with the non-CDR regions of SEQ ID NO: 197 and a LCVR
with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 212.
The present invention also relates to a DEP1-binding domain, comprising a combination of three heavy chain variable region (HCVR)'s complementary-determining regions (CDRs) and three light chain variable region (LCVR)'s CDRs, said combination being as defined in Table 1.
In one embodiment, the DEP1-binding domain comprises:
a) a HCVR which comprises the following three CDRs:
VH-CDR1 selected from the group consisting of SEQ ID NO: 10, 11 and 5;
VH-CDR2 selected from the group consisting of SEQ ID NO: 21, 25 and 12;
VH-CDR3 selected from the group consisting of SEQ ID NO: 30, 32 and 29;
b) a LCVR which comprises the following three CDRs:
VL-CDR1 selected from the group consisting of SEQ ID NO: 37, 38 and 33;
VL-CDR2 selected from the group consisting of SEQ ID NO: 44, 46 and 40;
VL-CDR3 selected from the group consisting of SEQ ID NO: 53, 52 and 49.
In one embodiment, the DEP1-binding domain is selected from the group consisting of:
i. a DEP1-binding domain comprising a VH-CDR1 with SEQ ID NO: 10, a VH-CDR2 with SEQ ID NO: 21, a VH-CDR3 with SEQ ID NO: 30, a VL-CDR1 with SEQ ID NO: 37, a VL-CDR2 with SEQ ID NO: 44 and a VL-CDR3 with SEQ ID NO: 53;
ii. a DEP1-binding domain comprising a VH-CDR1 with SEQ ID NO: 11, a VH-CDR2 with SEQ ID NO: 25, a VH-CDR3 with SEQ ID NO: 32, a VL-CDR1 with SEQ ID NO: 38, a VL-CDR2 with SEQ ID NO: 46 and a VL-CDR3 with SEQ ID NO: 52; and
of sequence identity with the non-CDR regions of SEQ ID NO: 185 and a LCVR
with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 213; and 5 ii. a DPP4-binding domain comprising a HCVR with a sequence sharing at least 80%
of sequence identity with the non-CDR regions of SEQ ID NO: 197 and a LCVR
with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 212.
The present invention also relates to a DEP1-binding domain, comprising a combination of three heavy chain variable region (HCVR)'s complementary-determining regions (CDRs) and three light chain variable region (LCVR)'s CDRs, said combination being as defined in Table 1.
In one embodiment, the DEP1-binding domain comprises:
a) a HCVR which comprises the following three CDRs:
VH-CDR1 selected from the group consisting of SEQ ID NO: 10, 11 and 5;
VH-CDR2 selected from the group consisting of SEQ ID NO: 21, 25 and 12;
VH-CDR3 selected from the group consisting of SEQ ID NO: 30, 32 and 29;
b) a LCVR which comprises the following three CDRs:
VL-CDR1 selected from the group consisting of SEQ ID NO: 37, 38 and 33;
VL-CDR2 selected from the group consisting of SEQ ID NO: 44, 46 and 40;
VL-CDR3 selected from the group consisting of SEQ ID NO: 53, 52 and 49.
In one embodiment, the DEP1-binding domain is selected from the group consisting of:
i. a DEP1-binding domain comprising a VH-CDR1 with SEQ ID NO: 10, a VH-CDR2 with SEQ ID NO: 21, a VH-CDR3 with SEQ ID NO: 30, a VL-CDR1 with SEQ ID NO: 37, a VL-CDR2 with SEQ ID NO: 44 and a VL-CDR3 with SEQ ID NO: 53;
ii. a DEP1-binding domain comprising a VH-CDR1 with SEQ ID NO: 11, a VH-CDR2 with SEQ ID NO: 25, a VH-CDR3 with SEQ ID NO: 32, a VL-CDR1 with SEQ ID NO: 38, a VL-CDR2 with SEQ ID NO: 46 and a VL-CDR3 with SEQ ID NO: 52; and
6 iii. a DEP1-binding domain comprising a VH-CDR1 with SEQ ID NO: 5, a VH-CDR2 with SEQ ID NO: 12, a VH-CDR3 with SEQ ID NO: 29, a VL-CDR1 with SEQ ID NO: 33, a VL-CDR2 with SEQ ID NO: 40 and a VL-CDR3 with SEQ ID NO: 49.
In one embodiment, the DEP1-binding domain is selected from the group consisting of:
i. a DEP1-binding domain comprising a HCVR with a sequence sharing at least 80%
of sequence identity with the non-CDR regions of SEQ ID NO: 68 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 89;
ii. a DEP1-binding domain comprising a HCVR with a sequence sharing at least 80%
of sequence identity with the non-CDR regions of SEQ ID NO: 72 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 93; and iii. a DEP1-binding domain comprising a HCVR with a sequence sharing at least 80%
of sequence identity with the non-CDR regions of SEQ ID NO: 58 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 78.
The present invention also relates to an isolated antibody or antigen-binding fragment thereof comprising the DPP4-binding domain or the DEP1-binding domain of the invention.
In one embodiment, the isolated antibody or antigen-binding fragment thereof is a bispecific antibody comprising the DPP4-binding domain and the DEP1-binding domain of the invention.
The present invention also relates to a chimeric antigen receptor (CAR) comprising:
a. at least one extracellular binding domain, comprising at least one DPP4-binding domain and/or at least one DEP1-binding domain of the invention, b. an extracellular spacer domain, c. a transmembrane domain, d. optionally, at least one costimulatory domain, and
In one embodiment, the DEP1-binding domain is selected from the group consisting of:
i. a DEP1-binding domain comprising a HCVR with a sequence sharing at least 80%
of sequence identity with the non-CDR regions of SEQ ID NO: 68 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 89;
ii. a DEP1-binding domain comprising a HCVR with a sequence sharing at least 80%
of sequence identity with the non-CDR regions of SEQ ID NO: 72 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 93; and iii. a DEP1-binding domain comprising a HCVR with a sequence sharing at least 80%
of sequence identity with the non-CDR regions of SEQ ID NO: 58 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 78.
The present invention also relates to an isolated antibody or antigen-binding fragment thereof comprising the DPP4-binding domain or the DEP1-binding domain of the invention.
In one embodiment, the isolated antibody or antigen-binding fragment thereof is a bispecific antibody comprising the DPP4-binding domain and the DEP1-binding domain of the invention.
The present invention also relates to a chimeric antigen receptor (CAR) comprising:
a. at least one extracellular binding domain, comprising at least one DPP4-binding domain and/or at least one DEP1-binding domain of the invention, b. an extracellular spacer domain, c. a transmembrane domain, d. optionally, at least one costimulatory domain, and
7 e. at least one intracellular signaling domain.
The present invention also relates to an immune cell engineered to express the CAR of the invention at its surface.
The present invention also relates to a population of immune cells, comprising a plurality of immune cells of the invention.
In one embodiment, the population of immune cells of the invention comprises:
a) a plurality of immune cells of the invention, engineered to express a CAR
comprising at least one DPP4-binding domain of the invention at its surface;
and a plurality of immune cells of the invention, engineered to express a CAR
comprising at least one DEP1-binding domain of the invention at its surface; or b) a plurality of immune cells of the invention, engineered to express a CAR
comprising at least one DPP4-binding domain of the invention and a CAR
comprising at least one DEP1-binding domain of the invention, at its surface; or c) a plurality of immune cells of the invention, engineered to express a CAR
comprising at least one DPP4-binding domain of the invention and at least one binding domain of the invention at its surface.
The present invention also relates to a composition comprising:
- the isolated antibody or antigen-binding fragment thereof of the invention, - the immune cell of the invention, and/or - the population of immune cells of the invention.
In one embodiment, the composition of the invention is a pharmaceutical composition and further comprising at least one pharmaceutically acceptable excipient.
In one embodiment, the composition of the invention is for use as a drug.
In one embodiment, the composition of the invention is for use in treating, preventing or alleviating a senescence-related disease or disorder, preferably selected from the group consisting of fibrotic diseases, premalignant disorders, inflammatory diseases and cancers.
The present invention also relates to an immune cell engineered to express the CAR of the invention at its surface.
The present invention also relates to a population of immune cells, comprising a plurality of immune cells of the invention.
In one embodiment, the population of immune cells of the invention comprises:
a) a plurality of immune cells of the invention, engineered to express a CAR
comprising at least one DPP4-binding domain of the invention at its surface;
and a plurality of immune cells of the invention, engineered to express a CAR
comprising at least one DEP1-binding domain of the invention at its surface; or b) a plurality of immune cells of the invention, engineered to express a CAR
comprising at least one DPP4-binding domain of the invention and a CAR
comprising at least one DEP1-binding domain of the invention, at its surface; or c) a plurality of immune cells of the invention, engineered to express a CAR
comprising at least one DPP4-binding domain of the invention and at least one binding domain of the invention at its surface.
The present invention also relates to a composition comprising:
- the isolated antibody or antigen-binding fragment thereof of the invention, - the immune cell of the invention, and/or - the population of immune cells of the invention.
In one embodiment, the composition of the invention is a pharmaceutical composition and further comprising at least one pharmaceutically acceptable excipient.
In one embodiment, the composition of the invention is for use as a drug.
In one embodiment, the composition of the invention is for use in treating, preventing or alleviating a senescence-related disease or disorder, preferably selected from the group consisting of fibrotic diseases, premalignant disorders, inflammatory diseases and cancers.
8 In one embodiment, the senescence-related disease or disorder is a fibrotic disease, preferably a pulmonary fibrotic disease.
In one embodiment, the composition of the invention is for use in depleting and/or killing senescent cells.
DEFINITIONS
"A", "an" and "the" are intended to include both singular and plural forms, unless the context clearly indicates otherwise.
"About", preceding a figure encompasses plus or minus 10%, or less, of the value of said figure. It is to be understood that the value to which the term "about" refers is itself also specifically, and preferably, disclosed.
"Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a cell-mediated cytotoxicity induced in an antibody-dependent manner when the Fc region of said antibody bound to its antigen binds to the Fc receptor on effector cells such as natural killer cells, macrophages, neutrophils, eosinophils and mononuclear cells (e.g., peripheral blood mononuclear cells), thereby leading to lysis of the target cell. ADCC
can be measured using assays that are known and available in the art (e.g., Clynes et al., 1998.
Proc Natl Acad Sci USA. 95(2):652-6).
"Antibody-dependent cell-mediated phagocytosis" or "ADCP" or "opsonisation"
refers to a cell-mediated reaction in which nonspecific cytotoxic cells (e.g., phagocytes, macrophages) that express Fc receptors (FcRs) recognize antibody bound on a target cell and induce phagocytosis of the target cell. ADCP can be measured using assays that are known and available in the art (e.g., Clynes et al., 1998. Proc Natl Acad Sci U S A.
95(2):652-6).
"Adnectins", also known as monobodies, is well known in the art and refer to proteins designed to bind with high affinity and specificity to antigens. They belong to the class of molecules collectively called "antibody mimetics".
In one embodiment, the composition of the invention is for use in depleting and/or killing senescent cells.
DEFINITIONS
"A", "an" and "the" are intended to include both singular and plural forms, unless the context clearly indicates otherwise.
"About", preceding a figure encompasses plus or minus 10%, or less, of the value of said figure. It is to be understood that the value to which the term "about" refers is itself also specifically, and preferably, disclosed.
"Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a cell-mediated cytotoxicity induced in an antibody-dependent manner when the Fc region of said antibody bound to its antigen binds to the Fc receptor on effector cells such as natural killer cells, macrophages, neutrophils, eosinophils and mononuclear cells (e.g., peripheral blood mononuclear cells), thereby leading to lysis of the target cell. ADCC
can be measured using assays that are known and available in the art (e.g., Clynes et al., 1998.
Proc Natl Acad Sci USA. 95(2):652-6).
"Antibody-dependent cell-mediated phagocytosis" or "ADCP" or "opsonisation"
refers to a cell-mediated reaction in which nonspecific cytotoxic cells (e.g., phagocytes, macrophages) that express Fc receptors (FcRs) recognize antibody bound on a target cell and induce phagocytosis of the target cell. ADCP can be measured using assays that are known and available in the art (e.g., Clynes et al., 1998. Proc Natl Acad Sci U S A.
95(2):652-6).
"Adnectins", also known as monobodies, is well known in the art and refer to proteins designed to bind with high affinity and specificity to antigens. They belong to the class of molecules collectively called "antibody mimetics".
9 "Allogeneic" refers to a graft derived from a different animal of the same species.
"Alphabody" that may also be referred to as Cell-Penetrating Alphabodies, refer to a type of antibody mimetics consisting of small 10 kDa proteins engineered to bind to a variety of antigens. Alphabodies are able to reach and bind to intracellular protein targets.
.. "Affibodies" are well-known in the art and refer to affinity proteins based on a 58 amino acid residue protein domain, derived from one of the IgG binding domain of staphylococcal protein A (Frejd & Kim, 2017. Exp Mol Med. 49(3):e306; Patent US5,831,012).
"Affilins" are well known in the art and refer to artificial proteins designed to selectively bind antigens. They resemble antibodies in their affinity and specificity to antigens but not in structure which makes them a type of antibody mimetic "Affinity" and "avidity"
are well-known in the art and are used to defined the strength of an antibody-antigen complex. Affinity measures the strength of interaction between an epitope and an antigen binding site on an antibody. It may be expressed by an affinity constant KA or by a dissociation constant KD. Avidity (or functional affinity) gives a measure of the overall strength of an antibody-antigen complex. It may depend on different parameters, including in particular the affinity of the antibody or antigen-binding fragment thereof for an epitope, (ii) the valency of both the antibody and the antigen and (iii) structural arrangement of the parts that interact. Affinities of antibodies or antigen-binding fragment thereof can be readily determined using conventional techniques, for example, those described by Scatchard, 1949. Ann NY Acad Sci. 51:660-672. Binding properties of an antibody or antigen-binding fragment thereof to antigens, cells or tissues may generally be determined and assessed using immunodetection methods including, for example, ELISA, immunofluorescence-based assays, such as immuno-histochemistry (IHC) and/or fluorescence-activated cell sorting (FACS) or by surface plasmon resonance (SPR, e.g., using BIAcore ).
"Antibody" and "immunoglobulin" may be used interchangeably and refer to a protein having a combination of two heavy and two light chains whether or not it possesses any relevant specific immunoreactivity. "Antibodies" refers to such assemblies which have significant known specific immunoreactive activity to an antigen of interest (e.g., human DEP1 and/or DPP4). The term "anti-DEP1 antibodies or anti-DPP4 antibodies" is used herein to refer to antibodies which exhibit immunological specificity for human DEP1 antigen or human DPP4 antigens, respectively. As explained elsewhere herein, 5 .. "specificity" for human DEP1 does not exclude cross-reaction with species homologues of human DEP1, such as, for example, with simian DEP1, and "specificity" for human DPP4 does not exclude cross-reaction with species homologues of human DPP4 such as, for example, with simian DPP4.
Antibodies and immunoglobulins comprise light and heavy chains, with or without an
"Alphabody" that may also be referred to as Cell-Penetrating Alphabodies, refer to a type of antibody mimetics consisting of small 10 kDa proteins engineered to bind to a variety of antigens. Alphabodies are able to reach and bind to intracellular protein targets.
.. "Affibodies" are well-known in the art and refer to affinity proteins based on a 58 amino acid residue protein domain, derived from one of the IgG binding domain of staphylococcal protein A (Frejd & Kim, 2017. Exp Mol Med. 49(3):e306; Patent US5,831,012).
"Affilins" are well known in the art and refer to artificial proteins designed to selectively bind antigens. They resemble antibodies in their affinity and specificity to antigens but not in structure which makes them a type of antibody mimetic "Affinity" and "avidity"
are well-known in the art and are used to defined the strength of an antibody-antigen complex. Affinity measures the strength of interaction between an epitope and an antigen binding site on an antibody. It may be expressed by an affinity constant KA or by a dissociation constant KD. Avidity (or functional affinity) gives a measure of the overall strength of an antibody-antigen complex. It may depend on different parameters, including in particular the affinity of the antibody or antigen-binding fragment thereof for an epitope, (ii) the valency of both the antibody and the antigen and (iii) structural arrangement of the parts that interact. Affinities of antibodies or antigen-binding fragment thereof can be readily determined using conventional techniques, for example, those described by Scatchard, 1949. Ann NY Acad Sci. 51:660-672. Binding properties of an antibody or antigen-binding fragment thereof to antigens, cells or tissues may generally be determined and assessed using immunodetection methods including, for example, ELISA, immunofluorescence-based assays, such as immuno-histochemistry (IHC) and/or fluorescence-activated cell sorting (FACS) or by surface plasmon resonance (SPR, e.g., using BIAcore ).
"Antibody" and "immunoglobulin" may be used interchangeably and refer to a protein having a combination of two heavy and two light chains whether or not it possesses any relevant specific immunoreactivity. "Antibodies" refers to such assemblies which have significant known specific immunoreactive activity to an antigen of interest (e.g., human DEP1 and/or DPP4). The term "anti-DEP1 antibodies or anti-DPP4 antibodies" is used herein to refer to antibodies which exhibit immunological specificity for human DEP1 antigen or human DPP4 antigens, respectively. As explained elsewhere herein, 5 .. "specificity" for human DEP1 does not exclude cross-reaction with species homologues of human DEP1, such as, for example, with simian DEP1, and "specificity" for human DPP4 does not exclude cross-reaction with species homologues of human DPP4 such as, for example, with simian DPP4.
Antibodies and immunoglobulins comprise light and heavy chains, with or without an
10 interchain covalent linkage between them. Basic immunoglobulin structures in vertebrate systems are relatively well understood. The generic term "immunoglobulin"
comprises five distinct classes of antibody that can be distinguished biochemically.
Although the following discussion will generally be directed to the IgG class of immunoglobulin molecules, all five classes of antibodies are within the scope of the present invention.
With regard to IgG, immunoglobulins comprise two identical light polypeptide chains of molecular weight of about 23 kDa, and two identical heavy chains of molecular weight of about 53-70 kDa. The four chains are joined by disulfide bonds in a "Y"
configuration wherein the light chains bracket the heavy chains starting at the mouth of the "Y" and continuing through the variable region. The light chains of an antibody are classified as either kappa (K) or lambda (k). Each heavy chain class may be bonded with either a K or k light chain. In general, the light and heavy chains are covalently bonded to each other, and the "tail" regions of the two heavy chains are bonded to each other by covalent disulfide linkages or non-covalent linkages when the immunoglobulins are generated either by hybridomas, B cells or genetically engineered host cells. In the heavy chain, the amino acid sequences run from an N-terminus at the forked ends of the Y
configuration to the C-terminus at the bottom of each chain. Those skilled in the art will appreciate that heavy chains are classified as gamma (y), mu (0, alpha (a), delta (6) or epsilon (6) with some subclasses among them (e.g., yl-y4). It is the nature of this chain that determines the "class" of the antibody as IgG, IgM, IgA IgD or IgE, respectively. The immunoglobulin subclasses or "isotypes" (e.g., IgGl, IgG2, IgG3, IgG4, IgAl, etc.) are well characterized and are known to confer functional specialization. Modified versions of each of these classes and isotypes are readily discernable to the skilled artisan in view
comprises five distinct classes of antibody that can be distinguished biochemically.
Although the following discussion will generally be directed to the IgG class of immunoglobulin molecules, all five classes of antibodies are within the scope of the present invention.
With regard to IgG, immunoglobulins comprise two identical light polypeptide chains of molecular weight of about 23 kDa, and two identical heavy chains of molecular weight of about 53-70 kDa. The four chains are joined by disulfide bonds in a "Y"
configuration wherein the light chains bracket the heavy chains starting at the mouth of the "Y" and continuing through the variable region. The light chains of an antibody are classified as either kappa (K) or lambda (k). Each heavy chain class may be bonded with either a K or k light chain. In general, the light and heavy chains are covalently bonded to each other, and the "tail" regions of the two heavy chains are bonded to each other by covalent disulfide linkages or non-covalent linkages when the immunoglobulins are generated either by hybridomas, B cells or genetically engineered host cells. In the heavy chain, the amino acid sequences run from an N-terminus at the forked ends of the Y
configuration to the C-terminus at the bottom of each chain. Those skilled in the art will appreciate that heavy chains are classified as gamma (y), mu (0, alpha (a), delta (6) or epsilon (6) with some subclasses among them (e.g., yl-y4). It is the nature of this chain that determines the "class" of the antibody as IgG, IgM, IgA IgD or IgE, respectively. The immunoglobulin subclasses or "isotypes" (e.g., IgGl, IgG2, IgG3, IgG4, IgAl, etc.) are well characterized and are known to confer functional specialization. Modified versions of each of these classes and isotypes are readily discernable to the skilled artisan in view
11 of the instant disclosure and, accordingly, are within the scope of the present invention.
As indicated above, the variable region of an antibody allows the antibody to selectively recognize and specifically bind epitopes on antigens. That is, the light chain variable domain (VL domain) and heavy chain variable domain (VH domain) of an antibody combine to form the variable region that defines a three-dimensional antigen binding site.
This quaternary antibody structure forms the antigen binding site presents at the end of each arm of the "Y". More specifically, the antigen binding site is defined by three complementarity determining regions (CDRs) on each of the VH and VL chains.
"Anticalins" are well known in the art and refer to an antibody mimetic technology, wherein the binding specificity is derived from lipocalins. Anticalins may also be formatted as dual targeting protein, called Duocalins.
"Antigen" refers any substance that is capable of stimulating an immune response, specifically activating immunes cells. In general, two main divisions of antigens are recognized: foreign antigens (or heteroantigens) and autoantigens (or self-antigens).
Antigen molecules possess by definition, at least one epitope (or antigenic sites) which produce corresponding antibodies.
"Antigen-binding fragment", as used herein, refers to a part or region of an antibody or chimeric antigen receptor (CAR), which comprises fewer amino acid residues than the whole antibody or CAR. An "antigen-binding fragment" binds to an antigen and/or competes with the whole antibody and/or CAR from which it was derived for antigen binding (e.g., specific binding to human senescent associated-cell antigen).
Antigen-binding fragments encompasses, without any limitation, single chain antibodies, Fv, Fab, Fab', Fab' -SH, F(ab)'2, Fd, defucosylated antibodies, diabodies, triabodies and tetrabodies.
"Armadillo repeat protein-based scaffold", as used herein, refers to a type of antibody mimetics corresponding to artificial peptide binding scaffolds based on armadillo repeat proteins. Armadillo repeat proteins are characterized by an armadillo domain, composed of tandem armadillo repeats of approximately 42 amino acids, which mediates interactions with peptides or proteins.
As indicated above, the variable region of an antibody allows the antibody to selectively recognize and specifically bind epitopes on antigens. That is, the light chain variable domain (VL domain) and heavy chain variable domain (VH domain) of an antibody combine to form the variable region that defines a three-dimensional antigen binding site.
This quaternary antibody structure forms the antigen binding site presents at the end of each arm of the "Y". More specifically, the antigen binding site is defined by three complementarity determining regions (CDRs) on each of the VH and VL chains.
"Anticalins" are well known in the art and refer to an antibody mimetic technology, wherein the binding specificity is derived from lipocalins. Anticalins may also be formatted as dual targeting protein, called Duocalins.
"Antigen" refers any substance that is capable of stimulating an immune response, specifically activating immunes cells. In general, two main divisions of antigens are recognized: foreign antigens (or heteroantigens) and autoantigens (or self-antigens).
Antigen molecules possess by definition, at least one epitope (or antigenic sites) which produce corresponding antibodies.
"Antigen-binding fragment", as used herein, refers to a part or region of an antibody or chimeric antigen receptor (CAR), which comprises fewer amino acid residues than the whole antibody or CAR. An "antigen-binding fragment" binds to an antigen and/or competes with the whole antibody and/or CAR from which it was derived for antigen binding (e.g., specific binding to human senescent associated-cell antigen).
Antigen-binding fragments encompasses, without any limitation, single chain antibodies, Fv, Fab, Fab', Fab' -SH, F(ab)'2, Fd, defucosylated antibodies, diabodies, triabodies and tetrabodies.
"Armadillo repeat protein-based scaffold", as used herein, refers to a type of antibody mimetics corresponding to artificial peptide binding scaffolds based on armadillo repeat proteins. Armadillo repeat proteins are characterized by an armadillo domain, composed of tandem armadillo repeats of approximately 42 amino acids, which mediates interactions with peptides or proteins.
12 "Atrimers" are well known in the art and refers to binding molecules for target protein that trimerize as a perquisite for their biological activity. They are relatively large compared to other antibody mimetic scaffolds.
"Autologous" is meant to refer to any material derived from the same individual to which it is later to be re-introduced into the individual.
"Avimers" are well known in the art and refer to an antibody mimetic technology.
"Complement-dependent cytotoxicity" or "CDC" refers to the induction of the lysis of antigen-expressing cells recognized by an antibody or antigen-binding fragment thereof of the invention in the presence of complement. The complement activation pathway is .. initiated by the binding of the first component of the complement system (Cl q) to a molecule (e.g., an antibody) complexed with a cognate antigen. CDC can be measured using assays that are known and available in the art (e.g., Clynes et al, 1998. Proc Natl Acad Sci U S A. 95(2):652-6; Gazzano-Santaro et al., 1997. J Immunol Methods.
202(2): 163-71).
"CDR" or "complementarity determining region" means the non-contiguous antigen combining sites found within the variable region of both heavy and light chain polypeptides. The precise amino acid sequence boundaries of a given CDR can be determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), "Sequences of Proteins of Immunological Interest" 5th Ed.
Public Health Service, National Institutes of Health, Bethesda, MD ("Kabat" numbering scheme), Al-Lazikani et al., 1997. J Mol Biol. 273(4):927-48 ("Chothia"
numbering scheme), or a combination thereof. More recently, a universal numbering system has been developed and widely adopted, ImMunoGeneTics (IMGT) Information System (Lefranc et al., 1999. Nucleic Acids Res. 27(4209-12). IMGT is an integrated information system specializing in immunoglobulins (IG), T cell receptors (TR) and major histocompatibility complex (MHC) of human and other vertebrates. Herein, the CDRs are referred to in terms of both the amino acid sequence and the location within the light or heavy chain. As the "location" of the CDRs within the structure of the immunoglobulin variable domain is conserved between species and present in structures
"Autologous" is meant to refer to any material derived from the same individual to which it is later to be re-introduced into the individual.
"Avimers" are well known in the art and refer to an antibody mimetic technology.
"Complement-dependent cytotoxicity" or "CDC" refers to the induction of the lysis of antigen-expressing cells recognized by an antibody or antigen-binding fragment thereof of the invention in the presence of complement. The complement activation pathway is .. initiated by the binding of the first component of the complement system (Cl q) to a molecule (e.g., an antibody) complexed with a cognate antigen. CDC can be measured using assays that are known and available in the art (e.g., Clynes et al, 1998. Proc Natl Acad Sci U S A. 95(2):652-6; Gazzano-Santaro et al., 1997. J Immunol Methods.
202(2): 163-71).
"CDR" or "complementarity determining region" means the non-contiguous antigen combining sites found within the variable region of both heavy and light chain polypeptides. The precise amino acid sequence boundaries of a given CDR can be determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), "Sequences of Proteins of Immunological Interest" 5th Ed.
Public Health Service, National Institutes of Health, Bethesda, MD ("Kabat" numbering scheme), Al-Lazikani et al., 1997. J Mol Biol. 273(4):927-48 ("Chothia"
numbering scheme), or a combination thereof. More recently, a universal numbering system has been developed and widely adopted, ImMunoGeneTics (IMGT) Information System (Lefranc et al., 1999. Nucleic Acids Res. 27(4209-12). IMGT is an integrated information system specializing in immunoglobulins (IG), T cell receptors (TR) and major histocompatibility complex (MHC) of human and other vertebrates. Herein, the CDRs are referred to in terms of both the amino acid sequence and the location within the light or heavy chain. As the "location" of the CDRs within the structure of the immunoglobulin variable domain is conserved between species and present in structures
13 called loops, by using numbering systems that align variable domain sequences according to structural features, CDR and framework residues may be readily identified.
This information can be used in grafting and replacement of CDR residues from immunoglobulins of one species into an acceptor framework from, typically, a human antibody. Correspondence between the Kabat numbering and the IMGT unique numbering system is also well known to one skilled in the art (e.g., Lefranc et al., supra).
Thus, in one embodiment, by CDR regions or CDR, it is intended to indicate the hypervariable regions of the heavy and light chains of the immunoglobulins as defined by IMGT numbering system (e.g. Lefranc et al., supra).
Heavy chain variable region (HCVR or VII) Approx. at residue 26 (always 4 after a Cys) Always 33 residues after Always 15 residues after according to end of VH-CDR2 the end of VH-CDR1 Chothia/AbM's definition eh' according to Kabat/AbM's definition Always 2 residues after a Kabat's definition starts 5 Cys residues later 4, Always Cys-Xaa-Xaa-Xaa, Always Cys-Xaa-Xaa, with t.) Typically, Leu-Glu-Trp-Ile--as t with Xaa being any amino Xaa being any amino acid Gly, but a number of acid according to p4 variations Chothia/AbM's definition Typically, Cys-Ala-Arg 4, Always Trp Lys/Arg- Always Trp-Gly-Xaa-Gly, Leu/IleNal/Phe/Thr/Ala- with Xaa being any amino c)..) Typically, Trp-Val, but Thr/Ser/Ile/Ala acid also, Trp-Ile or Trp-Ala to 12 residues according to AbM's definition 16 to 19 residues according to Kabat's definition r)io Chothia's definition 3 to 25 residues 0.) excludes the last 4 residues AbM's definition ends 7 residues earlier 5 to 7 residues according to Kabat's definition Light chain variable region (LCVR or VL) Always 33 residues after *)) end of VL-CDR2 (except Always 16 residues after at Approx. at residue 24 NEW (PDB ID: 7FAB) eh' the end of VL-CDR1 which has the deletion at the end of CDR-L2*)
This information can be used in grafting and replacement of CDR residues from immunoglobulins of one species into an acceptor framework from, typically, a human antibody. Correspondence between the Kabat numbering and the IMGT unique numbering system is also well known to one skilled in the art (e.g., Lefranc et al., supra).
Thus, in one embodiment, by CDR regions or CDR, it is intended to indicate the hypervariable regions of the heavy and light chains of the immunoglobulins as defined by IMGT numbering system (e.g. Lefranc et al., supra).
Heavy chain variable region (HCVR or VII) Approx. at residue 26 (always 4 after a Cys) Always 33 residues after Always 15 residues after according to end of VH-CDR2 the end of VH-CDR1 Chothia/AbM's definition eh' according to Kabat/AbM's definition Always 2 residues after a Kabat's definition starts 5 Cys residues later 4, Always Cys-Xaa-Xaa-Xaa, Always Cys-Xaa-Xaa, with t.) Typically, Leu-Glu-Trp-Ile--as t with Xaa being any amino Xaa being any amino acid Gly, but a number of acid according to p4 variations Chothia/AbM's definition Typically, Cys-Ala-Arg 4, Always Trp Lys/Arg- Always Trp-Gly-Xaa-Gly, Leu/IleNal/Phe/Thr/Ala- with Xaa being any amino c)..) Typically, Trp-Val, but Thr/Ser/Ile/Ala acid also, Trp-Ile or Trp-Ala to 12 residues according to AbM's definition 16 to 19 residues according to Kabat's definition r)io Chothia's definition 3 to 25 residues 0.) excludes the last 4 residues AbM's definition ends 7 residues earlier 5 to 7 residues according to Kabat's definition Light chain variable region (LCVR or VL) Always 33 residues after *)) end of VL-CDR2 (except Always 16 residues after at Approx. at residue 24 NEW (PDB ID: 7FAB) eh' the end of VL-CDR1 which has the deletion at the end of CDR-L2*)
14 -0 0 Generally, Ile-Tyr, but also Always Cys Val-Tyr, Ile-Lys or Ile-Phe' Always Cys 1:4 Always Trp Always Phe-Gly-Xaa-Gly, MS a) Typically, Trp-Tyr-Gln, but with Xaa being any amino 0.) r:4 also, Trp-Leu-Gln, Trp- acid Phe-Gln or Trp-Tyr-Leu Always 7 residues (except NEW (PDB ID: 7FAB) c 10 to 17 residues . 7 to 11 residues which has a deletion in this region*) * Saul & Poljak, 1992. Proteins. 14(3):363-71 "Cell", "cell line" and "cell culture" may be used interchangeably. All of these terms also include their progeny, which is any and all subsequent generations. It is understood that all progeny may not be identical due to deliberate or inadvertent mutations. In the context of expressing a heterologous nucleic acid sequence, "host cell" refers to a eukaryotic cell that is capable of replicating a vector and/or expressing a heterologous gene encoded by a vector. A host cell can, and has been, used as a recipient for vectors.
A host cell may be "transfected" or "transformed," which refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell. A
transformed cell includes the primary subject cell and its progeny. As used herein, the terms "engineered"
and "recombinant" cells or host cells are intended to refer to a cell into which an exogenous nucleic acid sequence, such as, for example, a vector, has been introduced.
Therefore, recombinant cells are distinguishable from naturally occurring cells which do not contain a recombinantly introduced nucleic acid "Chimeric antigen receptor" or "CAR refers to engineered receptors, which graft an antigen specificity onto cells with intracellular signal generation (such as, for example, T cells or phagocytic cells). CARs are also known as artificial T cell receptors, chimeric T cell receptors or chimeric immunoreceptors.
"Co-stimulatory domain" or "CSD", when used in a relationship with a chimeric antigen receptor (CAR), refers to the portion of the CAR which enhances the proliferation, survival and/or development of memory cells. The CARs of the invention may comprise one or more co-stimulatory domains. Co-stimulatory domains are apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention.
"DARPins" or "Designed Ankyrin Repeat Proteins" are well known in the art and refer 5 to an antibody mimetic DRP (designed repeat protein) technology developed to exploit the binding abilities of non-antibody polypeptides.
"DEP1", also known as PTPRJ, SCC1, CD148, HPTPeta or R-PTP-ETA, refers to a protein encoded by a gene which is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular 10 processes, including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region containing five fibronectin type III repeats, a single transmembrane region, and a single intracytoplasmic catalytic domain, and thus represents a receptor-type PTP. This protein is present in all hematopoietic lineages, and was shown to negatively regulate T cell receptor signaling
A host cell may be "transfected" or "transformed," which refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell. A
transformed cell includes the primary subject cell and its progeny. As used herein, the terms "engineered"
and "recombinant" cells or host cells are intended to refer to a cell into which an exogenous nucleic acid sequence, such as, for example, a vector, has been introduced.
Therefore, recombinant cells are distinguishable from naturally occurring cells which do not contain a recombinantly introduced nucleic acid "Chimeric antigen receptor" or "CAR refers to engineered receptors, which graft an antigen specificity onto cells with intracellular signal generation (such as, for example, T cells or phagocytic cells). CARs are also known as artificial T cell receptors, chimeric T cell receptors or chimeric immunoreceptors.
"Co-stimulatory domain" or "CSD", when used in a relationship with a chimeric antigen receptor (CAR), refers to the portion of the CAR which enhances the proliferation, survival and/or development of memory cells. The CARs of the invention may comprise one or more co-stimulatory domains. Co-stimulatory domains are apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention.
"DARPins" or "Designed Ankyrin Repeat Proteins" are well known in the art and refer 5 to an antibody mimetic DRP (designed repeat protein) technology developed to exploit the binding abilities of non-antibody polypeptides.
"DEP1", also known as PTPRJ, SCC1, CD148, HPTPeta or R-PTP-ETA, refers to a protein encoded by a gene which is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular 10 processes, including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region containing five fibronectin type III repeats, a single transmembrane region, and a single intracytoplasmic catalytic domain, and thus represents a receptor-type PTP. This protein is present in all hematopoietic lineages, and was shown to negatively regulate T cell receptor signaling
15 possibly through interfering with the phosphorylation of Phospholipase C
Gamma 1 and Linker for Activation of T Cells. This protein can also dephosphorylate the PDGF beta receptor, and may be involved in UV-induced signal transduction. In human, multiple transcript variants encoding different isoforms have been found for this gene.
In the sense of the present invention, human DEP1 (or hDEP1) is a protein with an amino acid sequence SEQ ID NO: 1.
SEQ ID NO: 1 MKPAAREARLPPR SP GLRWALPLLLLLLRL GQILCAGGTP SPIPDP S VATVAT GE
NGITQIS STAESFHICQNGTGTPQVETNT SEDGE S SGAND SLRTPEQ GSNGTD GA S
QKTP S ST GP SPVFDIKAVSI SP TNVILTWK SNDTAASEYKYVVKHKMENEKTITV
VHQPWCNITGLRPAT SYVF SITPGIGNETWGDPRVIKVITEPIPVSDLRVALTGVR
KAALSW SNGNGTASCRVLLE SIGSHEELTQD SRL QVNI S GLKP GVQYNINPYLL
Q SNKTKGDPLGTEGGLDASNTERSRAGSPTAPVHDE SLVGPVDP S SGQQ SRDTE
VLLVGLEPGTRYNATVYSQAANGTEGQPQAIEFRTNAIQVFDVTAVNISATSLT
LIWKVSDNES S SNYTYKIHVAGETD S SNLNVSEPRAVIPGLRS STFYNITVCPVL
GDIEGTPGFLQVHTPPVPVSDFRVTVVSTTEIGLAW S SHDAESFQMHITQEGAG
Gamma 1 and Linker for Activation of T Cells. This protein can also dephosphorylate the PDGF beta receptor, and may be involved in UV-induced signal transduction. In human, multiple transcript variants encoding different isoforms have been found for this gene.
In the sense of the present invention, human DEP1 (or hDEP1) is a protein with an amino acid sequence SEQ ID NO: 1.
SEQ ID NO: 1 MKPAAREARLPPR SP GLRWALPLLLLLLRL GQILCAGGTP SPIPDP S VATVAT GE
NGITQIS STAESFHICQNGTGTPQVETNT SEDGE S SGAND SLRTPEQ GSNGTD GA S
QKTP S ST GP SPVFDIKAVSI SP TNVILTWK SNDTAASEYKYVVKHKMENEKTITV
VHQPWCNITGLRPAT SYVF SITPGIGNETWGDPRVIKVITEPIPVSDLRVALTGVR
KAALSW SNGNGTASCRVLLE SIGSHEELTQD SRL QVNI S GLKP GVQYNINPYLL
Q SNKTKGDPLGTEGGLDASNTERSRAGSPTAPVHDE SLVGPVDP S SGQQ SRDTE
VLLVGLEPGTRYNATVYSQAANGTEGQPQAIEFRTNAIQVFDVTAVNISATSLT
LIWKVSDNES S SNYTYKIHVAGETD S SNLNVSEPRAVIPGLRS STFYNITVCPVL
GDIEGTPGFLQVHTPPVPVSDFRVTVVSTTEIGLAW S SHDAESFQMHITQEGAG
16 NSRVEITTNQSIIIGGLFPGTKYCFEIVPKGPNGTEGASRTVCNRTVP SAVFDIHV
VYVT T TEMWLDWK SPD GA SEYVYHLVIE SKHGSNHT STYDKAITLQGLIPGTL
YNITISPEVDHVWGDPNSTAQYTRP SNVSNIDVSTNTTAATL SWQNFDDASPTY
SYCLLIEKAGNS SNATQVVTDIGITDATVTELIPGS SYTVEIFAQVGDGIKSLEPG
RIC SF C TDPASMASFDCEVVPKEP ALVLKW TCPP GANAGF ELEVS SGAWNNATH
LESC SSENGTEYRTEVTYLNF ST SYNISITTVSCGKMAAPTRNTCTTGITDPPPPD
GSPNITSVSHNSVKVKF SGFEASHGPIKAYAVILTTGEAGHP SADVLKYTYEDFK
KGASDTYVTYLIRTEEKGRSQSLSEVLKYEIDVGNESTTLGYYNGKLEPLGSYR
AC VAGF TNI TFHP QNK GL ID GAE S YV SF SRY SD AV SLP QDP GVIC GAVF GC IF GA
LVIVTVGGF IFWRICKRKDAKNNEV SF SQIKPKKSKLIRVENFEAYFKKQQADSN
C GF AEE YEDL KLVGI S QP K YAAELAENRGKNRYNNVLP YD I SRVKL SVQTHST
DDYINANYMPGYHSKKDFIATQGPLPNTLKDFWRMVWEKNVYAIIMLTKCVE
QGRTKCEEYWP SKQAQDYGDITVAMT SEIVLPEWTIRDFTVKNIQT SE SHPLRQ
FHFTSWPDHGVPDTTDLLINFRYLVRDYMKQSPPESPILVHCSAGVGRTGTFIAI
DRLI Y Q IENENT VD VY GIVYD LRMHRPLMVQ T ED Q YVF LNQ C VLD IVR S Q KD S
KVDLIYQNTTAMTIYENLAPVTTFGKTNGYIA
hDEP1 is composed of several domains, as follows:
- a signal peptide, comprising or consisting of amino acid residues 1 ¨
35 of SEQ ID NO: 1;
- an extracellular domain, comprising or consisting of amino acid residues 36 ¨ 975 of SEQ ID NO: 1, itself comprising:
= a fibronectin type-III domain 1, comprising or consisting of amino acid residues 121 ¨ 209 of SEQ ID NO: 1;
= a fibronectin type-III domain 2, comprising or consisting of amino acid residues 207 ¨ 291 of SEQ ID NO: 1;
= a fibronectin type-III domain 3, comprising or consisting of amino acid residues 271 ¨ 364 of SEQ ID NO: 1;
= a fibronectin type-III domain 4, comprising or consisting of amino acid residues 368 ¨ 456 of SEQ ID NO: 1;
= a fibronectin type-III domain 5, comprising or consisting of amino acid residues 457 ¨ 541 of SEQ ID NO: 1;
VYVT T TEMWLDWK SPD GA SEYVYHLVIE SKHGSNHT STYDKAITLQGLIPGTL
YNITISPEVDHVWGDPNSTAQYTRP SNVSNIDVSTNTTAATL SWQNFDDASPTY
SYCLLIEKAGNS SNATQVVTDIGITDATVTELIPGS SYTVEIFAQVGDGIKSLEPG
RIC SF C TDPASMASFDCEVVPKEP ALVLKW TCPP GANAGF ELEVS SGAWNNATH
LESC SSENGTEYRTEVTYLNF ST SYNISITTVSCGKMAAPTRNTCTTGITDPPPPD
GSPNITSVSHNSVKVKF SGFEASHGPIKAYAVILTTGEAGHP SADVLKYTYEDFK
KGASDTYVTYLIRTEEKGRSQSLSEVLKYEIDVGNESTTLGYYNGKLEPLGSYR
AC VAGF TNI TFHP QNK GL ID GAE S YV SF SRY SD AV SLP QDP GVIC GAVF GC IF GA
LVIVTVGGF IFWRICKRKDAKNNEV SF SQIKPKKSKLIRVENFEAYFKKQQADSN
C GF AEE YEDL KLVGI S QP K YAAELAENRGKNRYNNVLP YD I SRVKL SVQTHST
DDYINANYMPGYHSKKDFIATQGPLPNTLKDFWRMVWEKNVYAIIMLTKCVE
QGRTKCEEYWP SKQAQDYGDITVAMT SEIVLPEWTIRDFTVKNIQT SE SHPLRQ
FHFTSWPDHGVPDTTDLLINFRYLVRDYMKQSPPESPILVHCSAGVGRTGTFIAI
DRLI Y Q IENENT VD VY GIVYD LRMHRPLMVQ T ED Q YVF LNQ C VLD IVR S Q KD S
KVDLIYQNTTAMTIYENLAPVTTFGKTNGYIA
hDEP1 is composed of several domains, as follows:
- a signal peptide, comprising or consisting of amino acid residues 1 ¨
35 of SEQ ID NO: 1;
- an extracellular domain, comprising or consisting of amino acid residues 36 ¨ 975 of SEQ ID NO: 1, itself comprising:
= a fibronectin type-III domain 1, comprising or consisting of amino acid residues 121 ¨ 209 of SEQ ID NO: 1;
= a fibronectin type-III domain 2, comprising or consisting of amino acid residues 207 ¨ 291 of SEQ ID NO: 1;
= a fibronectin type-III domain 3, comprising or consisting of amino acid residues 271 ¨ 364 of SEQ ID NO: 1;
= a fibronectin type-III domain 4, comprising or consisting of amino acid residues 368 ¨ 456 of SEQ ID NO: 1;
= a fibronectin type-III domain 5, comprising or consisting of amino acid residues 457 ¨ 541 of SEQ ID NO: 1;
17 = a fibronectin type-III domain 6, comprising or consisting of amino acid residues 542 ¨ 623 of SEQ ID NO: 1;
= a fibronectin type-III domain 7, comprising or consisting of amino acid residues 625 ¨ 720 of SEQ ID NO: 1;
= a fibronectin type-III domain 8, comprising or consisting of amino acid residues 721 ¨ 817 of SEQ ID NO: 1; and = a fibronectin type-III domain 9, comprising or consisting of amino acid residues 816¨ 902 of SEQ ID NO: 1;
a transmembrane domain, comprising or consisting of amino acid residues 976 ¨ 996 of SEQ ID NO: 1; and a cytoplasmic domain, comprising or consisting of amino acid residues 997¨
of SEQ ID NO: 1.
"Diabodies", as used herein, refers to small antibody fragments prepared by constructing scFv fragments with short linkers (about 5-10 residues) between the HCVR and LCVR
such that inter-chain but not intra-chain pairing of the variable domains is achieved, resulting in a bivalent fragment, i.e., fragment having two antigen-binding sites.
Bispecific diabodies are heterodimers of two "crossover" scFv fragments in which the HCVR and LCVR of the two antibodies are present on different polypeptide chains.
Diabodies are described more fully in European patent EP0404097, International patent application W01993011161; and in Holliger et al., 1993. Proc Natl Acad Sci USA.
90(14):6444-8.
"Domain antibodies" are well-known in the art and refer to the smallest functional binding units of antibodies, corresponding to the variable regions of either the heavy or light chains of antibodies.
"Domain kunitz peptide" refer to a type of antibody mimetics, and is based on the active domains of proteins inhibiting the function of proteases.
"DPP4" (also known as ADABP, adenosine deaminase complexing protein 2, ADCP-2, dipeptidyl peptidase IV, DPP IV, CD26, or TP103) refers to an intrinsic membrane
= a fibronectin type-III domain 7, comprising or consisting of amino acid residues 625 ¨ 720 of SEQ ID NO: 1;
= a fibronectin type-III domain 8, comprising or consisting of amino acid residues 721 ¨ 817 of SEQ ID NO: 1; and = a fibronectin type-III domain 9, comprising or consisting of amino acid residues 816¨ 902 of SEQ ID NO: 1;
a transmembrane domain, comprising or consisting of amino acid residues 976 ¨ 996 of SEQ ID NO: 1; and a cytoplasmic domain, comprising or consisting of amino acid residues 997¨
of SEQ ID NO: 1.
"Diabodies", as used herein, refers to small antibody fragments prepared by constructing scFv fragments with short linkers (about 5-10 residues) between the HCVR and LCVR
such that inter-chain but not intra-chain pairing of the variable domains is achieved, resulting in a bivalent fragment, i.e., fragment having two antigen-binding sites.
Bispecific diabodies are heterodimers of two "crossover" scFv fragments in which the HCVR and LCVR of the two antibodies are present on different polypeptide chains.
Diabodies are described more fully in European patent EP0404097, International patent application W01993011161; and in Holliger et al., 1993. Proc Natl Acad Sci USA.
90(14):6444-8.
"Domain antibodies" are well-known in the art and refer to the smallest functional binding units of antibodies, corresponding to the variable regions of either the heavy or light chains of antibodies.
"Domain kunitz peptide" refer to a type of antibody mimetics, and is based on the active domains of proteins inhibiting the function of proteases.
"DPP4" (also known as ADABP, adenosine deaminase complexing protein 2, ADCP-2, dipeptidyl peptidase IV, DPP IV, CD26, or TP103) refers to an intrinsic membrane
18 glycoprotein and a serine exopeptidase that cleaves X-proline dipeptides from the N-terminus of polypeptides.
In the sense of the present invention, human DPP4 (or hDPP4) is a protein with an amino acid sequence SEQ ID NO: 101.
SEQ ID NO: 101 MKTPWKVLLGLLGAAALVTIITVPVVLLNKGTDDATADSRKTYTLTDYLKNTY
RLKLYSLRWISDHEYLYKQENNILVFNAEYGNSSVFLENSTFDEFGHSINDYSIS
PDGQFILLEYNYVKQWRHSYTASYDIYDLNKRQLITEERIPNNTQWVTW SPVG
HICLAYVWNNDIYVKIEPNLP SYRITWTGKEDIIYNGITDWVYEEEVF S AY S ALW
W SPNGTFLAYAQFND TEVPLIE Y SF Y SDE SL QYPKTVRVPYPKAGAVNP TVKFF
VVNTDSL S SVTNAT SIQITAPASMLIGDHYLCDVTWATQERISLQWLRRIQNYS
VMDICDYDESSGRWNCLVARQHIEMSTTGWVGRFRP SEPHFTLDGNSFYKIISN
EEGYRHICYFQIDKKDCTFITKGTWEVIGIEALTSDYLYYISNEYKGMPGGRNLY
KIQL SDYTKVTCL SCELNPERCQYYSVSF SKEAKYYQLRCSGPGLPLYTLHS SV
NDKGLRVLEDNSALDKMLQNVQMP SKKLDFIILNETKFWYQMILPPHFDKSKK
YPLLLDVYAGPC SQKADTVFRLNWATYLASTENIIVASFDGRGSGYQGDKIMH
AINRRLGTFEVEDQIEAARQF SKMGFVDNKRIAIWGW SYGGYVT SMVL GS GSG
VFKCGIAVAPVSRWEYYDSVYTERYMGLPTPEDNLDHYRNSTVMSRAENFKQ
VEYLLIHGTADDNVHFQQSAQISKALVDVGVDFQAMWYTDEDHGIAS STAHQ
HIYTHMSHFIKQCF SLP
hDPP4 is composed of several domains, as follows:
- a cytoplasmic domain, comprising or consisting of amino acid residues 1 ¨ 6 of SEQ ID NO: 101;
- a transmembrane domain, comprising or consisting of amino acid residues 7 ¨ 28 of SEQ ID NO: 101; and - an extracellular domain, comprising or consisting of amino acid residues 29 ¨ 766 of SEQ ID NO: 101.
"Epitope", also known as "antigenic determinant", refers to a specific arrangement of amino acids located on a protein or proteins (or antigen(s)) to which an antibody or antigen-binding fragment thereof or chimeric antigen receptor (CAR) binds.
Epitopes
In the sense of the present invention, human DPP4 (or hDPP4) is a protein with an amino acid sequence SEQ ID NO: 101.
SEQ ID NO: 101 MKTPWKVLLGLLGAAALVTIITVPVVLLNKGTDDATADSRKTYTLTDYLKNTY
RLKLYSLRWISDHEYLYKQENNILVFNAEYGNSSVFLENSTFDEFGHSINDYSIS
PDGQFILLEYNYVKQWRHSYTASYDIYDLNKRQLITEERIPNNTQWVTW SPVG
HICLAYVWNNDIYVKIEPNLP SYRITWTGKEDIIYNGITDWVYEEEVF S AY S ALW
W SPNGTFLAYAQFND TEVPLIE Y SF Y SDE SL QYPKTVRVPYPKAGAVNP TVKFF
VVNTDSL S SVTNAT SIQITAPASMLIGDHYLCDVTWATQERISLQWLRRIQNYS
VMDICDYDESSGRWNCLVARQHIEMSTTGWVGRFRP SEPHFTLDGNSFYKIISN
EEGYRHICYFQIDKKDCTFITKGTWEVIGIEALTSDYLYYISNEYKGMPGGRNLY
KIQL SDYTKVTCL SCELNPERCQYYSVSF SKEAKYYQLRCSGPGLPLYTLHS SV
NDKGLRVLEDNSALDKMLQNVQMP SKKLDFIILNETKFWYQMILPPHFDKSKK
YPLLLDVYAGPC SQKADTVFRLNWATYLASTENIIVASFDGRGSGYQGDKIMH
AINRRLGTFEVEDQIEAARQF SKMGFVDNKRIAIWGW SYGGYVT SMVL GS GSG
VFKCGIAVAPVSRWEYYDSVYTERYMGLPTPEDNLDHYRNSTVMSRAENFKQ
VEYLLIHGTADDNVHFQQSAQISKALVDVGVDFQAMWYTDEDHGIAS STAHQ
HIYTHMSHFIKQCF SLP
hDPP4 is composed of several domains, as follows:
- a cytoplasmic domain, comprising or consisting of amino acid residues 1 ¨ 6 of SEQ ID NO: 101;
- a transmembrane domain, comprising or consisting of amino acid residues 7 ¨ 28 of SEQ ID NO: 101; and - an extracellular domain, comprising or consisting of amino acid residues 29 ¨ 766 of SEQ ID NO: 101.
"Epitope", also known as "antigenic determinant", refers to a specific arrangement of amino acids located on a protein or proteins (or antigen(s)) to which an antibody or antigen-binding fragment thereof or chimeric antigen receptor (CAR) binds.
Epitopes
19 often consist of a chemically active surface grouping of molecules such as amino acids or sugar side chains, and have specific three-dimensional structural characteristics as well as specific charge characteristics. Epitopes can be linear (or sequential) or conformational, i.e., involving two or more sequences of amino acids in various regions of the antigen that may not necessarily be contiguous.
"Evasins" are well known in the art and refer to a class of chemokine-binding proteins.
"Extracellular spacer domain" or "ESD" or "hinge domain", when used in a relationship with a chimeric antigen receptor (CAR), refers to the hydrophilic region which is between the antigen-specific targeting region and the transmembrane domain.
The extracellular spacer domains are apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention.
"Framework region" or "FR region" includes the amino acid residues that are part of the variable region, but are not part of the CDRs (e.g., using the IMGT
numbering definition of CDRs). The framework regions for the light chain are similarly separated by each of the LCVR's CDRs. In naturally occurring antibodies, the six CDRs present on each monomeric antibody are short, non-contiguous sequences of amino acids that are specifically positioned to form the antigen binding site as the antibody assumes its three-dimensional configuration in an aqueous environment. The remainders of the heavy and light variable domains show less inter-molecular variability in amino acid sequence and are termed the framework regions. The framework regions largely adopt a 13-sheet conformation and the CDRs form loops which connect, and in some cases form part of, the 13-sheet structure. Thus, these framework regions act to form a scaffold that provides for positioning the six CDRs in correct orientation by inter-chain, non-covalent interactions. The antigen binding site formed by the positioned CDRs defines a surface complementary to the epitope on the immunoreactive antigen. This complementary surface promotes the non-covalent binding of the antibody to the immunoreactive antigen epitope. The position of CDRs can be readily identified by one of ordinary skill in the art.
"Fc domain" "Fc portion" and "Fc region" refer to a C-terminal fragment of an antibody heavy chain, e.g., from about amino acid (aa) 230 to about aa 450 of human gamma heavy chain or its counterpart sequence in other types of antibody heavy chains (e.g., a, (3, c and for human antibodies), or a naturally occurring allotype thereof.
"Fynomers" are well known in the art and refer to proteins that belong to the class of antibody mimetic. They are attractive binding molecules due to their high thermal 5 stability and reduced immunogenicity.
as used herein, refers to the minimum antibody fragment that contains a complete antigen-recognition and -binding site. This fragment consists of a dimer of one HCVR
and one LCVR in tight, non-covalent association. From the folding of these two domains emanate six hypervariable loops (three loops each from the heavy and light chain) that 10 contribute to antigen binding and confer antigen binding specificity to the antibody.
However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
"Heavy chain region" includes amino acid sequences derived from the constant domains 15 of an immunoglobulin heavy chain. A protein comprising a heavy chain region comprises at least one of a CH1 domain, a hinge (e.g., upper, middle, and/or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment thereof In an embodiment, the antibody or antigen-binding fragment thereof according to the present invention may comprise the Fc region of an immunoglobulin heavy chain (e.g., a hinge portion, a CH2
"Evasins" are well known in the art and refer to a class of chemokine-binding proteins.
"Extracellular spacer domain" or "ESD" or "hinge domain", when used in a relationship with a chimeric antigen receptor (CAR), refers to the hydrophilic region which is between the antigen-specific targeting region and the transmembrane domain.
The extracellular spacer domains are apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention.
"Framework region" or "FR region" includes the amino acid residues that are part of the variable region, but are not part of the CDRs (e.g., using the IMGT
numbering definition of CDRs). The framework regions for the light chain are similarly separated by each of the LCVR's CDRs. In naturally occurring antibodies, the six CDRs present on each monomeric antibody are short, non-contiguous sequences of amino acids that are specifically positioned to form the antigen binding site as the antibody assumes its three-dimensional configuration in an aqueous environment. The remainders of the heavy and light variable domains show less inter-molecular variability in amino acid sequence and are termed the framework regions. The framework regions largely adopt a 13-sheet conformation and the CDRs form loops which connect, and in some cases form part of, the 13-sheet structure. Thus, these framework regions act to form a scaffold that provides for positioning the six CDRs in correct orientation by inter-chain, non-covalent interactions. The antigen binding site formed by the positioned CDRs defines a surface complementary to the epitope on the immunoreactive antigen. This complementary surface promotes the non-covalent binding of the antibody to the immunoreactive antigen epitope. The position of CDRs can be readily identified by one of ordinary skill in the art.
"Fc domain" "Fc portion" and "Fc region" refer to a C-terminal fragment of an antibody heavy chain, e.g., from about amino acid (aa) 230 to about aa 450 of human gamma heavy chain or its counterpart sequence in other types of antibody heavy chains (e.g., a, (3, c and for human antibodies), or a naturally occurring allotype thereof.
"Fynomers" are well known in the art and refer to proteins that belong to the class of antibody mimetic. They are attractive binding molecules due to their high thermal 5 stability and reduced immunogenicity.
as used herein, refers to the minimum antibody fragment that contains a complete antigen-recognition and -binding site. This fragment consists of a dimer of one HCVR
and one LCVR in tight, non-covalent association. From the folding of these two domains emanate six hypervariable loops (three loops each from the heavy and light chain) that 10 contribute to antigen binding and confer antigen binding specificity to the antibody.
However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
"Heavy chain region" includes amino acid sequences derived from the constant domains 15 of an immunoglobulin heavy chain. A protein comprising a heavy chain region comprises at least one of a CH1 domain, a hinge (e.g., upper, middle, and/or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment thereof In an embodiment, the antibody or antigen-binding fragment thereof according to the present invention may comprise the Fc region of an immunoglobulin heavy chain (e.g., a hinge portion, a CH2
20 domain, and a CH3 domain). In another embodiment, the antibody or antigen-binding fragment thereof according to the present invention lacks at least a region of a constant domain (e.g., all or part of a CH2 domain). In certain embodiments, at least one, and preferably all, of the constant domains are derived from a human immunoglobulin heavy chain. For example, in one preferred embodiment, the heavy chain region comprises a fully human hinge region. In other preferred embodiments, the heavy chain region comprising a fully human Fc region (e.g., hinge, CH2 and CH3 domain sequences from a human immunoglobulin). In certain embodiments, the constituent constant domains of the heavy chain region are from different immunoglobulin molecules. For example, a heavy chain region of a protein may comprise a CH2 domain derived from an IgG1 molecule and a hinge region derived from an IgG3 or IgG4 molecule. In other
21 embodiments, the constant domains are chimeric domains comprising regions of different immunoglobulin molecules. For example, a hinge may comprise a first region from an IgG1 molecule and a second region from an IgG3 or IgG4 molecule. As set forth above, it will be understood by one of ordinary skill in the art that the constant domains of the heavy chain region may be modified such that they vary in amino acid sequence from the naturally occurring (wild-type) immunoglobulin molecule. That is, the antibody or antigen-binding fragment thereof according to the present invention may comprise alterations or modifications to one or more of the heavy chain constant domains (CH1, hinge, CH2 or CH3) and/or to the light chain constant domain (CL). Exemplary modifications include additions, deletions or substitutions of one or more amino acids in one or more domains.
"Hinge region", when used in a relationship with an antibody, includes the region of a heavy chain molecule that joins the CH1 domain to the CH2 domain in an antibody. This hinge region comprises approximately 25 residues and is flexible, thus allowing the two N-terminal antigen binding regions to move independently. Hinge regions can be subdivided into three distinct domains: upper, middle, and lower domains (Roux et al., 1998. J Immunol. 161(8):4083-90).
"Hypervariable loop" is not strictly synonymous to complementarity determining region (CDR), since the hypervariable loops (HVs) are defined on the basis of structure, whereas CDRs are defined based on sequence variability (Kabat et al, 1991. Sequences of proteins of immunological interest (5th ed.). Bethesda, MD: U.S. Dep. of Health and Human Services) and the limits of the HVs and the CDRs may be different in some VH
and Vi.
domains. The CDRs of the Vi. and VH domains can typically be defined by the Kabat/Chothia definition as already explained hereinabove.
"Identity" or "identical", when used in a relationship between the sequences of two or more amino acid sequences, or of two or more nucleic acid sequences, refers to the degree of sequence relatedness between amino acid sequences or nucleic acid sequences, as determined by the number of matches between strings of two or more amino acid residues or nucleic acid residues. "Identity" measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular
"Hinge region", when used in a relationship with an antibody, includes the region of a heavy chain molecule that joins the CH1 domain to the CH2 domain in an antibody. This hinge region comprises approximately 25 residues and is flexible, thus allowing the two N-terminal antigen binding regions to move independently. Hinge regions can be subdivided into three distinct domains: upper, middle, and lower domains (Roux et al., 1998. J Immunol. 161(8):4083-90).
"Hypervariable loop" is not strictly synonymous to complementarity determining region (CDR), since the hypervariable loops (HVs) are defined on the basis of structure, whereas CDRs are defined based on sequence variability (Kabat et al, 1991. Sequences of proteins of immunological interest (5th ed.). Bethesda, MD: U.S. Dep. of Health and Human Services) and the limits of the HVs and the CDRs may be different in some VH
and Vi.
domains. The CDRs of the Vi. and VH domains can typically be defined by the Kabat/Chothia definition as already explained hereinabove.
"Identity" or "identical", when used in a relationship between the sequences of two or more amino acid sequences, or of two or more nucleic acid sequences, refers to the degree of sequence relatedness between amino acid sequences or nucleic acid sequences, as determined by the number of matches between strings of two or more amino acid residues or nucleic acid residues. "Identity" measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular
22 mathematical model or computer program (i.e., "algorithms"). Identity of related amino acid sequences or nucleic acid sequences can be readily calculated by known methods.
Such methods include, but are not limited to, those described in Lesk A. M.
(1988).
Computational molecular biology: Sources and methods for sequence analysis.
New York, NY: Oxford University Press; Smith D. W. (1993). Biocomputing:
Informatics and genome projects. San Diego, CA: Academic Press; Griffin A. M. & Griffin H. G.
(1994).
Computer analysis of sequence data, Part 1. Totowa, NJ: Humana Press; von Heijne G.
(1987). Sequence analysis in molecular biology: treasure trove or trivial pursuit. San Diego, CA: Academic press; Gribskov M. R. & Devereux J. (1991). Sequence analysis primer. New York, NY: Stockton Press; Carillo et at, 1988. SIAM J Appl Math.
48(5):1073-82. Preferred methods for determining identity are designed to give the largest match between the sequences tested. Methods of determining identity are described in publicly available computer programs. Preferred computer program methods for determining identity between two sequences include the GCG program package, including GAP (Genetics Computer Group, University of Wisconsin, Madison, WI;
Devereux et al., 1984. Nucleic Acids Res. 12(1 Pt 1):387-95), BLASTP, BLASTN, and FASTA (Altschul et al., 1990. J Mol Biol. 215(3):403-10). The BLASTX program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul et al. NCB/NLM/NIH Bethesda, Md. 20894).
The well-known Smith Waterman algorithm may also be used to determine identity.
"Intracellular signaling domain" or "ISD" or "cytoplasmic domain", when used in a relationship with a chimeric antigen receptor (CAR), refers to the portion of the CAR
which transduces the effector function signal and directs the cell to perform its specialized function. Intracellular signaling domains are be apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention.
"Isolated" means altered or removed from the natural state. For example, a nucleic acid or a peptide naturally present in a living animal is not "isolated" but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is "isolated". An isolated nucleic acid or protein can exist in substantially purified form, or can exist in a non-native environment such as, for example, a host cell.
Such methods include, but are not limited to, those described in Lesk A. M.
(1988).
Computational molecular biology: Sources and methods for sequence analysis.
New York, NY: Oxford University Press; Smith D. W. (1993). Biocomputing:
Informatics and genome projects. San Diego, CA: Academic Press; Griffin A. M. & Griffin H. G.
(1994).
Computer analysis of sequence data, Part 1. Totowa, NJ: Humana Press; von Heijne G.
(1987). Sequence analysis in molecular biology: treasure trove or trivial pursuit. San Diego, CA: Academic press; Gribskov M. R. & Devereux J. (1991). Sequence analysis primer. New York, NY: Stockton Press; Carillo et at, 1988. SIAM J Appl Math.
48(5):1073-82. Preferred methods for determining identity are designed to give the largest match between the sequences tested. Methods of determining identity are described in publicly available computer programs. Preferred computer program methods for determining identity between two sequences include the GCG program package, including GAP (Genetics Computer Group, University of Wisconsin, Madison, WI;
Devereux et al., 1984. Nucleic Acids Res. 12(1 Pt 1):387-95), BLASTP, BLASTN, and FASTA (Altschul et al., 1990. J Mol Biol. 215(3):403-10). The BLASTX program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul et al. NCB/NLM/NIH Bethesda, Md. 20894).
The well-known Smith Waterman algorithm may also be used to determine identity.
"Intracellular signaling domain" or "ISD" or "cytoplasmic domain", when used in a relationship with a chimeric antigen receptor (CAR), refers to the portion of the CAR
which transduces the effector function signal and directs the cell to perform its specialized function. Intracellular signaling domains are be apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention.
"Isolated" means altered or removed from the natural state. For example, a nucleic acid or a peptide naturally present in a living animal is not "isolated" but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is "isolated". An isolated nucleic acid or protein can exist in substantially purified form, or can exist in a non-native environment such as, for example, a host cell.
23 "Knottin" or "inhibitor cystine knot" refer to an antibody mimetic comprising a protein structural motif containing three disulfide bridges.
"Monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprised in the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations that include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier "monoclonal" is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies or antigen-binding fragment thereof according to the present invention may be prepared by the hybridoma methodology first described by Kohler et al, 1975. Nature. 256(5517):495-7, or may be made using recombinant DNA
methods in bacterial, eukaryotic animal or plant cells (Patent US4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson et al, 1991. Nature. 352(6336):624-8 and Marks et al., 1991. J
Mol Biol. 222(3):581-97, for example.
"Linker", when used in a relationship with a chimeric antigen receptor (CAR), refers to an oligo- or polypeptide region from about 1 to 100 amino acids in length, which links together any of the domains/regions of the CAR of the invention. Linkers may be composed of flexible residues like glycine and serine so that the adjacent protein domains are free to move relative to one another. Longer linkers may be used when it is desirable to ensure that two adjacent domains do not sterically interfere with one another. Linkers may be cleavable or non-cleavable. Linkers are apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention.
"Nanobodies" are well-known in the art and refer to antibody-derived therapeutic proteins that contain the unique structural and functional properties of naturally-occurring heavy chain antibodies (Muyldermans, 2013. Annu Rev Biochem. 82:775-97). These
"Monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprised in the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations that include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier "monoclonal" is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies or antigen-binding fragment thereof according to the present invention may be prepared by the hybridoma methodology first described by Kohler et al, 1975. Nature. 256(5517):495-7, or may be made using recombinant DNA
methods in bacterial, eukaryotic animal or plant cells (Patent US4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson et al, 1991. Nature. 352(6336):624-8 and Marks et al., 1991. J
Mol Biol. 222(3):581-97, for example.
"Linker", when used in a relationship with a chimeric antigen receptor (CAR), refers to an oligo- or polypeptide region from about 1 to 100 amino acids in length, which links together any of the domains/regions of the CAR of the invention. Linkers may be composed of flexible residues like glycine and serine so that the adjacent protein domains are free to move relative to one another. Longer linkers may be used when it is desirable to ensure that two adjacent domains do not sterically interfere with one another. Linkers may be cleavable or non-cleavable. Linkers are apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention.
"Nanobodies" are well-known in the art and refer to antibody-derived therapeutic proteins that contain the unique structural and functional properties of naturally-occurring heavy chain antibodies (Muyldermans, 2013. Annu Rev Biochem. 82:775-97). These
24 heavy chain antibodies may contain a single variable domain (VHH) and two constant domains (CH2 and CH3).
"Prevent", "preventing" and "prevention" refer to prophylactic and preventative measures, wherein the object is to reduce the chances that a subject will develop the pathologic condition or disorder over a given period of time. Such a reduction may be reflected, e.g., in a delayed onset of at least one symptom of the pathologic condition or disorder in the subject.
"Proliferating cell" refers to a cell that is undergoing cell division.
"Promoter" is used to define a control sequence, that is a region of a vector at which initiation and rate of transcription are controlled. It may contain genetic elements to which regulatory proteins and molecules may bind, such as RNA polymerase and other transcription factors, to initiate the specific transcription a nucleic acid sequence. The phrases "operatively positioned" "operatively linked" "under control" and "under transcriptional control" mean that a promoter is in a correct functional location and/or orientation in relation to a nucleic acid to control transcriptional initiation and/or expression of that nucleic acid.
A promoter typically comprises a sequence that functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as, for example, the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the 5V40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation.
Additional promoter elements regulate the frequency of transcriptional initiation.
Typically, these are located in the region 110 bp upstream of the start site, although a number of promoters have been shown to contain functional elements downstream of the start site as well. To bring a coding sequence "under the control of' a promoter, one positions the 5' end of the transcription initiation site of the transcriptional reading frame "downstream" of (i.e., 3' of) the chosen promoter. The "upstream" promoter stimulates transcription of the DNA
and promotes expression of the encoded RNA.
The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either cooperatively or independently to activate transcription.
A promoter may or may not be used in conjunction with an "enhancer", which refers to a cis-acting 5 regulatory sequence involved in the transcriptional activation of a nucleic acid sequence.
A promoter may be one naturally associated with a nucleic acid, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment and/or exon. Such a promoter can be referred to as "endogenous". Similarly, an enhancer may be one naturally associated with a nucleic acid, located either downstream or upstream of 10 that sequence. Alternatively, certain advantages will be gained by positioning the coding nucleic acid segment under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with a nucleic acid sequence in its natural environment. A recombinant or heterologous enhancer refers also to an enhancer not normally associated with a nucleic acid sequence in its natural environment. Such 15 promoters or enhancers may include promoters or enhancers of other genes, and promoters or enhancers isolated from any other virus, or prokaryotic or eukaryotic cell, and promoters or enhancers not "naturally occurring", i.e., containing different elements of different transcriptional regulatory regions, and/or mutations that alter expression. For example, promoters that are most commonly used in recombinant DNA construction 20 include the lactamase (penicillinase), lactose and tryptophan (trp) promoter systems. In addition to producing nucleic acid sequences of promoters and enhancers synthetically, sequences may be produced using recombinant cloning and/or nucleic acid amplification technology, including PCRTM, in connection with the compositions disclosed herein (see US patents 4,683,202 and 5,928,906). Furthermore, it is contemplated the control
"Prevent", "preventing" and "prevention" refer to prophylactic and preventative measures, wherein the object is to reduce the chances that a subject will develop the pathologic condition or disorder over a given period of time. Such a reduction may be reflected, e.g., in a delayed onset of at least one symptom of the pathologic condition or disorder in the subject.
"Proliferating cell" refers to a cell that is undergoing cell division.
"Promoter" is used to define a control sequence, that is a region of a vector at which initiation and rate of transcription are controlled. It may contain genetic elements to which regulatory proteins and molecules may bind, such as RNA polymerase and other transcription factors, to initiate the specific transcription a nucleic acid sequence. The phrases "operatively positioned" "operatively linked" "under control" and "under transcriptional control" mean that a promoter is in a correct functional location and/or orientation in relation to a nucleic acid to control transcriptional initiation and/or expression of that nucleic acid.
A promoter typically comprises a sequence that functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as, for example, the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the 5V40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation.
Additional promoter elements regulate the frequency of transcriptional initiation.
Typically, these are located in the region 110 bp upstream of the start site, although a number of promoters have been shown to contain functional elements downstream of the start site as well. To bring a coding sequence "under the control of' a promoter, one positions the 5' end of the transcription initiation site of the transcriptional reading frame "downstream" of (i.e., 3' of) the chosen promoter. The "upstream" promoter stimulates transcription of the DNA
and promotes expression of the encoded RNA.
The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either cooperatively or independently to activate transcription.
A promoter may or may not be used in conjunction with an "enhancer", which refers to a cis-acting 5 regulatory sequence involved in the transcriptional activation of a nucleic acid sequence.
A promoter may be one naturally associated with a nucleic acid, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment and/or exon. Such a promoter can be referred to as "endogenous". Similarly, an enhancer may be one naturally associated with a nucleic acid, located either downstream or upstream of 10 that sequence. Alternatively, certain advantages will be gained by positioning the coding nucleic acid segment under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with a nucleic acid sequence in its natural environment. A recombinant or heterologous enhancer refers also to an enhancer not normally associated with a nucleic acid sequence in its natural environment. Such 15 promoters or enhancers may include promoters or enhancers of other genes, and promoters or enhancers isolated from any other virus, or prokaryotic or eukaryotic cell, and promoters or enhancers not "naturally occurring", i.e., containing different elements of different transcriptional regulatory regions, and/or mutations that alter expression. For example, promoters that are most commonly used in recombinant DNA construction 20 include the lactamase (penicillinase), lactose and tryptophan (trp) promoter systems. In addition to producing nucleic acid sequences of promoters and enhancers synthetically, sequences may be produced using recombinant cloning and/or nucleic acid amplification technology, including PCRTM, in connection with the compositions disclosed herein (see US patents 4,683,202 and 5,928,906). Furthermore, it is contemplated the control
25 sequences that direct transcription and/or expression of sequences within non-nuclear organelles such as mitochondria, chloroplasts, and the like, can be employed as well.
Naturally, it will be important to employ a promoter and/or enhancer that effectively directs the expression of the DNA segment in the organelle, cell type, tissue, organ, or organism chosen for expression. Those of skill in the art of molecular biology generally know the use of promoters, enhancers, and cell type combinations for protein expression, (see, for example Sambrook et al. 1989). The promoters employed may be constitutive, tissue-specific, inducible, and/or useful under the appropriate conditions to direct high-
Naturally, it will be important to employ a promoter and/or enhancer that effectively directs the expression of the DNA segment in the organelle, cell type, tissue, organ, or organism chosen for expression. Those of skill in the art of molecular biology generally know the use of promoters, enhancers, and cell type combinations for protein expression, (see, for example Sambrook et al. 1989). The promoters employed may be constitutive, tissue-specific, inducible, and/or useful under the appropriate conditions to direct high-
26 level expression of the introduced DNA segment, such as is advantageous in the large-scale production of recombinant proteins and/or peptides. The promoter may be heterologous or endogenous.
Additionally, any promoter/enhancer combination could also be used to drive expression.
Use of a T3, T7 or SP6 cytoplasmic expression system is another possible embodiment.
Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct.
The identity of tissue-specific promoters or elements, as well as assays to characterize a specific initiation signal also may be required for efficient translation of coding sequences. These signals include the ATG initiation codon or adjacent sequences.
Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals.
"Recombinant antibody" refers to antibodies which are produced, expressed, generated or isolated by recombinant means, such as antibodies which are expressed using a recombinant expression vector transfected into a host cell; antibodies isolated from a recombinant combinatorial antibody library; antibodies isolated from an animal (e.g., a mouse) which is transgenic due to human immunoglobulin genes; or antibodies which are produced, expressed, generated or isolated in any other way in which particular immunoglobulin gene sequences (such as human immunoglobulin gene sequences) are assembled with other DNA sequences. Recombinant antibodies include, for example, chimeric and humanized antibodies.
"Senescent cells" refers to cells that are in cell cycle arrest, generally during the G1 transition of the cell cycle or in few cases in G2, elicited by replicative exhaustion due to telomere attrition or in response to stresses such as DNA damage, chemotherapeutic drugs, or aberrant expression of oncogenes. According to one embodiment, the senescent cells are generally characterized by at least one or more of the following characteristics:
activation of the p53/p21CIP1 and/or pRb/p16INK4A tumor suppressor pathways, cells whose proliferation is irreversibly arrested, shortening of telomere size, expression of
Additionally, any promoter/enhancer combination could also be used to drive expression.
Use of a T3, T7 or SP6 cytoplasmic expression system is another possible embodiment.
Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct.
The identity of tissue-specific promoters or elements, as well as assays to characterize a specific initiation signal also may be required for efficient translation of coding sequences. These signals include the ATG initiation codon or adjacent sequences.
Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals.
"Recombinant antibody" refers to antibodies which are produced, expressed, generated or isolated by recombinant means, such as antibodies which are expressed using a recombinant expression vector transfected into a host cell; antibodies isolated from a recombinant combinatorial antibody library; antibodies isolated from an animal (e.g., a mouse) which is transgenic due to human immunoglobulin genes; or antibodies which are produced, expressed, generated or isolated in any other way in which particular immunoglobulin gene sequences (such as human immunoglobulin gene sequences) are assembled with other DNA sequences. Recombinant antibodies include, for example, chimeric and humanized antibodies.
"Senescent cells" refers to cells that are in cell cycle arrest, generally during the G1 transition of the cell cycle or in few cases in G2, elicited by replicative exhaustion due to telomere attrition or in response to stresses such as DNA damage, chemotherapeutic drugs, or aberrant expression of oncogenes. According to one embodiment, the senescent cells are generally characterized by at least one or more of the following characteristics:
activation of the p53/p21CIP1 and/or pRb/p16INK4A tumor suppressor pathways, cells whose proliferation is irreversibly arrested, shortening of telomere size, expression of
27 senescent-associated beta-galactosidase activity, specific chromatin modification, specific secretome, increase in reactive oxygen species and altered overall mitochondrial activity. Senescent cells and senescent cell-associated antigens can be detected by techniques and procedures described in the art.
"Single chain antibody", as used herein, refers to any antibody or fragment thereof that is a protein having a primary structure comprising or consisting of one uninterrupted sequence of contiguous amino acid residues, including without limitation (1) single-chain Fv molecules (scFv); (2) single chain proteins containing only one light chain variable domain, or a fragment thereof that contains the three CDRs of the light chain variable domain, without an associated heavy chain moiety; and (3) single chain proteins containing only one heavy chain variable region, or a fragment thereof containing the three CDRs of the heavy chain variable region, without an associated light chain moiety.
"Single-chain Fv", also abbreviated as "sFv" or "scFv", refers to antibody fragments that comprise the VH and VL antibody domains connected into a single amino acid chain.
Preferably, the scFv amino acid sequence further comprises a flexible peptidic linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding (Pluckthun, 1994. "Antibodies from Escherichia coil". In Rosenberg &
Moore (Eds.), The pharmacology of monoclonal antibodies. Handbook of Experimental Pharmacology, 113:269-315. Springer: Berlin, Heidelberg). Flexible peptidic linkers are generally composed of small, non-polar (e.g., glycine, Gly, G) or polar (e.g., serine, Ser, S; or threonine, Thr, T) amino acids, as suggested by Argos (1990. J Mol Biol.
211(4):943-958). The small size of these amino acids provides flexibility, and allows for mobility of the connecting functional domains, such as the VH and VL domains.
In one embodiment, the flexible peptidic linker may be a short oligo- or polypeptide, preferably having a length ranging from 2 to 30 amino acids. In one embodiment, the flexible peptidic linker comprises glycine-serine repeats. In one embodiment, the flexible peptidic linker comprises one, or several repeats of, such as 2, 3, 4, 5 or more repeats of, GS
linker(s) (i.e., a sequence of one Gly and one Ser), G25 linker(s) (i.e., a sequence of two Gly and one Ser), G35 linker(s) (i.e., a sequence of three Gly and one Ser), G45 linker(s)
"Single chain antibody", as used herein, refers to any antibody or fragment thereof that is a protein having a primary structure comprising or consisting of one uninterrupted sequence of contiguous amino acid residues, including without limitation (1) single-chain Fv molecules (scFv); (2) single chain proteins containing only one light chain variable domain, or a fragment thereof that contains the three CDRs of the light chain variable domain, without an associated heavy chain moiety; and (3) single chain proteins containing only one heavy chain variable region, or a fragment thereof containing the three CDRs of the heavy chain variable region, without an associated light chain moiety.
"Single-chain Fv", also abbreviated as "sFv" or "scFv", refers to antibody fragments that comprise the VH and VL antibody domains connected into a single amino acid chain.
Preferably, the scFv amino acid sequence further comprises a flexible peptidic linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding (Pluckthun, 1994. "Antibodies from Escherichia coil". In Rosenberg &
Moore (Eds.), The pharmacology of monoclonal antibodies. Handbook of Experimental Pharmacology, 113:269-315. Springer: Berlin, Heidelberg). Flexible peptidic linkers are generally composed of small, non-polar (e.g., glycine, Gly, G) or polar (e.g., serine, Ser, S; or threonine, Thr, T) amino acids, as suggested by Argos (1990. J Mol Biol.
211(4):943-958). The small size of these amino acids provides flexibility, and allows for mobility of the connecting functional domains, such as the VH and VL domains.
In one embodiment, the flexible peptidic linker may be a short oligo- or polypeptide, preferably having a length ranging from 2 to 30 amino acids. In one embodiment, the flexible peptidic linker comprises glycine-serine repeats. In one embodiment, the flexible peptidic linker comprises one, or several repeats of, such as 2, 3, 4, 5 or more repeats of, GS
linker(s) (i.e., a sequence of one Gly and one Ser), G25 linker(s) (i.e., a sequence of two Gly and one Ser), G35 linker(s) (i.e., a sequence of three Gly and one Ser), G45 linker(s)
28 (i.e., a sequence of four Gly and one Ser), or G5S linker(s) (i.e., a sequence of five Gly and one Ser).
"Subject" refers to a mammal, preferably a human. In one embodiment, a subject may be a "patient", i.e., a warm-blooded animal, more preferably a human, who/which is awaiting the receipt of, or is receiving medical care or was/is/will be the object of a medical procedure, or is monitored for the development of a disease. The term "mammal"
refers here to any mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc.
Preferably, the mammal is a primate, more preferably a human.
"Therapeutically effective amount" refers to the level or amount of an antibody as described herein that is aimed at, without causing significant negative or adverse side effects to the target, (1) delaying or preventing the onset of a disease, disorder, or condition; (2) slowing down or stopping the progression, aggravation, or deterioration of one or more symptoms of the disease, disorder, or condition; (3) bringing about ameliorations of the symptoms of the disease, disorder, or condition; (4) reducing the severity or incidence of the disease, disorder, or condition; or (5) curing the disease, disorder, or condition. A therapeutically effective amount may be administered prior to the onset of the disease, disorder, or condition, for a prophylactic or preventive action.
Alternatively or additionally, the therapeutically effective amount may be administered after initiation of the disease, disorder, or condition, for a therapeutic action.
"Transfected" or "transformed" or "transduced" as used herein refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell.
A
"transfected" or "transformed" or "transduced" cell is one which has been transfected, transformed or transduced with exogenous nucleic acid.
"Transmembrane domain" or "TMD", when used in a relationship with a chimeric antigen receptor (CAR), refers to the region of the CAR which crosses the plasma membrane. The transmembrane domain of the CAR of the invention is the transmembrane region of a transmembrane protein (for example Type I
transmembrane proteins), an artificial hydrophobic sequence or a combination thereof Other
"Subject" refers to a mammal, preferably a human. In one embodiment, a subject may be a "patient", i.e., a warm-blooded animal, more preferably a human, who/which is awaiting the receipt of, or is receiving medical care or was/is/will be the object of a medical procedure, or is monitored for the development of a disease. The term "mammal"
refers here to any mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc.
Preferably, the mammal is a primate, more preferably a human.
"Therapeutically effective amount" refers to the level or amount of an antibody as described herein that is aimed at, without causing significant negative or adverse side effects to the target, (1) delaying or preventing the onset of a disease, disorder, or condition; (2) slowing down or stopping the progression, aggravation, or deterioration of one or more symptoms of the disease, disorder, or condition; (3) bringing about ameliorations of the symptoms of the disease, disorder, or condition; (4) reducing the severity or incidence of the disease, disorder, or condition; or (5) curing the disease, disorder, or condition. A therapeutically effective amount may be administered prior to the onset of the disease, disorder, or condition, for a prophylactic or preventive action.
Alternatively or additionally, the therapeutically effective amount may be administered after initiation of the disease, disorder, or condition, for a therapeutic action.
"Transfected" or "transformed" or "transduced" as used herein refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell.
A
"transfected" or "transformed" or "transduced" cell is one which has been transfected, transformed or transduced with exogenous nucleic acid.
"Transmembrane domain" or "TMD", when used in a relationship with a chimeric antigen receptor (CAR), refers to the region of the CAR which crosses the plasma membrane. The transmembrane domain of the CAR of the invention is the transmembrane region of a transmembrane protein (for example Type I
transmembrane proteins), an artificial hydrophobic sequence or a combination thereof Other
29 transmembrane domains are apparent to those of skill in the art and may be used in connection with alternate embodiments of the invention.
"Treating" or "treatment" or "alleviation" refers to both therapeutic treatment and prophylactic or preventative measures; wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented. A subject or mammal is successfully "treated" for a cancer or an infection if, after receiving a therapeutic amount of an antibody according to the methods of the present invention, the patient shows observable and/or measurable reduction in or absence of one or more of the following: reduction in the number of cancer cells (or tumor size), or pathogenic cells; reduction in the percent of total cells that are cancerous or pathogenic; and/or relief to some extent, one or more of the symptoms associated with the specific disease or condition; reduced morbidity and mortality, and improvement in quality of life issues. The above parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician.
"Unibodies" are well known in the art and refer to an antibody fragment lacking the hinge region of IgG4 antibodies. The deletion of the hinge region results in a molecule that is essentially half the size of traditional IgG4 antibodies and has a univalent binding region rather than the bivalent biding region of IgG4 antibodies.
"Variable" refers to the fact that certain regions of the variable domains \Tx and VL differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its target antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called "hypervariable loops" in each of the VL domain and the \Tx domain which form part of the antigen binding site. The first, second and third hypervariable loops of the Vk light chain domain are referred to herein as Li (k), L2 (k) and L3 (k) and may be defined as comprising residues 24-33 (Li(), consisting of 9, 10 or 11 amino acid residues), 49-53 L2 (k), consisting of 3 residues) and 90-96 (L3(k), consisting of 6 residues) in the VL domain (Morea et al., 2000. Methods. 20(3):267-79). The first, second and third hypervariable loops of the Vic light chain domain are referred to herein as Ll(x), L2(x) and L3(x) and may be defined as comprising residues 25-33 (L1(x), consisting of 6, 7, 8, 11, 12 or 13 residues), 49-53 (L2(x), consisting of 3 residues) and 90-97 (L3(x), consisting of 6 residues) in the VL domain (Morea et al., 2000.
Methods.
5 20(3):267-79). The first, second and third hypervariable loops of the VH
domain are referred to herein as H1, H2 and H3 and may be defined as comprising residues (H1, consisting of 7, 8 or 9 residues), 52-56 (H2, consisting of 3 or 4 residues) and 91-105 (H3, highly variable in length) in the VH domain (Morea et al., 2000.
Methods.
20(3):267-79). Unless otherwise indicated, the terms Li, L2 and L3 respectively refer to 10 the first, second and third hypervariable loops of a VL domain, and encompass hypervariable loops obtained from both Vic and Vk isotypes. The terms H1, H2 and H3 respectively refer to the first, second and third hypervariable loops of the VH domain, and encompass hypervariable loops obtained from any of the known heavy chain isotypes, including gamma (y), mu ( ), alpha (a), delta (6) or epsilon (6). The hypervariable loops 15 Li, L2, L3, H1, H2 and H3 may each comprise part of a "complementarity determining region" or "CDR", as defined hereinabove.
"Vector" is used to refer to a carrier nucleic acid molecule into which a nucleic acid sequence can be inserted, for introduction into a cell where it can be replicated. A nucleic acid sequence can be "exogenous", which means that it is foreign to the cell into which 20 the vector is being introduced or that the sequence is homologous to a sequence in the cell but in a position within the host cell nucleic acid in which the sequence is ordinarily not found. Vectors include plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs). One skilled in the art would be well equipped to construct a vector through standard recombinant techniques (see, e.g., 25 Maniatis et al., 1988 and Ausubel et al, 1994).
In one embodiment, the vector can be an "expression vector". This term refers to any type of genetic construct comprising a nucleic acid coding for an RNA capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. In other cases, these sequences are not translated, e.g., in the production of
"Treating" or "treatment" or "alleviation" refers to both therapeutic treatment and prophylactic or preventative measures; wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented. A subject or mammal is successfully "treated" for a cancer or an infection if, after receiving a therapeutic amount of an antibody according to the methods of the present invention, the patient shows observable and/or measurable reduction in or absence of one or more of the following: reduction in the number of cancer cells (or tumor size), or pathogenic cells; reduction in the percent of total cells that are cancerous or pathogenic; and/or relief to some extent, one or more of the symptoms associated with the specific disease or condition; reduced morbidity and mortality, and improvement in quality of life issues. The above parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician.
"Unibodies" are well known in the art and refer to an antibody fragment lacking the hinge region of IgG4 antibodies. The deletion of the hinge region results in a molecule that is essentially half the size of traditional IgG4 antibodies and has a univalent binding region rather than the bivalent biding region of IgG4 antibodies.
"Variable" refers to the fact that certain regions of the variable domains \Tx and VL differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its target antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called "hypervariable loops" in each of the VL domain and the \Tx domain which form part of the antigen binding site. The first, second and third hypervariable loops of the Vk light chain domain are referred to herein as Li (k), L2 (k) and L3 (k) and may be defined as comprising residues 24-33 (Li(), consisting of 9, 10 or 11 amino acid residues), 49-53 L2 (k), consisting of 3 residues) and 90-96 (L3(k), consisting of 6 residues) in the VL domain (Morea et al., 2000. Methods. 20(3):267-79). The first, second and third hypervariable loops of the Vic light chain domain are referred to herein as Ll(x), L2(x) and L3(x) and may be defined as comprising residues 25-33 (L1(x), consisting of 6, 7, 8, 11, 12 or 13 residues), 49-53 (L2(x), consisting of 3 residues) and 90-97 (L3(x), consisting of 6 residues) in the VL domain (Morea et al., 2000.
Methods.
5 20(3):267-79). The first, second and third hypervariable loops of the VH
domain are referred to herein as H1, H2 and H3 and may be defined as comprising residues (H1, consisting of 7, 8 or 9 residues), 52-56 (H2, consisting of 3 or 4 residues) and 91-105 (H3, highly variable in length) in the VH domain (Morea et al., 2000.
Methods.
20(3):267-79). Unless otherwise indicated, the terms Li, L2 and L3 respectively refer to 10 the first, second and third hypervariable loops of a VL domain, and encompass hypervariable loops obtained from both Vic and Vk isotypes. The terms H1, H2 and H3 respectively refer to the first, second and third hypervariable loops of the VH domain, and encompass hypervariable loops obtained from any of the known heavy chain isotypes, including gamma (y), mu ( ), alpha (a), delta (6) or epsilon (6). The hypervariable loops 15 Li, L2, L3, H1, H2 and H3 may each comprise part of a "complementarity determining region" or "CDR", as defined hereinabove.
"Vector" is used to refer to a carrier nucleic acid molecule into which a nucleic acid sequence can be inserted, for introduction into a cell where it can be replicated. A nucleic acid sequence can be "exogenous", which means that it is foreign to the cell into which 20 the vector is being introduced or that the sequence is homologous to a sequence in the cell but in a position within the host cell nucleic acid in which the sequence is ordinarily not found. Vectors include plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs). One skilled in the art would be well equipped to construct a vector through standard recombinant techniques (see, e.g., 25 Maniatis et al., 1988 and Ausubel et al, 1994).
In one embodiment, the vector can be an "expression vector". This term refers to any type of genetic construct comprising a nucleic acid coding for an RNA capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. In other cases, these sequences are not translated, e.g., in the production of
30 antisense molecules or ribozymes. Expression vectors can contain a variety of control sequences, which refer to nucleic acid sequences necessary for the transcription and
31 possibly translation of an operably linked coding sequence in a particular host cell. In addition to control sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well and are described herein. In particular, expression vectors can contain one or several promoter(s), enhancer(s), internal ribosome entry site(s) (TRES), multiple cloning site(s) (MCS), splicing site(s), termination signal(s), origin(s) of replication, and/or selectable marker(s).
The vector may be a "plasmid vector". In general, plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell are used in connection with these hosts. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells. In a non-limiting example, E. colt is often transformed using derivatives of pBR322, a plasmid derived from an E. colt species. pBR322 contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR plasmid, or other microbial plasmid or phage must also contain, or be modified to contain, for example, promoters which can be used by the microbial organism for expression of its own proteins.
In addition, phage vectors containing replicon and control sequences that are compatible with the host microorganism can be used as transforming vectors in connection with these hosts. For example, the phage lambda GEMTm 11 may be utilized in making a recombinant phage vector which can be used to transform host cells, such as, for example, E. colt LE392.
Further useful plasmid vectors include pIN vectors (Inouye et al., 1985); and pGEX
vectors, for use in generating glutathione S transferase (GST) soluble fusion proteins for later purification and separation or cleavage. Other suitable fusion proteins are those with galactosidase, ubiquitin, and the like.
Bacterial host cells, for example, E. colt, comprising the expression vector, are grown in any of a number of suitable media, for example, LB. The expression of the recombinant protein in certain vectors may be induced, as would be understood by those of skill in the art, by contacting a host cell with an agent specific for certain promoters, e.g., by adding IPTG to the media or by switching incubation to a higher temperature. After culturing the
The vector may be a "plasmid vector". In general, plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell are used in connection with these hosts. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells. In a non-limiting example, E. colt is often transformed using derivatives of pBR322, a plasmid derived from an E. colt species. pBR322 contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR plasmid, or other microbial plasmid or phage must also contain, or be modified to contain, for example, promoters which can be used by the microbial organism for expression of its own proteins.
In addition, phage vectors containing replicon and control sequences that are compatible with the host microorganism can be used as transforming vectors in connection with these hosts. For example, the phage lambda GEMTm 11 may be utilized in making a recombinant phage vector which can be used to transform host cells, such as, for example, E. colt LE392.
Further useful plasmid vectors include pIN vectors (Inouye et al., 1985); and pGEX
vectors, for use in generating glutathione S transferase (GST) soluble fusion proteins for later purification and separation or cleavage. Other suitable fusion proteins are those with galactosidase, ubiquitin, and the like.
Bacterial host cells, for example, E. colt, comprising the expression vector, are grown in any of a number of suitable media, for example, LB. The expression of the recombinant protein in certain vectors may be induced, as would be understood by those of skill in the art, by contacting a host cell with an agent specific for certain promoters, e.g., by adding IPTG to the media or by switching incubation to a higher temperature. After culturing the
32 bacteria for a further period, generally of between 2 and 24 hours, the cells are collected by centrifugation and washed to remove residual media.
The vector may be a "viral vector". The ability of certain viruses to infect cells or enter cells via receptor mediated endocytosis, and to integrate into host cell genome and express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign nucleic acids into cells (e.g., mammalian cells).
In one embodiment, the viral vector may be an adenoviral vector. Although adenoviral vectors are known to have a low capacity for integration into genomic DNA, this feature is counterbalanced by the high efficiency of gene transfer afforded by these vectors.
In one embodiment, the viral vector may be an adeno-associated viral (AAV) vector.
Increased transfection efficiencies have been reported in cell systems using adenovirus coupled systems (Kelleher & Vos, 1994. Biotechniques. 17(6)1110-7; Cotten et al., 1992. Proc Natl Acad Sci USA. 89(13):6094-8; Curiel, 1994. Nat Immun. 13(2-3):141-64). AAV is an attractive vector system as it has a high frequency of integration and it can infect non-dividing cells, thus making it useful for delivery of genes into mammalian cells, for example, in tissue culture (Muzyczka, 1992) or in vivo. AAV has a broad host range for infectivity (Tratschin et al., 1984; Laughlin et al, 1986; Lebkowski et al, 1988;
McLaughlin et al., 1988). Details concerning the generation and use of rAAV
vectors are described in US patents 5,139,941 and 4,797,368.
In one embodiment, the viral vector may be a retroviral vector. Retroviruses are useful as delivery vectors because of their ability to integrate their genes into the host genome, transferring a large amount of foreign genetic material, infecting a broad spectrum of species and cell types and of being packaged in special cell lines. In order to construct a retroviral vector, a nucleic acid (e.g., one encoding the desired sequence) is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication defective. In order to produce virions, a packaging cell line containing the gag, pol, and env genes but without the LTR and packaging components is constructed. When a recombinant plasmid containing a cDNA, together with the retroviral LTR and packaging sequences is introduced into a special cell line (e.g., by calcium phosphate precipitation), the packaging sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media.
The media containing the recombinant retroviruses is then collected, optionally
The vector may be a "viral vector". The ability of certain viruses to infect cells or enter cells via receptor mediated endocytosis, and to integrate into host cell genome and express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign nucleic acids into cells (e.g., mammalian cells).
In one embodiment, the viral vector may be an adenoviral vector. Although adenoviral vectors are known to have a low capacity for integration into genomic DNA, this feature is counterbalanced by the high efficiency of gene transfer afforded by these vectors.
In one embodiment, the viral vector may be an adeno-associated viral (AAV) vector.
Increased transfection efficiencies have been reported in cell systems using adenovirus coupled systems (Kelleher & Vos, 1994. Biotechniques. 17(6)1110-7; Cotten et al., 1992. Proc Natl Acad Sci USA. 89(13):6094-8; Curiel, 1994. Nat Immun. 13(2-3):141-64). AAV is an attractive vector system as it has a high frequency of integration and it can infect non-dividing cells, thus making it useful for delivery of genes into mammalian cells, for example, in tissue culture (Muzyczka, 1992) or in vivo. AAV has a broad host range for infectivity (Tratschin et al., 1984; Laughlin et al, 1986; Lebkowski et al, 1988;
McLaughlin et al., 1988). Details concerning the generation and use of rAAV
vectors are described in US patents 5,139,941 and 4,797,368.
In one embodiment, the viral vector may be a retroviral vector. Retroviruses are useful as delivery vectors because of their ability to integrate their genes into the host genome, transferring a large amount of foreign genetic material, infecting a broad spectrum of species and cell types and of being packaged in special cell lines. In order to construct a retroviral vector, a nucleic acid (e.g., one encoding the desired sequence) is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication defective. In order to produce virions, a packaging cell line containing the gag, pol, and env genes but without the LTR and packaging components is constructed. When a recombinant plasmid containing a cDNA, together with the retroviral LTR and packaging sequences is introduced into a special cell line (e.g., by calcium phosphate precipitation), the packaging sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media.
The media containing the recombinant retroviruses is then collected, optionally
33 concentrated, and used for gene transfer. Retroviral vectors are able to infect a broad variety of cell types. However, integration and stable expression require the division of host cells. Lentiviruses are complex retroviruses, which, in addition to the common retroviral genes gag, poi, and env, contain other genes with regulatory or structural function. Lentiviral vectors are well known in the art (see, e.g., US patents 6,013,516 and 5,994,136). Some examples of lentivirus include the human immunodeficiency viruses HIV-1 and HIV-2, and the simian immunodeficiency virus SW. Lentiviral vectors have been generated by attenuating the HIV virulence genes, for example, the genes env, vif, vpr, vpu and nef are deleted making the vector biologically safe. Recombinant lentiviral vectors are capable of infecting non-dividing cells and can be used for both in vivo and ex vivo gene transfer and expression of nucleic acid sequences. For example, recombinant lentivirus capable of infecting a non-dividing cell wherein a suitable host cell is transfected with two or more vectors carrying the packaging functions, namely gag, pol and env, as well as rev and tat is described in US patent 5,994,136. One may target the recombinant virus by linkage of the envelope protein with an antibody or a particular ligand for targeting to a receptor of a particular cell-type. By inserting a sequence (including a regulatory region) of interest into the viral vector, along with another gene which encodes the ligand for a receptor on a specific target cell, for example, the vector is now target-specific.
Other viral vectors may also be employed in the present invention. Vectors derived from viruses such as vaccinia virus, sindbis virus, cytomegalovirus and herpes simplex virus may be employed. They offer several attractive features for various mammalian cells.
"Versabodies" are well known in the art and refer to another antibody mimetic technology. They are small proteins of 3-5 kDa with >15% cysteines, which form a high disulfide density scaffold, replacing the hydrophobic core the typical proteins have. The replacement of a large number of hydrophobic amino acids, comprising the hydrophobic core, with a small number of disulfides results in a protein that is smaller, more hydrophilic (less aggregation and non-specific binding), more resistant to proteases and heat, and has a lower density of T cell epitopes, because the residues that contribute most to MHC presentation are hydrophobic. All four of these properties are well-known to
Other viral vectors may also be employed in the present invention. Vectors derived from viruses such as vaccinia virus, sindbis virus, cytomegalovirus and herpes simplex virus may be employed. They offer several attractive features for various mammalian cells.
"Versabodies" are well known in the art and refer to another antibody mimetic technology. They are small proteins of 3-5 kDa with >15% cysteines, which form a high disulfide density scaffold, replacing the hydrophobic core the typical proteins have. The replacement of a large number of hydrophobic amino acids, comprising the hydrophobic core, with a small number of disulfides results in a protein that is smaller, more hydrophilic (less aggregation and non-specific binding), more resistant to proteases and heat, and has a lower density of T cell epitopes, because the residues that contribute most to MHC presentation are hydrophobic. All four of these properties are well-known to
34 affect immunogenicity, and together they are expected to cause a large decrease in immunogenicity.
"Xenogeneic" refers to a graft derived from an animal of a different species.
DETAILED DESCRIPTION
A first object of the present invention is an antigen-binding domain directed to a senescent cell-associated antigen.
In one embodiment, the antigen-binding domain of the invention recognizes and is capable of binding to a senescent cell-associated antigen.
The presence of senescent cells can be determined by detection of senescent cell-associated molecules include growth factors, proteases, cytokines (e.g., inflammatory cytokines), chemokines, cell-related metabolites, reactive oxygen species (e.g., H202), and other molecules that stimulate inflammation and/or other biological effects or reactions that may promote or exacerbate the underlying disease of the subject.
Senescent cell-associated molecules include those that are described in the art as comprising the senescence-associated secretory phenotype (SASP, i.e., which includes secreted factors which may make up the pro-inflammatory phenotype of a senescent cell), senescent-messaging secretome, and DNA damage secretory program (DDSP). For example, the presence of senescent cells in tissues can be analyzed by histochemistry or immunohistochemistry techniques that detect the senescence marker, SA-beta gal (SA-Bgal) (see, for exemple, Dimri et al , 1995. Proc Natl Acad Sci USA.
92(20):9363-7).
Senescent cell-associated antigens include molecules that are overexpressed in senescent cells compared to their quiescent or non-senescent counterparts. Certain senescent cell-associated antigens are tissue specific while others are ubiquitously overexpressed in senescent cells. In particular embodiments of the immunogenic compositions described herein, a senescent cell-associated antigen is an antigen present on the cell surface of a senescent cell (e.g., receptor proteins, channel forming proteins, proteins that facilitate diffusion or active transport of molecules and ion across the membrane, cell recognition proteins, and enzymes). These antigens may be present on the cell surface of a cell exclusively or at a greater level on senescent cells compared with non-senescent cells and are therefore useful as immunogens for evoking a specific immune response.
Examples of senescent cell-associated antigens include polypeptides and proteins (including 5 glycoproteins), lipids, glycolipids, and carbohydrate molecules that contribute to or are markers of a senescence cell.
In one embodiment, the senescent cell according to the present invention expresses a senescent cell-associated antigen or a combination of senescent cell-associated antigens that are characteristic of senescence. Such senescent cell-associated antigens include, but 10 are not limited to, actin cytoplasmic 1 (ACTB), A disintegrin and metalloproteinase with thrombospondin motifs 7 (ADAMTS7), amyloid-like protein 2 (APLP2), armadillo repeat-containing X-linked protein 3 (ARMCX-3), ATP synthase subunit alpha mitochondrial (ATP5F1A), V-type proton ATPase subunit d 2 (ATP6V0D2), beta-2-microglobulin (B2MG), cholinesterase (BCHE), uncharacterized protein C 1 1 orf87 (C1 lorf87), 15 membrane cofactor protein (CD46), CD57, cyclin-dependent kinase inhibitor 2A
"p16INK4a" (CDKN2A), cathepsin B (CTSB), neuferricin (CYB5D2), dipeptidyl peptidase 4 "DPP4" (DPP4), electron transfer flavoprotein beta subunit lysine methyltransferase (ETFB), F-box/LRR-repeat protein 7 (FBXL 7), integral membrane protein GPR137B (GPR137B), interferon alpha-inducible protein 27-like protein 20 (IF127L1), interleukin-15 receptor subunit alpha (IL15RA), killer cell lectin-like receptor subfamily G member 1 (KLRG1), lysosome-associated membrane glycoprotein 2 (LAMP2), glutathione S-transferase LANCL1 (LANCL1), major vault protein (MVP), unconventional myosin-X (MY010), sialidase-1 (NEW), NETS-like protein 2 (NHSL2), neurogenic locus notch homolog protein 3 (NOTCH3), neuronal PAS domain-containing 25 protein 2 (NPAS2), olfactory receptor 1F1 (OR1F1), prolyl 4-hydroxylase beta subunit precursor (P4HB), protein disulfide isomerase (PD]), astrocytic phosphoprotein (PEA15), phospholipase D3 (PLD3), receptor-type tyrosine-protein phosphatase C
isoform RA "CD45RA" (PTPRC), receptor-type tyrosine-protein phosphatase eta "DEP1" (PTPRI), Ras-related protein Rab-23 (RAB23), retinoic acid receptor beta 30 (RARB), RNA-binding region-containing protein 3 (RNPC3), protein adenylyltransferase Sel0 mitochondrial (SELO), thioredoxin reductase-like selenoprotein T (SEL7), semaphorin-5B (SEMA5B), stress-associated endoplasmic reticulum protein 1 (SERPI), plasminogen activator inhibitor 1 (SERPINEI), sodium/hydrogen exchanger 7 (SLC9A 7), sorting nexin-3 (SNX3), syntaxin-4 (STX4), TBC1 domain family member 1 (TBCIDI), transforming growth factor beta regulator 1 (TBRGI), transcription elongation factor A
N-terminal and central domain-containing protein (TCEANC), tissue factor pathway inhibitor (TFP1), BTB/POZ domain-containing adapter for CUL3-mediated RhoA
degradation protein 2 (INFAIP1), tumor necrosis factor receptor superfamily member 10D "DCR2" (TNFRSFIOD), tubulin gamma-2 chain (TUBG2), Ubl carboxyl-terminal hydrolase 18 (USP 18), vesicle-associated membrane protein 3 (VAMP3), vacuolar protein sorting-associated protein 26A (VPS26A), and zinc finger protein 419 (ZNF4I9).
In one embodiment, the senescent cell-associated antigen is selected from the group comprising or consisting of DEP1 and DPP4.
In one embodiment, the senescent cell according to the present invention expresses the DEP1 and/or DPP4 antigen.
The presence of the senescent cell-associated antigens, in particular of DEP1 and/or DPP4, can be determined by any one of numerous immunochemistry methods practiced in the art, such as immunoblotting analysis.
In one embodiment, the senescent cell-associated antigen is DEP1, such as, e.g., human DEP1, or orthologs thereof, including murine and rat DEP1. In one embodiment, the senescent cell-associated antigen is human DEP1 (hDEP1) with SEQ ID NO: 1.
In one embodiment, the antigen-binding domain of the invention recognizes and is capable of binding to DEP1, such as, e.g., to human DEP1, or orthologs thereof, including murine and rat DEP1. Hence, the antigen-binding domain of the invention is a "DEP1-binding domain".
In one embodiment, the DEP1-binding domain of the invention recognizes and is capable of binding to human DEP1 (hDEP1) with SEQ ID NO: 1.
In one embodiment, the DEP1-binding domain of the invention recognizes and is capable of binding to the extracellular domain of human DEP1 (hDEP1) comprising or consisting of amino acid residues 36 ¨ 975 of SEQ ID NO: 1.
The binding between the DEP1-binding domain of the invention and DEP1 implies that said DEP1-binding domain exhibits appreciable affinity for DEP1. In other words, the DEP1-binding domain of the invention is specific for, or is immunospecific for, or specifically bind to, DEP1.
The affinity between the DEP1-binding domain of the invention and DEP1 can be determined by various methods well known from the one skilled in the art.
These methods include, but are not limited to, biosensor analysis (including, e.g., Biacore analysis), Blitz analysis and Scatchard plot.
Alternatively or additionally, whether the DEP1-binding domain of the invention binds to DEP1 can be tested readily by, inter alia, comparing the reaction of said DEP1-binding domain with DEP1 or a fragment thereof (in particular, a fragment comprising or consisting of an epitope of DEP1) with the reaction of said DEP1-binding domain with proteins or antigens other than DEP1 or a fragment thereof In one embodiment, the DEP1-binding domain of the invention recognizes and is capable of binding to DEP1 with a KD-affinity constant less than or equal to 10' M, preferably less than or equal to 10-7 M, 5.10-8 M, 10-8 M, 5.10-9 M, 10-9 M or less; as may be determined, e.g., by biosensor analysis, particularly by Biacore Analysis.
In one embodiment, the DEP1-binding domain of the invention comprises a heavy chain variable region (abbreviated herein as HCVR or VH) which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
V11-CDR1: any one of SEQ ID NO: 5 to 11;
V11-CDR2: any one of SEQ ID NO: 12 to 25;
V11-CDR3: any one of SEQ ID NO: 26 to 32.
SEQ ID SEQ ID
SEQUENCE SEQUENCE
NO NO
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 5;
5 VH-CDR2: SEQ ID NO: 12;
VH-CDR3: SEQ ID NO: 26.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
10 VH-CDR1: SEQ ID NO: 6;
VH-CDR2: SEQ ID NO: 13;
VH-CDR3: SEQ ID NO: 27.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 7;
VH-CDR2: SEQ ID NO: 14;
VH-CDR3: SEQ ID NO: 28.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 5;
VH-CDR2: SEQ ID NO: 12;
VH-CDR3: SEQ ID NO: 29.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 6;
VH-CDR2: SEQ ID NO: 15;
VH-CDR3: SEQ ID NO: 27.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 5;
VH-CDR2: SEQ ID NO: 16;
VH-CDR3: SEQ ID NO: 26.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 8;
VH-CDR2: SEQ ID NO: 16;
VH-CDR3: SEQ ID NO: 26.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
5 VH-CDR1: SEQ ID NO: 5;
VH-CDR2: SEQ ID NO: 16;
VH-CDR3: SEQ ID NO: 26.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three 10 complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 8;
VH-CDR2: SEQ ID NO: 17;
VH-CDR3: SEQ ID NO: 26.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which 15 .. comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 9;
VH-CDR2: SEQ ID NO: 18;
VH-CDR3: SEQ ID NO: 28.
20 .. In one embodiment, the DEP1-binding domain of the invention comprises a HCVR which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 10;
VH-CDR2: SEQ ID NO: 19;
25 VH-CDR3: SEQ ID NO: 30.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 11;
V11-CDR2: SEQ ID NO: 20;
SEQ ID NO: 31.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
V11-CDR1: SEQ ID NO: 10;
V11-CDR2: SEQ ID NO: 21;
V11-CDR3: SEQ ID NO: 30.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which .. comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
V11-CDR1: SEQ ID NO: 11;
V11-CDR2: SEQ ID NO: 22;
V11-CDR3: SEQ ID NO: 31.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
V11-CDR1: SEQ ID NO: 11;
V11-CDR2: SEQ ID NO: 23;
V11-CDR3: SEQ ID NO: 31.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
V11-CDR1: SEQ ID NO: 11;
V11-CDR2: SEQ ID NO: 24;
SEQ ID NO: 31.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 11;
VH-CDR2: SEQ ID NO: 25;
VH-CDR3: SEQ ID NO: 32.
In one embodiment, the DEP1-binding domain of the invention comprises a light chain variable region (abbreviated herein as LCVR or VI) which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: any one of SEQ ID NO: 33 to 39;
VL-CDR2: any one of SEQ ID NO: 40 to 46;
VL-CDR3: any one of SEQ ID NO: 47 to 54.
SEQ ID NO SEQUENCE SEQ ID NO SEQUENCE
"Xenogeneic" refers to a graft derived from an animal of a different species.
DETAILED DESCRIPTION
A first object of the present invention is an antigen-binding domain directed to a senescent cell-associated antigen.
In one embodiment, the antigen-binding domain of the invention recognizes and is capable of binding to a senescent cell-associated antigen.
The presence of senescent cells can be determined by detection of senescent cell-associated molecules include growth factors, proteases, cytokines (e.g., inflammatory cytokines), chemokines, cell-related metabolites, reactive oxygen species (e.g., H202), and other molecules that stimulate inflammation and/or other biological effects or reactions that may promote or exacerbate the underlying disease of the subject.
Senescent cell-associated molecules include those that are described in the art as comprising the senescence-associated secretory phenotype (SASP, i.e., which includes secreted factors which may make up the pro-inflammatory phenotype of a senescent cell), senescent-messaging secretome, and DNA damage secretory program (DDSP). For example, the presence of senescent cells in tissues can be analyzed by histochemistry or immunohistochemistry techniques that detect the senescence marker, SA-beta gal (SA-Bgal) (see, for exemple, Dimri et al , 1995. Proc Natl Acad Sci USA.
92(20):9363-7).
Senescent cell-associated antigens include molecules that are overexpressed in senescent cells compared to their quiescent or non-senescent counterparts. Certain senescent cell-associated antigens are tissue specific while others are ubiquitously overexpressed in senescent cells. In particular embodiments of the immunogenic compositions described herein, a senescent cell-associated antigen is an antigen present on the cell surface of a senescent cell (e.g., receptor proteins, channel forming proteins, proteins that facilitate diffusion or active transport of molecules and ion across the membrane, cell recognition proteins, and enzymes). These antigens may be present on the cell surface of a cell exclusively or at a greater level on senescent cells compared with non-senescent cells and are therefore useful as immunogens for evoking a specific immune response.
Examples of senescent cell-associated antigens include polypeptides and proteins (including 5 glycoproteins), lipids, glycolipids, and carbohydrate molecules that contribute to or are markers of a senescence cell.
In one embodiment, the senescent cell according to the present invention expresses a senescent cell-associated antigen or a combination of senescent cell-associated antigens that are characteristic of senescence. Such senescent cell-associated antigens include, but 10 are not limited to, actin cytoplasmic 1 (ACTB), A disintegrin and metalloproteinase with thrombospondin motifs 7 (ADAMTS7), amyloid-like protein 2 (APLP2), armadillo repeat-containing X-linked protein 3 (ARMCX-3), ATP synthase subunit alpha mitochondrial (ATP5F1A), V-type proton ATPase subunit d 2 (ATP6V0D2), beta-2-microglobulin (B2MG), cholinesterase (BCHE), uncharacterized protein C 1 1 orf87 (C1 lorf87), 15 membrane cofactor protein (CD46), CD57, cyclin-dependent kinase inhibitor 2A
"p16INK4a" (CDKN2A), cathepsin B (CTSB), neuferricin (CYB5D2), dipeptidyl peptidase 4 "DPP4" (DPP4), electron transfer flavoprotein beta subunit lysine methyltransferase (ETFB), F-box/LRR-repeat protein 7 (FBXL 7), integral membrane protein GPR137B (GPR137B), interferon alpha-inducible protein 27-like protein 20 (IF127L1), interleukin-15 receptor subunit alpha (IL15RA), killer cell lectin-like receptor subfamily G member 1 (KLRG1), lysosome-associated membrane glycoprotein 2 (LAMP2), glutathione S-transferase LANCL1 (LANCL1), major vault protein (MVP), unconventional myosin-X (MY010), sialidase-1 (NEW), NETS-like protein 2 (NHSL2), neurogenic locus notch homolog protein 3 (NOTCH3), neuronal PAS domain-containing 25 protein 2 (NPAS2), olfactory receptor 1F1 (OR1F1), prolyl 4-hydroxylase beta subunit precursor (P4HB), protein disulfide isomerase (PD]), astrocytic phosphoprotein (PEA15), phospholipase D3 (PLD3), receptor-type tyrosine-protein phosphatase C
isoform RA "CD45RA" (PTPRC), receptor-type tyrosine-protein phosphatase eta "DEP1" (PTPRI), Ras-related protein Rab-23 (RAB23), retinoic acid receptor beta 30 (RARB), RNA-binding region-containing protein 3 (RNPC3), protein adenylyltransferase Sel0 mitochondrial (SELO), thioredoxin reductase-like selenoprotein T (SEL7), semaphorin-5B (SEMA5B), stress-associated endoplasmic reticulum protein 1 (SERPI), plasminogen activator inhibitor 1 (SERPINEI), sodium/hydrogen exchanger 7 (SLC9A 7), sorting nexin-3 (SNX3), syntaxin-4 (STX4), TBC1 domain family member 1 (TBCIDI), transforming growth factor beta regulator 1 (TBRGI), transcription elongation factor A
N-terminal and central domain-containing protein (TCEANC), tissue factor pathway inhibitor (TFP1), BTB/POZ domain-containing adapter for CUL3-mediated RhoA
degradation protein 2 (INFAIP1), tumor necrosis factor receptor superfamily member 10D "DCR2" (TNFRSFIOD), tubulin gamma-2 chain (TUBG2), Ubl carboxyl-terminal hydrolase 18 (USP 18), vesicle-associated membrane protein 3 (VAMP3), vacuolar protein sorting-associated protein 26A (VPS26A), and zinc finger protein 419 (ZNF4I9).
In one embodiment, the senescent cell-associated antigen is selected from the group comprising or consisting of DEP1 and DPP4.
In one embodiment, the senescent cell according to the present invention expresses the DEP1 and/or DPP4 antigen.
The presence of the senescent cell-associated antigens, in particular of DEP1 and/or DPP4, can be determined by any one of numerous immunochemistry methods practiced in the art, such as immunoblotting analysis.
In one embodiment, the senescent cell-associated antigen is DEP1, such as, e.g., human DEP1, or orthologs thereof, including murine and rat DEP1. In one embodiment, the senescent cell-associated antigen is human DEP1 (hDEP1) with SEQ ID NO: 1.
In one embodiment, the antigen-binding domain of the invention recognizes and is capable of binding to DEP1, such as, e.g., to human DEP1, or orthologs thereof, including murine and rat DEP1. Hence, the antigen-binding domain of the invention is a "DEP1-binding domain".
In one embodiment, the DEP1-binding domain of the invention recognizes and is capable of binding to human DEP1 (hDEP1) with SEQ ID NO: 1.
In one embodiment, the DEP1-binding domain of the invention recognizes and is capable of binding to the extracellular domain of human DEP1 (hDEP1) comprising or consisting of amino acid residues 36 ¨ 975 of SEQ ID NO: 1.
The binding between the DEP1-binding domain of the invention and DEP1 implies that said DEP1-binding domain exhibits appreciable affinity for DEP1. In other words, the DEP1-binding domain of the invention is specific for, or is immunospecific for, or specifically bind to, DEP1.
The affinity between the DEP1-binding domain of the invention and DEP1 can be determined by various methods well known from the one skilled in the art.
These methods include, but are not limited to, biosensor analysis (including, e.g., Biacore analysis), Blitz analysis and Scatchard plot.
Alternatively or additionally, whether the DEP1-binding domain of the invention binds to DEP1 can be tested readily by, inter alia, comparing the reaction of said DEP1-binding domain with DEP1 or a fragment thereof (in particular, a fragment comprising or consisting of an epitope of DEP1) with the reaction of said DEP1-binding domain with proteins or antigens other than DEP1 or a fragment thereof In one embodiment, the DEP1-binding domain of the invention recognizes and is capable of binding to DEP1 with a KD-affinity constant less than or equal to 10' M, preferably less than or equal to 10-7 M, 5.10-8 M, 10-8 M, 5.10-9 M, 10-9 M or less; as may be determined, e.g., by biosensor analysis, particularly by Biacore Analysis.
In one embodiment, the DEP1-binding domain of the invention comprises a heavy chain variable region (abbreviated herein as HCVR or VH) which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
V11-CDR1: any one of SEQ ID NO: 5 to 11;
V11-CDR2: any one of SEQ ID NO: 12 to 25;
V11-CDR3: any one of SEQ ID NO: 26 to 32.
SEQ ID SEQ ID
SEQUENCE SEQUENCE
NO NO
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 5;
5 VH-CDR2: SEQ ID NO: 12;
VH-CDR3: SEQ ID NO: 26.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
10 VH-CDR1: SEQ ID NO: 6;
VH-CDR2: SEQ ID NO: 13;
VH-CDR3: SEQ ID NO: 27.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 7;
VH-CDR2: SEQ ID NO: 14;
VH-CDR3: SEQ ID NO: 28.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 5;
VH-CDR2: SEQ ID NO: 12;
VH-CDR3: SEQ ID NO: 29.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 6;
VH-CDR2: SEQ ID NO: 15;
VH-CDR3: SEQ ID NO: 27.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 5;
VH-CDR2: SEQ ID NO: 16;
VH-CDR3: SEQ ID NO: 26.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 8;
VH-CDR2: SEQ ID NO: 16;
VH-CDR3: SEQ ID NO: 26.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
5 VH-CDR1: SEQ ID NO: 5;
VH-CDR2: SEQ ID NO: 16;
VH-CDR3: SEQ ID NO: 26.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three 10 complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 8;
VH-CDR2: SEQ ID NO: 17;
VH-CDR3: SEQ ID NO: 26.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which 15 .. comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 9;
VH-CDR2: SEQ ID NO: 18;
VH-CDR3: SEQ ID NO: 28.
20 .. In one embodiment, the DEP1-binding domain of the invention comprises a HCVR which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 10;
VH-CDR2: SEQ ID NO: 19;
25 VH-CDR3: SEQ ID NO: 30.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 11;
V11-CDR2: SEQ ID NO: 20;
SEQ ID NO: 31.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
V11-CDR1: SEQ ID NO: 10;
V11-CDR2: SEQ ID NO: 21;
V11-CDR3: SEQ ID NO: 30.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which .. comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
V11-CDR1: SEQ ID NO: 11;
V11-CDR2: SEQ ID NO: 22;
V11-CDR3: SEQ ID NO: 31.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
V11-CDR1: SEQ ID NO: 11;
V11-CDR2: SEQ ID NO: 23;
V11-CDR3: SEQ ID NO: 31.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
V11-CDR1: SEQ ID NO: 11;
V11-CDR2: SEQ ID NO: 24;
SEQ ID NO: 31.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 11;
VH-CDR2: SEQ ID NO: 25;
VH-CDR3: SEQ ID NO: 32.
In one embodiment, the DEP1-binding domain of the invention comprises a light chain variable region (abbreviated herein as LCVR or VI) which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: any one of SEQ ID NO: 33 to 39;
VL-CDR2: any one of SEQ ID NO: 40 to 46;
VL-CDR3: any one of SEQ ID NO: 47 to 54.
SEQ ID NO SEQUENCE SEQ ID NO SEQUENCE
35 QASQDIGNNLI 46 YANPLHD
36 RSSQSLKHSDGKTYLN 47 LQYDEFPPT
37 QASQDIGNWLA 48 CQGSYSPYT
38 LASEGISNYLA 49 LQYDEWPYT
39 LASEDIYSYLA 50 LQYDEYPPT
40 RATNLAD 51 QQTSSTPWT
41 QVSKLDS 52 QQGYKFPYT
42 YATNLAN 53 QQASSAPWT
43 RATTLAD 54 QQGYKFPYS
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 33;
VL-CDR2: SEQ ID NO: 40;
VL-CDR3: SEQ ID NO: 47.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 34;
VL-CDR2: SEQ ID NO: 41;
VL-CDR3: SEQ ID NO: 48.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 35;
VL-CDR2: SEQ ID NO: 42;
VL-CDR3: SEQ ID NO: 47.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 33;
VL-CDR2: SEQ ID NO: 40;
VL-CDR3: SEQ ID NO: 49.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 36;
VL-CDR2: SEQ ID NO: 41;
VL-CDR3: SEQ ID NO: 48.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 33;
VL-CDR2: SEQ ID NO: 40;
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 33;
VL-CDR2: SEQ ID NO: 40;
VL-CDR3: SEQ ID NO: 47.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 34;
VL-CDR2: SEQ ID NO: 41;
VL-CDR3: SEQ ID NO: 48.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 35;
VL-CDR2: SEQ ID NO: 42;
VL-CDR3: SEQ ID NO: 47.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 33;
VL-CDR2: SEQ ID NO: 40;
VL-CDR3: SEQ ID NO: 49.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 36;
VL-CDR2: SEQ ID NO: 41;
VL-CDR3: SEQ ID NO: 48.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 33;
VL-CDR2: SEQ ID NO: 40;
44 VL-CDR3: SEQ ID NO: 50.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 33;
VL-CDR2: SEQ ID NO: 43;
VL-CDR3: SEQ ID NO: 50.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 37;
VL-CDR2: SEQ ID NO: 44;
VL-CDR3: SEQ ID NO: 51.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 38;
VL-CDR2: SEQ ID NO: 45;
VL-CDR3: SEQ ID NO: 52.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 37;
VL-CDR2: SEQ ID NO: 44;
VL-CDR3: SEQ ID NO: 53.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 38;
VL-CDR2: SEQ ID NO: 45;
VL-CDR3: SEQ ID NO: 54.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three 5 complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 39;
VL-CDR2: SEQ ID NO: 45;
VL-CDR3: SEQ ID NO: 52.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which 10 comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 38;
VL-CDR2: SEQ ID NO: 46;
VL-CDR3: SEQ ID NO: 52.
15 In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 1.
In one embodiment, the DEP1-binding domain of the invention comprises a combination 20 of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 1.
TABLE 1. Preferred combinations of HCVR's and LCVR's CDRs. The CDRs are defined by their SEQ ID NOs. First column indicates the clone's name.
Vll- Vii- Vll- VL- VL- VL-Clone's name In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-13-R2A-C1, 5738-13-D3, 5738-13-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R3A-C6, 5738-10-D5, 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R4A-G12, 5738-D11, and 5738-13-R2A-H4.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of .. any one of the following clones as defined in Table 1: 5738-13-R4A-D11, and R2A-H4.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-C1 as defined in Table 1. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-D3 as defined in Table 1. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R4A-D11 as defined in Table 1. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-F5 as defined in Table 1. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R4A-F11 as defined in Table 1. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-H3 as defined in Table 1. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-H4 as defined in Table 1. 5738-13-R4A-H9 as defined in Table 1. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R4A-H11 as defined in Table 1.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 55; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 55.
SEQ ID NO: 55 QVQLKQSGAELAKPGSSVKISCKASGYTFTSYYISWIKQTTGQGLEYIGYINTGS
GGTNYNEKFKGKATLTVDKS S STAFMQL S SLTPDDSAVYYCARYFDYWGQGV
MVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 56; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 56.
SEQ ID NO: 56 E VKLVES GGGLVQPKE SLKI SC AA S GF TF SNIAMYWVRQAPGKGLEWVAHIRT
KPHNF AT YYAN S VKGRF TISRDD SKNMVYLQMDNLKPEDTAMYYC SVGF GDY
WGQGVMVTVSS
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 57; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 57.
SEQ ID NO: 57 EVQLQQSGAELAKPGS SVKISCKASGYTFTNYTISWIKQTTGQGLEYIGYIYAGT
GDTNYNEKFKGKATLTVDKS SNTAFMQL S SLTPDD SAVYYCARYFDHWGQGV
MVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 58; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 58.
SEQ ID NO: 58 EVQLQQSGAELAKPGS SVKISCKASGYTFTSYYISWIKQTTGQGLEYIGYINTGS
GGTNYNEKFKGKATLTVDKS S STAFMQL S SLTPDDSAVYYCARDKWVDWGQ
GVMVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 59; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 59.
SEQ ID NO: 59 EVQLEESGGGLVQPKESLKISCAVSGFTFSNIAMYWVRQAPGKGLEWVGHIRT
KPHNYATYYAD S VKGRFTISRDD SNNMVYLEMDNLKPEDTAMYYC SVGF GDY
WGQGVMVTVSS
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 60; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 60.
SEQ ID NO: 60 QVQLKQSGAELAKPGSSVKISCKASGYTFTSYYISWIKQTTGQGLEYIGYIHPGS
GVTNYNEKFKGKATLTVDKS S STAFMQL SSLTPDDSAIYYCARYFDYWGQGV
MVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 61; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 61.
SEQ ID NO: 61 QVQLKQ SGVELAKPGS S VKISCKASGYTF T SD SISWIKQTTGQGLEYIGYIHPGS
MVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 62; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 10 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 62.
SEQ ID NO: 62 EVQLQQSGVELAKPGS SVKISCKASGYTFT SD SISWIKQTTGQGLEYIGYIHPGS
GVTNYNEKFKGKATLTVDKS S STAFMQL SSLTPDDSAIYYCARYFDYWGQGV
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 63; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework 20 .. regions) of SEQ ID NO: 63.
SEQ ID NO: 63 EVQLQQSGVELAKPGS SVKISCKASGYTFT SD SISWIKQTTGQGLEYIGYIHPGS
GVTNYNEKFRGKATLTVDKS S STAFMQL S SLTPDDSAIYYCARYFDYWGQGV
MVTVS S
25 In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 64; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 64.
SEQ ID NO: 64 QVQLQQPRAELAKPGSSVKISCKASGYTFTNYSISWIKQTTGQGLEYIGYIYPGS
GDTNYNEKFKGKATLTVDKS S STAFMQL S SL TPDD SAVYYC ARYFDHWGQ GT
LVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 65; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 65.
SEQ ID NO: 65 QVQLKESGAELAKPGS SVKISCKASGYTF T SD SISWIKQTTGQ GLEYIGYIHPGS
GVTNYNEKFKGKATLTVDKS S STAFMQL SSLTPDDSAIYYCARYFDYWGQGV
MVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 66; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 66.
SEQ ID NO: 66 QVQLKESGGGLVQPGRSLKL SC AA S GF TF SDYNMAWVRQAPKKGLEWVATIS
YDD SRTYYRDSVKGRFAISRDDAKGTLNLQMDSLRSEDTATYYCARQGGIIRG
VWFPYWGQGTLVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 67; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 67.
SEQ ID NO: 67 E VKLVES GGGLVQP GGSLKL S CAA S GF TF SNYYMAWVRQ APTKGLEWVAYIT
NSFGSAYYRDSVKGRFTISRDNAKSTLYLQMDSLRSEDTATYYCSTVPLGAFVY
WGQGTLVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 68; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 68.
SEQ ID NO: 68 QVQLKESGGGLVQPGRSLKL SC AA S GF SF GDYNMAWVRQAPKKGLEWVATIS
YDDYRTYYRDSVKGRFTISRDDAKATLYLQMDSLRSEDTATYYCARQGGIIRG
VWFPYWGQGTLVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 69; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 69.
SEQ ID NO: 69 E VKLVES GGGLVQP GGSLKL S CAA S GF TF SNYYMAWVRQ APTKGLEWVAYIT
NSLGSAYYRDSVKGRFTISRDNAKSTLYLQMDSLRSEDTATYYC STVPLGAFV
YWGQGTLVTVSS
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 70; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 70.
SEQ ID NO: 70 E VKLVES GGGLVQP GGSLKL S CAA S GF TF SNYYMAWVRQ APTKGLEWVAYIT
NSF GSTYYRD S VKGRF TISRDNAK STLYLQMD SLRSEDTATYYC STVPLGAFVY
WGQGTLVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 71; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 71.
SEQ ID NO: 71 E VKLVES GGGLVQP GRSLKL S CAA S GF TF SNYYMAWVRQAPTKGLEWVAYIT
NGYGSTYYRDSVKGRFTISRDNAKSTLYLQMDSLRSEDTATYYCSTVPLGAFV
YWGQGTLVTVSS
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 72; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 72.
SEQ ID NO: 72 E VKLVES GGGLVQP GRSLKL S CAA S GF TF SNYYMAWVRQAPTKGLEWVAYIT
NGF GSTYYRD S VKGRF TISRDNAK STLYLQMD SLRSEDTATYYC STVPLGAF VS
WGQGTLVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 73; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 73.
SEQ ID NO: 73 E VKLVES GGGLVQP GRSLKL S CAA S GF TF SNYYMAWVRQAPTKGLEWVAYIT
NGFGSTYYRDSVKGRFTISRDNAKSTLYLQMDSLRSEDAATYYCSTVPLGAFVS
WGQGTLVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 74; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 74.
SEQ ID NO: 74 E VKLVES GGGLVQP GGSLKL S CAA S GF TF SNYYMAWVRQ APTKGLEWVAYIT
NGF GSTYYRD S VKGRF TISRDNAK STLYLQMD SLRSEDTATYYC STVPLGAF VS
WGQGTLVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 75; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 75.
SEQ ID NO: 75 DIVMTQ SP S SM SVSL GDTVTITCRA S QDVGIYVNWF QQKP GKPPRRMIYRATNL
ADGVPSRFSGTRSGSDYSLTIS SLESEDVADYHCLQYDEFPPTFGSGTKLDIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 76; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 76.
SEQ ID NO: 76 DIVMTQAPLSL SVAIGQSASISCKSSQSLKHSDGKTYLNWIFQSPGQSPKRLIYQ
VSKLDSGVPDRF S GTGSETDF TLKI SRVEAEDL GVYYCC Q GS Y SP YTF GAGTKL
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 77; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework 10 regions) of SEQ ID NO: 77.
SEQ ID NO: 77 DILMTQ SP S SM SA SL GDRVTITCQ A S QDIGNNLIWF QQKP GK SPRRMIYYATNL
ANGVPSRFSGSRSGSDYSL SIS SLESEDVADYHCLQYDEFPPTFGSGTKLEIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
15 comprising or consisting of the sequence SEQ ID NO: 78; or a LCVR
comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 78.
SEQ ID NO: 78 ADGVP SRF SGSRSGSNYSLTIRSLE SEDVADYHCLQYDEWPYTF GAGTKLELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 79; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 25 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 79.
SEQ ID NO: 79 DIVMTQAPLSL SVDIGQSASISCRS SQ SLKHSDGKTYLNWVFQSPGQSPKRLIYQ
VSKLDSGVPDRF SGSGSEADFTLKISRVEAEDLGVYYCCQGSYSPYTFGAGTKL
ELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 80; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 80.
SEQ ID NO: 80 DIQL TQ SP S SMSVSQGDTVTITCRASQDVGIYVNWFQQKPGKSPRRMIYRATNL
ADGVPSRFSGSRSGSDYSLTIASLESEDVADYHCLQYDEFPPTFGSGTNLEIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 81; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 81.
SEQ ID NO: 81 DILMTQ SP S SMSVSLGDTVTITCRASQDVGIYVNWFQQIPGKSPRRLIYRATNLA
DGVPSRF SGSRSGSDYSLTIASLESEDVADYHCLQYDEFPPTFGSGTKLEIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 82; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 82.
SEQ ID NO: 82 DILMTQ SP S SMSVSQGDTVTITCRASQDVGIYVNWFQQKPGKSPRRMIHRATNL
ADGVP SRF SGSRSGSDYSLTIT SLESEDVADYHCLQYDEYPPTFGSGTNLEIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 83; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 83.
SEQ ID NO: 83 DILMT Q SP S SMSVSLGDTVTITCRASQDVGIYVNWFQQKPGKSPRRMIHRATNL
ADGVPSRFSGSRSGSDYSLTIS SLESEDVADYHCLQYDEYPPTFGSGTKLEIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 84; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 84.
SEQ ID NO: 84 DIVMTQ SP SSMSVSLGDTVTITCRASQDVGIYVNWFQQKPGKSPRRMIYRATNL
ADGVPSRFSGSRSGSDYSLTIASLESEDVADYHCLQYDEFPPTFGSGTKLEIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 85; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 85.
SEQ ID NO: 85 DILMT Q SP S SMSVSLGDTVTITCRASQDVGIYVNWFQQKPGKSPRRMIYRATTL
ADGVPSRFSGSRSGSDYSLTIS SLESEDVADYHCLQYDEYPPTFGSGTKLEIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 86; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 86.
SEQ ID NO: 86 DILMTQ SP S SM S V SLGD TVTIT CRA S QDVGIYVNWF Q QKP GK SPRRMIYRATNL
ADGVPSRF SGSRSGSDYSLTIS SLESEDVADYHCLQYDEYPPTF GGGTKLELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 87; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 87.
SEQ ID NO: 87 DIQLTQ SPASL SASLEEIVTITCQASQDIGNWLAWYQQKPGKSPHLLIYGATTLA
DGVPSRSGSRSGTQYSLKISRLQVEDVGMYYCQQTS STPWTFGGGTKLELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 88; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 88.
SEQ ID NO: 88 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLISHANPLH
DGVPSRFSGDGSGTQYSLKIRNMQPEDEGVYYCQQGYKFPYTFGAGTKLELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 89; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 89.
SEQ ID NO: 89 DIQMTQTPASL SASLEEIVTITCQASQDIGNWLAWYQQKPGKSPHLLIYGATTL
ADGVPSRF SGSRSGTQYSLKISRLQAEDIGIYYCQQASSAPWTFGGGTKLELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 90; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 90.
SEQ ID NO: 90 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLISHANPLH
DGVPSRF SGSGSGTQYSLKIRNMQPEDEGVYYCQQGYKFPYSFGAGTKLELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 91; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 91.
SEQ ID NO: 91 DIQLTQ SPASL SASLGETVSIECLASEDIYSYLAWYQQKPGKSPQLLISHANPLH
DGVPSRF SGSGSGTQYSLKIRNMQPEDEGVYYCQQGYKFPYTFGAGTKLELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 92; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 92.
SEQ ID NO: 92 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLISHANPLH
DGVPSRF SGSGSGTQYSLKIRNMQPEDEGVYYCQQGYKFPYTFGAGTKLELK
5 .. In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 93; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 93.
10 SEQ ID NO: 93 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLISYANPLH
DGVPSRF SGSGSGTQF SLKIRNMQPEDEGVYYCQQGYKFPYTFGAGTKLELT
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 94; or a LCVR comprising or 15 consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 94.
SEQ ID NO: 94 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLISHANPLH
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, said combination being as defined in Table 2.
TABLE 2. Preferred combinations of HCVR and LCVR. The HCVR and LCVR are defined by their SEQ ID NOs. First column indicates the clone's name.
Clone's name HCVR LCVR
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-13-R2A-C1, 5738-13-R2A-D3, 5738-13-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-10-R3A-C6, 5738-10-R3A-D5, 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R2A-C1 as defined in Table 2. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R2A-D3 as defined in Table 2. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R4A-D11 as defined in Table 2. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R3A-F5 as defined in Table 2.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R4A-F11 as defined in Table 2. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R2A-H3 as defined in Table 2. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R2A-H4 as defined in Table 2. In one embodiment, the binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R4A-H9 as defined in Table 2. 5738-13-H11 as defined in Table 2.
In one embodiment, the senescent cell-associated antigen is DPP4, such as, e.g., human DPP4 or orthologs thereof, including murine and rat DPP4. In one embodiment, the senescent cell-associated antigen is human DPP4 (hDPP4) with SEQ ID NO: 101.
In one embodiment, the antigen-binding domain of the invention recognizes and is capable of binding to DPP4, such as, e.g., to human DPP4, or orthologs thereof, including murine and rat DPP4. Hence, the antigen-binding domain of the invention is a "DPP4-binding domain".
In one embodiment, the DPP4-binding domain of the invention recognizes and is capable of binding to human DPP4 (hDPP4) with SEQ ID NO: 101.
In one embodiment, the DPP4-binding domain of the invention recognizes and is capable of binding to the extracellular domain of human DPP4 (hDPP4) comprising or consisting of amino acid residues 29- 766 of SEQ ID NO: 101.
The binding between the DPP4-binding domain of the invention and DPP4 implies that said DPP4-binding domain exhibits appreciable affinity for DPP4. In other words, the DPP4-binding domain of the invention is specific for, or is immunospecific for, or specifically bind to, DPP4.
The affinity between the DPP4-binding domain of the invention and DPP4 can be determined by various methods well known from the one skilled in the art.
These methods include, but are not limited to, biosensor analysis (including, e.g., Biacore analysis), Blitz analysis and Scatchard plot.
Alternatively or additionally, whether the DPP4-binding domain of the invention binds to DPP4 can be tested readily by, inter alia, comparing the reaction of said DPP4-binding domain with DPP4 or a fragment thereof (in particular, a fragment comprising or consisting of an epitope of DPP4) with the reaction of said DPP4-binding domain with proteins or antigens other than DPP4 or a fragment thereof In one embodiment, the DPP4-binding domain of the invention recognizes and is capable of binding to DPP4 with a KD-affinity constant less than or equal to 10' M, preferably less than or equal to 10-7 M, 5.10-8 M, 10-8 M, 5.10-9 M, 10-9 M or less; as may be determined, e.g., by biosensor analysis, particularly by Biacore Analysis.
In one embodiment, the DPP4-binding domain of the invention comprises a heavy chain variable region (abbreviated herein as HCVR or VH) which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: any one of SEQ ID NO: 104 to 112;
VH-CDR2: any one of SEQ ID NO: 113 to 129;
VH-CDR3: any one of SEQ ID NO: 130 to 142.
SEQ ID SEQ ID
SEQUENCE SEQUENCE
NO NO
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 104;
5 VH-CDR2: SEQ ID NO: 113;
VH-CDR3: SEQ ID NO: 130.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
10 VH-CDR1: SEQ ID NO: 104;
VH-CDR2: SEQ ID NO: 114;
VH-CDR3: SEQ ID NO: 131.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three 15 complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 105;
VH-CDR2: SEQ ID NO: 115;
VH-CDR3: SEQ ID NO: 132.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which 20 comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 104;
VH-CDR2: SEQ ID NO: 116;
VH-CDR3: SEQ ID NO: 133.
25 In one embodiment, the DPP4-binding domain of the invention comprises a HCVR which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 104;
VH-CDR2: SEQ ID NO: 117;
VH-CDR3: SEQ ID NO: 134.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 104;
VH-CDR2: SEQ ID NO: 113;
VH-CDR3: SEQ ID NO: 135.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 104;
VH-CDR2: SEQ ID NO: 116;
VH-CDR3: SEQ ID NO: 136.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 106;
VH-CDR2: SEQ ID NO: 118;
VH-CDR3: SEQ ID NO: 131.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 107;
VH-CDR2: SEQ ID NO: 119;
VH-CDR3: SEQ ID NO: 137.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 120;
VH-CDR3: SEQ ID NO: 138.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 121;
VH-CDR3: SEQ ID NO: 138.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 109;
VH-CDR2: SEQ ID NO: 122;
VH-CDR3: SEQ ID NO: 139.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 123;
VH-CDR3: SEQ ID NO: 138.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 124;
VH-CDR3: SEQ ID NO: 138.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 110;
VH-CDR2: SEQ ID NO: 125;
VH-CDR3: SEQ ID NO: 140.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 126;
VH-CDR3: SEQ ID NO: 141.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 126;
VH-CDR3: SEQ ID NO: 138.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 111;
VH-CDR2: SEQ ID NO: 127;
VH-CDR3: SEQ ID NO: 138.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 110;
VH-CDR2: SEQ ID NO: 128;
VH-CDR3: SEQ ID NO: 140.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 112;
VH-CDR2: SEQ ID NO: 125;
VH-CDR3: SEQ ID NO: 140.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 127;
VH-CDR3: SEQ ID NO: 138.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 127;
VH-CDR3: SEQ ID NO: 142.
In one embodiment, the DPP4-binding domain of the invention comprises a light chain variable region (abbreviated herein as LCVR or VI) which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: any one of SEQ ID NO: 143 to 151;
VL-CDR2: any one of SEQ ID NO: 152 to 163;
VL-CDR3: any one of SEQ ID NO: 164 to 173.
SEQ ID NO SEQUENCE SEQ ID NO SEQUENCE
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 143;
5 VL-CDR2: SEQ ID NO: 152;
VL-CDR3: SEQ ID NO: 164.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
10 VL-CDR1: SEQ ID NO: 143;
VL-CDR2: SEQ ID NO: 152;
VL-CDR3: SEQ ID NO: 165.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three 15 complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 144;
VL-CDR2: SEQ ID NO: 153;
VL-CDR3: SEQ ID NO: 166.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 143;
VL-CDR2: SEQ ID NO: 154;
VL-CDR3: SEQ ID NO: 167.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 143;
VL-CDR2: SEQ ID NO: 155;
VL-CDR3: SEQ ID NO: 168.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 145;
VL-CDR2: SEQ ID NO: 156;
VL-CDR3: SEQ ID NO: 166.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 143;
VL-CDR2: SEQ ID NO: 154;
VL-CDR3: SEQ ID NO: 169.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 146;
VL-CDR2: SEQ ID NO: 157;
VL-CDR3: SEQ ID NO: 170.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 147;
VL-CDR2: SEQ ID NO: 158;
VL-CDR3: SEQ ID NO: 171.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 147;
VL-CDR2: SEQ ID NO: 159;
VL-CDR3: SEQ ID NO: 171.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 148;
VL-CDR2: SEQ ID NO: 160;
VL-CDR3: SEQ ID NO: 172.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 149;
VL-CDR2: SEQ ID NO: 159;
VL-CDR3: SEQ ID NO: 171.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 146;
VL-CDR2: SEQ ID NO: 161;
VL-CDR3: SEQ ID NO: 170.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 150;
VL-CDR2: SEQ ID NO: 159;
VL-CDR3: SEQ ID NO: 171.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 151;
VL-CDR2: SEQ ID NO: 159;
VL-CDR3: SEQ ID NO: 171.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 146;
VL-CDR2: SEQ ID NO: 162;
VL-CDR3: SEQ ID NO: 170.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 149;
VL-CDR2: SEQ ID NO: 159;
VL-CDR3: SEQ ID NO: 173.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 146;
VL-CDR2: SEQ ID NO: 163;
VL-CDR3: SEQ ID NO: 170.
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 3.
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 3.
TABLE 3. Preferred combinations of HCVR's and LCVR's CDRs. The CDRs are defined by their SEQ ID NOs. First column indicates the clone's name.
Vii- Vii- Vii- VL- VL- VL-Clone's name In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-A10, 5826-B1, 5826-13-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13-5 R4A-E6, 5826-13-R4A-E9, 5826-13-R4A-F10, 5826-13-R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12.
In one embodiment, the DPP4-binding domain of the invention comprises a combination 10 of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-8-R6A-E10, 5826-8-G8, 5826-8-R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-D5, 5826-13-H5, and 5826-13-R4A-H12.
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-A10 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-B1 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-B3 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-D5 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-D6 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-E2 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-E6 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-E9 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-F10 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-G11 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-G12 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H1 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H2 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-H3 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H4 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H5 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H6 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H9 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-H10 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H11 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H12 as defined in Table 3.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 174; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 174.
SEQ ID NO: 174 EVQLEESGGGLVQPGRSLKL S CAA S GF TFNNYGMAWVRQAP TKGLEWVATI S
YDGNDTYYRDSVKGRFTVSRDNAKSTLYLQMDSLRSEDTATYYCVRHRLIYTT
DYYYEVMDVWGQGASVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 175; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 175.
SEQ ID NO: 175 QVQLKESGGGLVQPGRSLKL SC AA S GF TF SNYGMAWVRQAPTKGLEWVATTS
YDGNDTYYRDSVKGRFTVSRDNAKNTLYLQMDSLRSEDTATYYCVRHRLIYT
TDYYYEVMDAWGQGASVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 176; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 176.
SEQ ID NO: 176 QVTLKESGPGILQPSQTL SLTC SF SGF SL S T SDRC VS WIRQP SGKGLEWLATICW
DD SKGYNPSLKNRLTISKDTSNNQAFLKITSVGTADIAKYYCARNSGDGRFAY
WGQGTLVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 177; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 177.
SEQ ID NO: 177 EVQLEESGGGLVQPGRSLKL SC AA S GF TF SNYGMAWVRQAPTKGLEWVATIN
YDGRNTYYRDSVKGRFTISRDNAKSTLYLQVDSLQSEDTATYYCTREIKLIYTT
DYYYEVMDAWGQGASVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 178; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 178.
SEQ ID NO: 178 EVKLVESGGGLVQPGRSLKLSCAASGF SF TNYGMAWVRQAPTKGLEWVATIN
YDGSNTYYRDSVKGRFTISRDNAKRTLDLQMDSLRSEDTATYYCARHRLMYT
TDYYYEVMDDWGQGASVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 179; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 179.
SEQ ID NO: 179 EVKLVESGGGLVQPGRSLKL SCAAS GF SFRNYGMAWVRQAPTKGQEWVATIS
YDGNDTYYRDSVKGRFTVSRDNAKSTLYLQMDSLRSEDTATYYCTRHRLIYTT
DYYYEVLDAWGQGASVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 180; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 180.
SEQ ID NO: 180 EVKLVESGGGLVQPGRSLKLSCTASGFTF SNYGMAWVRQAPTKGLEWVATIN
D YY YEVMDVWGQ GA S VAVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 181; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 10 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 181.
SEQ ID NO: 181 EVKLVESGGALVQPGRSLKLSCAASGFTF SNFGMAWVRQAPTKGLEWVATIN
YDGRDTYYRDSVKGRFTVSRDNAKSTLYLQMDSLRSEDTATYYCTRHRLIYTT
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 182; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework 20 regions) of SEQ ID NO: 182.
SEQ ID NO: 182 EVKLVESGPGLVKPSQSL SLAC SITDYSITDNYWGWIRKFPGNKMEWIGHISHS
GS STYNPSLKSRISFTRDTSKNQFFLQLNSVTPEDTATYFCARYGAGASFDYWG
QGVMVTVSS
25 In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 183; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 183.
SEQ ID NO: 183 EVQLQQSGAELTKPGSSVKISCKASGFTFTTYDIGWLKQRPGQALEWIGYINPG
SGGIGYNEKFKGKATLTVDKSS STAFMQL S SLTPEDTAVYYCARPLRRVLDYW
GQGVMVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 184; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 184.
SEQ ID NO: 184 EVQLQQ SGAGLTKPGAS VKISCKASGYTF TTYDIGWIKQRPGQALEWIGSINPG
SGGIAYSEKFKGKATLTVDKS S STAFMQLS SLTPEDTAVYYCARPLRRVLDYW
GQGVLVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 185; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 185.
SEQ ID NO: 185 E VKL VE S GP GL VKP SQ SL SLTC S VTGYF IT GNYL AWIRKFPGNKMEW IGHIK S S
GTTTYNPSLKSRVSITRDTSKNQFFLQLNSVTSEDTATYYCARHGHYVMDVWG
QGASVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 186; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 186.
SEQ ID NO: 186 EVQLQQSGAELTKPGS SVKISCKASGYTFTTYDIGWIKQRPGQALEWIGSINPGS
GGIGYNERFKGKATLTVDKS S STAFMQL S SLTPEDTAVYYCARPLRRVLDYWG
QGVMVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 187; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 187.
SEQ ID NO: 187 QVQLKQSGAELTKPGS SVKISCKASGYTFTTYDIGWLKQRPGQALEWIGYINPG
GGGIGYNEKFKGKATLTVDKS S STAFMQL S SLTPEDTAVYYCARPLRRVLDYW
GQGVMVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 188; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 188.
SEQ ID NO: 188 DVKLQESGPGLVKPSQSLSLTC SVTGHSITSNYWGWIRKFPGNKMEWIGQISHS
GSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCGRYGAGSSFDYWG
QGVMVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 189; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 189.
SEQ ID NO: 189 EVQLQQSGAELTKPGS SVKISCKASGYTFTTYDIGWIKQRPGQALEWIGSINPGS
GGIGYNEKFKGKATLTVDKS SSTVFMQL S SLTPEDTAVYYCARPLRRVLDNWG
QGVLVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 190; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 190.
SEQ ID NO: 190 EVQLQQSGAELAKPGS SVKISCKASGYTFTTYDIGWIKQRPGQALEWIGSINPGS
GGIGYNEKFKGKATLTVDKS SRTVFMQL SSLTPEDTAVYYCARPLRRVLDYWG
QGVMVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 191; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 191.
SEQ ID NO: 191 EVQLQQSGPELAKPGS SVKISCKASGYTFTTYDIGWIKQRPGQALEWIGSINPGS
GGIGYNEKFKGKATLTVDKS SSTAFMQL S SLTPEDTAVYYCARPLRRVLDYWG
QGVMVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 192; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 192.
SEQ ID NO: 192 EVQL QQ S GAGL TKP GA S VKI SC TA S GYTF T TYDRGWLRQRPGQ ALEWIGSINP G
GGGTGYNEKFKGNATLTVDKS S STAFMQL S SL TPED TAD YYCARPLRRVLD Y
WGQGVLVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 193; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 193.
SEQ ID NO: 193 DVKLQESGPGLVKPSQSLSLTCSVTGHSITSNYWGWIRKLPGNKMEWIGQISHS
GST SYNP SLISRISITRDT SNQFFLQLNSVTTEDTATYYCGRYGAGS SFDYWGQG
VMVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 194; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 194.
SEQ ID NO: 194 EVQLQQSGAELTKPGS SVKISCKASGYTFTTYDIGWIKQRPGQALEWIGSINPGS
GGIGYNEKFKGKATLTVDRS S STAFMQL S SLTPEDTAVYYCARPLRRVLDNWG
QGVLVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 195; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 195.
SEQ ID NO: 195 EVQLQQSGGELTKPGS SVKISCKASGYTF STYDIGWIKQRPGQALEWIGSINPGS
QGVMVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 196; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 10 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 196.
SEQ ID NO: 196 DVKLQESGPGLVKPSQSLSLTC SVTGHSITGNYWGWIRKFPGNKMEWIGQISHS
GSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCGRYGAGSSFDYWG
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 197; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework 20 regions) of SEQ ID NO: 197.
SEQ ID NO: 197 EVQLQQ SGAGLTKPGGS VKISCKVSGYTF TTYDIGWLKQRPGQALEWIGSINPG
GGGTGYNEKFKGKATLTVDKS S STAFMQL S SLTPEDTAVYYCARPLRRVLDY
WGQGVLVTVS S
25 In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 198; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 198.
SEQ ID NO: 198 EVQLQQ SGAGLTKPGAS VKISCKASGYTF TTYDIGWLKQRPGQALEWIGSINPG
GGGTGYNEKFKGKATLTVDKS SSTAFMQL SSLTPEDTAVYYCARPLRVLDYW
GQGVLVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 199; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 199.
SEQ ID NO: 199 EVQLQQSGAELTKPGS SVKISCKASGYTFTTYDIGWIKQRPGQALEWIGSINPGS
GGIGYNERFKGKATLTVDKS S STAFMQL S SLTPEDTAVYYCARPLRRVLDYWG
RGVMVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 200; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 200.
SEQ ID NO: 200 EVQLEESGPGLVKPSQSLSLTC SVTGHSITSNYWGWIRKFPGNKMEWIGQISHS
GSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCGRYGAGSSFDYWG
QGVMVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 201; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 201.
SEQ ID NO: 201 QVQLKESGPGLVKPSHSLSLTC SVTGHSITSNYWGWIRKFPGNKMEWIGQISHT
GS S TYNP SLK SRISF TRDT SKNQFFLQLNS VTTED SATYYCGRYGAGS SFDYWG
QGVMVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 202; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 202.
SEQ ID NO: 202 DVLMTQTPS SQAASAGEKVTMSCKS SQSLLYNENKKNYLAWFQQKPGQSPKL
LIYWASTRESGVPDRFIGGGSGTDFTLTIS SVQAEDLAVYYCQEYYKFPWTFGG
GTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 203; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 203.
SEQ ID NO: 203 DIVMTQ SP S SQAVSAGEKVTMSCK S SQSLLYNENKKNYLAWFQQKPGQSPKLL
IYWASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLAVYYCQDYYHFPWTFGGG
TKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 204; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 204.
SEQ ID NO: 204 DVLMTQTPPTLSATIGQSVSISCKS SQSLLHSNGNTYLNWLLQRPGQSPQLLIYS
VSKLESGVPNRF S GS GS QTDF TLKISEVEAEDMGVYYCMQATHAPF TF GSWTK
LEIK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 205; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 205.
SEQ ID NO: 205 DIVMTQAP S SQAVSPGEKVTMSCKS SQSLLYNENKKNYLAWYQQKPGQSPKLL
IYWASTREAGVPDRFIGSGSGTDFTLTISSVQAEDLAVYYCQQYYKFPWPFGGG
TKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 206; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 206.
SEQ ID NO: 206 DIVMTQAP S SQAVSAGEKVTMSCK SSQ SLLYNENKKNYLAWFQQKPGQSPKLL
IYWAS TRK S GVPDRFIGS GS GTDF TLTI S SVQAEDLAVYYCQQYYKFPWTFGGG
TKLELR
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 207; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 207.
SEQ ID NO: 207 DIVMTQ SP S SQAVSPGEKVTMNCKS SQSLLYNENKKNYLAWYQQKPGQSPKLL
IYWASTREAGVPDRFIGSGSGTDFTLTISSVQAEDLAVYYCQQYYKFPWPFGGG
TKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 208; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 208.
SEQ ID NO: 208 DVLMTQTPPTLSATIGQSVSISCRS SQ SLLHSNGNTYLNWLLQRPGQ SP QLLIY S
VSNLESGVPNRF S GS GSETDF TLKI SGVEAEDL GVYYCMQATHAPF TF GSGTKL
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 209; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 209.
SEQ ID NO: 209 DIVMTQ SP S SQAVSPGEKVTMNCKS SQSLLYNENKKNYLAWYQQKPGQSPKLL
IYWA S TREAGVPDRFIGS GS GTDF TL TI S S VQAEDLAVYYCQ Q YYKFP YTF GAG
TKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 210; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 210.
SEQ ID NO: 210 DIQLTQSPHSLSASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLIYYT SSLQD
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 211; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework 10 regions) of SEQ ID NO: 211.
SEQ ID NO: 211 DIVMTQ SP S SLPASLGERVTISCRASQ GISNKLNWYQQKPDGTIKPLIYYT SRLQ S
GVPSRF SGSGSGTDYSLTIS SLEPEDFAMYYCQQDASFPPTFGAGTKVELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
15 comprising or consisting of the sequence SEQ ID NO: 212; or a LCVR
comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 212.
SEQ ID NO: 212 GVPSRF SGSGSGTDYSLTIS SLEPEDFAMYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 213; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 25 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 213.
SEQ ID NO: 213 DIVLTQ SPVLAVSLGQRATISCRASQ SVS T S TYNFMIHWYQQKPGQQPRLLIYDA
SHLASSVPARF SGSGSGTDFTLTINPVQADDIATYYCQQSRELPLTFGSGTKLEIK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 214; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 214.
SEQ ID NO: 214 DILMTQ SP S SLSASLGERVTISCRASQGIGNKLNWYQQKPDGTIKPLIYYTSNLQ
SGVP SRF SGSGSGTDYSLTISSLEPEDFAMYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 215; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 215.
SEQ ID NO: 215 DIQLTQ SP S SLPASLGERVTISCRASQGISNKLNWYQQKPDGTIKPLIYYT SNLQ S
GVPSRF S GS GS GTDY SLTI S SLEPEDFAMYFCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 216; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 216.
SEQ ID NO: 216 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLIYYTS SF Q
DGVPSRF SGSGSGTQYSLKISNMQPEDEGVYYCQQGYKYPWTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 217; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 217.
SEQ ID NO: 217 DILMTQ SP S SRPASLGERVTISCRASQGIGNKLNWYQQKPDGTIKPLIYYT SNLQ
SGVP SRF SGSGSGTDYSLTISSLEPEDFAMYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 218; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 218.
SEQ ID NO: 218 DIQMTQTP S SLPASLGERVTISCRASQ GISKKLNWYQQKPDGTIKPLIYYT SNLQ
SGVP SRF SGSGSGTDYSLTIS SLEPEDFAIYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 219; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 219.
SEQ ID NO: 219 DIQLTQ SP S SLPASLGERVTISCRASQGISKKLNWYQQKPDGTIKPLIYYT SNLQS
GVPSRF SGS SGTDYSLTIS SLEPEDFAMYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 220; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 220.
SEQ ID NO: 220 DILMTQ SP S SLPASLGERVTISCGASQGIGNKVNWYQQKPDGTIKPLIYYTSNLQ
SGVP SRF SGSGTGTDYSLTIS SLEPEDFAMYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 221; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 221.
SEQ ID NO: 221 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQRKPGK SPQLLIYYTISLQD
GVP SRF SGSGSGTQYSLKISNMQPEDEGVFYCQQGYKYPWTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 222; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 222.
SEQ ID NO: 222 DIQLTQ SP S SLPASLGERVTISCRASQGIGNKLNWYQQKPDGTIKPLIYYTSNLQS
GVPSRF SGSGSGTDYSLTIS SLEPEDFAMYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 223; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 223.
SEQ ID NO: 223 DILMTQ SP S SLSASLGERVTISCRASQGIGNKLNWYQQKPDGTIKPLIYYTSNLQ
SGVP SRF SGSGSGTDYSLTIS SLEPEDFAMYYCQQDTSFPPTFGAGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 224; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 224.
SEQ ID NO: 224 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLIYYTISLQ
DGVPSRF SGSGSGTQYSLKISNMQPEDEGVFYCQQGYKYPWTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 225; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 225.
SEQ ID NO: 225 DIQMTQTP SSLPASLERVTISCRASQGISNKLNWYQKKPDGTIKPLIYYTSNLQS
GVPSRF SGSGSGTDYSLTIS SLEPEDFAMYFCQQDASFPPTFGGGTQLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 226; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 226.
SEQ ID NO: 226 DIQLTQ SP S SRPASLGERVTISCRASQGIGNKLNWYQQKPDGTIKPLIYYTSNLQS
GVPSRF SGSGSGTDYSLTIS SLEPEDFAMYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 227; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework 5 regions) of SEQ ID NO: 227.
SEQ ID NO: 227 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLIYYAS SLQ
DGVPSRF SGSGSGTQYSLKISNMQPEDEGVYYCQQGYKYPWTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a combination 10 of (i) a HCVR and (ii) a LCVR, said combination being as defined in Table 4.
TABLE 4. Preferred combinations of HCVR and LCVR. The HCVR and LCVR are defined by their SEQ ID NOs. First column indicates the clone's name.
Clone's name HCVR LCVR
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-13-R3A-A10, 5826-13-R3A-B1, 5826-13-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13-R4A-E6, 5826-13-R4A-E9, 5826-13-R4A-F10, 5826-13-R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12.
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-8-R6A-E10, 5826-8-R5A-G8, 5826-8-R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-A10 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-B1 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-B3 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-D5 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-D6 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-E2 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-E6 as defined in Table 4. In one embodiment, the binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-E9 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-F10 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-G11 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-G12 as defined in Table 4. In one embodiment, the binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H1 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H2 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-H3 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H4 as defined in Table 4. In one embodiment, the binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H5 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H6 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-H9 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H10 as defined in Table 4. In one embodiment, the binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H11 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H12 as defined in Table 4.
Another object of the present invention is an isolated antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment thereof recognizes and is capable of binding to a senescent cell-associated antigen, as defined hereinabove.
In one embodiment, the senescent cell-associated antigen is selected from the group comprising or consisting of DEP1 and DPP4.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention recognizes and is capable of binding to DEP1, such as, e.g., human DEP1, or orthologs thereof, including murine and rat DEP1. In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention recognizes and is capable of binding to human DEP1 (hDEP1) with SEQ ID NO: 1. In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention recognizes and is capable of binding to the extracellular domain of human DEP1 (hDEP1) comprising or consisting of amino acid residues 36 ¨975 of SEQ ID NO: 1. Hence, the isolated antibody or antigen-binding fragment thereof of the invention is an isolated "anti-DEP1 antibody or antigen-binding fragment thereof'.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention recognizes and is capable of binding to DPP4, such as, e.g., human DPP4 or orthologs thereof, including murine and rat DPP4. In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention recognizes and is capable of binding to human DPP4 (hDPP4) with SEQ ID NO: 101. In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention recognizes and is capable of binding to the extracellular domain of human DPP4 (hDPP4) comprising or consisting of amino acid residues 29 - 766 of SEQ ID NO: 101. Hence, the antigen-binding fragment of the invention is an isolated "anti-DPP4 antibody or antigen-binding fragment thereof'.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention recognizes and is capable of binding to DEP1 and DPP4.
The binding between the anti-DEP1 antibody or antigen-binding fragment thereof of the invention and DEP1, or between the anti-DPP4 antibody or antigen-binding fragment thereof of the invention and DPP4, implies that said antibody or antigen-binding fragment thereof exhibits appreciable affinity for DEP1 or DPP4, respectively. In other words, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention or the anti-DPP4 antibody or antigen-binding fragment thereof of the invention, is specific for, or is immunospecific for, or specifically binds to, DEP1 or DPP4, respectively.
An antibody or antigen-binding fragment thereof is said to be "specific for", "immunospecific for" or to "specifically bind to" an antigen if it reacts with said antigen (e.g., DEP1 and/or DPP4). An antibody or antigen-binding fragment thereof is said to be "specific for", "immunospecific for" or to "specifically bind to" an antigen if it recognizes and is capable of binding to antigen with a KD-affinity constant less than or equal to 10-6 M, preferably less than or equal to 10-7 M, 5.10-8 M, 10-8 M, 5.10-9 M, 10-9 M or less; as may be determined, e.g., by biosensor analysis, particularly by Biacore Analysis.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention comprises an antigen-binding domain, as described hereinabove.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain, as described hereinabove.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 1.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 1.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-13-R2A-C1, 5738-13-R2A-D3, 13-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R3A-C6, 5738-10-R3A-D5, 10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R2A-C1 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-D3 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-D11 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R3A-F5 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-F11 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-H3 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R2A-H4 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R4A-H9 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H11 as defined in Table 1.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, said combination being as defined in Table 2.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-13-R2A-C1, 5738-13-R2A-D3, 5738-13-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-10-R3A-C6, 5738-10-R3A-D5, 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13 -R2A-H4 .
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5738-13-R2A-C1 as defined in Table 2.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5738-13-R2A-D3 as defined in Table 2.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5738-13-R4A-D11 as defined in Table 2. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R3A-F5 as defined in Table 2. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R4A-F11 as defined in Table 2. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R2A-H3 as defined in Table 2. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R2A-H4 as defined in Table 2. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-H9 as defined in Table 2. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-H11 as defined in Table 2.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain, as described hereinabove.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 3.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 3.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-A10, 5826-13-R3A-B1, 13-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13-R4A-E6, 5826-13-R4A-E9, 5826-13-R4A-F10, 5826-13-R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-8-R6A-E10, 5826-8-R5A-G8, R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R3A-A10 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-B1 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R3A-B3 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-D5 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R3A-D6 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-E2 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-E6 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-E9 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-F10 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-G11 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-G12 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H1 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H2 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H3 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H4 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H5 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H6 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H9 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H10 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H11 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H12 as defined in Table 3.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, said combination being as defined in Table 4.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-13-R3A-A10, 5826-13-R3A-B1, 5826-13-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13-R4A-E6, 5826-13-R4A-E9, 5826-13-R4A-F10, 5826-13-R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-8-R6A-E10, 5826-8-R5A-G8, 5826-8-R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
.. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R3A-A10 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-B1 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-B3 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-D5 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-D6 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-E2 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-E6 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-E9 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-F10 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-G11 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-G12 as defined in Table 4. 5826-13-R4A-H1 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H2 as defined in Table 4.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H3 as defined in Table 4.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H4 as defined in Table 4.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H5 as defined in Table 4.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H6 as defined in Table 4.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H9 as defined in Table 4.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H10 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H11 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H12 as defined in Table 4.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a molecule selected from the group comprising or consisting of a whole antibody, a single-chain variable fragment (scFv), a dimeric single-chain variable fragment (di-scFv, such as a tandem scFv or a diabody), a trimeric single-chain variable fragment (tri-scFv, such as a triabody), a tetrameric single-chain variable fragment (tetra-scFv, such as a tetrabody), a Fv, a Fab, a Fab', a Fab'-SH, a F(ab')2, a Fabc, and a Fd.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a mimetic selected from the group comprising or consisting of an affibody, an alphabody, an armadillo repeat protein based scaffold, a knottin, a kunitz domain peptide, an affilin, an affitin, an adnectin, an atrimer, an evasin, a DARPin, an anticalin, an avimer, a fynomer, a versabody or a duocalin.
Antigen-binding fragment of antibodies comprising specific antigen-binding domains may be generated by known methods. Methods for producing such antigen-binding fragments of antibodies are known in the art, for example as described in Lo (Ed.), 2004.
Antibody Engineering: Methods and Protocols (1st ed., Vol. 248). Totowa, NJ:
Humana Press; and McCafferty, Hoogenboom & Chiswell (Eds.), 1996. Antibody Engineering: a Practical Approach (1st ed., Vol. 169). Oxford: 1RL Press at Oxford University Press. For example, F(ab')2 fragments can be produced by pepsin digestion of the whole antibody molecule, and Fab fragments can be generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity, as described for example in Huse et al., 1989. Science. 246(4935):1275-81.
Antibodies may be generated using known methods. For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with an appropriate antigen. Depending on the host species, various adjuvants may be used to increase an immunological response. Such adjuvants include Freund's adjuvant, mineral gels such as aluminium hydroxide, and surface-active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Adjuvants are commercially available.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is polyclonal. In another embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is monoclonal.
Methods of producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art (see, for example, Harlow and Lane, Antibodies: A
Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988).
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a purified antibody or a purified antigen-binding fragment thereof In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is purified to:
(1) greater than 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% or more by weight of antibody or antigen-binding fragment thereof, as may be determined, e.g., by the Lowry method; and most preferably more than 96%, 97%, 98% or 99% by weight of antibody or antigen-binding fragment thereof;
(2) a degree sufficient to obtain at least 15 amino acid residues of the N-terminal, or of an internal, amino acid sequence, e.g., by use of a spinning cup sequenator;
and/or (3) homogeneity as shown, e.g., by SDS-PAGE under reducing or non-reducing conditions and using, e.g., Coomassie blue staining or more preferably silver staining.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention has an isotype selected from the group comprising or consisting of IgG
(including IgGl, IgG2, IgG3 and IgG4), IgM, IgA (including IgAl and IgA2), IgD
and IgE. The immunoglobulin subclasses or "isotypes" (e.g.õ IgAl, etc.).
The constant region of an antibody is important in the ability of an antibody to fix complement and mediate cell-dependent cytotoxicity and phagocytosis. Thus, as discussed herein, the isotype of an antibody may be selected on the basis of whether it is desirable for the antibody to mediate cytotoxicity/phagocytosis. Determination or selection of the isotype of an antibody may be by known methods in the art.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a murine, a chimeric or a humanized antibody or antigen-binding fragment thereof.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a murine antibody or antigen-binding fragment thereof A "murine antibody or antigen-binding fragment thereof' refers to those antibodies or antigen-binding fragments thereof in which the variable region (including the CDRs and FRs) and the constant region are derived from a mouse.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a chimeric antibody or antigen-binding fragment thereof A "chimeric antibody or antigen-binding fragment thereof' broadly refers to an antibody or antigen-binding fragment thereof comprising a first amino acid sequence linked to a second amino acid sequence with which it is not naturally linked in nature.
The amino acid sequences may normally exist in separate proteins that are brought together in the fusion protein or they may normally exist in the same protein but are placed in a new arrangement in the fusion protein. A chimeric protein may be created, for example, by chemical synthesis, or by creating and translating a polynucleotide in which the peptide regions are encoded in the desired relationship. The term "chimeric antibody or antigen-binding fragment thereof' encompasses herein antibodies and antigen-binding fragments thereof in which:
(a) the constant region (Fc), or a portion thereof, is altered, replaced or exchanged so that the variable region is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region (Fv), or a portion thereof, is altered, replaced or exchanged with a variable region, or portion thereof, having a different or altered antigen specificity; or with corresponding sequences from another species or from another antibody class or subclass.
Method to produce chimeric antibodies are well known in the art. For example, chimeric antibodies may be produced as described in Morrison et al., 1984. Proc Natl Acad Sci U
SA. 81(21):6851-5; Neuberger et al., 1984. Nature. 312(5995):604-608; and Takeda et al., 1985. Nature, 314(6010):452-454.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a humanized antibody or antigen-binding fragment thereof.
A "humanized antibody or antigen-binding fragment thereof' refers to a chimeric antibody or antigen-binding fragment thereof which contains only minimal sequence derived from a non-human immunoglobulin. It includes antibodies made by a non-human cell having variable and constant regions which have been altered to more closely resemble antibodies that would be made by a human cell, e.g., by altering the non-human antibody amino acid sequence to incorporate amino acids found in human germline immunoglobulin sequences. Humanized antibodies or antigen-binding fragment thereof of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs.
The term "humanized antibody or antigen-binding fragment thereof' also includes antibodies and antigen-binding fragment thereof in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. In other words, the term "humanized antibody or antigen-binding fragment thereof' refers to an antibody or antigen-binding fragment thereof in which the CDRs of a recipient human antibody are replaced by CDRs from a donor non-human antibody.
Humanized antibodies or antigen-binding fragments thereof may also comprise residues of donor origin in the framework sequences. The humanized antibody or antigen-binding fragment thereof can also comprise at least a portion of a human immunoglobulin constant region. Humanized antibodies and or antigen-binding fragments thereof may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. Humanization can be performed using methods known in the art (e.g., Jones et al, 1986. Nature. 321(6069):522-5; Riechmann et al, 1988. Nature.
332(6162):323-7; Verhoeyen etal., 1988. Science. 239(4847):1534-6; Presta, 1992. Curr Opin Biotechnol. 3(4):394-8; Patent US4,816,567), including techniques such as "superhumanizing" antibodies (e.g., Tan et al., 2002. J Immunol. 169(2):1119-25) and "resurfacing" (e.g., Staelens etal., 2006. Mol Immunol. 43(8):1243-57; Roguska et at, 1994. Proc Natl Acad Sci USA. 91(3):969-73). A "humanized antibody or antigen-binding fragment thereof' retains a similar antigenic specificity as the original antibody.
However, using certain methods of humanization, the affinity and/or specificity of binding of the antibody may be increased.
Methods for humanizing the isolated antibody or antigen-binding fragment thereof of the invention are well-known in the art. The choice of human variable domains, both light and heavy, to be used in making the humanized antibody or antigen-binding fragment thereof is very important to reduce antigenicity. According to the so-called "best-fit"
method, the sequence of the variable domain of an isolated antibody or antigen-binding fragment thereof of the invention is screened against the entire library of known human variable-domain sequences. The human sequence that is closest to the mouse sequence is then accepted as the human framework (FR) for the humanized antibody (Sims et al, 1993. J Immunol. 151(4):2296-308; Chothia & Lesk, 1987. JMolBiol. 196(4):901-17).
Another method for humanizing the isolated antibody or antigen-binding fragment thereof of the invention uses a particular framework from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework can be used for several different humanized antibodies (Carter et al, 1992.
Proc Natl Acad Sci USA. 89(144285-9; Presta et al., 1993. J Immunol. 151(5):2623-32). It is further important that antibodies be humanized with retention of high affinity for DEP1 or DPP4 and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies and antigen-binding fragments thereof are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its epitope. In this way, CDR residues can be selected and combined from the consensus and import sequences so that the desired antibody characteristic, such as an increased affinity for DEP1 or DPP4, is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding.
Another method for humanizing the isolated antibody or antigen-binding fragment thereof of the invention is to use a transgenic or transchromosomic animal carrying parts of the human immune system for immunization. As a host, these animals have had their immunoglobulin genes replaced by functional human immunoglobulin genes. Thus, antibodies produced by these animals or in hybridomas made from the B cells of these animals are already humanized. Examples of such transgenic or transchromosomic animal include, without limitation:
- the XenoMouse (Abgenix, Fremont, CA), described in Patents US5,939,598, US6,075,181, US6,114,598, US6,150,584 and US6,162,963;
- the HuMAb Mouse (Medarex, Inc.), described in Lonberg et al, 1994. Nature.
368(6474):856-859; Lonberg & Huszar, 1995. Int Rev Immunol. 13(1):65-93;
Harding & Lonberg, 1995. Ann N Y Acad Sci. 764:536-46; Taylor et al., 1992.
Nucleic Acids Res. 20(23):6287-95; Chen et al., 1993. Int Immunol. 5(6):647-56;
Tuaillon et al., 1993. Proc Natl Acad Sci USA. 90(8):3720-4; Choi et al, 1993.
Nat Genet. 4(2): 117-23; Chen et al, 1993. EMBO J. 12(3):821-30; Tuaillon et al., 1994. J Immunol. 152(6):2912-20; Taylor et al., 1994. Int Immunol. 6(4):579-91;
Fishwild et al, 1996. Nat Biotechnol. 14(7):845-51;
- the KM Mouse , described in Patent application W02002043478;
- the TC mice, described in Tomizuka et al., 2000. Proc Nati Acad Sci USA.
97(2):722-7; and - the OmniRatTM (OMT, Inc.), described in Patent application W02008151081;
Geurts et al, 2009. Science. 325(5939):433; Menoret et al., 2010. Eur J
Immunol.
40(10):2932-41.
Humanized antibodies and antigen-binding fragments thereof may also be produced according to various other techniques, such as by using, for immunization, other transgenic animals that have been engineered to express a human antibody repertoire (Jakobovitz et al, 1993. Nature. 362(6417):255-8), or by selection of antibody repertoires using phage display methods. Such techniques are known to the skilled person and can be implemented starting from monoclonal antibodies or antigen-binding fragments thereof as disclosed in the present application.
Whether chimeric or humanized, the isolated antibody or antigen-binding fragment thereof of the invention may comprise a constant region (Fc) of human origin.
In one embodiment, especially when the isolated antibody or antigen-binding fragment thereof of the invention is intended for human therapeutic uses, it is typical for the entire constant region (Fc), or at least a part thereof, to have a fully or substantially human amino acid sequence. Therefore, one or more of, or any combination of, the CH1 domain, hinge region, CH2 domain, CH3 domain and CL domain and CH4 domain (when present) may be fully or substantially human with respect to its amino acid sequence.
Advantageously, the CH1 domain, hinge region, CH2 domain, CH3 domain and CL domain and CH4 domain (when present) may all have a fully or substantially human amino acid sequence.
The term "substantially human", in the context of the constant region (Fc) of a chimeric or humanized antibody or antigen-binding fragment thereof, refers to an amino acid sequence identity of at least 70%, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more with a human constant region (Fc).
The term "human amino acid sequence", in this context, refers to an amino acid sequence which is encoded by a human immunoglobulin gene, which includes germline, rearranged and somatically mutated genes. The present invention also contemplates proteins comprising constant domains of "human" sequence which have been altered, by one or more amino acid additions, deletions or substitutions with respect to the human sequence, excepting those embodiments where the presence of a "fully human hinge region" is expressly required.
The presence of a "fully human hinge region" in the isolated antibody or antigen-binding fragment thereof of the invention may be beneficial both to minimize immunogenicity and to optimize stability of the antibody. It is considered that one or more amino acid substitutions, insertions or deletions may be made within the constant region of the heavy and/or the light chain, particularly within the Fc region.
Amino acid substitutions may result in replacement of the substituted amino acid with a different naturally occurring amino acid, or with a non-natural or modified amino acid.
Other structural modifications are also permitted, such as for example changes in glycosylation pattern (e.g., by addition or deletion of N- or 0-linked glycosylation sites).
Depending on the intended use of the antibody or antigen-binding fragment thereof, it may be desirable to modify the isolated antibody or antigen-binding fragment thereof of the invention with respect to its binding properties to Fc receptors, for example to modulate effector function. For example, cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved effector function (Caron et al, 1992. J Exp Med.
176(4):1191-5; Shopes, 1992. J Immunol. 148(9):2918-22).
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention may be a bispecific antibody (BsAb) with antigen binding to at least two senescent cell-associated antigens. In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention may be a bispecific antibody (BsAb) which binds to both DEP1 and DPP4.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention may be a bispecific antibody (BsAb) with antigen binding to at one senescent cell-associated antigen and one non-senescent cell-associated antigen. In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention may be a bispecific antibody (BsAb) which binds to either of DEP1 or DPP4 on the one hand, and to one non-senescent cell-associated antigen on the other hand.
In one embodiment, the non-senescent cell-associated antigen is a T cell receptor or part thereof, such as, e.g., any one of the CD36, CD3y, CD3E or CD3 subunit.
Examples of bispecific antibodies (BsAb) include, but are not limited to, quadromas, knobs-in-holes, CrossMab Fab, CrossMab VH-VL, CrossMab CH1-CL, TriMab, one-arm single-chain Fab-immunoglobulin gamma (0AscFab-IgG), disulfide stabilized Fv-IgG
(dsFv-IgG), DuetMab, controlled Fab-arm exchanged-IgG1 (cFAE-IgG1), charged pair scFv-Fc, strand-exchange engineered domain body (SEEDbody), two-arm leucine zipper heterodimeric monoclonal antibodies (two-arm LUZ-Y), kappa lambda body (K-body), bi-specific T cell engagers (BiTEs), diabodies, .tandab, dual-affinity retargeting molecules (DARTs), bispecific killer cell engagers (BiKEs), trispecific killer cell engagers (TriKEs), monomeric Fc-VH (mFc-VH) and Fc antigen binding (Fcab), all reviewed and described in Liu et al, 2017 (Front Immunol. 8:38).
Methods for producing bispecific antibodies (BsAb) are well known in the art.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a recombinant isolated antibody or antigen-binding fragment thereof Thus accordingly, the isolated antibody or antigen-binding fragment thereof of the invention may be produced recombinantly by methods known in the art, such as, e.g., by expression in Escherichia coil expression systems (see, e.g., US patent 4,816,567).
Antigen binding fragment may also be produced by phage display technologies, which are known in the art.
It will also be appreciated that the isolated antibody or antigen-binding fragment thereof of the invention can be modified using methods well known in the art, e.g., to improve the properties of the isolated antibody or antigen-binding fragment thereof For example, to slow clearance in vivo and obtain a more desirable pharmacokinetic profile, the isolated antibody or antigen-binding fragment thereof may be modified with polyethylene glycol (PEG). Methods for coupling and site-specifically conjugating PEG to an antibody or antigen-binding fragment thereof are described in, e.g., Leong et al., 2001.
Cytokine.
16(3):106-19; Delgado et al., 1996. Br J Cancer. 73(2):175-82. Another non-limiting example of modification consist in the modification of the human Fc region of the antibody in order to enhance their affinity for an Fcy receptor. Methods of enhancing Fc receptor binding include Fc amino acid modification and modification of Fc carbohydrate structures. For immunoglobulins, it has been demonstrated that the attachment of an N-linked oligosaccharide to Asn-297 of the CH2 domain is critical for ADCC
activity.
Removal of the N-linked oligosaccharide through mutation of the N-linked consensus site or by enzymatic means results in little or no ADCC activity. Removal of the core a-1,6-fucose moiety from IgG1 Fc oligosaccharides has been demonstrated to improve FcyRIII
binding and ADCC activity (see, e.g., Carter, 2001. Nat Rev Cancer. 1(2):118-29; Kanda et at, 2007. Glycobiology. 17(1):104-18; Shields et al., 2002. J Biol Chem.
277(30):26733-40; Shinkawa et al., 2003. J Biol Chem. 278(5):3466-73; Niwa et al., 2004. Cancer Res. 64(6):2127-33). The level of another glycoform, bisected N-linked carbohydrate, has also been suggested to increase ADCC (see, e.g., Umalia et al., 1999.
NatBiotechnol. 17(2):176-80; Hodoniczky eta, 2005. BiotechnolProg. 21(6):1644-52).
A variety of Fc sequence variants with optimized binding affinity for FcyRs and/or enhanced ADCC have been described and are known in the art.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention targets, blocks, depletes and/or kills senescent cells to which it is bound.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention targets, blocks, depletes and/or kills senescent cells expressing at least one senescent cell-associated antigen, as defined hereinabove.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention may comprise human HCCRs (heavy chain constant regions) and allows to target, block, deplete and/or kill DEP1-expressing cells to which it is bound.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention may comprise human HCCRs (heavy chain constant regions) and allow to target, block, deplete and/or kill DPP4-expressing cells to which it is bound.
In one embodiment where the isolated antibody or antigen-binding fragment thereof is a bispecific antibody as described above, said bispecific antibody may comprise human HCCRs (heavy chain constant regions) and allow to target, block, and/or deplete DEP1-and/or DPP4-expressing cells to which it is bound.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention depletes and/or kills DEP1-expressing cells to which it is bound.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention depletes and/or kills DPP4-expressing cells to which it is bound.
In one embodiment where the isolated antibody or antigen-binding fragment thereof is a bispecific antibody as described above, said bispecific antibody depletes and/or kills DEP1- and/or DPP4-expressing cells to which it is bound.
By "deplete" or "depleting", it is referred to the killing, elimination, lysis, or induction of such killing, elimination or lysis, so as to negatively affect the number of cells to which the isolated antibody or antigen-binding fragment thereof is bound (such as, e.g., DEP1-and/or DPP4-expressing cells) present in a sample or in a subject. In one embodiment, such depletion occurs via ADCC. In one embodiment, such depletion occurs via ADCP.
In one embodiment, such depletion occurs via CDC.
Thus, in one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention leads, directly or indirectly, to the depletion of senescent cells, in particular of DEP1- and/or DPP4-expressing cells.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention leads, directly or indirectly, to the depletion of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of senescent cells, in particular of DEP1- and/or expressing cells.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention leads, directly or indirectly, to a decrease by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more elimination of the number of senescent cells, in particular of DEP1- and/or DPP4-expressing cells.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention induces any one or several, such as two or three, of:
- antibody dependent cellular cytotoxicity (ADCC);
- antibody-dependent cell-mediated phagocytosis (ADCP);
- complement-dependent cytotoxicity (CDC).
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is from the IgG1 subclass and has any one or several, such as two or three, of:
- antibody dependent cellular cytotoxicity (ADCC);
- antibody-dependent cell-mediated phagocytosis (ADCP);
- complement-dependent cytotoxicity (CDC).
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is linked/fused/conjugated to a payload, e.g., a therapeutic moiety.
Such conjugates are referred to herein as an "antibody drug conjugates" or "ADCs".
In one embodiment, the payload is selected from chemotherapeutic agents, targeted therapy agents, cytotoxic agents, antibiotics, antivirals, cell cycle-synchronizing agents, ligands for cellular receptor(s), immunomodulatory agents, pro-apoptotic agents, anti-angiogenic agents, cytokines, growth factors, hormones, coding or non-coding oligonucleotides, photodetectable labels, contrast agents, radiolabels, and the like.
Another object of the present invention is a nucleic acid encoding the antigen-binding domain, the antibody or the antigen-binding fragment thereof of the invention.
Another object of the present invention is a vector comprising the nucleic acid encoding the antigen-binding domain, the antibody or the antigen-binding fragment thereof of the invention.
In one embodiment, the vector is an expression vector and further comprises regulatory elements allowing for expression of the antigen-binding domain, the antibody or the antigen-binding fragment thereof, in a cell.
In one embodiment, the expression vector may be monocistronic. By "monocistronic", it is meant that a single nucleic acid encoding a single protein is expressed in a single expression vector.
In one embodiment, the expression vector comprises a sequence encoding the HCVR of the antigen-binding domain, the antibody or the antigen-binding fragment thereof of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises a sequence encoding the HCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment thereof of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises a sequence encoding the HCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 55 to 74.
In one embodiment, the expression vector comprises a sequence encoding the HCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises a sequence encoding the HCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 174 to 201.
In one embodiment, the expression vector comprises a sequence encoding the LCVR of the antigen-binding domain, the antibody or the antigen-binding fragment thereof of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises a sequence encoding the LCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises a sequence encoding the LCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 75 to 94.
In one embodiment, the expression vector comprises a sequence encoding the LCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises a sequence encoding the LCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 202 to 227.
In one embodiment, the expression vector may be polycistronic. By "polycistronic", it is meant that at least two or more nucleic acids, each encoding a single protein, are expressed in a single expression vector.
In one embodiment, the expression vector comprises:
- a sequence encoding the HCVR of the antigen-binding domain, the antibody or the antigen-binding fragment thereof of the invention, preferably operably linked to regulatory elements, and - a sequence encoding the LCVR of the antigen-binding domain, the antibody or the antigen-binding fragment thereof of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises:
- a sequence encoding the HCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, and - a sequence encoding the LCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises:
- a sequence encoding the HCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 55 to 74, and - a sequence encoding the LCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 75 to 94.
In one embodiment, the expression vector comprises:
- a sequence encoding the HCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, and - a sequence encoding the LCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, wherein said sequence encoding the HCVR and said sequence encoding the LCVR
are selected from the group comprising or consisting of the combinations of HCVR
and LCVR as defined in Table 2.
In one embodiment, the expression vector comprises:
- a sequence encoding the HCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, and - a sequence encoding the LCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises:
- a sequence encoding the HCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 174 to 201, and - a sequence encoding the LCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 202 to 227.
In one embodiment, the expression vector comprises:
- a sequence encoding the HCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, and - a sequence encoding the LCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, wherein said sequence encoding the HCVR and said sequence encoding the LCVR
are selected from the group comprising or consisting of the combinations of HCVR
and LCVR as defined in Table 4.
Another object of the invention is a method of producing and purifying the isolated antibody or antigen-binding fragment thereof of the invention.
In one embodiment, the method comprises:
- culturing host cells comprising the nucleic acid or expression vector of the present invention, under conditions suitable for expression of the antibody or antigen-binding fragment thereof, and - recovering the expressed antibody or antigen-binding fragment thereof.
This recombinant process can be used for large scale production of antibodies or antigen-binding fragments thereof, including monoclonal antibodies intended for in vitro, ex vivo and/or in vivo therapeutic and/or diagnostic uses.
The nucleic acid or expression vector encoding the antibody or antigen-binding fragment, as described herein, may be propagated and expressed according to any of a variety of routinely practiced procedures for nucleic acid excision, ligation, transformation, and transfection. In certain embodiments, expression of the antibody or antigen-binding fragment thereof may be carried out in a prokaryotic host cell (i.e., the host cell comprising the nucleic acid or expression vector of the present invention is a prokaryotic host cell), such as Escherichia coli (see, e.g., Pluckthun et al, 1989.
Methods Enzymol.
178:497-515). In certain other embodiments, the antibody or antigen-binding fragment thereof may be expressed in a eukaryotic host cell (i.e., the host cell comprising the nucleic acid or expression vector of the present invention is an eukaryotic host cell), including animal cells (such as mammalian cells), yeast (e.g., Saccharomyces cerevisiae, Schizosaccharomyces porn be, or Pichia pastoris); and plant cells. Examples of suitable animal cells include, but are not limited to, myeloma, HEK293, COS, or CHO
cells.
Examples of plant cells include tobacco, corn, soybean, and rice cells. By methods known to those having ordinary skill in the art and based on the present disclosure, a nucleic acid vector may be designed for expressing foreign sequences in a particular host system, and then polynucleotide sequences encoding the cellular polypeptide may be inserted. The regulatory elements will vary as appropriate for the particular host.
All these processes are well known in the art (Subramanian (Ed.), 2004.
Antibodies (1st ed., Vol. 1: Production and Purification). New York, NY: Springer US).
In an embodiment, the expressed antibody or antigen-binding fragment thereof is further purified.
Methods to purify the antibody or antigen-binding fragment thereof of the invention are well known in the art (Subramanian (Ed.), 2004. Antibodies (1st ed., Vol. 1:
Production and Purification). New York, NY: Springer US), and include, without limitation, chromatography, preferably by affinity chromatography, more preferably by affinity chromatography on protein L agarose.
Another object of the present invention is a chimeric antigen receptor (CAR) comprising:
(i) at least one extracellular binding domain, comprising or consisting of at least one antigen-binding domain directed to a senescent cell-associated antigen, (ii) an extracellular spacer domain, (iii) a transmembrane domain, (iv) optionally, at least one costimulatory domain, and (v) at least one intracellular signaling domain.
In one embodiment, the CAR of the invention comprises at least one extracellular binding domain (also called ectodomain), wherein said at least one extracellular binding domain recognizes and is capable of binding to a senescent cell-associated antigen, as defined hereinabove. In one embodiment, the extracellular binding domain comprises or consists of an antigen-binding domain directed to a senescent cell-associated antigen, which recognizes and is capable of binding to a senescent cell-associated antigen, as defined hereinabove.
In one embodiment, the senescent cell-associated antigen is selected from the group comprising or consisting of DEP1 and DPP4. Hence, in one embodiment, the at least one extracellular binding domain of the CAR of the invention recognizes and is capable of binding to DEP1 and/or DPP4. In one embodiment, the extracellular binding domain comprises or consists of an antigen-binding domain directed to DEP1 and/or DPP4, which recognizes and is capable of binding to DEP1 and/or DPP4, as defined hereinabove.
In one embodiment, the at least one extracellular binding domain in the CAR of the invention recognizes and is capable of binding to DEP1, such as, e.g., human DEP1, or orthologs thereof, including murine and rat DEP1. In one embodiment, the at least one extracellular binding domain in the CAR of the invention recognizes and is capable of binding to human DEP1 (hDEP1) with SEQ ID NO: 1. In one embodiment, the at least one extracellular binding domain in the CAR of the invention recognizes and is capable of binding to the extracellular domain of human DEP1 (hDEP1) comprising or consisting of amino acid residues 36 ¨ 975 of SEQ ID NO: 1. In one embodiment, the extracellular binding domain comprises or consists of a DEP1-binding domain, as defined hereinabove. Hence, the CAR of the invention is an "anti-DEP1 chimeric antigen receptor (CAR)".
In one embodiment, the at least one extracellular binding domain in the CAR of the invention recognizes and is capable of binding to DPP4, such as, e.g., human DPP4 or orthologs thereof, including murine and rat DPP4. In one embodiment, the at least one extracellular binding domain in the CAR of the invention recognizes and is capable of binding to human DPP4 (hDPP4) with SEQ ID NO: 101. In one embodiment, the at least one extracellular binding domain in the CAR of the invention recognizes and is capable of binding to the extracellular domain of human DPP4 (hDPP4) comprising or consisting of amino acid residues 29 - 766 of SEQ ID NO: 101. In one embodiment, the extracellular binding domain comprises or consists of a DPP4-binding domain, as defined hereinabove.
Hence, the CAR of the invention is an "anti-DDP4 chimeric antigen receptor (CAR)".
In one embodiment, the at least one extracellular binding domain in the CAR of the invention comprises an antigen-binding domain, as described hereinabove.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain, as described hereinabove.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 1.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 1.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-13-R2A-C1, 5738-13-R2A-D3, 5738-13-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R3A-C6, 5738-10-R3A-D5, 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-13-R4A-D11, .. and 5738-13-R2A-H4.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-C1 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R2A-D3 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R4A-D11 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R3A-F5 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-F11 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-H3 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-H4 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H9 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R4A-H11 as defined in Table 1.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, said combination being as defined in Table 2.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-13-R2A-C1, 5738-13-R2A-D3, 5738-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-10-R3A-C6, 5738-10-R3A-D5, 5738-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-10-R4A-G12, 5738-13-R4A-D11, and .. 5738-13-R2A-H4.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R2A-C1 as defined in Table 2. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R2A-D3 as defined in Table 2. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5738-13-R4A-D11 as defined in Table 2. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R3A-F5 as defined in Table 2. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R4A-F11 as defined in Table 2. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5738-13-R2A-H3 as defined in Table 2.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R2A-H4 as defined in Table 2. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R4A-H9 as defined in Table 2. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5738-13-R4A-H11 as defined in Table 2.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain, as described hereinabove.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 3.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 3.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-A10, 5826-13-R3A-B1, 5826-13-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13 -R4A-E6, 5826-13 -R4A-E9, 5826-13 -R4A-F10, 5826-13 -R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-8-R6A-E10, 5826-8-R5A-G8, 5826-8-R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-A10 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R3A-B1 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-B3 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-D5 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the .. invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R3A-D6 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-E2 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-E6 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-E9 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-F10 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination .. being that of clone 5826-13-R4A-G11 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-G12 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H1 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H2 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H3 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H4 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H5 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H6 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H9 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H10 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H11 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H12 as defined in Table 3.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, said combination being as defined in Table 4.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-13-R3A-A10, 5826-13-R3A-B1, 5826-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13-R4A-E6, 5826-13-R4A-E9, 5826-13-R4A-F10, 5826-13-R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-8-R6A-E10, 5826-8-R5A-G8, 5826-8-R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-13-R3A-D5, 5826-13-R4A-H5, and 13-R4A-H12.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R3A-A10 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-B1 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the .. invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R3A-B3 as defined in Table 4.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R3A-D5 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-D6 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-E2 as defined in Table 4.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-E6 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-E9 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-F10 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-G11 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-G12 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H1 as defined in Table 4.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-H2 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H3 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H4 as defined in Table 4.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-H5 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H6 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H9 as defined in Table 4.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-H10 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H11 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H12 as defined in Table 4.
In one embodiment, the extracellular binding domain of the CAR of the invention comprises or consists a single chain variable region (scFv) or a Fab fragment, preferably a scFv, comprising an one antigen-binding domain as defined hereinabove.
In one embodiment, the CAR of the invention comprises more than one extracellular binding domain, such as 2 extracellular binding domains, 3 extracellular binding domains or more. Such CARs are called "tandem CARs" or "multispecific CARs", such as bispecific, trispecific, etc.
In this embodiment, the CAR of the invention is multispecific and comprises extracellular binding domains, wherein at least one of the extracellular binding domains recognizes and is capable of binding to a senescent cell-associated antigen.
In one embodiment, the CAR of the invention is multispecific and comprises extracellular binding domains, each of which recognizes and is capable of binding to a different senescent cell-associated antigen.
In one embodiment, the CAR of the invention is multispecific and comprises extracellular binding domains, wherein one extracellular binding domain recognizes and is capable of binding to either of DEP1 or DPP4, and at least one other extracellular binding domain recognizes and is capable of binding to another senescent cell-associated antigen.
In one embodiment, the CAR of the invention is multispecific and comprises extracellular binding domains, wherein one extracellular binding domain recognizes and is capable of binding to DEP1, and at least one other extracellular binding domain recognizes and is capable of binding to DPP4.
In one embodiment, the CAR of the invention is bispecific and comprises two extracellular binding domains, wherein one extracellular binding domain recognizes and is capable of binding to DEP1, and the other extracellular binding domain recognizes and is capable of binding to DPP4.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 1; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 3, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 1; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 3, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-13-R2A-C1, 5738-13-R2A-D3, 5738-13-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-A10, 5826-13-R3A-B1, 5826-13-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13-R4A-E6, 5826-13-R4A-E9, 5826-13-R4A-F10, 5826-13-R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R3A-C6, 5738-10-R3A-D5, 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-8-R6A-E10, 5826-8-R5A-G8, 5826-8-R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-13-R4A-D11, and 5738-13-R2A-H4; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, said combination being as defined in Table 2; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, said combination being as defined in Table 4, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2:
5738-13-R2A-C1, 5738-13-R2A-D3, 5738-13-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4:
5826-13-R3A-A10, 5826-13-R3A-B1, 5826-13-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13-R4A-E6, 5826-13-R4A-E9, 5826-13-R4A-F10, 5826-13-R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2:
5738-10-R3A-C6, 5738-10-R3A-D5, 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4:
5826-8-R6A-E10, 5826-8-R5A-G8, 5826-8-R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2:
5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4:
5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2:
5738-13-R4A-D11, and 5738-13-R2A-H4; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4:
5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12, as described and defined hereinabove.
Additionally or alternatively, the CAR of the invention is multispecific and comprises extracellular binding domains, wherein at least two extracellular binding domains recognize and are capable of binding to the same senescent cell-associated antigen, but on different epitopes of said senescent cell-associated antigen.
Such multispecific CARs typically comprise:
(i) two of more extracellular binding domains, as defined hereinabove, (ii) one extracellular spacer domain, (iii) one transmembrane domain, (iv) optionally, at least one costimulatory domain, and (v) at least one intracellular signaling domain.
In a multispecific CAR, each extracellular binding domain comprises or consists of a single chain variable region (scFv) or a Fab fragment, preferably a scFv, comprising the antigen-binding domain as defined hereinabove.
In one embodiment, the extracellular binding domains in the multispecific CAR
of the invention are linked or fused together through a flexible peptidic linker, enabling each extracellular binding domain to form the desired structure for antigen binding (Pluckthun, 1994. "Antibodies from Escherichia coli". In Rosenberg & Moore (Eds.), The pharmacology of monoclonal antibodies. Handbook of Experimental Pharmacology, 113:269-315. Springer: Berlin, Heidelberg). Flexible peptidic linkers are generally composed of small, non-polar (e.g., glycine, Gly, G) or polar (e.g., serine, Ser, S; or threonine, Thr, T) amino acids, as suggested by Argos (1990. J Mol Biol.
211(4):943-958). The small size of these amino acids provides flexibility, and allows for mobility of the connecting functional domains, such as the extracellular binding domains.
In one embodiment, the flexible peptidic linker may be a short oligo- or polypeptide, preferably having a length ranging from 2 to 30 amino acids. In one embodiment, the flexible peptidic linker comprises glycine-serine repeats. In one embodiment, the flexible peptidic linker comprises one, or several repeats of, such as 2, 3, 4, 5 or more repeats of, GS
linker(s) (i.e., a sequence of one Gly and one Ser), G2S linker(s) (i.e., a sequence of two Gly and one Ser), G3S linker(s) (i.e., a sequence of three Gly and one Ser), G4S linker(s) (i.e., a sequence of four Gly and one Ser), or G5S linker(s) (i.e., a sequence of five Gly and one Ser).
In one embodiment, the CAR of the invention comprises an extracellular spacer domain (also called hinge domain).
In one embodiment, the at least one extracellular binding domain is connected to one transmembrane domain through one extracellular spacer domain.
The extracellular spacer domain typically facilitates proper protein folding, provides flexibility to the at least one extracellular binding domain and helps avoiding steric hindrance. It typically comprises a hydrophilic region linking the at least one extracellular binding domain and the transmembrane domain.
Extracellular spacer domains may include, but are not limited to, Fc fragments of antibodies or fragments or derivatives thereof, hinge regions of antibodies or fragments or derivatives thereof, CH2 regions of antibodies, CH3 regions antibodies, artificial spacer sequences or combinations thereof.
Examples of extracellular spacer domains include, but are not limited to, CD8a hinge;
CD28 hinge; flexible peptidic linkers (such as, e.g., Gly3); or hinge region, CH1, CH2 and/or CH3 domains of IgG' s (such as human IgG4).
In one embodiment, the extracellular spacer domain is selected from the group comprising or consisting of (i) a hinge region, CH2 domain and CH3 domain of IgG4, (ii) a hinge region of IgG4, (iii) a hinge region and CH2 domain of IgG4, (iv) a hinge region of CD8a, (v) a hinge region, CH2 domain and CH3 domain of IgGl, (vi) a hinge region of IgG1 (vii) a hinge region and CH2 domain of IgGl, and (viii) a hinge region of CD28;
and combinations thereof Additional extracellular spacer domains will be apparent to those skilled in the art and may be used in connection with alternate embodiments of the invention.
In one embodiment, the CAR of the invention comprises a transmembrane domain.
In one embodiment, the transmembrane domain comprises an amino acid sequence derived from the transmembrane domain of any protein which has such transmembrane domain, including any of the type I, type II or type III transmembrane proteins.
In one embodiment, the transmembrane domain may also comprise an artificial hydrophobic sequence.
Examples of transmembrane domains that are suitable in the CAR of the invention include, but are not limited to, transmembrane domains of an a, 0 or chain of a T cell receptor, or of CD28, CD3y, CD36, CD3c, CD3c CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, 0X40, CD2, CD27, LFA-1 (CD1 la, CD18), ICOS (CD278), 4-1BB (CD137), GITR (CD357), .. CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2Ry, IL7Ra, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD 1 1 a, LFA-1, ITGAM, CD1 lb, PD1, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM
(CD355), Ly9 (CD229), CD160 (BY55), PSGL1, CDIO0 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IP0-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG/Cbp, NKp44, NKp30, NKp46, NKG2D or NKG2C.
In one embodiment, the transmembrane domain comprises an amino acid sequence derived from the transmembrane domain of CD28 or CD3.
Additional transmembrane domains will be apparent to those skilled in the art and may be used in connection with alternate embodiments of the invention.
In one embodiment, the transmembrane domain may be recombinant, in which case it will comprise predominantly hydrophobic amino acids, such as, e.g., valine, Val, V or leucine, Leu, L.
In one embodiment, the CAR of the invention can optionally comprise one or several costimulatory domain(s).
Costimulatory domains enhance cell proliferation, cell survival and development of memory cells.
Examples of costimulatory domains that are suitable in the CAR of the invention include, but are not limited to, costimulatory domains of any of the members of the TNFR super family, CD28, CD137 (4-1BB), CD134 (0X40), Dap10, CD27, CD2, CD5, ICAM-1, Lck, TNFR-1, TNFR-II, Fas, CD30, CD40, CTLA-4, ICOS, PD-1, and combinations thereof.
Costimulatory domains from other proteins may also be used with the CARs of the invention. Additional costimulatory domains will be apparent to those skilled in the art and may be used in connection with alternate embodiments of the invention.
If the CAR of the invention comprises more than one costimulatory domain, these domains may be arranged in tandem, optionally separated by a linker, such as a flexible peptidic linker as has been described above.
In one embodiment, the costimulatory domain comprises a T cell costimulatory molecule, or a sequence derived therefrom.
In one embodiment, the CAR of the invention comprises at least one costimulatory domain selected from the group comprising or consisting of 4-1BB, ICOS, CD27, 0X40, CD28, CTLA4 and PD-1.
In one embodiment, the CAR of the invention comprises at least one intracellular signaling domain (also called endodomain).
The intracellular signaling domain is cytoplasmic, and allows to transduce the effector function signal and direct the cell to perform its specialized function upon binding of the extracellular binding domain to its antigen.
Examples of intracellular signaling domains that are suitable in the CAR of the invention include, but are not limited to, chain of the T cell receptor or any of its homologs (such as, e.g., q chain, FccRly and 0 chains, 1V1B1 (Iga) chain, B29 (Igf3) chain, etc.), CD3 polypeptides (such as, e.g., A, 6 and 6), syk family tyrosine kinases (such as, e.g., Syk, ZAP 70, etc.), src family tyrosine kinases (such as, e.g., Lck, Fyn, Lyn, etc.) and other molecules involved in T cell transduction, such as, e.g., CD2, CD5 and CD28.
In one embodiment, the intracellular signaling domain may be human CD3 chain, FcyRIII, FccRI, cytoplasmic tails of Fc receptors, immunoreceptor tyrosine-based activation motif (ITAM) bearing cytoplasmic receptors or combinations thereof Additional intracellular signaling domains will be apparent to those skilled in the art and may be used in connection with alternate embodiments of the invention.
In one embodiment, the at least one intracellular signaling domain may comprise the entire intracellular portion, or the entire native intracellular signaling domain, of the molecule from which it is derived, or a functional fragment or derivative thereof In one embodiment, the at least one intracellular signaling domain comprises or consists of a T cell primary signaling domain (or a sequence derived therefrom).
In one embodiment, the T cell primary signaling domain comprises or consists of a signaling domain of a protein selected in the group of CD3, CD3y, CD3, CD3c, common FcRy (FCER1G), FcRE (Fc Epsilon Rib), CD79a, CD79b, FcyRIIa, DAP10, DAP12, and sequences derived therefrom.
In one embodiment, the T cell primary signaling domain comprises or consists of a functional signaling domain of CD3.
T cell primary signaling domains that act in a stimulatory manner may comprise signaling motifs known as immunoreceptor tyrosine-based activation motifs (ITAMS).
Examples of ITAM containing T cell primary intracellular signaling domains that are of particular use in the invention include, but are not limited to, those of (or derived from) CD3c common FcRy (FCER1G), FcyRIIa, FcRf3 (FccR1b), CD3y, CD36, CD3c, CD5, CD22, CD66b, CD79a, CD79b, DAP10, and DAP12.
In one embodiment, the T cell primary signaling domain comprises a modified ITAM
domain (e.g., a mutated ITAM domain which has altered e.g., increased or decreased) activity as compared to the native ITAM domain. In one embodiment, a primary signaling domain comprises a modified ITAM-containing primary intracellular signaling domain, e.g., an optimized and/or truncated ITAM-containing primary intracellular signaling domain. In one embodiment, a primary signaling domain comprises one, two, three, four or more ITAM motifs.
In one embodiment, the at least one intracellular signaling domain and the at least one costimulatory domain, if present, may be linked to each other in tandem, in a random or in a specified order.
Optionally, a linker, such as a flexible peptidic linker as has been described above, may form the linkage between distinct intracellular signaling domains, and/or between a costimulatory domain and an intracellular signaling domain. Besides flexible peptidic linkers described above, a single amino acid (such as, e.g., alanine, Ala, A
or glycine, Gly, G) may also be a suitable linker.
In one embodiment, the CAR of the invention comprises more than one intracellular signaling domain, such as 2, 3, 4, 5, or more, intracellular signaling domains.
In one embodiment, the CAR of the invention may further comprise a tag, such as, e.g., a tag for quality control, enrichment, tracking in vivo and the like.
In one embodiment, said tag is localized N-terminally, C-terminally and/or internally.
Examples of tags that that are suitable in the CAR of the invention include, but are not limited to, hemagglutinin tag, poly-arginine tag, poly-histidine tag, Myc tag, strep tag, S-tag, HAT tag, 3xFlag tag, calmodulin-binding peptide (CBP) tag, SBP tag, chitin binding domain (CBD) tag, GST tag, maltose-binding protein (MBP) tag, fluorescent protein tag, T7 tag, V5 tag and Xpress tag.
The CAR of the invention may be a first-generation, second-generation or third-generation CAR.
The first generation of CARs was developed more than 30 years ago (Kuwana et al., 1987. Biochem Biophys Res Commun. 149(3):960-968; Gross et al., 1989.
Transplant Proc. 21(1 Pt 1):127-130; Gross et al., 1989. Proc Natl Acad Sci USA.
86(24):10024-10028).
In one embodiment, the CAR of the invention is a first-generation CAR and comprises:
(i) at least one extracellular binding domain, (ii) an extracellular spacer domain, (iii) a transmembrane domain, and (iv) one or more intracellular signaling domain(s).
A first-generation CAR can be, for example, a CAR in which signaling is provided by CD3c i.e., the intracellular signaling domain is CD3.
Second-generation CARs add a co-stimulatory domain, such as, e.g., CD28 or 4-1BB.
The involvement of these intracellular signaling domains improve T cell proliferation, cytokine secretion, resistance to apoptosis, and in vivo persistence.
In one embodiment, the CAR of the invention is a second-generation CAR and comprises:
(i) at least one extracellular binding domain, (ii) an extracellular spacer domain, (iii) a transmembrane domain, (iv) a costimulatory domain(s), and (v) one or more intracellular signaling domain(s).
Third-generation CARs combine multiple co-stimulatory domains, such as, e.g., 4-1BB or CD28-0X40, to increase T cell activity.
In one embodiment, the CAR of the invention is a third-generation CAR and comprises:
(i) at least one extracellular binding domain, (ii) an extracellular spacer domain, (iii) a transmembrane domain, (iv) at least two costimulatory domains, and (v) one or more intracellular signaling domain(s).
Another object of the present invention is a nucleic acid encoding the CAR of the invention.
Another object of the present invention is a vector comprising the nucleic acid encoding the CAR of the invention.
In one embodiment, the nucleic acid or vector of the invention comprises a nucleic acid sequence of the extracellular binding domain(s) operably linked to the nucleic acid sequence of an extracellular spacer domain, operably linked to the nucleic acid sequence of a transmembrane domain, operably linked to the nucleic acid sequence of a cytoplasmic domain (i.e., at least one intracellular signaling domain and optionally, at least one costimulatory domain).
The nucleic acid or the vector of the invention can be prepared in conventional ways (e.g., recombinant methods), where the genes and regulatory regions may be isolated, as appropriate, ligated, and cloned in an appropriate cloning host, analyzed by restriction or sequencing, or other convenient means. Particularly, using PCR, individual fragments including all or portions of a functional unit may be isolated, where one or more mutations may be introduced using "primer repair", ligation, in vitro mutagenesis, etc., as appropriate. Alternatively, the gene of interest can be produced synthetically, rather than cloned.
In one embodiment, the vector comprises a first nucleic acid encoding a CAR of the invention, and further comprises a second nucleic acid encoding an antibody or antigen-binding fragment thereof, a bispecific antibody (e.g., a BiTE), a cytokine or a costimulatory ligand. In one embodiment, the first nucleic acid and the second nucleic acid are each operably linked to a promoter. In one embodiment, the first nucleic acid is operably linked to a first promoter and the second nucleic acid is operably linked to a second promoter. The promoter can be a constitutively-expressed promoter (e.g., an EFla promoter) or an inducibly-expressed promoter (e.g., a NFAT promoter).
In one embodiment, expression of the CAR and expression of the antibody or antigen-binding fragment thereof, bispecific antibody (e.g., a BiTE), cytokine or costimulatory ligand are driven by the same promoter, e.g., a constitutively expressed promoter (e.g., an EF la promoter). In one embodiment, expression of the CAR and expression of the antibody or antigen-binding fragment thereof, bispecific antibody (e.g., a BiTE), cytokine or costimulatory ligand are driven by different promoters.
In one embodiment, the nucleic acid encoding the CAR can be located upstream or downstream of the second nucleic acid encoding the antibody or antigen-binding fragment thereof, the bispecific antibody (e.g., a BiTE), the cytokine or the costimulatory ligand.
Another object of the present invention is an immune cell, preferably an isolated immune cell engineered to express the chimeric antigen receptor (CAR) of the invention at its surface.
In one embodiment, the immune cell of the invention expresses at its cell surface a CAR
comprising an extracellular binding domain comprising or consisting of an antigen-binding domain directed to a senescent cell-associated antigen, which recognizes and is capable of binding to a senescent cell-associated antigen, as defined hereinabove.
In one embodiment, the immune cell of the invention expresses at its cell surface an anti-DEP1 chimeric antigen receptor (CAR), as defined hereinabove.
In one embodiment, the immune cell of the invention expresses at its cell surface an anti-DPP4 chimeric antigen receptor (CAR), as defined hereinabove.
In one embodiment, the immune cell of the invention expresses at its cell surface at least two CARs, wherein the first CAR and the second CAR recognize two different senescent cell-associated antigens.
In one embodiment, the immune cell of the invention expresses at its cell surface at least two CARs, wherein the first CAR is an anti-DEP1 chimeric antigen receptor, and the second CAR is an anti-DPP4 chimeric antigen receptor, as defined hereinabove.
In one embodiment, the immune cell of the invention expresses at its cell surface a multispecific CAR, as defined hereinabove.
In one embodiment, the immune cell of the invention expresses at its cell surface a bispecific CAR, comprising two extracellular binding domains, wherein one extracellular binding domain recognizes and is capable of binding to DEP1, and the other extracellular binding domain recognizes and is capable of binding to DPP4, as defined hereinabove.
In one embodiment, the immune cell of the invention further expresses at its cell surface a bispecific T cell engager (BiTE).
In one embodiment, the BiTE binds to at least one senescent cell-associated antigen and at least one non-senescent cell-associated antigen, as defined hereinabove.
In one embodiment, the immune cell of the invention is a T cell, preferably an isolated T cell. In one embodiment, the immune cell is a CDS+ T cell, a CD4+ T cells, a natural killer (NK) cell or an NKT cell.
In one embodiment, the immune cell of the invention is a cytotoxic T cell (also known as TC, cytotoxic T lymphocyte, CTL, T-killer cell, cytolytic T cell, CDS+ T cells or killer T cell). NK cells and NKT cells are also encompassed in the invention.
In one embodiment, the T cell is a CDS+ T cytotoxic lymphocyte cell selected from the group comprising or consisting of naive CDS+ T cells, CDS+ memory T cells, central memory CDS+ T cells, regulatory CDS+ T cells, IPS-derived CDS+ T cells, effector memory CDS+ T cells and bulk CDS+ T cells.
In one embodiment, the T cell is a CD4+ T helper lymphocyte cell selected from the group comprising or consisting of naive CD4+ T cells, CD4+ memory T cells, central memory CD4+ T cells, regulatory CD4+ T cells, IPS-derived CD4+ T cells, effector memory CD4+
T cells and bulk CD4+ T cells.
In one embodiment, the immune cell of the invention is cytotoxic for cells expressing at their surface the senescent cell-associated antigen recognized by the CAR
(such as, e.g., DEP1 and/or DPP4). In one embodiment, the immune cell of the invention is not cytotoxic for cells expressing at their surface the senescent cell-associated antigen recognized by the CAR (such as, e.g., DEP1 and/or DPP4).
In one embodiment, the immune cell of the invention is a phagocytic cell.
In one embodiment, the immune cell of the invention is a phagocytic cell selected from the group comprising or consisting of macrophages, monocytes, histiocytes, Kupffer cells, alveolar macrophages, microglial cells and dendritic cells.
In one embodiment, the immune cell of the invention is a mammal immune cell, preferably a human immune cell.
In one embodiment, the immune cells of the invention is an autologous cell, a syngeneic cell, an allogenic cell, or a xenogeneic cell.
Another object of the present invention is a population of immune cells, comprising a plurality of immune cells of the invention.
In one embodiment, the population of immune cells may be homogeneous, i.e., composed at more than 50%, such as more than 60%, 70%, 80%, 90%, 95% or more of the same immune cells, i.e., immune cells of same nature, origin, and/or expressing the same CAR
at their cell surface.
In one embodiment, the population of immune cells may be heterogeneous, i.e., composed of a mix of different immune cells, i.e., immune cells of different nature, origin, and/or expressing a different CAR at their cell surface.
Another object of the present invention is a method of obtaining an immune cell expressing the CAR of the invention at its surface, or a population of such immune cells.
Means and methods to obtain immune cells expressing the CAR of the invention at its surface, or a population of such immune cells, are well known in the art.
In one embodiment, the method for obtaining an immune cell expressing the CAR
of the invention at its surface, or a population of such immune cells, comprises one or several of:
- a step of isolating an immune cell or population of immune cells (e.g., T cells or phagocytic cells) from a sample obtained from a subject, - optionally, a step of selecting a specific subpopulation of immune cells, - a step of transducing the immune cell or population of immune cells with a nucleic acid encoding the CAR of the invention, - optionally, a step of expanding the transduced immune cell or population of immune cells, - optionally, a step of washing the immune cell or population of immune cells, - optionally, a step of cryopreserving the immune cell or population of immune cells.
Prior to transduction and expansion of the immune cell of the invention, a source of immune cells (e.g., T cells or phagocytic cells) is obtained from a subject.
Thus, in one embodiment, the immune cell or the population of immune cells of the invention is isolated and/or substantially purified.
T cells and/or phagocytic cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors.
In one embodiment, any number of T cell and/or phagocytic cells lines available in the art may be used.
In one embodiment, T cells and/or phagocytic cells can be obtained from a unit of blood collected from a subject using any number of techniques known to those skilled in the art, such as FicollTM separation.
In one embodiment, cells from the circulating blood of a subject are obtained by apheresis. The apheresis product typically contains lymphocytes, including T
cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets.
.. In one embodiment, cells from the circulating blood of a subject are obtained by leukapheresis. In one embodiment, cells collected by leukapheresis may be washed to remove the plasma fraction and to place the cells in an appropriate buffer or media for subsequent processing steps. In one embodiment of the invention, the cells are washed with phosphate buffered saline (PBS). In one embodiment, the wash solution lacks .. calcium, and may lack magnesium or many if not all divalent cations. After washing, the cells may be resuspended in a variety of biocompatible buffers, such as, e.g., Ca2+-free, Mg2+-free PBS, PlasmaLyte A, or other saline solution with or without buffer.
Alternatively, the undesirable components of the leukapheresis sample may be removed and the cells directly resuspended in culture media.
In one embodiment, T cells and/or phagocytic cells are isolated from peripheral blood lymphocytes by lysing the red blood cells and depleting the monocytes, e.g., by centrifugation through a PERCOLLTM gradient or by counterflow centrifugal elutriation.
A specific subpopulation of T cells can be further isolated by positive or negative selection techniques. Those skilled in the art would recognize that multiple rounds of selection can also be used in the context of this invention.
In one embodiment, it may be desirable to perform the selection procedure and use the "unselected" cells in the activation and expansion process. "Unselected" cells can also be subjected to further rounds of selection. Enrichment of a T cell population by negative selection can be accomplished with a combination of antibodies directed to surface markers unique to the negatively selected cells. One method is cell sorting and/or selection via negative magnetic immuno-adherence or flow cytometry that uses a cocktail of monoclonal antibodies directed to cell surface markers present on the cells negatively selected.
For example, to enrich CD4+ cells by negative selection, a monoclonal antibody cocktail typically includes antibodies directed to CD14, CD20, CD1 lb, CD16, HLA-DR, and CD8. To deplete T regulatory cells, anti-CD25 conjugated beads or other similar method of selection can be used. To enrich a population of monocytes, macrophages and/or dendritic cells by negative selection, a monoclonal antibody cocktail typically includes antibodies to CD34, CD3, CD4, CD8, CD14, CD19 or CD20. Those skilled in the art are familiar with such means and methods.
In one embodiment, the immune cell or population of immune cells of the invention is transduced with a nucleic acid encoding the CAR of the invention, or with a vector comprising the nucleic acid encoding the CAR of the invention, and optionally expanded.
Methods for transfecting eukaryotic cells and tissues removed from an organism in an ex vivo method are known to those skilled in the art. In one embodiment, the method is an ex vivo method. Thus, it is contemplated that cells or tissues may be removed and transfected ex vivo using nucleic acids or vectors of the invention. In one embodiment, the transplanted cells or tissues may be placed into an organism. In one embodiment, a nucleic acid is expressed in the transplanted immune cell population.
The nucleic acid encoding the CAR of the invention, once completed and demonstrated to have the appropriate sequences, may be introduced into the immune cell by any convenient means, including, but not limited to, by fusion, electroporation, biolistics, transfection, lipofection, or the like. Alternatively, the nucleic acid encoding the CAR of the invention may also be integrated and packaged into non-replicating, defective viral genomes like adenovirus, adeno-associated virus (AAV), or herpes simplex virus (HSV) or others, including retroviral vectors or lentiviral vectors, for infection or transduction into cells. The nucleic acid encoding the CAR of the invention may include viral sequences for transfection, if desired. The engineered cells may be grown and expanded in culture before introduction of the construct(s), followed by the appropriate treatment for introduction of the construct(s) and integration of the construct(s). The engineered cells are then expanded and screened by virtue of a marker present in the construct.
Various markers that may be used successfully include hprt, neomycin resistance, thymidine kinase, hygromycin resistance, etc.
In one embodiment, one may have a target site for homologous recombination, where it is desired that a nucleic acid be integrated at a particular locus. For example, one can knock-out an endogenous gene and replace it (at the same locus or elsewhere) with the gene encoded for by the construct using materials and methods as are known in the art for homologous recombination. For homologous recombination, one may use either OMEGA or 0-vectors. See, e.g., Thomas & Capecchi, 1987. Cell. 51(3):503-12;
Mansour et al., 1988. Nature. 336(6197):348-352; and Joyner et al., 1989. Nature.
338(6211):153-156.
The nucleic acid encoding the CAR of the invention may be introduced as a single DNA
molecule encoding at least the CAR of the invention and optionally another gene, or different DNA molecules having one or more genes. Other genes include genes that encode therapeutic molecules or suicide genes, for example. The constructs may be introduced simultaneously or consecutively, each with the same or different markers.
In one embodiment, suicide gene technology may be used. Different suicide gene technologies are described in the art depending on their mechanism of action (Jones et al, 2014. Front Pharmacol. 5:254). Examples of gene-directed enzyme prodrug therapy (GDEPT) converting a nontoxic drug to a toxic drug include herpes simplex virus thymidine kinase (HSV-TK) and cytosine deaminase (CD). Other examples are chimeric proteins composed of a drug binding domain linked to apoptotic components such as for example the inducible Fas (iFas) or the inducible Caspase 9 (iCasp9) systems.
Other examples include systems mediated by therapeutic antibodies such as inducing overexpression of c-myc at the surface of the engineered cell to induce their deletion by administration of an anti-c-myc antibody. The use of EGFR is described as a similar system compared to the c-myc system.
Vectors containing useful elements such as bacterial or yeast origins of replication, selectable and/or amplifiable markers, promoter/enhancer elements for expression in prokaryotes or eukaryotes, etc. that may be used to prepare stocks of construct DNAs and for carrying out transfections are well known in the art, and many are commercially available.
In one embodiment, the step of transducing the immune cell or population of immune cells corresponds to a gene disruption step, a gene correction step or a gene addition step, preferably a gene addition step.
The immune cells that have been transduced with the nucleic acid encoding the CAR of the invention are then grown in culture under selective conditions, to retain only those cells which were successfully transduced.
In one embodiment, the immune cell or the population of immune cells of the invention is or comprises or consists of a genetically modified immune cell.
In one embodiment, the genetically modified immune cell or the population of immune cells of the invention can be or comprise or consist of an allogeneic immune cell. For example, the allogeneic immune cell can be an immune cell lacking expression of a functional human leukocyte antigen (HLA), e.g., HLA class I and/or HLA class II or a T cell receptor (TCR).
In one embodiment, the immune cell or the population of immune cells of the invention can be engineered such that the immune cell does not express a functional HLA
and/or TCR on its surface. For example, an immune cell can be engineered such that cell surface expression HLA, e.g., HLA class 1 and/or HLA class II or non-classical HLA
molecules, is downregulated.
Modified immune cells that lack expression of a functional HLA and/or TCR can be obtained by any suitable means, including a knock-out or knock-down of one or more subunit of HLA. For example, the immune cell can include a knock-down of HLA
using siRNA, shRNA, clustered regularly interspaced short palindromic repeats (CRISPR) transcription-activator like effector nuclease (TALEN), zinc finger endonuclease (ZFN), meganuclease (mn, also known as homing endonuclease), or megaTAL (combining a TAL effector with a mn cleavage domain). Such systems are well known in the art.
In one embodiment, the nucleic acid encoding a CAR as described herein is inserted at a specific locus in the genome of an immune cell, such as, e.g., at the locus of a gene to be deleted. In one embodiment, the nucleic acid encoding a CAR as described herein is inserted within an HLA locus, thereby resulting in the inhibition of HLA
expression.
In one embodiment, the CAR of the invention, when expressed by a T cell or phagocytic cell, confers to the T cell or phagocytic cell the ability to bind to cells expressing DEP1 and/or DPP4 on their cell surface and be activated by DEP1 and/or DPP4, differently from the antigen that the T cells or phagocytic cell are or would have been specific or activated by.
The immune cell population of the invention may thus be defined as a redirected immune cell population. The term "redirected" refers to such immune cells, e.g., a T
cell or phagocytic cell, which carries a CAR as described herein, conferring to the immune cell the ability to bind to and be activated by a ligand that is different from the one the immune cell is or would have been specific or be activated by.
In one embodiment, the immune cell or population of immune cell of the invention can express certain gene products that can kill the modified cells under controlled conditions, such as inducible suicide genes.
In one embodiment, the immune cell or the population of immune cells of the invention is cultured for expansion. In one embodiment, the immune cell or the population of immune cells of the invention comprises or consists of progenitor cells, which are cultured for differentiation and expansion of the immune cells or population of immune cells as described herein.
Whether prior to or after transduction of the immune cells (i.e., T cells or phagocytic cells) to express a desirable CAR as described herein, the immune cells (i.e., T cells and/or phagocytic cells) can be activated and expanded generally using methods as described, e.g., in US6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466;
6,905,681;
7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874;
6,797,514; 6,867,041; and 7,572,631.
In one embodiment, immune cells may be cryopreserved, either after isolation and optionally, selection, and/or after transduction and expansion.
In one embodiment, cryopreserved cells are thawed and washed as described herein and allowed to rest for one hour at room temperature prior to activation.
Also contemplated in the context of the invention is the collection of blood samples or leukapheresis product from a subject at a time period prior to when the expanded cells as described herein might be needed. As such, the source of the cells to be expanded can be collected at any time point necessary, and desired cells, such as T cells and/or phagocytic cells, isolated and frozen for later use in cell therapy for any number of diseases or conditions that would benefit from cell therapy, such as those described herein.
In one embodiment, a blood sample or a leukapheresis product is taken from a generally healthy subject. In one embodiment, a blood sample or a leukapheresis product is taken from a healthy subject who is at risk of developing a disease, but who has not yet developed said disease, and the cells of interest are isolated and cryopreserved for later use. In one embodiment, the T cells and/or phagocytic cells may be expanded, frozen, and used at a later time.
Another object of the invention is a composition comprising, consisting of or consisting essentially of:
an antigen-binding domain, as described above;
an antibody or antigen-binding fragment thereof, as described above;
a nucleic acid encoding the antigen-binding domain, the antibody or the antigen-binding fragment thereof, as described above;
a vector comprising the nucleic acid encoding the antigen-binding domain, the antibody or the antigen-binding fragment thereof, as described above;
a CAR, as described above;
a nucleic acid encoding the CAR, as described above;
- a vector comprising the nucleic acid encoding the CAR, as described above;
an immune cell engineered to express the CAR at its cell surface, as described above;
a population of immune cells engineered to express the CAR at their cell surface, as described above.
In one embodiment, the composition comprises, consists of or consists essentially of:
a DEP1-binding domain, as described above;
an anti-DEP1 antibody or antigen-binding fragment thereof, as described above;
a nucleic acid encoding the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment thereof, as described above;
a vector comprising the nucleic acid encoding the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment thereof, as described above;
an anti-DEP1 CAR, as described above;
a nucleic acid encoding the anti-DEP1 CAR, as described above;
- a vector comprising the nucleic acid encoding the anti-DEP1 CAR, as described above;
an immune cell engineered to express the anti-DEP1 CAR at its cell surface, as described above;
a population of immune cells engineered to express the anti-DEP1 CAR at their cell surface, as described above.
In one embodiment, the composition comprises, consists of or consists essentially of:
a DPP4-binding domain, as described above;
an anti-DPP4 antibody or antigen-binding fragment thereof, as described above;
a nucleic acid encoding the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment thereof, as described above;
a vector comprising the nucleic acid encoding the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment thereof, as described above;
an anti-DPP4 CAR, as described above;
a nucleic acid encoding the anti-DPP4 CAR, as described above;
- a vector comprising the nucleic acid encoding the anti-DPP4 CAR, as described above;
an immune cell engineered to express the anti-DPP4 CAR at its cell surface, as described above;
a population of immune cells engineered to express the anti-DPP4 CAR at their cell surface, as described above.
In one embodiment, the composition comprises, consists of or consists essentially of:
a DEP1-binding domain and a DPP4-binding domain, as described above;
an anti-DEP1 antibody or antigen-binding fragment thereof and an anti-DPP4 antibody or antigen-binding fragment thereof, as described above;
- an anti-DEP1/anti-DPP4 bispecific antibody;
a nucleic acid encoding the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment thereof and a nucleic acid encoding the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment thereof, as described above;
- a nucleic acid encoding the anti-DEP1/anti-DPP4 bispecific antibody, as described above;
a vector comprising the nucleic acid encoding the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment thereof and a vector comprising the nucleic acid encoding the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment thereof, as described above;
a vector comprising the nucleic acid encoding the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment thereof and the nucleic acid encoding the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment thereof, as described above;
- a vector comprising the nucleic acid the anti-DEP1/anti-DPP4 bispecific antibody, as described above;
an anti-DEP1 CAR and an anti-DPP4 CAR, as described above;
an anti-DEP1/anti-DPP4 bispecific CAR, as described above;
a nucleic acid encoding the anti-DEP1 CAR and the anti-DPP4 CAR, as described above;
a nucleic acid encoding the anti-DEP1/anti-DPP4 bispecific CAR, as described above;
a vector comprising a nucleic acid encoding the anti-DEP1 CAR and a vector comprising the nucleic acid encoding the anti-DPP4 CAR, as described above;
- a vector comprising a nucleic acid encoding the anti-DEP1 CAR and the nucleic acid encoding the anti-DPP4 CAR, as described above;
a vector comprising a nucleic acid encoding the anti-DEP1/anti-DPP4 bispecific CAR, as described above;
an immune cell engineered to express the anti-DEP1 CAR and an immune cell engineered to express the anti-DPP4 CAR, as described above;
- an immune cell engineered to express the anti-DEP1 CAR and the anti-DPP4 CAR, as described above;
an immune cell engineered to express the anti-DEP1/anti-DPP4 bispecific CAR, as described above;
a population of immune cells engineered to express the anti-DEP1 CAR and a population of immune cells engineered to express the anti-DPP4 CAR, as described above;
a population of immune cells engineered to express the anti-DEP1 CAR and the anti-DPP4 CAR, as described above;
a population of immune cells engineered to express the anti-DEP1/anti-DPP4 bispecific CAR, as described above.
In one embodiment, the composition has been frozen and thawed. In one embodiment, the composition is lyophilized.
In one embodiment, the compositions of the invention are pharmaceutical compositions and further comprise at least one pharmaceutically acceptable excipient.
The term "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. Said excipient does not produce an adverse, allergic or other untoward reaction when administered to an animal, preferably a human. For human administration, preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by regulatory offices, such as, for example, FDA
Office or EMA.
Pharmaceutically acceptable excipients that may be used in the pharmaceutical composition of the invention include, without being not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances (for example sodium carboxymethylcellulose), polyethylene glycol, polyacrylates, waxes, polyethylene- polyoxypropylene- block polymers, polyethylene glycol and wool fat.
In one embodiment, the compositions according to the present invention are medicaments.
As used herein, the term "consisting essentially of', with reference to a composition, pharmaceutical composition or medicament, means that the antigen-binding domain, antibody or antigen-binding fragment thereof, nucleic acid, vector, CAR, immune cell or population of immune cells of the invention is/are the only therapeutic agent, or agent with a biologic activity, within said composition, pharmaceutical composition or medicament.
Such compositions and medicaments may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine;
antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives.
Since the present invention selectively target senescent cells, it is contemplated that the compositions according to the present invention may be cosmetic compositions, and further comprise at least one dermatologically acceptable excipient.
The term "dermatologically acceptable excipient" refers to excipient which are suitable for external topical application. Examples of dermatologically acceptable excipients include, but are not limited to, sebum-regulating agents, antibacterial agents, antifungal agents, keratolytic agents, keratoregulating agents, astringents, anti-inflammatory agents, anti-irritants, antioxidants, free-radical scavengers, cicatrizing agents, anti-aging agents and moisturizing agents.
The administration of the composition, pharmaceutical composition, medicament or cosmetic composition of the invention may be carried out in any convenient manner, including by injection, aerosol inhalation, topical delivery (such as, for example, by transdermal delivery), oral delivery, rectal delivery, nasal delivery, or vaginal delivery.
In one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition of the present invention is in a form adapted for injection, such as, e.g., for trans-arterial, intravenous (iv.), intramuscular, intraperitoneal (i.p.), intrapleural, intradermal, subcutaneous, transdermal injection or infusion.
Examples of forms suitable for injectable use include, but are not limited to, sterile solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The prevention against contamination by microorganisms can be brought about by adding in the composition preservatives such as, e.g., various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like). In one embodiment, it may be preferable to include isotonic agents, e.g., sugars or sodium chloride, to reduce pain during injection. In one embodiment, prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, e.g., aluminum monostearate and gelatin.
In one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition of the present invention is in an adapted form for a parenteral administration. Thus, in one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition of the invention is to be administered parenterally.
In one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition of the invention is in an adapted form for an intravenous administration. Thus, in one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition of the present invention is to be administered intravenously.
In one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition of the present invention may be injected directly into the site of the disease or disorder to be treated.
In one embodiment, a lyophilized composition, a lyophilized pharmaceutical composition, a lyophilized medicament or a lyophilized cosmetic composition of the invention is solubilized in water for injection and gently mixed, the mixture is gently mixed and charged into a suitable syringe. This invention thus also relates to a medical device, including a syringe filled or prefilled with a composition, pharmaceutical composition, medicament or cosmetic composition of the invention.
In one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition of the invention is formulated for topical administration. Thus, in one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition is to be administered topically.
Examples of forms adapted for topical administration include, without being limited to, liquid, paste or solid compositions, and more particularly aqueous solutions, drops, dispersions, sprays, microcapsules, micro- or nanoparticles, polymeric patch, or controlled-release patch, and the like.
In particular embodiments where the compositions of the invention comprise a CAR, an immune cell or a population of immune cells as described above, such compositions may be administered by intradermal or subcutaneous injection, such as by i.v.
injection.
In one embodiment, the compositions comprising a CAR, an immune cell or a population of immune cells may be injected directly into a lymph node, site of infection, site of inflammation or site of tissue or organ rejection. In one embodiment, the compositions comprising a CAR, an immune cell or a population of immune cells may be injected directly into the site of the autoimmune and/or inflammatory disease.
In one embodiment, the subject is administered, or is to be administered, with autologous cells. In some embodiments, the subject is administered, or is to be administered, with allogenic cells.
In one embodiment, the subject may be a mammal. In one embodiment, the subject may be a human.
Another object of the present invention is the use of the composition, pharmaceutical composition or medicament described herein, as a medicament.
Another object of the present invention is the use of the composition, pharmaceutical composition or medicament described herein, in treating, preventing or alleviating senescence-related diseases or disorders.
Another object of the present invention is a method of treating, preventing or alleviating senescence-related diseases or disorders in a subject in need thereof, comprising administering to said subject the composition, pharmaceutical composition or medicament described herein.
As used herein, the term "senescence-associated", "senescence-related" or "age-related" diseases, disorders, or conditions refers to a physiological condition that presents with one or more symptoms or signs, wherein a subject having the condition needs or would benefit from a lessening of such symptoms or signs. The condition is senescence-associated if it is caused or mediated in part by senescent cells, which may be induced by multiple etiologic factors including age, DNA damage, oxidative stress, genetic defects, etc. Lists of senescence-associated disorders that can potentially be treated or managed using the methods and products taught in this disclosure include those discussed in this disclosure and the previous disclosures to which this application claims priority.
Non-limiting examples of senescence-related diseases include : fibrotic diseases, chronic inflammatory diseases (e.g., arthritis or arthrosis), cancer, premalignant lesions, atherosclerosis, osteoarthritis, diabetes, diabetic ulcers, kyphosis, scoliosis, hepatic insufficiency, cirrhosis, Hutchinson-Gilford progeria syndrome (HGPS), laminopathies, osteoporosis, dementia, (cardio)vascular diseases (e.g., angina, arrhythmia, atherosclerosis, cardiomyopathy, congestive heart failure, coronary artery disease (CAD), carotid artery disease, endocarditis, heart attack, coronary thrombosis, myocardial infarction, high blood pressure/hypertension, hypercholesterolemia/hyperlipidemia, mitral valve prolapsed, peripheral artery disease (PAD) and stroke), obesity, metabolic syndrome, acute myocardial infarction, emphysema, insulin sensitivity, boutonneuse fever, sarcopenia, neurodegenerative diseases (e.g., Alzheimer's, Huntington's or Parkinson's disease), cataract, anemia, hypertension, age-related macular degeneration, COPD, asthma, renal insufficiency, incontinence, hearing loss such as deafness, vision loss such as blindness, sleeping disturbances, pain such as joint pain or leg pain, imbalance, fear, depression, breathlessness, weight loss, hair loss, muscle loss, loss of bone density, frailty and/or reduced fitness.
Another object of the present invention is the use of the composition, pharmaceutical composition or medicament described herein, in treating, preventing or alleviating fibrotic diseases, premalignant lesions, inflammatory diseases and cancers.
Another object of the present invention is a method of treating, preventing or alleviating fibrotic diseases, premalignant lesions, inflammatory diseases and cancers in a subject in need thereof, comprising administering to said subject the composition, pharmaceutical composition or medicament described herein.
Senescent cells are present in fibrosis of many tissues including, but not limited, to skin, liver, lung, pancreas and prostate.
Thus, in one embodiment, the senescence-related disease or disorder to be treated is a fibrotic disease. Exemplary fibrotic diseases which may be treated by the invention include but are not limited to eosinophilic esophagitis, hypereosinophilic syndromes (HES), Loeffler's endomyocarditis, endomyocardial fibrosis, idiopathic pulmonary fibrosis, and scleroderma.
In one embodiment, the pulmonary fibrotic disease to be treated, prevented or alleviated is selected from the group comprising idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) acute respiratory distress syndrome (ARDS), combined pulmonary fibrosis and emphysema (CPFR), pulmonary edema, Loffler's syndrome, eosinophilic pneumonia, respiratory hypersensitivity, allergic bronchopulmonary aspergillosis (ABPA), Hamman-Rich syndrome, sarcoidosis, pneumoconiosis, and hypersensitivity pneumonitis (HP).
In one embodiment, the pulmonary fibrotic disease to be treated, prevented or alleviated is chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis.
In one embodiment, the senescence-related disease or disorder to be treated is a premalignant lesion.
As used herein, the phrase "premalignant lesion" refers to a mass of cells and/or tissue having increased probability of transforming into a malignant tumor.
Examples of premalignant lesions include, but are not limited to, adenomatous polyps, Barrett's esophagus, pancreatic intraepithelial neoplasia (PanIN), IPMN
(intraductal papillary mucinus neoplasia), DCIS (ductal carcinoma in situ) in the breast, leukoplakia and erythroplakia. Thus, the premalignant lesion to be treated by the invention can transform into a malignant solid or non-solid (e.g., hematological malignancies) cancer (or tumor).
In one embodiment, the premalignant lesion which is to be treated is an adenomatous polyp of the colon, an adenomatous polyp of the rectum, an adenomatous polyp of the small bowel or Barrett's esophagus.
As used herein, the term "inflammatory diseases" refers to any abnormality associated with inflammation, such as, for example, chronic inflammatory diseases, acute inflammatory diseases.
Examples of inflammatory disorders include, but are not limited to, rheumatic diseases, neurological diseases, cardiovascular diseases, uro-gynecological diseases, eye and ear diseases, mucocutaneous diseases, infectious diseases, graft rejection diseases and allergic diseases.
Examples of rheumatic diseases include, but are not limited to, arthritis, osteoarthritis, rheumatoid arthritis, osteoporosis, fibromyalgia, lupus, systemic lupus erythematosus and scleroderma.
Examples of neurological diseases include, but are not limited to, multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury, spinal cord injury, dystonia, chronic regional pain syndrome, motor neuron disease/amyotrophic lateral sclerosis, Guillain-Barre syndrome, muscular dystrophy, cerebral palsy, neuropathy and myositis.
Examples of cardiovascular diseases include, but are not limited to, coronary heart disease, stroke, hypertensive heart disease, inflammatory heart disease, rheumatic heart disease, aortic aneurysm and dissection, congenital heart disease, deep vein thrombosis and pulmonary embolism and atherosclerosis.
Examples of uro-gynecological diseases include, but are not limited to, glomerulonephritis, urinary incontinence and prolapse.
Examples of eye and ear diseases include, but are not limited to, cataract, glaucoma, age-related macular degeneration (AMD), presbyopia, dry eyes, corneal diseases, diabetic retinopathy, vertigo, tinnitus and Meniere's disease.
Examples of mucocutaneous diseases include, but are not limited to, eczema, xeroderma pigmentosum, oral lichen planus, mucous membrane pemphigoid and pemphigus vulgaris.
Examples of infectious diseases include, but are not limited to, chronic infectious diseases, subacute infectious diseases, acute infectious diseases, viral diseases, bacterial diseases, protozoan diseases, parasitic diseases, fungal diseases, mycoplasma diseases and prion diseases.
Examples of diseases associated with transplantation of a graft include, but are not limited to, graft rejection, chronic graft rejection, subacute graft rejection, hyperacute graft rejection, acute graft rejection and graft versus host disease.
Examples of allergic diseases include, but are not limited to, asthma, hives, urticaria, pollen allergy, dust mite allergy, venom allergy, cosmetics allergy, latex allergy, chemical allergy, drug allergy, insect bite allergy, animal dander allergy, stinging plant allergy, poison ivy allergy and food allergy.
In one embodiment, the senescence-related disease or disorder to be treated is cancer.
Non-limiting examples of cancers which may be treated according to this aspect of the present invention include, but are not limited to, adenocarcinoma, adrenal gland tumor, ameloblastoma, anaplastic, anaplastic carcinoma of the thyroid, angiofibroma, angioma, angiosarcoma, apudoma, argentaffmoma, arrhenoblastoma, ascites tumor cell, ascitic tumor, astroblastoma, astrocytoma, ataxia-telangiectasia, atrial myxoma, a basal cell carcinoma cell, bone cancer, brainstem glioma, brain tumor, breast cancer, Burkitt's lymphoma, cerebellar astrocytoma, cervical cancer, cherry angioma, cholangiocarcinoma, cholangioma, chondroblastoma, chondroma, chondrosarcoma, chorioblastoma, choriocarcinoma, colon cancer, common acute lymphoblastic leukemia, craniopharyngioma, cystocarcinoma, cystofbroma, cystoma, ductal carcinoma in situ, ductal papilloma, dysgerminoma, encephaloma, endometrial carcinoma, endothelioma, ependymoma, epithelioma, erythroleukemia, Ewing's sarcoma, extra nodal lymphoma, feline sarcoma, fibro adenoma, fibro sarcoma, follicular cancer of the thyroid, ganglioglioma, gastrinoma cell, glioblastoma multiform, glioma, gonadoblastoma, haemangioblastoma, haemangioendothelioblastoma, haemangioendothelioma, haemangiopericytoma, haematolymphangioma, haemocytoblastoma, haemocytoma, hairy cell leukemia, hamartoma, hepatocarcinoma, hepatocellular carcinoma, hepatoma, histoma, Hodgkin's disease, hypernephroma, infiltrating cancer, infiltrating ductal cell carcinoma, insulinoma, juvenile angioforoma, Kaposi sarcoma, kidney tumor, large cell lymphoma, leukemia, a leukemia, acute leukemia, lipoma, liver cancer, liver metastases, Lucke carcinoma, lymphadenoma, lymphangioma, lymphocytic leukemia, lymphocytic lymphoma, lymphoeytoma, lymphoedema, lymphoma, lung cancer, malignant mesothelioma, malignant teratoma, mastocytoma, medulloblastome., melanoma, meningioma, mesothelioma, Morton's neuroma, multiple myeloma, myeloblastoma, myeloid leukemia, myelolipoma, myeloma, myoblastoma, myxoma, nasopharyngeal carcinoma, neoplastic, nephroblastoma, neuroblastoma, neurofibroma, neurofibromatosis, neuroglioma, neuroma, non-Hodgkin's lymphoma, oligodendroglioma, optic glioma, osteochondroma, osteogenic sarcoma, osteosarcoma, ovarian cancer, Paget's disease of the nipple, pancoast tumor, pancreatic cancer, phaeochromocytoma, pheoehromocytoma, plasmacytoma, primary brain tumor, progonoma, prolactinoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, rhabdo sarcoma, a solid tumor, sarcoma, a secondary tumor, seminoma, skin cancer, small cell carcinoma, squamous cell carcinoma, strawberry haemangioma, T cell lymphoma, teratoma, testicular cancer, thymoma, trophoblastic tumor, and Wilm's tumor.
In one embodiment, the composition, pharmaceutical composition or medicament described herein is used alone. In one embodiment, the composition , pharmaceutical composition, or medicament described herein is used in combination with at least one anti-cancer agent.
Indeed, many of existing and potential anti-cancer agents induce senescence of cancer cells, therefore the present invention can be used in combination with these agents to increase the efficacy of an anti-cancer treatment. Treatment by these agents can also reduce side effects of radiotherapy or chemotherapy with DNA-damaging agents.
Thus, the composition, pharmaceutical composition or medicament described herein can be used as an adjuvant therapy along with other treatment modalities for cancers, which are selected based on cancer type, location, the cell type and the grade of malignancy.
Conventional therapies include surgery, radiation therapy, and chemotherapy.
Exemplary anti-cancer drugs that can be co-administered with the composition, pharmaceutical composition or medicament described herein include, but are not limited to, acivicin, aclarubicin, acodazole hydrochloride, acronine, adriamycin, adozelesin, aldesleukin, altretamine, ambomycin, ametantrone acetate, aminoglutethimide, amsacrine, anastrozole, anthramycin, asparaginase, asperlin, azacytidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene hydrochloride, bisnafide dimesylate, bizelesin, bleomycin sulfate, brequinar sodium, bropirimine, busulfan, cactinomycin, calusterone, caracemide, carbetimer, carboplatin, carmustine, carubicin hydrochloride, carzelesin, cedefingol, chlorambucil, cirolemycin, cisplatin, cladribine, crisnatol mesylate, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, .. daunorubicin hydrochloride, decitabine, dexormaplatin, dezaguanine, dezaguanine mesylate, diaziquone, docetaxel, doxorubicin, doxorubicin hydrochloride, droloxifene, droloxifene citrate, dromostanolone propionate, duazomycin, edatrexate, eflornithine hydrochloride, elsamitrucin, enloplatin, enpromate, epipropidine, epirubicin hydrochloride, erbulozole, esorubicin hydrochloride, estramustine, estramustine phosphate sodium, etanidazole, etoposide, etoposide phosphate, etoprine, fadrozole hydrochloride, fazarabine, fenretinide, floxuridine, fludarabine phosphate, fluorouracil, fluorocitabine, fosquidone, fostriecin sodium, gemcitabine, gemcitabine hydrochloride, hydroxyurea, idarubicin hydrochloride, ifosfamide, ilmofosine, interferon alfa-2a, interferon alfa-2b, interferon alfa-nl, interferon alfa-n3, interferon beta-la, interferon gamma-lb, iproplatin, irinotecan hydrochloride, lanreotide acetate, letrozole, leuprolide acetate, liarozole hydrochloride, lometrexol sodium, lomustine, losoxantrone hydrochloride, masoprocol, maytansine, mechlorethamine hydrochloride, megestrol acetate, melengestrol acetate, melphalan, menogaril, mercaptopurine, methotrexate, methotrexate sodium, metoprine, meturedepa, mitindomide, mitocarcin, mitocromin, mitogillin, mitomalcin, mitomycin, mitosper, mitotane, mitoxantrone hydrochloride, mycophenolic acid, nocodazole, nogalamycin, ormaplatin, oxisuran, paclitaxel, pegaspargase, peliomycin, pentamustine, peplomycin sulfate, perfosfamide, pipobroman, piposulfan, piroxantrone hydrochloride, plicamycin, plomestane, porfimer sodium, porfiromycin, prednimustine, procarbazine hydrochloride, puromycin, puromycin hydrochloride, pyrazofurin, riboprine, rogletimide, safingol, safingol hydrochloride, semustine, simtrazene, sparfosate sodium, sparsomycin, spirogermanium hydrochloride, spiromustine, spiroplatin, streptonigrin, streptozocin, sulofenur, talisomycin, taxol, tecogalan sodium, tegafur, teloxantrone hydrochloride, temoporfin, teniposide, teroxirone, testolactone, thiamiprine, thioguanine, thiotepa, tiazofuirin, tirapazamine, topotecan hydrochloride, toremifene citrate, trestolone acetate, triciribine phosphate, trimetrexate, trimetrexate glucuronate, triptorelin, tubulozole hydrochloride, uracil mustard, uredepa, vapreotide, verteporfin, vinblastine sulfate, vincristine sulfate, vindesine, vindesine sulfate, vinepidine sulfate, vinglycinate sulfate, vinleurosine sulfate, vinorelbine tartrate, vinrosidine sulfate, vinzolidine sulfate, vorozole, zeniplatin, zinostatin, and zorubicin hydrochloride.
Additional antineoplastic agents include those disclosed in Chabner et al., 2001.
"Antineoplastic agents". In Goodman et al. (Eds.), Goodman & Gilman' s The pharmacological basis of therapeutics (le ed., pp. 1315-1404). New York, NY:
McGraw-Hill.
Another object of the present invention is the use of the cosmetic composition described herein, as cosmetics.
Indeed, since the present invention selectively target senescent cells, it is contemplated that the present invention can be used for skin care, skin anti-aging and/or skin rejuvenation.
Another object of the present invention is thus a method for rejuvenating the skin in a subject in need thereof, comprising administering to the subject the cosmetic composition described herein.
Because senescent cells drive age-related pathologies, a selective elimination of these cells can prevent or delay age-related deterioration. Thus, senescent cells may be therapeutic targets in the treatment of aging and age-related disease. As such, removal of senescent cells may delay tissue dysfunction and extend health span. Clearance of senescent cells is expected to improve tissue milieu, thereby improving the function of the remaining non-senescent cells.
Another object of the present invention is thus the use of the composition, pharmaceutical composition or medicament described herein, for depleting and/or killing senescent cells.
Another object of the present invention is thus a method for depleting and/or killing senescent cells in a subject, comprising administering to the subject the composition, pharmaceutical composition or medicament described herein.
In one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition described herein is to be administered to a subject in need thereof in a therapeutically effective amount.
It will be however understood that the total daily usage of the composition, pharmaceutical composition, medicament or cosmetic composition described herein will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disease being treated and the severity of the disease;
activity of the therapeutic agent in the composition, pharmaceutical composition, medicament or cosmetic composition (antigen-binding domain, antibody or antigen-binding fragment thereof, nucleic acid, vector, CAR, immune cell or population of immune cells of the invention) employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific composition, pharmaceutical composition, medicament or cosmetic composition employed; the duration of the treatment; drugs used in combination or coincidental with the composition, pharmaceutical composition, medicament or cosmetic composition employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. The total dose required for each treatment may be administered by multiple doses or in a single dose.
Disclosed herein is a chimeric antigen receptor (CAR) comprising:
(i) at least one extracellular binding domain, comprising at least one antigen-binding domain directed to a senescent cell-associated antigen, preferably to DEP1 and/or DPP4, (ii) an extracellular spacer domain, (iii) a transmembrane domain, (iv) optionally at least one costimulatory domain, and (v) at least one intracellular signaling domain.
In one embodiment, said at least one antigen-binding domain is directed to DEP1.
In one embodiment, said at least one antigen-binding domain is directed to DPP4.
In one embodiment, said CAR is a bispecific CAR comprising two antigen-binding domains.
In one embodiment, each of the at least two antigen-binding domains binds to a different antigen, preferably to DEP1 and DPP4.
Also disclosed herein is an isolated immune cell population expressing at least one CAR
according to the present disclosure, preferably the isolated immune cell population expresses:
at least one CAR directed to DEP1 and at least one CAR directed to DPP4; or - at least one bispecific CAR comprising two antigen-binding domains, preferably wherein each of the at least two antigen-binding domains binds to a different antigen, preferably to DEP1 and DPP4.
In one embodiment, the isolated immune cell population according to the present disclosure comprises immune cells selected from the group comprising T cells, natural killer (NK) cells, or a combination thereof.
Also disclosed herein is an isolated bispecific antibody or a fragment thereof, comprising at least two antigen binding domains directed to at least two senescent cell-associated antigens, preferably the at least two senescent cell-associated antigens are DEP1 and DPP4.
In one embodiment, the isolated bispecific antibody or fragment thereof according to the present disclosure comprises:
(i) an antigen-binding domain of an anti-human DEP1 antibody or a fragment thereof;
and (ii) an antigen-binding domain of an anti-human DPP4 antibody or a fragment thereof.
Also disclosed herein is a composition comprising:
the isolated immune cell population according to the present disclosure;
the isolated bispecific antibody or fragment thereof according to the present disclosure; or a mixture of an isolated anti-human DEP1 antibody or a fragment thereof and an isolated anti-human DPP4 antibody or a fragment thereof.
In one embodiment, the composition according to the present disclosure is a pharmaceutical composition and further comprises at least one pharmaceutically acceptable excipient.
In one embodiment, the composition or pharmaceutical composition according to the present disclosure is for use as a medicament.
In one embodiment, the composition or pharmaceutical composition according to the present disclosure is:
- for use in treating, preventing or alleviating senescence-related diseases or disorders; or for depleting and/or killing senescent cells.
In one embodiment, senescence-related diseases or disorders are selected from the group comprising fibrotic diseases, premalignant lesions, inflammatory diseases and cancers.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 ¨ 'The structure of CAR vector' ¨ is a schema illustrating the construction of the full-length CAR expression cassette, subcloned into Lenti-EFla-rhuMAB 41-VH-Linker-VL-CFPCART, pCDCAR1. The full length of chimeric antigen receptor was synthesized and subcloned into lentivirus vector. The insert was confirmed by Sanger sequencing and is schematically illustrated in the figure. This CAR vector was used in the CAR-T assays for the proof-of-concept experiments.
Figure 2 ¨ 'The assessment of senescent state and DPP4 levels in target cells' ¨ is a graph showing the senescent state of WI-38 and GM21808 cells, confirmed by senescence .. associated P-galactosidase activity. Representative results of control versus senescent fibroblasts are shown. DPP4 levels of the cells were monitored by quantitative RT-PCR.
Relative quantities of DPP4 in young WI-38 (low passage number: PDL < 20) or old WI-38 (high passage number: PDL > 50) and in GM21808 cells, untreated or cultured with DNA-damaging agent etoposide (adding etoposide every two days for fourteen days) were calculated. Fold-change, or relative quantity, of DPP4 in each sample was calculated relative to young WI-38 or untreated GM21808.
Figure 3 ¨ 'The ADCC Assay' ¨ is a graph showing the relative toxicity in young and old fibroblast cells (WI-38 cells), using 0.05 p.g/mL or 0.5 p.g/m1 of anti-DPP4 antibody.
Figure 4 ¨ 'The CAR-T assay' ¨ is a graph showing the results of selective elimination of senescent cells by engineered CAR-T against DPP4.
Figure 5¨ 'The quantification of experimental CAR-T assay results' ¨ is a graph showing the results of the CAR-T assay on control (WI-38/GM21808) versus senescent cells. Cells were incubated with increasing ratios of CAR-T to target cells (1:1, 5:1 and 10:1).
Figure 6 ¨ scEv library screening by phage display' ¨ is a graph showing the panning using hDEP1 Peptide #4/BSA as target and standard elution strategy. Four rounds were carried out in order to isolate specific binders. The reactivity of phages eluted after each round against the targeted peptide was assessed in phage-ELISA.
Figure 7 ¨ scEv library screening by phage display' ¨ is a graph showing the panning using hDEP1-ECD-His as target and standard elution strategy. Four rounds were carried out in order to isolate specific binders. The reactivity of phages eluted after each round against the targeted peptide was assessed in phage-ELISA.
Figure 8¨ 'DPP4 and DEP I mRNA levels in normal and diseased primary human lung fibroblasts' ¨ is a graph showing the relative quantity of DPP4 and DEP-1 in normal and diseased human lung fibroblasts. Expression levels in NHLF (normal human lung fibroblast), idiopathic pulmonary fibroblast (IPF) and chronic obstructive pulmonary disease (COPD) human fibroblast cells were calculated relative to NHLF.
Figure 9 ¨ 'DPP4 staining in fibroblasts' is a set of three graphs showing the staining of various primary human fibroblasts and different senescence-stressors in terms of DPP4 surface antigen presentation in target senescent cells versus normal/young cells. The data also include normal human cells versus human lung fibrosis disease cells. WI-(PDL < 20), GM21808 ( etoposide), normal human lung fibroblast (NHLF), idiopathic pulmonary fibroblast (IPF) and chronic obstructive pulmonary disease (COPD) human fibroblast cells were stained with anti-DPP4 antibodies or scFv. Control staining comprising secondary antibody only was included for all cell types, but only the control staining for NHLF cells is shown for illustration. Percentage of positive cells is indicated on the right side, with MFI indicated in parenthesis.
Figure 9A: staining with monoclonal antibody(Creative Biolabs);
Figure 9B: staining with 5826-13-R3A-D5;
Figure 9C: staining with 5826-13-R4A-H5.
Figure 10 ¨ 'DEP 1 staining in fibroblasts' is a set of three graphs showing the staining of various primary human fibroblasts and different senescence-stressors in terms of DEP1 surface antigen presentation in target senescent cells versus normal/young cells. The data also include normal human cells versus human lung fibrosis disease cells. WI-(PDL < 20), GM21808 ( etoposide), normal human lung fibroblast (NHLF), idiopathic pulmonary fibroblast (IPF) and chronic obstructive pulmonary disease (COPD) human fibroblast cells were stained with anti-DEP1 antibodies or scFv. Control staining comprising secondary antibody only was included for all cell types, but only the control staining for NHLF cells is shown for illustration. Percentage of positive cells is indicated on the right side, with MFI indicated in parenthesis.
Figure 10A: staining with monoclonal antibody(AbCam) Figure 10B: staining with 5738-10-R3A-D5;
Figure 10C: staining with 5738-13 -R4A-D 11;
Figure 10D: staining with 5738-13-R2A-H4.
EXAMPLES
The present invention is further illustrated by the following examples.
Example 1 ¨ DPP4 is expressed on the surface of senescent cells Materials and Methods Expression of DPP 4 (rhuMAB 41) antibody and antigen The full-length of the antigen was synthesized and subcloned into an expression vector.
The insert was confirmed by Sanger sequencing. After the vector was verified by sequencing, the vector was expressed in CHO-S cell line with chemically defined culture media. After 9 days cultivation, the protein was purified by Nickel columns, ultrafiltration and then subjected to 0.2-micron sterile filtration to get the bulk of high purity.
The heavy chain and light chain of the rhuMAB 41 antibody (Creative Biolabs) were synthesized and subcloned into Creative Biolabs property expression vector, respectively.
The insert was confirmed by Sanger sequencing. After the vectors were verified by sequencing, they were expressed in HEK293 cell line with chemically defined culture media. After 9 days of cultivation, the protein was purified by Protein A
affinity chromatography, ultrafiltration and then subjected to 0.2-micron sterile filtration to get the bulk of high purity.
Expression of DPP4 (rhuMAB 41) scFv The scFv consists of variable regions of heavy and light chains that are joined together .. by a flexible peptide linker. In the scFv, the order of the domains can be either VH-linker-VL or VL-linker-VH. The affinity of the two construction types to the target might be different. Hence, the two construction types can lead to secretory expression in different level.
The scFv(s) were expressed and tested by flow cytometry to evaluate the binding affinity to target cells. 5 x 105 WI-38 cells were co-cultured with rhuMAB 41 antibody (humanized antibody), VL-Linker-VH antibody and VH-Linker-VL antibody (1 [tg/tube), respectively, and then analyzed by using PE-anti-human IgG Fc as secondary antibody.
The results indicated that VH-linker-VL antibody has higher affinity for target cell WI-38 and was chosen for CAR development.
CAR-T cell preparation and construction Primary human T cells were used for CAR-T generation. Human primary T cells were isolated from PBMCs of healthy donors by magnetic beads and stimulated in growth medium supplemented with IL-2. Activated T cells were then transduced with lentivirus expressing customized chimeric antigen receptor. After CAR-T cell expansion, CAR-transduction efficiency was examined by FACS and qPCR.
The full-length of chimeric antigen receptor was synthesized and subcloned into lentivirus vector. The insert was confirmed by Sanger sequencing. The structure of CAR
vector is schematically illustrated in Figure 1.
Lentiviral vectors, which were derived from immunodeficiency viruses, were used for their relatively high efficiency for T cell transduction and their ability of infection of the non-proliferating cells. A second generation of the packaging system was utilized to generate transduction-ready pseudoviral particles in HEK293T cells. The titer of the lentivirus particle was determined by qPCR and cell-based titration assay. The results of lentivirus titration showed that prepared virus stock was at a high titer of 3.27 x 108 TU/mL.
Primary human T lymphocytes preparation and CAR-T preparation PBMC from a healthy human donor was stimulated with anti-CD3/CD28 magnetic beads and the T cells were isolated using magnetic cell separation system. To generate CAR-T
cells, the lentivirus particles with DPP4-CAR coding gene were incubated with the T cells in the presence of polybrene. After T cell expansion, the CAR-T cells were used for in vitro cytotoxicity assays.
Target cell preparation WI-38 target cells were obtained at population doubling 19 (PD19) and passaged until they stopped proliferating. They were further analyzed by FACS for the detection of their surface antigen DPP4 and by qRT-PCT for the detection of their relative DPP4 mRNA
expression level.
Cellular senescence induced by DNA damage was also induced in GM21808 fibroblasts by adding etoposide, as previously described (Robles et al., 1999. Biochem Pharmacol.
58(4):675-685; Gey & Seeger, 2013. Mech Ageing Dev. 134(3-4):130-138).
Untreated (control) and treated cells were further analyzed by qRT-PCT for the detection of their relative DPP4 mRNA expression level.
Natural killer (NK) cell preparation Effector cells (NK cells) were freshly prepared before the ADCC assay. By using EasySepTM Human NK Cell Isolation Kit (STEMCELL, Catalog:17955), NK cells were isolated from a healthy human donor and resuspended in RPMI 1640 medium at .. 5 x 106/mL.
ADCC assay The target cells (WI-38), i.e., the senescent cells and proliferating cells, were plated into a 24-well plate at 1 x 105 cell/well in 100 [tL RPMI-1640 supplied with 5% FBS
24 hour and cultured overnight. On the day of the assay, anti-DPP4 antibody (rhuMAB
41) was .. added into each well at a final concentration of 0 [tg/mL, 0.05 [tg/mL, and 0.5 [tg/mL.
After 30 minutes of incubation at 37 C with 5% CO2, 100 [tL NK cells (5 x 105 cell/well) were added to each well at E/T=5:1. After incubation for 6 hours at 37 C with 5% CO2, the cells were stained with eBioscienceTM Annexin V Apoptosis Detection Kit PE
(Invitrogen, Catalog: 88-8102-74) with 7-AAD and analyzed by flow cytometry.
In vitro CAR-T activity assay by FACS
In vitro analysis was used for evaluation of the targeting effect of DPP4-CAR-T. The target cells (WI-38 or GM21808), i.e., the senescent cells and proliferating cells, were plated into a 24-well plate at 1 x 105 cell/well in 100 [tL RPMI-1640 supplied with 5%
FBS and cultured overnight. On the day of the assay, effector cells (5 x 105 cell/well) .. were added to each well at E/T=5:1. After incubation for 6 hours at 37 C
with 5% CO2, the cells were stained with eBioscienceTM Annexin V Apoptosis Detection Kit PE
(Invitrogen, Catalog: 88-8102-74) with 7-AAD and analyzed by flow cytometry.
The relative percentage was quantified by normalizing the results to control CAR-T.
Results Assessment of senescent state and DPP4 levels in target cells The senescent state of the cells was confirmed by senescence associated fl-galactosidase activity. DPP4 levels were monitored by quantitative RT-PCR. Figure 2 shows that DPP4 is expressed selectively in senescent cells, but not in proliferating human diploid fibroblasts or healthy foreskin fibroblasts.
ADCC Assay In vitro Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) assays are common tools for immunotherapeutic drug discovery and biosimilar development. For this experiment, cytotoxicity is defined as apoptosis monitored by annexin-V
positive and 7-ADD negative cells counted.
Results of a standard ADCC assay are shown in Figure 3. This experiment depicts a difference between young and old fibroblast cells at indicated antibody concentration as listed 1.5 and 1.65-fold, respectively.
Our results show that high abundance of DPP4 on the surface of senescent cells lead to a 1.5-fold selective elimination of senescent cells using anti-DPP4 antibody under optimal conditions.
DPP4- CAR-T Assay When we used the same cells with control and DPP4-CAR-T cells, we observe a 3-fold selective elimination of old senescent cells with respect to the young ones.
CAR-T cells engineered against DPP4 show high specificity against DPP4-bearing senescent cells (Figure 4). The quantification of experimental results also shows that increasing CAR-T
levels are only cytotoxic to senescent cells, but not to control cells (Figure 5). This indicates that the CAR-T assay selectively eliminates target cells, i.e., senescent cells.
Conclusion DPP4 is a novel senescent surface marker identified in human fibroblasts both in replicative and oncogene-induced (RAS) senescence. DPP4 is robustly upregulated on the plasma membrane of senescent cells.
DPP4 is expressed selectively in senescent cells, but not proliferating human diploid fibroblasts, making it a suitable target for senolytic therapy (Figure 2). We showed that, upon two different senescent-inducing stimuli in two different types of fibroblasts, CAR-T cell therapy against DPP4 selectively eliminates DPP4-positive senescent cells (Figure 5).
Example 2 ¨ Development of scFv against human DEP1 Materials Rat immunization and splenectomy - "hDEP1 Peptide #1": amino acid residues 36-48 of SEQ ID NO: 1, conjugated to BSA
- "hDEP1 Peptide #2": amino acid residues 436-452 of SEQ ID NO: 1, conjugated to BSA
- "hDEP1 Peptide #3": amino acid residues 728-741 of SEQ ID NO: 1, conjugated to BSA
- "hDEP1 Peptide #4": amino acid residues 864-881 of SEQ ID NO: 1, conjugated to BSA
- "hDEP1-ECD-Fc": amino acid residues 621-969 of SEQ ID NO: 1 conjugated to an IgG1 Fc domain (SEQ ID NO: 2), produced recombinantly in CHO cells and purified on protein A resin - "hDEP1-ECD-His": amino acid residues 621-969 of SEQ ID NO: 1 conjugated to a 6xHis tag through a linker (SEQ ID NO: 3), produced recombinantly in CHO
cells and purified on Ni-NTA resin - B SA (NEB) - Freund's complete and incomplete adjuvants (Sigma, F5881 and F5506) - Standard ELISA material - Fc-specific polyclonal anti-rat immunoglobulin G (IgG) (Jackson 112-036-071;
1/5000) RNA extraction - RNAse AWAY (Molecular Bio-products, Cat. n 7002) - Tri reagent (Molecular research center Inc, Cat. n TR118) - BCP (Molecular research center Inc, Cat. n 13P-ISI) - Isopropanol, ethanol 75% (molecular grade) RT-PCR, library pre-cloning - SuperScript Reverse Transcriptase (Invitrogen, Cat. n 18064-014) - Murine Primers set - Taq DNA polymerase, recombinant (Invitrogen, Cat. 10342-020) - pGemT Vector System (Promega, Cat. A3600) - Electroporation device and material - Electrocompetent Sure bacteria (E. coli) (Stratagene, Cat. 200227) - Nucleobond AX (Macherey-Nagel, Cat. 740 573-100) Ampli6;ingVH and VL
- Red Taq (Sigma, Hamburg) + 10x buffer - dNTP mix (10 mM each) - Oligonucleotide primer - Agarose (Serva, Heidelberg) - TAE-buffer 50x (2 M TrisHC1, 1 M acetic acid, 0.05 M EDTA pH 8) - Nucleospin Extract 2 Kit (Macherey-Nagel, DUren) Cloning VH and VL
- NotI, MluI, NcoI, HindIII (NEB) - Buffer 2, Buffer 3 (NEB) - BSA (NEB) - Calf intestine phosphatase (CIP) (MBI Fermentas, St. Leon-Rot) - T4 ligase (Promega, Mannheim) - 3 M sodium acetate pH 5.2 - E. coli XL1-Blue MRF (Stratagene, Amsterdam), genotype: A(mcrA)183 A(mcrCB-hsdSMR-mrr)173 endAl supE44 thi-1 recAl gyrA96 relAl lac [F' proAB lacIqZAM15 Tn10 (Tetr)]
- Electroporator MicroPulser (BIO-RAD, Munchen) - 2 M glucose (sterile filtered) - 2 M magnesium solution (1 M MgCl, 1 M MgSO4) - SOC medium pH 7.0 (2 w/v tryptone, 0.5 % w/v yeast extract, 0.05 %
w/v NaCl, 20 mM Mg solution, 20 mM glucose) - 2xYT-medium pH 7.0 (1.6 % w/v tryptone, 1 % w/v yeast extract, 0.5 % w/v NaCl) - 2xYT-GAT (2xYT + 100 mM glucose + 100 p.g/mL ampiciline + 20 p.g/mL
tetracycline) - Ampiciline (100 mg/mL stock) - Tetracycline (10 mg/mL stock) - 9 cm-Petrie dishes - 25 cm-square Petri dishes ("pizza plates") - 2xYT-GAT agar plates (2xYT-GAT, 1.5 % w/v agar-agar) - Nucleobond Plasmid Midi Kit (Macherey-Nagel) - Glycerol 99.5 % (Roth, Karlsruhe) Library packaging - 2xYT-medium pH 7.0 (1.6 % w/v tryptone, 1 % w/v yeast extract, 0.5 %
w/v NaCl) - 2xTY-GA (2xTY, 100 mM glucose, 100 p.g/mL ampicillin) - M13K07 Helperphage for monovalent display (Stratagene) - 2x TY-AK (2x TY + 100 p.g/mL ampicillin + 50 p.g/mL kanamycin) - Sorval Centrifuge RC5B Plus, rotor G53 and SS34 (Thermo Scientific, Waltham) - Polyethylenglycol (PEG) solution (20 % w/v PEG 6000, 2.5 M NaCl) - Phage dilution buffer (10 mM Tris-HC1 pH 7.5, 20 mM NaCl, 2 mM EDTA) Library screening - Microtiter plate (Nunc Maxisorp) - 3 % BSA in TBS (50 mM Tris; 137 mM NaCl; 2.7 mM KCl; pH adjusted to 8.0) - TBS supplemented with 0.1 % Tween20 - E. coli (SURE strain, Stratagene) - SB (super broth) supplemented with tetracycline (10 p.g/mL) and carbenicillin (50 lig/mL).
SB supplemented with tetracycline (10 ug/mL), carbenicillin (50 ug/mL) and kanamycin (70 ug/mL) Polyethylenglycol (PEG) solution (20 % w/v PEG 6000, 2.5 M NaCl) Sorval Centrifuge RC5B Plus, rotor G53 and SS34 (Thermo Scientific, Waltham) scFv production and purification E. coli strain HB2151 SB (super broth) supplemented with carbenicillin (50 ug/mL) and 1 % glucose 1 mM IPTG
Polymyxin B sulfate - His-Trap column (GE Healthcare, Buckinghamshire, UK) Methods Rat immunization 12 rats were immunized with i.p. injections of 50 ug of hDEP1 Peptide #1, Peptide #2, Peptide #3 or Peptide #4 (3 rats/peptide). In parallel, 5 rats were immunized with i.p.
injections of 50 ug of hDEP1-ECD-Fc.
The three first injections were administered at 14 days intervals (DO, D14 and D28). A
fourth injection was administered after animal selection according to the titer reached.
The first injection at DO was mixed with complete Freund's adjuvant. The remaining injections were carried out with incomplete Freund's adjuvant.
The rat immune response was evaluated by ELISA performed in 96-well microtiter plates using hDEP1 Peptide #1, Peptide #2, Peptide #3, Peptide #4, hDEP1-ECD-His, or BSA.
Pre-immune serum was used as a negative control. For detection, Fc-specific polyclonal anti-rat IgG was used and the titer was measured as the reciprocal of the highest dilution of immune serum giving a signal at 50 % of the highest OD.
RNA extraction, RT-PCR, library pre-cloning After the fourth injection, RNA was isolated with Tri Reagent/BCP method from the spleen of the immunized rats and used for reverse transcription.
Oligonucleotides sets were used for amplification of the DNA encoding the lc and k light chain and to amplify the DNA encoding Fd fragments of the heavy y chain. To obtain two sub-libraries encoding the Fd fragment and light chain, the corresponding PCR products were pooled and sub-cloned into the pGEMT vector.
Library construction The final library was constructed starting from these two sub-libraries. The DNA
encoding the Fd fragment and the light chain was re-amplified with two individual oligonucleotide sets introducing the required restrictions sites for library-cloning using the pTH1 vector. First the pTH1 vector and the VL-amplified repertoire were digested with MluI and NotI. Afterwards, the enzyme reaction was terminated and the vector was dephosphorylated with calf intestinal phosphatase. The vector and the VL-repertoire were purified using NucleoSpinII Gel and PCR Clean-up Kit (Macherey-Nagel) and 270 ng of the VL-repertoire was cloned into 1 lig of dephosphorylated vector using T4 DNA-ligase.
The pellet was washed twice with 70 % ethanol and resuspended in 30 tL H20 before it was used for electroporation (1.7 kV) with 25 tL of XL1-BlueMRF'. The transformed bacteria were cultured on 2x YT agar plates supplemented with 100 [tg/mL
ampicillin, 20 [tg/mL tetracycline and 100 mM glucose. The colonies were harvested by resuspension in 40 mL of 2x YT medium with a Drigalsky spatula and plasmids were isolated with the Nucleobond Plasmid Midi Kit. Following this, the VL-library and the VH-repertoire were digested with SfiI and HindIII, ligated and electroporated as described for VL, but this time 250 ng of the digested and purified VH-repertoire was inserted into 1 lig of the VL-library. The harvested bacteria of the final scFv antibody gene library were pooled, aliquoted and stored at -80 C. The library was packaged with M13K07.
Library packaging To package the library, inoculate 400 mL 2 x TY-GA in a 1 L Erlenmeyer flask with 1 mL
antibody gene library stock and then infect 25 mL bacteria culture (¨ 1.25 x 1010 cells) with 2.5 x 1011 colony forming units (cfu) of the helper phage M13K07.
Produce scFv-phage overnight at 250 rpm and 30 C. Pellet the bacteria by centrifugation for 10 minutes at 10000 g. Precipitate the phage from the supernatant by adding 1/5 volume PEG solution. Incubate for 1 hour at 4 C with gentle shaking, followed by centrifugation for 1 hour at 10000g. Discard the supernatant, resolve each pellet in 10 mL
phage dilution buffer and add 1/5 volume PEG solution. Incubate on ice for 20 minutes and pellet the phage by centrifugation for 30 minutes at 10000 g. Discard the supernatant and put the open tubes upside down on tissue paper. Let the viscous PEG
solution move out completely. Resuspend the phage pellet in 1 mL phage dilution buffer.
Library screening For isolation of anti-DEP I specific scFv, microtiter plates were coated overnight with hDEP1-ECD-His or Peptide #4 at 10 1.tg/mL in PBS at 4 C. The plates were then blocked with 3% BSA in TBS for 2 hours at 37 C. After a washing step, the antibody phage display library was added and incubated for an additional 2 hours at 37 C.
During the first round of panning, the plates were washed 5 times with TBS
supplemented with 0.1 % Tween20. The plates were finally rinsed with sterile PBS and phage were eluted with trypsin (1 mg/mL in TBS) for 30 minutes at 37 C. The eluted phages were used to infect E. coli cultured in SB supplemented with tetracycline and carbenicillin.
For the production of new phage particles, infected E. coli were co-infected with M13K07 and cultured overnight at 37 C in SB supplemented with tetracycline, carbenicillin and kanamycin. Phage particles were precipitated in PEG/NaCl (4 % w/v PEG8000, 3 %
w/v NaCl) and used for the next round of panning. This was performed as described above, with the exception that the plates were washed with increasing stringency.
The infected E. coli of the last round of panning were grown on SB media in petri dishes and used for screening by ELISA using hDEP1-ECD-His or Peptide #4.
scFv production and purification For expression of soluble scFv, the DNA encoding the selected scFv was used to transform the non-suppressor E. coil strain HB2151. Transformed E. coil were then used to inoculate 500 mL of SB medium and cultivated at 30 C until OD600 1.5. Then, 1 mM
IPTG was added to induce the expression of scFv and the culture was incubated overnight at 22 C. After harvesting by centrifugation at 2500 g for 15 minutes at 4 C, scFv were extracted with polymyxin B sulfate and purified using a His-Trap column according to the manufacturer's instructions. Purified scFv were quantified by Dm and controlled by SDS-PAGE analysis.
Confirmation of selected scFv by ELISA against screening peptide The soluble anti-DEP1 scFv were tested in indirect ELISA for reactivities against the 4 peptides (Peptide #1, Peptide #2, Peptide #3, and Peptide #4), against hDEP1-ECD-His and its murine counterpart with SEQ ID NO: 4; and against BSA as negative control.
Reactivity was assessed by OD450, in serial dilutions.
Results Serum of the 17 rats was collected on D38 (after the third immunization, on D28) and Fc-specific polyclonal anti-rat IgG was used to measure the titer at 50 % of maximum signal.
Results are given in Table 5.
Table 5 hDEP1 hDEP1 hDEP1 hDEP1 hDEP1-Peptide Peptide Peptide Peptide BSA
ECD-His #1 #2 #3 #4 hDEP1 Rat 1 380000 ND ND ND ND ND
Peptide Rat 2 55000 ND ND ND ND ND
#1 Rat 3 11000 ND ND ND ND ND
hDEP1 Rat 4 ND 27000 ND ND ND
ND
Peptide Rat 5 ND 23000 ND ND ND ND
#2 Rat 6 A7) 1'0000 Ni) :\7) NI) (demi) hDEP1 Rat 7 ND ND 12000 ND 500 ND
Peptide Rat 8 ND ND 18000 ND 500 ND
#3 Rat 9 ND ND 22000 ND 500 ND
hDEP1 Rat 10 ND ND ND 113000 6000 ND
Peptide Rat 11 ND ND ND 110000 4500 ND
#4 Rat 12 ND ND ND
Rat 13 500 500 500 ND 321000 ND
Rat 14 ND ND 500 ND 64000 500 hDEP1-Rat 15 ND ND 500 ND 180000 500 ECD-Fc Rat 16 500 500 500 500 82000 ND
Rat 17 ND ND 500 ND 40000 ND
High titers were harvested against each immunogenic peptide.
Peptides #1 and #4 appeared to be more immunogenic than Peptides #2 and #3, allowing better immune responses. Rats immunized with Peptide #4 also presented a positive immune response for the recombinant hDEP1-ECD-His protein, while rats immunized with Peptides #1 and #2 did not present such positive immune response.
Overall, rat 10 seemed to be the best candidate among rats 1 to 12.
High titers were also harvested against the recombinant protein hDEP1-ECD-His, ranging from 1/40000 to 1/321000. Overall, rat 13 seemed to be the best candidate among rats 13 to 17.
A splenectomy was carried out on rats 10 and 13. RNA were extracted from the spleens, and total RNA was quantified (Table 6) and controlled on agarose gel (not shown).
Table 6 Sample Concentration (pg/mL) A260nm A280nm A260nmi A280nm A260nmi A230nm Rat 10 2108.9 52.7 29.5 1.78 1.55 Rat 13 2370.77 59.3 33.4 1.77 1.42 The first step of the library construction consisted of the VL fragments cloning in a phagemid vector, and then the VH fragments were inserted into the vector containing the VL repertoire. The vector format VH/VL-6xHis-Flag was selected for constructions.
Rat 10 The final scFv library consisted of 1 x 107 independent clones with a full-size insert rate of 92 % (by colony-PCR) and was finally packaged in M13K07 phage.
The panning was performed using hDEP1 Peptide #4/BSA as target and standard elution strategy. Four rounds were carried out in order to isolate specific binders.
After each round, only the phages having interacted with hDEP1 Peptide #4/BSA were eluted.
Between the first and the last round of panning, the number of eluted phages increased, indicating that amplification/selection of reactive phages was expected from this panning.
The reactivity of the phages eluted after each round against the targeted peptide was assessed in phage-ELISA and confirmed that potential binders were eluted in rounds 3 and 4 (Figure 6).
96 isolated clones from the second, third and fourth rounds of panning were hand-picked and used to produce the respective soluble scFv in microtiter plate. Each clone was then tested in ELISA against hDEP1 Peptide #4/BSA.
48 isolated clones showing a specific signal against hDEP1 Peptide #4/BSA
compared to negative control (BSA) were selected. Their DNA was extracted and sequenced.
Sequences with an early stop codon or with an incorrect size were considered as recombined. The non-recombined sequences were aligned for redundancy analysis in order to identify the identical sequences (referred to as "redundant"
sequences).
Twelve sequences corresponding to non-recombined and non-redundant scFv sequences were identified, grouped into two clusters (Table 7).
Table 7. HCVR and LCVR column indicate the amino acid sequence of the heavy chain and light chain variable regions, respectively.
Cluster Clone's name Redundancy HCVR LC VR
Cluster 1 Cluster 2 According to sequence and redundancy analysis, the following clones were selected:
- 5738-10-R3A-C6 (cluster 1) - 5738-10-R3A-D5 (cluster 2) - 5738-10-R4A-G12 (cluster 2) After transformation of the 3 selected clones DNA in an E. coli strain dedicated to production, the clones were expressed as soluble scFv and purified using the His tag on an Ni-NTA column. These soluble anti-hDEP1 scFv were tested in indirect ELISA
for reactivities against the 4 peptides and DEP1 proteins (human and murine) and against the negative control (BSA only).
All three scFv were reactive against hDEP1 Peptide #4, as expected, especially the two scFv of cluster 2. No reactivity could be observed against the 3 other peptides. Only clone 5738-10-R4A-G12 showed a reactivity against hDEP1, with no response for the mDEP1 or the negative control.
Rat /3 The final scFy library consisted of 1 x 107 independent clones with a full-size insert rate of 88 % (by colony-PCR) and was finally packaged in M13K07 phage.
The panning was performed using hDEP1-ECD-His as target and standard elution strategy. Four rounds were carried out in order to isolate specific binders.
After each round, only the phages having interacted with hDEP1-ECD-His were eluted.
Between the first and the last round of panning, the number of eluted phages increased, indicating that amplification/selection of reactive phages was expected from this panning. The reactivity of the phages eluted after each round against the targeted peptide was assessed in phage-ELISA and confirmed that potential binders were eluted in rounds 2, 3 and 4 (Figure 7).
96 isolated clones from the second, third and fourth rounds of panning were hand-picked and used to produce the respective soluble scFy in microtiter plate. Each clone was then tested in ELISA against hDEP1-ECD-His.
48 isolated clones showing a specific signal against hDEP1-ECD-His compared to negative control (BSA) were selected. Their DNA was extracted and sequenced.
Sequences with an early stop codon or with an incorrect size were considered as recombined. The non-recombined sequences were aligned for redundancy analysis in order to identify the identical sequences (referred to as "redundant"
sequences).
Nine sequences corresponding to non-recombined and non-redundant scFy sequences were identified, grouped into two clusters (Table 8).
Table 8. HCVR and LCVR column indicate the amino acid sequence of the heavy chain and light chain variable regions, respectively.
Cluster Clone's name Redundancy HCVR LCVR
Cluster 1 Cluster 2 573 8-13 -R3A-F5 1 69 90 According to sequence and redundancy analysis, the following clones were selected:
- 5738-13-R4A-D11 (cluster 1) - 5738-13-R2A-H4 (cluster 2) After transformation of the 2 selected clones DNA in an E. coli strain dedicated to production, the clones were expressed as soluble scFv and purified using the His tag on an Ni-NTA column. These soluble anti-hDEP1 scFv were tested in indirect ELISA
for reactivities against the 4 peptides and DEP1 proteins (human and murine) and against the negative control (BSA only).
The two scFv were reactive against hDEP1, as expected. No reactivity could be observed against any of the 4 peptides, the mDEP1 or the negative control.
Example 3 ¨ Development of scFv against human DPP4 Materials Rat immunization and splenectomy - "hDPP4 Peptide P2": amino acid residues 170-191 of SEQ ID NO: 101, conjugated to BSA
- "hDPP4 Peptide P3": amino acid residues 235-254 of SEQ ID NO: 101, conjugated to BSA
- "hDPP4 Peptide P5": amino acid residues 492-517 of SEQ ID NO: 101, conjugated to BSA
- "hDPP4 Peptide P6": amino acid residues 533-551 of SEQ ID NO: 101, conjugated to BSA
- "hDPP4-ECD-His": SEQ ID NO: 102 - "mDPP4": murine DDP with SEQ ID NO: 103 - BSA (NEB) - Freund's complete and incomplete adjuvants (Sigma, F5881 and F5506) - Standard ELISA material - Fc-specific polyclonal anti-rat immunoglobulin G (IgG) (Jackson 112-036-071;
1/5000) RNA extraction - RNAse AWAY (Molecular Bio-products, Cat. n 7002) - Tri reagent (Molecular research center Inc, Cat. n TR118) - BCP (Molecular research center Inc, Cat. n'BP-ISI) - Isopropanol, ethanol 75% (molecular grade) RT-PCR, library pre-cloning - SuperScript Reverse Transcriptase (Invitrogen, Cat. n 18064-014) - Murine Primers set - Tag DNA polymerase, recombinant (Invitrogen, Cat. 10342-020) - pGemT Vector System (Promega, Cat. A3600) - Electroporation device and material - Electrocompetent Sure bacteria (E. coli) (Stratagene, Cat. 200227) - Nucleobond AX (Macherey-Nagel, Cat. 740 573-100) Amplifying VH and VL
- Red Tag (Sigma, Hamburg) + 10x buffer - dNTP mix (10 mM each) - Oligonucleotide primer - Agarose (Serva, Heidelberg) - TAE-buffer 50x (2 M TrisHC1, 1 M acetic acid, 0.05 M EDTA pH 8) - Nucleospin Extract 2 Kit (Macherey-Nagel, Diiren) CloningVH and VL
- NotI, MluI, NcoI, HindIII (NEB) - Buffer 2, Buffer 3 (NEB) - BSA (NEB) - Calf intestine phosphatase (CIP) (MBI Fermentas, St. Leon-Rot) - T4 ligase (Promega, Mannheim) - 3 M sodium acetate pH 5.2 - E. coli XL1-Blue MRF (Stratagene, Amsterdam), genotype: A(mcrA)183 A(mcrCB-hsdSMR-mrr)173 endAl supE44 thi-1 recAl gyrA96 relAl lac [F' proAB lacIqZAM15 Tn10 (Tetr)]
- Electroporator MicroPulser (BIO-RAD, Munchen) - 2 M glucose (sterile filtered) - 2 M magnesium solution (1 M MgCl, 1 M MgSO4) - SOC medium pH 7.0 (2 w/v tryptone, 0.5 % w/v yeast extract, 0.05 %
w/v NaCl, mM Mg solution, 20 mM glucose) - 2 xYT-medium pH 7.0 (1.6 % w/v tryptone, 1 % w/v yeast extract, 0.5 %
w/v NaCl) 15 - 2xYT-GAT (2xYT + 100 mM glucose + 100 ug/mL ampiciline + 20 ug/mL
tetracycline) - Ampiciline (100 mg/mL stock) - Tetracycline (10 mg/mL stock) - 9 cm-Petrie dishes 20 - 25 cm-square Petri dishes ("pizza plates") - 2 xYT-GAT agar plates (2 xYT-GAT, 1.5 % w/v agar-agar) - Nucleobond Plasmid Midi Kit (Macherey-Nagel) - Glycerol 99.5 % (Roth, Karlsruhe) Library packaging - 2 xYT-medium pH 7.0 (1.6 % w/v tryptone, 1 % w/v yeast extract, 0.5 % w/v NaCl) - 2xTY-GA (2xTY, 100 mM glucose, 100 ug/mL ampicillin) - M13K07 Helperphage for monovalent display (Stratagene) - 2x TY-AK (2x TY + 100 ug/mL ampicillin + 50 ug/mL kanamycin) - Sorval Centrifuge RC5B Plus, rotor G53 and SS34 (Thermo Scientific, Waltham) - Polyethylenglycol (PEG) solution (20 % w/v PEG 6000, 2.5 M NaCl) - Phage dilution buffer (10 mM Tris-HC1 pH 7.5, 20 mM NaCl, 2 mM EDTA) Library screening - Microtiter plate (Nunc Maxisorp) - 3 % BSA in TBS (50 mM Tris; 137 mM NaCl; 2.7 mM KC1; pH adjusted to 8.0) - TBS supplemented with 0.1 % Tween20 - E. coli (SURE strain, Stratagene) - SB (super broth) supplemented with tetracycline (10 p.g/mL) and carbenicillin (50 lig/mL).
- SB supplemented with tetracycline (10 pg/mL), carbenicillin (50 p.g/mL) and kanamycin (70 lig/mL) - Polyethylenglycol (PEG) solution (20 % w/v PEG 6000, 2.5 M NaCl) - Sorval Centrifuge RC5B Plus, rotor G53 and SS34 (Thermo Scientific, Waltham) scFv production and purification - E. coli strain HB2151 - SB (super broth) supplemented with carbenicillin (50 lig/mL) and 1 %
glucose - 1 mM IPTG
- Polymyxin B sulfate - His-Trap column (GE Healthcare, Buckinghamshire, UK) Methods Rat immunization 12 rats were immunized with i.p. injections of 50 lig of hDDP4 Peptide P1, Peptide P3, Peptide P5 or Peptide P6 (3 rats/peptide). In parallel, 5 rats were immunized with i.p.
injections of 50 lig of hDDP4-ECD-His.
The three first injections were administered at 14 days intervals (DO, D14 and D28). A
fourth injection was administered after animal selection according to the titer reached.
The first injection at DO was mixed with complete Freund' s adjuvant. The remaining injections were carried out with incomplete Freund's adjuvant.
The rat immune response was evaluated by ELISA performed in 96-well microtiter plates using hDDP4 Peptide P1, Peptide P3, Peptide P5, Peptide P6, hDPP4-ECD-His, mDPP4, or B SA.
Pre-immune serum was used as a negative control. For detection, Fc-specific polyclonal anti-rat IgG was used and the titer was measured as the reciprocal of the highest dilution of immune serum giving a signal at 50 % of the highest OD.
RNA extraction, RT-PCR, library pre-cloning After the fourth injection, RNA was isolated with Tri Reagent/BCP method from the spleen of the immunized rats and used for reverse transcription.
Oligonucleotides sets were used for amplification of the DNA encoding the lc and k light chain and to amplify the DNA encoding Fd fragments of the heavy y chain. To obtain two sub-libraries encoding the Fd fragment and light chain, the corresponding PCR products were pooled and sub-cloned into the pGEMT vector.
Library construction The final library was constructed starting from these two sub-libraries. The DNA
encoding the Fd fragment and the light chain was re-amplified with two individual oligonucleotide sets introducing the required restrictions sites for library-cloning using the pTH1 vector. First the pTH1 vector and the VL-amplified repertoire were digested with MluI and NotI. Afterwards, the enzyme reaction was terminated and the vector was dephosphorylated with calf intestinal phosphatase. The vector and the VL-repertoire were purified using NucleoSpinII Gel and PCR Clean-up Kit (Macherey-Nagel) and 270 ng of the VL-repertoire was cloned into 1 lig of dephosphorylated vector using T4 DNA-ligase.
The pellet was washed twice with 70 % ethanol and resuspended in 30 tL H20 before it was used for electroporation (1.7 kV) with 25 tL of XL1-BlueMRF'. The transformed bacteria were cultured on 2x YT agar plates supplemented with 10011g/mL
ampicillin, 20 1.tg/mL tetracycline and 100 mM glucose. The colonies were harvested by DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 33;
VL-CDR2: SEQ ID NO: 43;
VL-CDR3: SEQ ID NO: 50.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 37;
VL-CDR2: SEQ ID NO: 44;
VL-CDR3: SEQ ID NO: 51.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 38;
VL-CDR2: SEQ ID NO: 45;
VL-CDR3: SEQ ID NO: 52.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 37;
VL-CDR2: SEQ ID NO: 44;
VL-CDR3: SEQ ID NO: 53.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 38;
VL-CDR2: SEQ ID NO: 45;
VL-CDR3: SEQ ID NO: 54.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three 5 complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 39;
VL-CDR2: SEQ ID NO: 45;
VL-CDR3: SEQ ID NO: 52.
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
which 10 comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 38;
VL-CDR2: SEQ ID NO: 46;
VL-CDR3: SEQ ID NO: 52.
15 In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 1.
In one embodiment, the DEP1-binding domain of the invention comprises a combination 20 of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 1.
TABLE 1. Preferred combinations of HCVR's and LCVR's CDRs. The CDRs are defined by their SEQ ID NOs. First column indicates the clone's name.
Vll- Vii- Vll- VL- VL- VL-Clone's name In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-13-R2A-C1, 5738-13-D3, 5738-13-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R3A-C6, 5738-10-D5, 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R4A-G12, 5738-D11, and 5738-13-R2A-H4.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of .. any one of the following clones as defined in Table 1: 5738-13-R4A-D11, and R2A-H4.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-C1 as defined in Table 1. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-D3 as defined in Table 1. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R4A-D11 as defined in Table 1. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-F5 as defined in Table 1. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R4A-F11 as defined in Table 1. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-H3 as defined in Table 1. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-H4 as defined in Table 1. 5738-13-R4A-H9 as defined in Table 1. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R4A-H11 as defined in Table 1.
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 55; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 55.
SEQ ID NO: 55 QVQLKQSGAELAKPGSSVKISCKASGYTFTSYYISWIKQTTGQGLEYIGYINTGS
GGTNYNEKFKGKATLTVDKS S STAFMQL S SLTPDDSAVYYCARYFDYWGQGV
MVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 56; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 56.
SEQ ID NO: 56 E VKLVES GGGLVQPKE SLKI SC AA S GF TF SNIAMYWVRQAPGKGLEWVAHIRT
KPHNF AT YYAN S VKGRF TISRDD SKNMVYLQMDNLKPEDTAMYYC SVGF GDY
WGQGVMVTVSS
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 57; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 57.
SEQ ID NO: 57 EVQLQQSGAELAKPGS SVKISCKASGYTFTNYTISWIKQTTGQGLEYIGYIYAGT
GDTNYNEKFKGKATLTVDKS SNTAFMQL S SLTPDD SAVYYCARYFDHWGQGV
MVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 58; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 58.
SEQ ID NO: 58 EVQLQQSGAELAKPGS SVKISCKASGYTFTSYYISWIKQTTGQGLEYIGYINTGS
GGTNYNEKFKGKATLTVDKS S STAFMQL S SLTPDDSAVYYCARDKWVDWGQ
GVMVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 59; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 59.
SEQ ID NO: 59 EVQLEESGGGLVQPKESLKISCAVSGFTFSNIAMYWVRQAPGKGLEWVGHIRT
KPHNYATYYAD S VKGRFTISRDD SNNMVYLEMDNLKPEDTAMYYC SVGF GDY
WGQGVMVTVSS
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 60; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 60.
SEQ ID NO: 60 QVQLKQSGAELAKPGSSVKISCKASGYTFTSYYISWIKQTTGQGLEYIGYIHPGS
GVTNYNEKFKGKATLTVDKS S STAFMQL SSLTPDDSAIYYCARYFDYWGQGV
MVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 61; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 61.
SEQ ID NO: 61 QVQLKQ SGVELAKPGS S VKISCKASGYTF T SD SISWIKQTTGQGLEYIGYIHPGS
MVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 62; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 10 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 62.
SEQ ID NO: 62 EVQLQQSGVELAKPGS SVKISCKASGYTFT SD SISWIKQTTGQGLEYIGYIHPGS
GVTNYNEKFKGKATLTVDKS S STAFMQL SSLTPDDSAIYYCARYFDYWGQGV
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 63; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework 20 .. regions) of SEQ ID NO: 63.
SEQ ID NO: 63 EVQLQQSGVELAKPGS SVKISCKASGYTFT SD SISWIKQTTGQGLEYIGYIHPGS
GVTNYNEKFRGKATLTVDKS S STAFMQL S SLTPDDSAIYYCARYFDYWGQGV
MVTVS S
25 In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 64; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 64.
SEQ ID NO: 64 QVQLQQPRAELAKPGSSVKISCKASGYTFTNYSISWIKQTTGQGLEYIGYIYPGS
GDTNYNEKFKGKATLTVDKS S STAFMQL S SL TPDD SAVYYC ARYFDHWGQ GT
LVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 65; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 65.
SEQ ID NO: 65 QVQLKESGAELAKPGS SVKISCKASGYTF T SD SISWIKQTTGQ GLEYIGYIHPGS
GVTNYNEKFKGKATLTVDKS S STAFMQL SSLTPDDSAIYYCARYFDYWGQGV
MVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 66; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 66.
SEQ ID NO: 66 QVQLKESGGGLVQPGRSLKL SC AA S GF TF SDYNMAWVRQAPKKGLEWVATIS
YDD SRTYYRDSVKGRFAISRDDAKGTLNLQMDSLRSEDTATYYCARQGGIIRG
VWFPYWGQGTLVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 67; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 67.
SEQ ID NO: 67 E VKLVES GGGLVQP GGSLKL S CAA S GF TF SNYYMAWVRQ APTKGLEWVAYIT
NSFGSAYYRDSVKGRFTISRDNAKSTLYLQMDSLRSEDTATYYCSTVPLGAFVY
WGQGTLVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 68; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 68.
SEQ ID NO: 68 QVQLKESGGGLVQPGRSLKL SC AA S GF SF GDYNMAWVRQAPKKGLEWVATIS
YDDYRTYYRDSVKGRFTISRDDAKATLYLQMDSLRSEDTATYYCARQGGIIRG
VWFPYWGQGTLVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 69; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 69.
SEQ ID NO: 69 E VKLVES GGGLVQP GGSLKL S CAA S GF TF SNYYMAWVRQ APTKGLEWVAYIT
NSLGSAYYRDSVKGRFTISRDNAKSTLYLQMDSLRSEDTATYYC STVPLGAFV
YWGQGTLVTVSS
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 70; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 70.
SEQ ID NO: 70 E VKLVES GGGLVQP GGSLKL S CAA S GF TF SNYYMAWVRQ APTKGLEWVAYIT
NSF GSTYYRD S VKGRF TISRDNAK STLYLQMD SLRSEDTATYYC STVPLGAFVY
WGQGTLVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 71; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 71.
SEQ ID NO: 71 E VKLVES GGGLVQP GRSLKL S CAA S GF TF SNYYMAWVRQAPTKGLEWVAYIT
NGYGSTYYRDSVKGRFTISRDNAKSTLYLQMDSLRSEDTATYYCSTVPLGAFV
YWGQGTLVTVSS
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 72; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 72.
SEQ ID NO: 72 E VKLVES GGGLVQP GRSLKL S CAA S GF TF SNYYMAWVRQAPTKGLEWVAYIT
NGF GSTYYRD S VKGRF TISRDNAK STLYLQMD SLRSEDTATYYC STVPLGAF VS
WGQGTLVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 73; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 73.
SEQ ID NO: 73 E VKLVES GGGLVQP GRSLKL S CAA S GF TF SNYYMAWVRQAPTKGLEWVAYIT
NGFGSTYYRDSVKGRFTISRDNAKSTLYLQMDSLRSEDAATYYCSTVPLGAFVS
WGQGTLVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 74; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 74.
SEQ ID NO: 74 E VKLVES GGGLVQP GGSLKL S CAA S GF TF SNYYMAWVRQ APTKGLEWVAYIT
NGF GSTYYRD S VKGRF TISRDNAK STLYLQMD SLRSEDTATYYC STVPLGAF VS
WGQGTLVTVS S
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 75; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 75.
SEQ ID NO: 75 DIVMTQ SP S SM SVSL GDTVTITCRA S QDVGIYVNWF QQKP GKPPRRMIYRATNL
ADGVPSRFSGTRSGSDYSLTIS SLESEDVADYHCLQYDEFPPTFGSGTKLDIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 76; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 76.
SEQ ID NO: 76 DIVMTQAPLSL SVAIGQSASISCKSSQSLKHSDGKTYLNWIFQSPGQSPKRLIYQ
VSKLDSGVPDRF S GTGSETDF TLKI SRVEAEDL GVYYCC Q GS Y SP YTF GAGTKL
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 77; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework 10 regions) of SEQ ID NO: 77.
SEQ ID NO: 77 DILMTQ SP S SM SA SL GDRVTITCQ A S QDIGNNLIWF QQKP GK SPRRMIYYATNL
ANGVPSRFSGSRSGSDYSL SIS SLESEDVADYHCLQYDEFPPTFGSGTKLEIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
15 comprising or consisting of the sequence SEQ ID NO: 78; or a LCVR
comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 78.
SEQ ID NO: 78 ADGVP SRF SGSRSGSNYSLTIRSLE SEDVADYHCLQYDEWPYTF GAGTKLELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 79; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 25 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 79.
SEQ ID NO: 79 DIVMTQAPLSL SVDIGQSASISCRS SQ SLKHSDGKTYLNWVFQSPGQSPKRLIYQ
VSKLDSGVPDRF SGSGSEADFTLKISRVEAEDLGVYYCCQGSYSPYTFGAGTKL
ELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 80; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 80.
SEQ ID NO: 80 DIQL TQ SP S SMSVSQGDTVTITCRASQDVGIYVNWFQQKPGKSPRRMIYRATNL
ADGVPSRFSGSRSGSDYSLTIASLESEDVADYHCLQYDEFPPTFGSGTNLEIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 81; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 81.
SEQ ID NO: 81 DILMTQ SP S SMSVSLGDTVTITCRASQDVGIYVNWFQQIPGKSPRRLIYRATNLA
DGVPSRF SGSRSGSDYSLTIASLESEDVADYHCLQYDEFPPTFGSGTKLEIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 82; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 82.
SEQ ID NO: 82 DILMTQ SP S SMSVSQGDTVTITCRASQDVGIYVNWFQQKPGKSPRRMIHRATNL
ADGVP SRF SGSRSGSDYSLTIT SLESEDVADYHCLQYDEYPPTFGSGTNLEIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 83; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 83.
SEQ ID NO: 83 DILMT Q SP S SMSVSLGDTVTITCRASQDVGIYVNWFQQKPGKSPRRMIHRATNL
ADGVPSRFSGSRSGSDYSLTIS SLESEDVADYHCLQYDEYPPTFGSGTKLEIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 84; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 84.
SEQ ID NO: 84 DIVMTQ SP SSMSVSLGDTVTITCRASQDVGIYVNWFQQKPGKSPRRMIYRATNL
ADGVPSRFSGSRSGSDYSLTIASLESEDVADYHCLQYDEFPPTFGSGTKLEIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 85; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 85.
SEQ ID NO: 85 DILMT Q SP S SMSVSLGDTVTITCRASQDVGIYVNWFQQKPGKSPRRMIYRATTL
ADGVPSRFSGSRSGSDYSLTIS SLESEDVADYHCLQYDEYPPTFGSGTKLEIK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 86; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 86.
SEQ ID NO: 86 DILMTQ SP S SM S V SLGD TVTIT CRA S QDVGIYVNWF Q QKP GK SPRRMIYRATNL
ADGVPSRF SGSRSGSDYSLTIS SLESEDVADYHCLQYDEYPPTF GGGTKLELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 87; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 87.
SEQ ID NO: 87 DIQLTQ SPASL SASLEEIVTITCQASQDIGNWLAWYQQKPGKSPHLLIYGATTLA
DGVPSRSGSRSGTQYSLKISRLQVEDVGMYYCQQTS STPWTFGGGTKLELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 88; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 88.
SEQ ID NO: 88 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLISHANPLH
DGVPSRFSGDGSGTQYSLKIRNMQPEDEGVYYCQQGYKFPYTFGAGTKLELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 89; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 89.
SEQ ID NO: 89 DIQMTQTPASL SASLEEIVTITCQASQDIGNWLAWYQQKPGKSPHLLIYGATTL
ADGVPSRF SGSRSGTQYSLKISRLQAEDIGIYYCQQASSAPWTFGGGTKLELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 90; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 90.
SEQ ID NO: 90 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLISHANPLH
DGVPSRF SGSGSGTQYSLKIRNMQPEDEGVYYCQQGYKFPYSFGAGTKLELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 91; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 91.
SEQ ID NO: 91 DIQLTQ SPASL SASLGETVSIECLASEDIYSYLAWYQQKPGKSPQLLISHANPLH
DGVPSRF SGSGSGTQYSLKIRNMQPEDEGVYYCQQGYKFPYTFGAGTKLELK
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 92; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 92.
SEQ ID NO: 92 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLISHANPLH
DGVPSRF SGSGSGTQYSLKIRNMQPEDEGVYYCQQGYKFPYTFGAGTKLELK
5 .. In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 93; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 93.
10 SEQ ID NO: 93 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLISYANPLH
DGVPSRF SGSGSGTQF SLKIRNMQPEDEGVYYCQQGYKFPYTFGAGTKLELT
In one embodiment, the DEP1-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 94; or a LCVR comprising or 15 consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 94.
SEQ ID NO: 94 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLISHANPLH
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, said combination being as defined in Table 2.
TABLE 2. Preferred combinations of HCVR and LCVR. The HCVR and LCVR are defined by their SEQ ID NOs. First column indicates the clone's name.
Clone's name HCVR LCVR
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-13-R2A-C1, 5738-13-R2A-D3, 5738-13-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-10-R3A-C6, 5738-10-R3A-D5, 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R2A-C1 as defined in Table 2. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R2A-D3 as defined in Table 2. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R4A-D11 as defined in Table 2. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R3A-F5 as defined in Table 2.
In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R4A-F11 as defined in Table 2. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R2A-H3 as defined in Table 2. In one embodiment, the DEP1-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R2A-H4 as defined in Table 2. In one embodiment, the binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R4A-H9 as defined in Table 2. 5738-13-H11 as defined in Table 2.
In one embodiment, the senescent cell-associated antigen is DPP4, such as, e.g., human DPP4 or orthologs thereof, including murine and rat DPP4. In one embodiment, the senescent cell-associated antigen is human DPP4 (hDPP4) with SEQ ID NO: 101.
In one embodiment, the antigen-binding domain of the invention recognizes and is capable of binding to DPP4, such as, e.g., to human DPP4, or orthologs thereof, including murine and rat DPP4. Hence, the antigen-binding domain of the invention is a "DPP4-binding domain".
In one embodiment, the DPP4-binding domain of the invention recognizes and is capable of binding to human DPP4 (hDPP4) with SEQ ID NO: 101.
In one embodiment, the DPP4-binding domain of the invention recognizes and is capable of binding to the extracellular domain of human DPP4 (hDPP4) comprising or consisting of amino acid residues 29- 766 of SEQ ID NO: 101.
The binding between the DPP4-binding domain of the invention and DPP4 implies that said DPP4-binding domain exhibits appreciable affinity for DPP4. In other words, the DPP4-binding domain of the invention is specific for, or is immunospecific for, or specifically bind to, DPP4.
The affinity between the DPP4-binding domain of the invention and DPP4 can be determined by various methods well known from the one skilled in the art.
These methods include, but are not limited to, biosensor analysis (including, e.g., Biacore analysis), Blitz analysis and Scatchard plot.
Alternatively or additionally, whether the DPP4-binding domain of the invention binds to DPP4 can be tested readily by, inter alia, comparing the reaction of said DPP4-binding domain with DPP4 or a fragment thereof (in particular, a fragment comprising or consisting of an epitope of DPP4) with the reaction of said DPP4-binding domain with proteins or antigens other than DPP4 or a fragment thereof In one embodiment, the DPP4-binding domain of the invention recognizes and is capable of binding to DPP4 with a KD-affinity constant less than or equal to 10' M, preferably less than or equal to 10-7 M, 5.10-8 M, 10-8 M, 5.10-9 M, 10-9 M or less; as may be determined, e.g., by biosensor analysis, particularly by Biacore Analysis.
In one embodiment, the DPP4-binding domain of the invention comprises a heavy chain variable region (abbreviated herein as HCVR or VH) which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: any one of SEQ ID NO: 104 to 112;
VH-CDR2: any one of SEQ ID NO: 113 to 129;
VH-CDR3: any one of SEQ ID NO: 130 to 142.
SEQ ID SEQ ID
SEQUENCE SEQUENCE
NO NO
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 104;
5 VH-CDR2: SEQ ID NO: 113;
VH-CDR3: SEQ ID NO: 130.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
10 VH-CDR1: SEQ ID NO: 104;
VH-CDR2: SEQ ID NO: 114;
VH-CDR3: SEQ ID NO: 131.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three 15 complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 105;
VH-CDR2: SEQ ID NO: 115;
VH-CDR3: SEQ ID NO: 132.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which 20 comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 104;
VH-CDR2: SEQ ID NO: 116;
VH-CDR3: SEQ ID NO: 133.
25 In one embodiment, the DPP4-binding domain of the invention comprises a HCVR which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 104;
VH-CDR2: SEQ ID NO: 117;
VH-CDR3: SEQ ID NO: 134.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 104;
VH-CDR2: SEQ ID NO: 113;
VH-CDR3: SEQ ID NO: 135.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 104;
VH-CDR2: SEQ ID NO: 116;
VH-CDR3: SEQ ID NO: 136.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 106;
VH-CDR2: SEQ ID NO: 118;
VH-CDR3: SEQ ID NO: 131.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 107;
VH-CDR2: SEQ ID NO: 119;
VH-CDR3: SEQ ID NO: 137.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 120;
VH-CDR3: SEQ ID NO: 138.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 121;
VH-CDR3: SEQ ID NO: 138.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 109;
VH-CDR2: SEQ ID NO: 122;
VH-CDR3: SEQ ID NO: 139.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 123;
VH-CDR3: SEQ ID NO: 138.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 124;
VH-CDR3: SEQ ID NO: 138.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 110;
VH-CDR2: SEQ ID NO: 125;
VH-CDR3: SEQ ID NO: 140.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 126;
VH-CDR3: SEQ ID NO: 141.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 126;
VH-CDR3: SEQ ID NO: 138.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 111;
VH-CDR2: SEQ ID NO: 127;
VH-CDR3: SEQ ID NO: 138.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 110;
VH-CDR2: SEQ ID NO: 128;
VH-CDR3: SEQ ID NO: 140.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 112;
VH-CDR2: SEQ ID NO: 125;
VH-CDR3: SEQ ID NO: 140.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 127;
VH-CDR3: SEQ ID NO: 138.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VH-CDR1: SEQ ID NO: 108;
VH-CDR2: SEQ ID NO: 127;
VH-CDR3: SEQ ID NO: 142.
In one embodiment, the DPP4-binding domain of the invention comprises a light chain variable region (abbreviated herein as LCVR or VI) which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: any one of SEQ ID NO: 143 to 151;
VL-CDR2: any one of SEQ ID NO: 152 to 163;
VL-CDR3: any one of SEQ ID NO: 164 to 173.
SEQ ID NO SEQUENCE SEQ ID NO SEQUENCE
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 143;
5 VL-CDR2: SEQ ID NO: 152;
VL-CDR3: SEQ ID NO: 164.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
10 VL-CDR1: SEQ ID NO: 143;
VL-CDR2: SEQ ID NO: 152;
VL-CDR3: SEQ ID NO: 165.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three 15 complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 144;
VL-CDR2: SEQ ID NO: 153;
VL-CDR3: SEQ ID NO: 166.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 143;
VL-CDR2: SEQ ID NO: 154;
VL-CDR3: SEQ ID NO: 167.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 143;
VL-CDR2: SEQ ID NO: 155;
VL-CDR3: SEQ ID NO: 168.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 145;
VL-CDR2: SEQ ID NO: 156;
VL-CDR3: SEQ ID NO: 166.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 143;
VL-CDR2: SEQ ID NO: 154;
VL-CDR3: SEQ ID NO: 169.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 146;
VL-CDR2: SEQ ID NO: 157;
VL-CDR3: SEQ ID NO: 170.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 147;
VL-CDR2: SEQ ID NO: 158;
VL-CDR3: SEQ ID NO: 171.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 147;
VL-CDR2: SEQ ID NO: 159;
VL-CDR3: SEQ ID NO: 171.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 148;
VL-CDR2: SEQ ID NO: 160;
VL-CDR3: SEQ ID NO: 172.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 149;
VL-CDR2: SEQ ID NO: 159;
VL-CDR3: SEQ ID NO: 171.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 146;
VL-CDR2: SEQ ID NO: 161;
VL-CDR3: SEQ ID NO: 170.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 150;
VL-CDR2: SEQ ID NO: 159;
VL-CDR3: SEQ ID NO: 171.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 151;
VL-CDR2: SEQ ID NO: 159;
VL-CDR3: SEQ ID NO: 171.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 146;
VL-CDR2: SEQ ID NO: 162;
VL-CDR3: SEQ ID NO: 170.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 149;
VL-CDR2: SEQ ID NO: 159;
VL-CDR3: SEQ ID NO: 173.
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
which comprises at least one, preferably at least two, more preferably the following three complementary-determining regions (CDRs):
VL-CDR1: SEQ ID NO: 146;
VL-CDR2: SEQ ID NO: 163;
VL-CDR3: SEQ ID NO: 170.
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 3.
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 3.
TABLE 3. Preferred combinations of HCVR's and LCVR's CDRs. The CDRs are defined by their SEQ ID NOs. First column indicates the clone's name.
Vii- Vii- Vii- VL- VL- VL-Clone's name In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-A10, 5826-B1, 5826-13-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13-5 R4A-E6, 5826-13-R4A-E9, 5826-13-R4A-F10, 5826-13-R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12.
In one embodiment, the DPP4-binding domain of the invention comprises a combination 10 of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-8-R6A-E10, 5826-8-G8, 5826-8-R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-D5, 5826-13-H5, and 5826-13-R4A-H12.
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-A10 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-B1 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-B3 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-D5 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-D6 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-E2 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-E6 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-E9 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-F10 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-G11 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-G12 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H1 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H2 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-H3 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H4 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H5 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H6 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H9 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-H10 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H11 as defined in Table 3. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H12 as defined in Table 3.
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 174; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 174.
SEQ ID NO: 174 EVQLEESGGGLVQPGRSLKL S CAA S GF TFNNYGMAWVRQAP TKGLEWVATI S
YDGNDTYYRDSVKGRFTVSRDNAKSTLYLQMDSLRSEDTATYYCVRHRLIYTT
DYYYEVMDVWGQGASVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 175; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 175.
SEQ ID NO: 175 QVQLKESGGGLVQPGRSLKL SC AA S GF TF SNYGMAWVRQAPTKGLEWVATTS
YDGNDTYYRDSVKGRFTVSRDNAKNTLYLQMDSLRSEDTATYYCVRHRLIYT
TDYYYEVMDAWGQGASVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 176; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 176.
SEQ ID NO: 176 QVTLKESGPGILQPSQTL SLTC SF SGF SL S T SDRC VS WIRQP SGKGLEWLATICW
DD SKGYNPSLKNRLTISKDTSNNQAFLKITSVGTADIAKYYCARNSGDGRFAY
WGQGTLVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 177; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 177.
SEQ ID NO: 177 EVQLEESGGGLVQPGRSLKL SC AA S GF TF SNYGMAWVRQAPTKGLEWVATIN
YDGRNTYYRDSVKGRFTISRDNAKSTLYLQVDSLQSEDTATYYCTREIKLIYTT
DYYYEVMDAWGQGASVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 178; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 178.
SEQ ID NO: 178 EVKLVESGGGLVQPGRSLKLSCAASGF SF TNYGMAWVRQAPTKGLEWVATIN
YDGSNTYYRDSVKGRFTISRDNAKRTLDLQMDSLRSEDTATYYCARHRLMYT
TDYYYEVMDDWGQGASVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 179; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 179.
SEQ ID NO: 179 EVKLVESGGGLVQPGRSLKL SCAAS GF SFRNYGMAWVRQAPTKGQEWVATIS
YDGNDTYYRDSVKGRFTVSRDNAKSTLYLQMDSLRSEDTATYYCTRHRLIYTT
DYYYEVLDAWGQGASVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 180; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 180.
SEQ ID NO: 180 EVKLVESGGGLVQPGRSLKLSCTASGFTF SNYGMAWVRQAPTKGLEWVATIN
D YY YEVMDVWGQ GA S VAVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 181; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 10 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 181.
SEQ ID NO: 181 EVKLVESGGALVQPGRSLKLSCAASGFTF SNFGMAWVRQAPTKGLEWVATIN
YDGRDTYYRDSVKGRFTVSRDNAKSTLYLQMDSLRSEDTATYYCTRHRLIYTT
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 182; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework 20 regions) of SEQ ID NO: 182.
SEQ ID NO: 182 EVKLVESGPGLVKPSQSL SLAC SITDYSITDNYWGWIRKFPGNKMEWIGHISHS
GS STYNPSLKSRISFTRDTSKNQFFLQLNSVTPEDTATYFCARYGAGASFDYWG
QGVMVTVSS
25 In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 183; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 183.
SEQ ID NO: 183 EVQLQQSGAELTKPGSSVKISCKASGFTFTTYDIGWLKQRPGQALEWIGYINPG
SGGIGYNEKFKGKATLTVDKSS STAFMQL S SLTPEDTAVYYCARPLRRVLDYW
GQGVMVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 184; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 184.
SEQ ID NO: 184 EVQLQQ SGAGLTKPGAS VKISCKASGYTF TTYDIGWIKQRPGQALEWIGSINPG
SGGIAYSEKFKGKATLTVDKS S STAFMQLS SLTPEDTAVYYCARPLRRVLDYW
GQGVLVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 185; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 185.
SEQ ID NO: 185 E VKL VE S GP GL VKP SQ SL SLTC S VTGYF IT GNYL AWIRKFPGNKMEW IGHIK S S
GTTTYNPSLKSRVSITRDTSKNQFFLQLNSVTSEDTATYYCARHGHYVMDVWG
QGASVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 186; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 186.
SEQ ID NO: 186 EVQLQQSGAELTKPGS SVKISCKASGYTFTTYDIGWIKQRPGQALEWIGSINPGS
GGIGYNERFKGKATLTVDKS S STAFMQL S SLTPEDTAVYYCARPLRRVLDYWG
QGVMVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 187; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 187.
SEQ ID NO: 187 QVQLKQSGAELTKPGS SVKISCKASGYTFTTYDIGWLKQRPGQALEWIGYINPG
GGGIGYNEKFKGKATLTVDKS S STAFMQL S SLTPEDTAVYYCARPLRRVLDYW
GQGVMVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 188; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 188.
SEQ ID NO: 188 DVKLQESGPGLVKPSQSLSLTC SVTGHSITSNYWGWIRKFPGNKMEWIGQISHS
GSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCGRYGAGSSFDYWG
QGVMVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 189; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 189.
SEQ ID NO: 189 EVQLQQSGAELTKPGS SVKISCKASGYTFTTYDIGWIKQRPGQALEWIGSINPGS
GGIGYNEKFKGKATLTVDKS SSTVFMQL S SLTPEDTAVYYCARPLRRVLDNWG
QGVLVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 190; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 190.
SEQ ID NO: 190 EVQLQQSGAELAKPGS SVKISCKASGYTFTTYDIGWIKQRPGQALEWIGSINPGS
GGIGYNEKFKGKATLTVDKS SRTVFMQL SSLTPEDTAVYYCARPLRRVLDYWG
QGVMVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 191; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 191.
SEQ ID NO: 191 EVQLQQSGPELAKPGS SVKISCKASGYTFTTYDIGWIKQRPGQALEWIGSINPGS
GGIGYNEKFKGKATLTVDKS SSTAFMQL S SLTPEDTAVYYCARPLRRVLDYWG
QGVMVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 192; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 192.
SEQ ID NO: 192 EVQL QQ S GAGL TKP GA S VKI SC TA S GYTF T TYDRGWLRQRPGQ ALEWIGSINP G
GGGTGYNEKFKGNATLTVDKS S STAFMQL S SL TPED TAD YYCARPLRRVLD Y
WGQGVLVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 193; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 193.
SEQ ID NO: 193 DVKLQESGPGLVKPSQSLSLTCSVTGHSITSNYWGWIRKLPGNKMEWIGQISHS
GST SYNP SLISRISITRDT SNQFFLQLNSVTTEDTATYYCGRYGAGS SFDYWGQG
VMVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 194; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 194.
SEQ ID NO: 194 EVQLQQSGAELTKPGS SVKISCKASGYTFTTYDIGWIKQRPGQALEWIGSINPGS
GGIGYNEKFKGKATLTVDRS S STAFMQL S SLTPEDTAVYYCARPLRRVLDNWG
QGVLVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 195; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 195.
SEQ ID NO: 195 EVQLQQSGGELTKPGS SVKISCKASGYTF STYDIGWIKQRPGQALEWIGSINPGS
QGVMVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 196; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 10 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 196.
SEQ ID NO: 196 DVKLQESGPGLVKPSQSLSLTC SVTGHSITGNYWGWIRKFPGNKMEWIGQISHS
GSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCGRYGAGSSFDYWG
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 197; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework 20 regions) of SEQ ID NO: 197.
SEQ ID NO: 197 EVQLQQ SGAGLTKPGGS VKISCKVSGYTF TTYDIGWLKQRPGQALEWIGSINPG
GGGTGYNEKFKGKATLTVDKS S STAFMQL S SLTPEDTAVYYCARPLRRVLDY
WGQGVLVTVS S
25 In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 198; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 198.
SEQ ID NO: 198 EVQLQQ SGAGLTKPGAS VKISCKASGYTF TTYDIGWLKQRPGQALEWIGSINPG
GGGTGYNEKFKGKATLTVDKS SSTAFMQL SSLTPEDTAVYYCARPLRVLDYW
GQGVLVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 199; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 199.
SEQ ID NO: 199 EVQLQQSGAELTKPGS SVKISCKASGYTFTTYDIGWIKQRPGQALEWIGSINPGS
GGIGYNERFKGKATLTVDKS S STAFMQL S SLTPEDTAVYYCARPLRRVLDYWG
RGVMVTVS S
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 200; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 200.
SEQ ID NO: 200 EVQLEESGPGLVKPSQSLSLTC SVTGHSITSNYWGWIRKFPGNKMEWIGQISHS
GSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCGRYGAGSSFDYWG
QGVMVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a HCVR
comprising or consisting of the sequence SEQ ID NO: 201; or a HCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 201.
SEQ ID NO: 201 QVQLKESGPGLVKPSHSLSLTC SVTGHSITSNYWGWIRKFPGNKMEWIGQISHT
GS S TYNP SLK SRISF TRDT SKNQFFLQLNS VTTED SATYYCGRYGAGS SFDYWG
QGVMVTVSS
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 202; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 202.
SEQ ID NO: 202 DVLMTQTPS SQAASAGEKVTMSCKS SQSLLYNENKKNYLAWFQQKPGQSPKL
LIYWASTRESGVPDRFIGGGSGTDFTLTIS SVQAEDLAVYYCQEYYKFPWTFGG
GTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 203; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 203.
SEQ ID NO: 203 DIVMTQ SP S SQAVSAGEKVTMSCK S SQSLLYNENKKNYLAWFQQKPGQSPKLL
IYWASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLAVYYCQDYYHFPWTFGGG
TKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 204; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 204.
SEQ ID NO: 204 DVLMTQTPPTLSATIGQSVSISCKS SQSLLHSNGNTYLNWLLQRPGQSPQLLIYS
VSKLESGVPNRF S GS GS QTDF TLKISEVEAEDMGVYYCMQATHAPF TF GSWTK
LEIK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 205; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 205.
SEQ ID NO: 205 DIVMTQAP S SQAVSPGEKVTMSCKS SQSLLYNENKKNYLAWYQQKPGQSPKLL
IYWASTREAGVPDRFIGSGSGTDFTLTISSVQAEDLAVYYCQQYYKFPWPFGGG
TKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 206; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 206.
SEQ ID NO: 206 DIVMTQAP S SQAVSAGEKVTMSCK SSQ SLLYNENKKNYLAWFQQKPGQSPKLL
IYWAS TRK S GVPDRFIGS GS GTDF TLTI S SVQAEDLAVYYCQQYYKFPWTFGGG
TKLELR
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 207; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 207.
SEQ ID NO: 207 DIVMTQ SP S SQAVSPGEKVTMNCKS SQSLLYNENKKNYLAWYQQKPGQSPKLL
IYWASTREAGVPDRFIGSGSGTDFTLTISSVQAEDLAVYYCQQYYKFPWPFGGG
TKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 208; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 208.
SEQ ID NO: 208 DVLMTQTPPTLSATIGQSVSISCRS SQ SLLHSNGNTYLNWLLQRPGQ SP QLLIY S
VSNLESGVPNRF S GS GSETDF TLKI SGVEAEDL GVYYCMQATHAPF TF GSGTKL
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 209; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 209.
SEQ ID NO: 209 DIVMTQ SP S SQAVSPGEKVTMNCKS SQSLLYNENKKNYLAWYQQKPGQSPKLL
IYWA S TREAGVPDRFIGS GS GTDF TL TI S S VQAEDLAVYYCQ Q YYKFP YTF GAG
TKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 210; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 210.
SEQ ID NO: 210 DIQLTQSPHSLSASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLIYYT SSLQD
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 211; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework 10 regions) of SEQ ID NO: 211.
SEQ ID NO: 211 DIVMTQ SP S SLPASLGERVTISCRASQ GISNKLNWYQQKPDGTIKPLIYYT SRLQ S
GVPSRF SGSGSGTDYSLTIS SLEPEDFAMYYCQQDASFPPTFGAGTKVELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
15 comprising or consisting of the sequence SEQ ID NO: 212; or a LCVR
comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 212.
SEQ ID NO: 212 GVPSRF SGSGSGTDYSLTIS SLEPEDFAMYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 213; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 25 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 213.
SEQ ID NO: 213 DIVLTQ SPVLAVSLGQRATISCRASQ SVS T S TYNFMIHWYQQKPGQQPRLLIYDA
SHLASSVPARF SGSGSGTDFTLTINPVQADDIATYYCQQSRELPLTFGSGTKLEIK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 214; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 214.
SEQ ID NO: 214 DILMTQ SP S SLSASLGERVTISCRASQGIGNKLNWYQQKPDGTIKPLIYYTSNLQ
SGVP SRF SGSGSGTDYSLTISSLEPEDFAMYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 215; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 215.
SEQ ID NO: 215 DIQLTQ SP S SLPASLGERVTISCRASQGISNKLNWYQQKPDGTIKPLIYYT SNLQ S
GVPSRF S GS GS GTDY SLTI S SLEPEDFAMYFCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 216; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 216.
SEQ ID NO: 216 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLIYYTS SF Q
DGVPSRF SGSGSGTQYSLKISNMQPEDEGVYYCQQGYKYPWTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 217; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 217.
SEQ ID NO: 217 DILMTQ SP S SRPASLGERVTISCRASQGIGNKLNWYQQKPDGTIKPLIYYT SNLQ
SGVP SRF SGSGSGTDYSLTISSLEPEDFAMYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 218; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 218.
SEQ ID NO: 218 DIQMTQTP S SLPASLGERVTISCRASQ GISKKLNWYQQKPDGTIKPLIYYT SNLQ
SGVP SRF SGSGSGTDYSLTIS SLEPEDFAIYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 219; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 219.
SEQ ID NO: 219 DIQLTQ SP S SLPASLGERVTISCRASQGISKKLNWYQQKPDGTIKPLIYYT SNLQS
GVPSRF SGS SGTDYSLTIS SLEPEDFAMYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 220; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 220.
SEQ ID NO: 220 DILMTQ SP S SLPASLGERVTISCGASQGIGNKVNWYQQKPDGTIKPLIYYTSNLQ
SGVP SRF SGSGTGTDYSLTIS SLEPEDFAMYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 221; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 221.
SEQ ID NO: 221 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQRKPGK SPQLLIYYTISLQD
GVP SRF SGSGSGTQYSLKISNMQPEDEGVFYCQQGYKYPWTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 222; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 222.
SEQ ID NO: 222 DIQLTQ SP S SLPASLGERVTISCRASQGIGNKLNWYQQKPDGTIKPLIYYTSNLQS
GVPSRF SGSGSGTDYSLTIS SLEPEDFAMYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 223; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 223.
SEQ ID NO: 223 DILMTQ SP S SLSASLGERVTISCRASQGIGNKLNWYQQKPDGTIKPLIYYTSNLQ
SGVP SRF SGSGSGTDYSLTIS SLEPEDFAMYYCQQDTSFPPTFGAGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 224; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 224.
SEQ ID NO: 224 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLIYYTISLQ
DGVPSRF SGSGSGTQYSLKISNMQPEDEGVFYCQQGYKYPWTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 225; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 225.
SEQ ID NO: 225 DIQMTQTP SSLPASLERVTISCRASQGISNKLNWYQKKPDGTIKPLIYYTSNLQS
GVPSRF SGSGSGTDYSLTIS SLEPEDFAMYFCQQDASFPPTFGGGTQLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 226; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework regions) of SEQ ID NO: 226.
SEQ ID NO: 226 DIQLTQ SP S SRPASLGERVTISCRASQGIGNKLNWYQQKPDGTIKPLIYYTSNLQS
GVPSRF SGSGSGTDYSLTIS SLEPEDFAMYYCQQDASFPPTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a LCVR
comprising or consisting of the sequence SEQ ID NO: 227; or a LCVR comprising or consisting of a sequence sharing at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the non-CDR regions (i.e., the framework 5 regions) of SEQ ID NO: 227.
SEQ ID NO: 227 DIQMTQTPHSL SASLGETVSIECLASEGISNYLAWYQQKPGKSPQLLIYYAS SLQ
DGVPSRF SGSGSGTQYSLKISNMQPEDEGVYYCQQGYKYPWTFGGGTKLELK
In one embodiment, the DPP4-binding domain of the invention comprises a combination 10 of (i) a HCVR and (ii) a LCVR, said combination being as defined in Table 4.
TABLE 4. Preferred combinations of HCVR and LCVR. The HCVR and LCVR are defined by their SEQ ID NOs. First column indicates the clone's name.
Clone's name HCVR LCVR
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-13-R3A-A10, 5826-13-R3A-B1, 5826-13-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13-R4A-E6, 5826-13-R4A-E9, 5826-13-R4A-F10, 5826-13-R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12.
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-8-R6A-E10, 5826-8-R5A-G8, 5826-8-R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-A10 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-B1 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-B3 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-D5 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-D6 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-E2 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-E6 as defined in Table 4. In one embodiment, the binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-E9 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-F10 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-G11 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-G12 as defined in Table 4. In one embodiment, the binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H1 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H2 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-H3 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H4 as defined in Table 4. In one embodiment, the binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H5 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H6 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-H9 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H10 as defined in Table 4. In one embodiment, the binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H11 as defined in Table 4. In one embodiment, the DPP4-binding domain of the invention comprises a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H12 as defined in Table 4.
Another object of the present invention is an isolated antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment thereof recognizes and is capable of binding to a senescent cell-associated antigen, as defined hereinabove.
In one embodiment, the senescent cell-associated antigen is selected from the group comprising or consisting of DEP1 and DPP4.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention recognizes and is capable of binding to DEP1, such as, e.g., human DEP1, or orthologs thereof, including murine and rat DEP1. In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention recognizes and is capable of binding to human DEP1 (hDEP1) with SEQ ID NO: 1. In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention recognizes and is capable of binding to the extracellular domain of human DEP1 (hDEP1) comprising or consisting of amino acid residues 36 ¨975 of SEQ ID NO: 1. Hence, the isolated antibody or antigen-binding fragment thereof of the invention is an isolated "anti-DEP1 antibody or antigen-binding fragment thereof'.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention recognizes and is capable of binding to DPP4, such as, e.g., human DPP4 or orthologs thereof, including murine and rat DPP4. In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention recognizes and is capable of binding to human DPP4 (hDPP4) with SEQ ID NO: 101. In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention recognizes and is capable of binding to the extracellular domain of human DPP4 (hDPP4) comprising or consisting of amino acid residues 29 - 766 of SEQ ID NO: 101. Hence, the antigen-binding fragment of the invention is an isolated "anti-DPP4 antibody or antigen-binding fragment thereof'.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention recognizes and is capable of binding to DEP1 and DPP4.
The binding between the anti-DEP1 antibody or antigen-binding fragment thereof of the invention and DEP1, or between the anti-DPP4 antibody or antigen-binding fragment thereof of the invention and DPP4, implies that said antibody or antigen-binding fragment thereof exhibits appreciable affinity for DEP1 or DPP4, respectively. In other words, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention or the anti-DPP4 antibody or antigen-binding fragment thereof of the invention, is specific for, or is immunospecific for, or specifically binds to, DEP1 or DPP4, respectively.
An antibody or antigen-binding fragment thereof is said to be "specific for", "immunospecific for" or to "specifically bind to" an antigen if it reacts with said antigen (e.g., DEP1 and/or DPP4). An antibody or antigen-binding fragment thereof is said to be "specific for", "immunospecific for" or to "specifically bind to" an antigen if it recognizes and is capable of binding to antigen with a KD-affinity constant less than or equal to 10-6 M, preferably less than or equal to 10-7 M, 5.10-8 M, 10-8 M, 5.10-9 M, 10-9 M or less; as may be determined, e.g., by biosensor analysis, particularly by Biacore Analysis.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention comprises an antigen-binding domain, as described hereinabove.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain, as described hereinabove.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 1.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 1.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-13-R2A-C1, 5738-13-R2A-D3, 13-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R3A-C6, 5738-10-R3A-D5, 10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R2A-C1 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-D3 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-D11 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R3A-F5 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-F11 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-H3 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R2A-H4 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R4A-H9 as defined in Table 1. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H11 as defined in Table 1.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, said combination being as defined in Table 2.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-13-R2A-C1, 5738-13-R2A-D3, 5738-13-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-10-R3A-C6, 5738-10-R3A-D5, 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13 -R2A-H4 .
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5738-13-R2A-C1 as defined in Table 2.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5738-13-R2A-D3 as defined in Table 2.
In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5738-13-R4A-D11 as defined in Table 2. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R3A-F5 as defined in Table 2. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R4A-F11 as defined in Table 2. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R2A-H3 as defined in Table 2. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R2A-H4 as defined in Table 2. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-H9 as defined in Table 2. In one embodiment, the anti-DEP1 antibody or antigen-binding fragment thereof of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-H11 as defined in Table 2.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain, as described hereinabove.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 3.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 3.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-A10, 5826-13-R3A-B1, 13-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13-R4A-E6, 5826-13-R4A-E9, 5826-13-R4A-F10, 5826-13-R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-8-R6A-E10, 5826-8-R5A-G8, R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R3A-A10 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-B1 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R3A-B3 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-D5 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R3A-D6 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-E2 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-E6 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-E9 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-F10 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-G11 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-G12 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H1 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H2 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H3 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H4 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H5 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H6 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H9 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H10 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H11 as defined in Table 3. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H12 as defined in Table 3.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, said combination being as defined in Table 4.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-13-R3A-A10, 5826-13-R3A-B1, 5826-13-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13-R4A-E6, 5826-13-R4A-E9, 5826-13-R4A-F10, 5826-13-R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-8-R6A-E10, 5826-8-R5A-G8, 5826-8-R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
.. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R3A-A10 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-B1 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-B3 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-D5 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-D6 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-E2 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-E6 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-E9 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-F10 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-G11 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-G12 as defined in Table 4. 5826-13-R4A-H1 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H2 as defined in Table 4.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H3 as defined in Table 4.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H4 as defined in Table 4.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H5 as defined in Table 4.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H6 as defined in Table 4.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H9 as defined in Table 4.
In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H10 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H11 as defined in Table 4. In one embodiment, the anti-DPP4 antibody or antigen-binding fragment thereof of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H12 as defined in Table 4.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a molecule selected from the group comprising or consisting of a whole antibody, a single-chain variable fragment (scFv), a dimeric single-chain variable fragment (di-scFv, such as a tandem scFv or a diabody), a trimeric single-chain variable fragment (tri-scFv, such as a triabody), a tetrameric single-chain variable fragment (tetra-scFv, such as a tetrabody), a Fv, a Fab, a Fab', a Fab'-SH, a F(ab')2, a Fabc, and a Fd.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a mimetic selected from the group comprising or consisting of an affibody, an alphabody, an armadillo repeat protein based scaffold, a knottin, a kunitz domain peptide, an affilin, an affitin, an adnectin, an atrimer, an evasin, a DARPin, an anticalin, an avimer, a fynomer, a versabody or a duocalin.
Antigen-binding fragment of antibodies comprising specific antigen-binding domains may be generated by known methods. Methods for producing such antigen-binding fragments of antibodies are known in the art, for example as described in Lo (Ed.), 2004.
Antibody Engineering: Methods and Protocols (1st ed., Vol. 248). Totowa, NJ:
Humana Press; and McCafferty, Hoogenboom & Chiswell (Eds.), 1996. Antibody Engineering: a Practical Approach (1st ed., Vol. 169). Oxford: 1RL Press at Oxford University Press. For example, F(ab')2 fragments can be produced by pepsin digestion of the whole antibody molecule, and Fab fragments can be generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity, as described for example in Huse et al., 1989. Science. 246(4935):1275-81.
Antibodies may be generated using known methods. For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with an appropriate antigen. Depending on the host species, various adjuvants may be used to increase an immunological response. Such adjuvants include Freund's adjuvant, mineral gels such as aluminium hydroxide, and surface-active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Adjuvants are commercially available.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is polyclonal. In another embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is monoclonal.
Methods of producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art (see, for example, Harlow and Lane, Antibodies: A
Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988).
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a purified antibody or a purified antigen-binding fragment thereof In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is purified to:
(1) greater than 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% or more by weight of antibody or antigen-binding fragment thereof, as may be determined, e.g., by the Lowry method; and most preferably more than 96%, 97%, 98% or 99% by weight of antibody or antigen-binding fragment thereof;
(2) a degree sufficient to obtain at least 15 amino acid residues of the N-terminal, or of an internal, amino acid sequence, e.g., by use of a spinning cup sequenator;
and/or (3) homogeneity as shown, e.g., by SDS-PAGE under reducing or non-reducing conditions and using, e.g., Coomassie blue staining or more preferably silver staining.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention has an isotype selected from the group comprising or consisting of IgG
(including IgGl, IgG2, IgG3 and IgG4), IgM, IgA (including IgAl and IgA2), IgD
and IgE. The immunoglobulin subclasses or "isotypes" (e.g.õ IgAl, etc.).
The constant region of an antibody is important in the ability of an antibody to fix complement and mediate cell-dependent cytotoxicity and phagocytosis. Thus, as discussed herein, the isotype of an antibody may be selected on the basis of whether it is desirable for the antibody to mediate cytotoxicity/phagocytosis. Determination or selection of the isotype of an antibody may be by known methods in the art.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a murine, a chimeric or a humanized antibody or antigen-binding fragment thereof.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a murine antibody or antigen-binding fragment thereof A "murine antibody or antigen-binding fragment thereof' refers to those antibodies or antigen-binding fragments thereof in which the variable region (including the CDRs and FRs) and the constant region are derived from a mouse.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a chimeric antibody or antigen-binding fragment thereof A "chimeric antibody or antigen-binding fragment thereof' broadly refers to an antibody or antigen-binding fragment thereof comprising a first amino acid sequence linked to a second amino acid sequence with which it is not naturally linked in nature.
The amino acid sequences may normally exist in separate proteins that are brought together in the fusion protein or they may normally exist in the same protein but are placed in a new arrangement in the fusion protein. A chimeric protein may be created, for example, by chemical synthesis, or by creating and translating a polynucleotide in which the peptide regions are encoded in the desired relationship. The term "chimeric antibody or antigen-binding fragment thereof' encompasses herein antibodies and antigen-binding fragments thereof in which:
(a) the constant region (Fc), or a portion thereof, is altered, replaced or exchanged so that the variable region is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region (Fv), or a portion thereof, is altered, replaced or exchanged with a variable region, or portion thereof, having a different or altered antigen specificity; or with corresponding sequences from another species or from another antibody class or subclass.
Method to produce chimeric antibodies are well known in the art. For example, chimeric antibodies may be produced as described in Morrison et al., 1984. Proc Natl Acad Sci U
SA. 81(21):6851-5; Neuberger et al., 1984. Nature. 312(5995):604-608; and Takeda et al., 1985. Nature, 314(6010):452-454.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a humanized antibody or antigen-binding fragment thereof.
A "humanized antibody or antigen-binding fragment thereof' refers to a chimeric antibody or antigen-binding fragment thereof which contains only minimal sequence derived from a non-human immunoglobulin. It includes antibodies made by a non-human cell having variable and constant regions which have been altered to more closely resemble antibodies that would be made by a human cell, e.g., by altering the non-human antibody amino acid sequence to incorporate amino acids found in human germline immunoglobulin sequences. Humanized antibodies or antigen-binding fragment thereof of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs.
The term "humanized antibody or antigen-binding fragment thereof' also includes antibodies and antigen-binding fragment thereof in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. In other words, the term "humanized antibody or antigen-binding fragment thereof' refers to an antibody or antigen-binding fragment thereof in which the CDRs of a recipient human antibody are replaced by CDRs from a donor non-human antibody.
Humanized antibodies or antigen-binding fragments thereof may also comprise residues of donor origin in the framework sequences. The humanized antibody or antigen-binding fragment thereof can also comprise at least a portion of a human immunoglobulin constant region. Humanized antibodies and or antigen-binding fragments thereof may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. Humanization can be performed using methods known in the art (e.g., Jones et al, 1986. Nature. 321(6069):522-5; Riechmann et al, 1988. Nature.
332(6162):323-7; Verhoeyen etal., 1988. Science. 239(4847):1534-6; Presta, 1992. Curr Opin Biotechnol. 3(4):394-8; Patent US4,816,567), including techniques such as "superhumanizing" antibodies (e.g., Tan et al., 2002. J Immunol. 169(2):1119-25) and "resurfacing" (e.g., Staelens etal., 2006. Mol Immunol. 43(8):1243-57; Roguska et at, 1994. Proc Natl Acad Sci USA. 91(3):969-73). A "humanized antibody or antigen-binding fragment thereof' retains a similar antigenic specificity as the original antibody.
However, using certain methods of humanization, the affinity and/or specificity of binding of the antibody may be increased.
Methods for humanizing the isolated antibody or antigen-binding fragment thereof of the invention are well-known in the art. The choice of human variable domains, both light and heavy, to be used in making the humanized antibody or antigen-binding fragment thereof is very important to reduce antigenicity. According to the so-called "best-fit"
method, the sequence of the variable domain of an isolated antibody or antigen-binding fragment thereof of the invention is screened against the entire library of known human variable-domain sequences. The human sequence that is closest to the mouse sequence is then accepted as the human framework (FR) for the humanized antibody (Sims et al, 1993. J Immunol. 151(4):2296-308; Chothia & Lesk, 1987. JMolBiol. 196(4):901-17).
Another method for humanizing the isolated antibody or antigen-binding fragment thereof of the invention uses a particular framework from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework can be used for several different humanized antibodies (Carter et al, 1992.
Proc Natl Acad Sci USA. 89(144285-9; Presta et al., 1993. J Immunol. 151(5):2623-32). It is further important that antibodies be humanized with retention of high affinity for DEP1 or DPP4 and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies and antigen-binding fragments thereof are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its epitope. In this way, CDR residues can be selected and combined from the consensus and import sequences so that the desired antibody characteristic, such as an increased affinity for DEP1 or DPP4, is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding.
Another method for humanizing the isolated antibody or antigen-binding fragment thereof of the invention is to use a transgenic or transchromosomic animal carrying parts of the human immune system for immunization. As a host, these animals have had their immunoglobulin genes replaced by functional human immunoglobulin genes. Thus, antibodies produced by these animals or in hybridomas made from the B cells of these animals are already humanized. Examples of such transgenic or transchromosomic animal include, without limitation:
- the XenoMouse (Abgenix, Fremont, CA), described in Patents US5,939,598, US6,075,181, US6,114,598, US6,150,584 and US6,162,963;
- the HuMAb Mouse (Medarex, Inc.), described in Lonberg et al, 1994. Nature.
368(6474):856-859; Lonberg & Huszar, 1995. Int Rev Immunol. 13(1):65-93;
Harding & Lonberg, 1995. Ann N Y Acad Sci. 764:536-46; Taylor et al., 1992.
Nucleic Acids Res. 20(23):6287-95; Chen et al., 1993. Int Immunol. 5(6):647-56;
Tuaillon et al., 1993. Proc Natl Acad Sci USA. 90(8):3720-4; Choi et al, 1993.
Nat Genet. 4(2): 117-23; Chen et al, 1993. EMBO J. 12(3):821-30; Tuaillon et al., 1994. J Immunol. 152(6):2912-20; Taylor et al., 1994. Int Immunol. 6(4):579-91;
Fishwild et al, 1996. Nat Biotechnol. 14(7):845-51;
- the KM Mouse , described in Patent application W02002043478;
- the TC mice, described in Tomizuka et al., 2000. Proc Nati Acad Sci USA.
97(2):722-7; and - the OmniRatTM (OMT, Inc.), described in Patent application W02008151081;
Geurts et al, 2009. Science. 325(5939):433; Menoret et al., 2010. Eur J
Immunol.
40(10):2932-41.
Humanized antibodies and antigen-binding fragments thereof may also be produced according to various other techniques, such as by using, for immunization, other transgenic animals that have been engineered to express a human antibody repertoire (Jakobovitz et al, 1993. Nature. 362(6417):255-8), or by selection of antibody repertoires using phage display methods. Such techniques are known to the skilled person and can be implemented starting from monoclonal antibodies or antigen-binding fragments thereof as disclosed in the present application.
Whether chimeric or humanized, the isolated antibody or antigen-binding fragment thereof of the invention may comprise a constant region (Fc) of human origin.
In one embodiment, especially when the isolated antibody or antigen-binding fragment thereof of the invention is intended for human therapeutic uses, it is typical for the entire constant region (Fc), or at least a part thereof, to have a fully or substantially human amino acid sequence. Therefore, one or more of, or any combination of, the CH1 domain, hinge region, CH2 domain, CH3 domain and CL domain and CH4 domain (when present) may be fully or substantially human with respect to its amino acid sequence.
Advantageously, the CH1 domain, hinge region, CH2 domain, CH3 domain and CL domain and CH4 domain (when present) may all have a fully or substantially human amino acid sequence.
The term "substantially human", in the context of the constant region (Fc) of a chimeric or humanized antibody or antigen-binding fragment thereof, refers to an amino acid sequence identity of at least 70%, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more with a human constant region (Fc).
The term "human amino acid sequence", in this context, refers to an amino acid sequence which is encoded by a human immunoglobulin gene, which includes germline, rearranged and somatically mutated genes. The present invention also contemplates proteins comprising constant domains of "human" sequence which have been altered, by one or more amino acid additions, deletions or substitutions with respect to the human sequence, excepting those embodiments where the presence of a "fully human hinge region" is expressly required.
The presence of a "fully human hinge region" in the isolated antibody or antigen-binding fragment thereof of the invention may be beneficial both to minimize immunogenicity and to optimize stability of the antibody. It is considered that one or more amino acid substitutions, insertions or deletions may be made within the constant region of the heavy and/or the light chain, particularly within the Fc region.
Amino acid substitutions may result in replacement of the substituted amino acid with a different naturally occurring amino acid, or with a non-natural or modified amino acid.
Other structural modifications are also permitted, such as for example changes in glycosylation pattern (e.g., by addition or deletion of N- or 0-linked glycosylation sites).
Depending on the intended use of the antibody or antigen-binding fragment thereof, it may be desirable to modify the isolated antibody or antigen-binding fragment thereof of the invention with respect to its binding properties to Fc receptors, for example to modulate effector function. For example, cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved effector function (Caron et al, 1992. J Exp Med.
176(4):1191-5; Shopes, 1992. J Immunol. 148(9):2918-22).
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention may be a bispecific antibody (BsAb) with antigen binding to at least two senescent cell-associated antigens. In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention may be a bispecific antibody (BsAb) which binds to both DEP1 and DPP4.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention may be a bispecific antibody (BsAb) with antigen binding to at one senescent cell-associated antigen and one non-senescent cell-associated antigen. In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention may be a bispecific antibody (BsAb) which binds to either of DEP1 or DPP4 on the one hand, and to one non-senescent cell-associated antigen on the other hand.
In one embodiment, the non-senescent cell-associated antigen is a T cell receptor or part thereof, such as, e.g., any one of the CD36, CD3y, CD3E or CD3 subunit.
Examples of bispecific antibodies (BsAb) include, but are not limited to, quadromas, knobs-in-holes, CrossMab Fab, CrossMab VH-VL, CrossMab CH1-CL, TriMab, one-arm single-chain Fab-immunoglobulin gamma (0AscFab-IgG), disulfide stabilized Fv-IgG
(dsFv-IgG), DuetMab, controlled Fab-arm exchanged-IgG1 (cFAE-IgG1), charged pair scFv-Fc, strand-exchange engineered domain body (SEEDbody), two-arm leucine zipper heterodimeric monoclonal antibodies (two-arm LUZ-Y), kappa lambda body (K-body), bi-specific T cell engagers (BiTEs), diabodies, .tandab, dual-affinity retargeting molecules (DARTs), bispecific killer cell engagers (BiKEs), trispecific killer cell engagers (TriKEs), monomeric Fc-VH (mFc-VH) and Fc antigen binding (Fcab), all reviewed and described in Liu et al, 2017 (Front Immunol. 8:38).
Methods for producing bispecific antibodies (BsAb) are well known in the art.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is a recombinant isolated antibody or antigen-binding fragment thereof Thus accordingly, the isolated antibody or antigen-binding fragment thereof of the invention may be produced recombinantly by methods known in the art, such as, e.g., by expression in Escherichia coil expression systems (see, e.g., US patent 4,816,567).
Antigen binding fragment may also be produced by phage display technologies, which are known in the art.
It will also be appreciated that the isolated antibody or antigen-binding fragment thereof of the invention can be modified using methods well known in the art, e.g., to improve the properties of the isolated antibody or antigen-binding fragment thereof For example, to slow clearance in vivo and obtain a more desirable pharmacokinetic profile, the isolated antibody or antigen-binding fragment thereof may be modified with polyethylene glycol (PEG). Methods for coupling and site-specifically conjugating PEG to an antibody or antigen-binding fragment thereof are described in, e.g., Leong et al., 2001.
Cytokine.
16(3):106-19; Delgado et al., 1996. Br J Cancer. 73(2):175-82. Another non-limiting example of modification consist in the modification of the human Fc region of the antibody in order to enhance their affinity for an Fcy receptor. Methods of enhancing Fc receptor binding include Fc amino acid modification and modification of Fc carbohydrate structures. For immunoglobulins, it has been demonstrated that the attachment of an N-linked oligosaccharide to Asn-297 of the CH2 domain is critical for ADCC
activity.
Removal of the N-linked oligosaccharide through mutation of the N-linked consensus site or by enzymatic means results in little or no ADCC activity. Removal of the core a-1,6-fucose moiety from IgG1 Fc oligosaccharides has been demonstrated to improve FcyRIII
binding and ADCC activity (see, e.g., Carter, 2001. Nat Rev Cancer. 1(2):118-29; Kanda et at, 2007. Glycobiology. 17(1):104-18; Shields et al., 2002. J Biol Chem.
277(30):26733-40; Shinkawa et al., 2003. J Biol Chem. 278(5):3466-73; Niwa et al., 2004. Cancer Res. 64(6):2127-33). The level of another glycoform, bisected N-linked carbohydrate, has also been suggested to increase ADCC (see, e.g., Umalia et al., 1999.
NatBiotechnol. 17(2):176-80; Hodoniczky eta, 2005. BiotechnolProg. 21(6):1644-52).
A variety of Fc sequence variants with optimized binding affinity for FcyRs and/or enhanced ADCC have been described and are known in the art.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention targets, blocks, depletes and/or kills senescent cells to which it is bound.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention targets, blocks, depletes and/or kills senescent cells expressing at least one senescent cell-associated antigen, as defined hereinabove.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention may comprise human HCCRs (heavy chain constant regions) and allows to target, block, deplete and/or kill DEP1-expressing cells to which it is bound.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention may comprise human HCCRs (heavy chain constant regions) and allow to target, block, deplete and/or kill DPP4-expressing cells to which it is bound.
In one embodiment where the isolated antibody or antigen-binding fragment thereof is a bispecific antibody as described above, said bispecific antibody may comprise human HCCRs (heavy chain constant regions) and allow to target, block, and/or deplete DEP1-and/or DPP4-expressing cells to which it is bound.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention depletes and/or kills DEP1-expressing cells to which it is bound.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention depletes and/or kills DPP4-expressing cells to which it is bound.
In one embodiment where the isolated antibody or antigen-binding fragment thereof is a bispecific antibody as described above, said bispecific antibody depletes and/or kills DEP1- and/or DPP4-expressing cells to which it is bound.
By "deplete" or "depleting", it is referred to the killing, elimination, lysis, or induction of such killing, elimination or lysis, so as to negatively affect the number of cells to which the isolated antibody or antigen-binding fragment thereof is bound (such as, e.g., DEP1-and/or DPP4-expressing cells) present in a sample or in a subject. In one embodiment, such depletion occurs via ADCC. In one embodiment, such depletion occurs via ADCP.
In one embodiment, such depletion occurs via CDC.
Thus, in one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention leads, directly or indirectly, to the depletion of senescent cells, in particular of DEP1- and/or DPP4-expressing cells.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention leads, directly or indirectly, to the depletion of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of senescent cells, in particular of DEP1- and/or expressing cells.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention leads, directly or indirectly, to a decrease by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more elimination of the number of senescent cells, in particular of DEP1- and/or DPP4-expressing cells.
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention induces any one or several, such as two or three, of:
- antibody dependent cellular cytotoxicity (ADCC);
- antibody-dependent cell-mediated phagocytosis (ADCP);
- complement-dependent cytotoxicity (CDC).
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is from the IgG1 subclass and has any one or several, such as two or three, of:
- antibody dependent cellular cytotoxicity (ADCC);
- antibody-dependent cell-mediated phagocytosis (ADCP);
- complement-dependent cytotoxicity (CDC).
In one embodiment, the isolated antibody or antigen-binding fragment thereof of the invention is linked/fused/conjugated to a payload, e.g., a therapeutic moiety.
Such conjugates are referred to herein as an "antibody drug conjugates" or "ADCs".
In one embodiment, the payload is selected from chemotherapeutic agents, targeted therapy agents, cytotoxic agents, antibiotics, antivirals, cell cycle-synchronizing agents, ligands for cellular receptor(s), immunomodulatory agents, pro-apoptotic agents, anti-angiogenic agents, cytokines, growth factors, hormones, coding or non-coding oligonucleotides, photodetectable labels, contrast agents, radiolabels, and the like.
Another object of the present invention is a nucleic acid encoding the antigen-binding domain, the antibody or the antigen-binding fragment thereof of the invention.
Another object of the present invention is a vector comprising the nucleic acid encoding the antigen-binding domain, the antibody or the antigen-binding fragment thereof of the invention.
In one embodiment, the vector is an expression vector and further comprises regulatory elements allowing for expression of the antigen-binding domain, the antibody or the antigen-binding fragment thereof, in a cell.
In one embodiment, the expression vector may be monocistronic. By "monocistronic", it is meant that a single nucleic acid encoding a single protein is expressed in a single expression vector.
In one embodiment, the expression vector comprises a sequence encoding the HCVR of the antigen-binding domain, the antibody or the antigen-binding fragment thereof of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises a sequence encoding the HCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment thereof of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises a sequence encoding the HCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 55 to 74.
In one embodiment, the expression vector comprises a sequence encoding the HCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises a sequence encoding the HCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 174 to 201.
In one embodiment, the expression vector comprises a sequence encoding the LCVR of the antigen-binding domain, the antibody or the antigen-binding fragment thereof of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises a sequence encoding the LCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises a sequence encoding the LCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 75 to 94.
In one embodiment, the expression vector comprises a sequence encoding the LCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises a sequence encoding the LCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 202 to 227.
In one embodiment, the expression vector may be polycistronic. By "polycistronic", it is meant that at least two or more nucleic acids, each encoding a single protein, are expressed in a single expression vector.
In one embodiment, the expression vector comprises:
- a sequence encoding the HCVR of the antigen-binding domain, the antibody or the antigen-binding fragment thereof of the invention, preferably operably linked to regulatory elements, and - a sequence encoding the LCVR of the antigen-binding domain, the antibody or the antigen-binding fragment thereof of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises:
- a sequence encoding the HCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, and - a sequence encoding the LCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises:
- a sequence encoding the HCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 55 to 74, and - a sequence encoding the LCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 75 to 94.
In one embodiment, the expression vector comprises:
- a sequence encoding the HCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, and - a sequence encoding the LCVR of the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, wherein said sequence encoding the HCVR and said sequence encoding the LCVR
are selected from the group comprising or consisting of the combinations of HCVR
and LCVR as defined in Table 2.
In one embodiment, the expression vector comprises:
- a sequence encoding the HCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, and - a sequence encoding the LCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements.
In one embodiment, the expression vector comprises:
- a sequence encoding the HCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 174 to 201, and - a sequence encoding the LCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, said sequence being selected from the group comprising or consisting of SEQ ID NOs: 202 to 227.
In one embodiment, the expression vector comprises:
- a sequence encoding the HCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, and - a sequence encoding the LCVR of the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment of the invention, preferably operably linked to regulatory elements, wherein said sequence encoding the HCVR and said sequence encoding the LCVR
are selected from the group comprising or consisting of the combinations of HCVR
and LCVR as defined in Table 4.
Another object of the invention is a method of producing and purifying the isolated antibody or antigen-binding fragment thereof of the invention.
In one embodiment, the method comprises:
- culturing host cells comprising the nucleic acid or expression vector of the present invention, under conditions suitable for expression of the antibody or antigen-binding fragment thereof, and - recovering the expressed antibody or antigen-binding fragment thereof.
This recombinant process can be used for large scale production of antibodies or antigen-binding fragments thereof, including monoclonal antibodies intended for in vitro, ex vivo and/or in vivo therapeutic and/or diagnostic uses.
The nucleic acid or expression vector encoding the antibody or antigen-binding fragment, as described herein, may be propagated and expressed according to any of a variety of routinely practiced procedures for nucleic acid excision, ligation, transformation, and transfection. In certain embodiments, expression of the antibody or antigen-binding fragment thereof may be carried out in a prokaryotic host cell (i.e., the host cell comprising the nucleic acid or expression vector of the present invention is a prokaryotic host cell), such as Escherichia coli (see, e.g., Pluckthun et al, 1989.
Methods Enzymol.
178:497-515). In certain other embodiments, the antibody or antigen-binding fragment thereof may be expressed in a eukaryotic host cell (i.e., the host cell comprising the nucleic acid or expression vector of the present invention is an eukaryotic host cell), including animal cells (such as mammalian cells), yeast (e.g., Saccharomyces cerevisiae, Schizosaccharomyces porn be, or Pichia pastoris); and plant cells. Examples of suitable animal cells include, but are not limited to, myeloma, HEK293, COS, or CHO
cells.
Examples of plant cells include tobacco, corn, soybean, and rice cells. By methods known to those having ordinary skill in the art and based on the present disclosure, a nucleic acid vector may be designed for expressing foreign sequences in a particular host system, and then polynucleotide sequences encoding the cellular polypeptide may be inserted. The regulatory elements will vary as appropriate for the particular host.
All these processes are well known in the art (Subramanian (Ed.), 2004.
Antibodies (1st ed., Vol. 1: Production and Purification). New York, NY: Springer US).
In an embodiment, the expressed antibody or antigen-binding fragment thereof is further purified.
Methods to purify the antibody or antigen-binding fragment thereof of the invention are well known in the art (Subramanian (Ed.), 2004. Antibodies (1st ed., Vol. 1:
Production and Purification). New York, NY: Springer US), and include, without limitation, chromatography, preferably by affinity chromatography, more preferably by affinity chromatography on protein L agarose.
Another object of the present invention is a chimeric antigen receptor (CAR) comprising:
(i) at least one extracellular binding domain, comprising or consisting of at least one antigen-binding domain directed to a senescent cell-associated antigen, (ii) an extracellular spacer domain, (iii) a transmembrane domain, (iv) optionally, at least one costimulatory domain, and (v) at least one intracellular signaling domain.
In one embodiment, the CAR of the invention comprises at least one extracellular binding domain (also called ectodomain), wherein said at least one extracellular binding domain recognizes and is capable of binding to a senescent cell-associated antigen, as defined hereinabove. In one embodiment, the extracellular binding domain comprises or consists of an antigen-binding domain directed to a senescent cell-associated antigen, which recognizes and is capable of binding to a senescent cell-associated antigen, as defined hereinabove.
In one embodiment, the senescent cell-associated antigen is selected from the group comprising or consisting of DEP1 and DPP4. Hence, in one embodiment, the at least one extracellular binding domain of the CAR of the invention recognizes and is capable of binding to DEP1 and/or DPP4. In one embodiment, the extracellular binding domain comprises or consists of an antigen-binding domain directed to DEP1 and/or DPP4, which recognizes and is capable of binding to DEP1 and/or DPP4, as defined hereinabove.
In one embodiment, the at least one extracellular binding domain in the CAR of the invention recognizes and is capable of binding to DEP1, such as, e.g., human DEP1, or orthologs thereof, including murine and rat DEP1. In one embodiment, the at least one extracellular binding domain in the CAR of the invention recognizes and is capable of binding to human DEP1 (hDEP1) with SEQ ID NO: 1. In one embodiment, the at least one extracellular binding domain in the CAR of the invention recognizes and is capable of binding to the extracellular domain of human DEP1 (hDEP1) comprising or consisting of amino acid residues 36 ¨ 975 of SEQ ID NO: 1. In one embodiment, the extracellular binding domain comprises or consists of a DEP1-binding domain, as defined hereinabove. Hence, the CAR of the invention is an "anti-DEP1 chimeric antigen receptor (CAR)".
In one embodiment, the at least one extracellular binding domain in the CAR of the invention recognizes and is capable of binding to DPP4, such as, e.g., human DPP4 or orthologs thereof, including murine and rat DPP4. In one embodiment, the at least one extracellular binding domain in the CAR of the invention recognizes and is capable of binding to human DPP4 (hDPP4) with SEQ ID NO: 101. In one embodiment, the at least one extracellular binding domain in the CAR of the invention recognizes and is capable of binding to the extracellular domain of human DPP4 (hDPP4) comprising or consisting of amino acid residues 29 - 766 of SEQ ID NO: 101. In one embodiment, the extracellular binding domain comprises or consists of a DPP4-binding domain, as defined hereinabove.
Hence, the CAR of the invention is an "anti-DDP4 chimeric antigen receptor (CAR)".
In one embodiment, the at least one extracellular binding domain in the CAR of the invention comprises an antigen-binding domain, as described hereinabove.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain, as described hereinabove.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 1.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 1.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-13-R2A-C1, 5738-13-R2A-D3, 5738-13-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R3A-C6, 5738-10-R3A-D5, 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-13-R4A-D11, .. and 5738-13-R2A-H4.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-C1 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R2A-D3 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R4A-D11 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R3A-F5 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-F11 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-H3 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R2A-H4 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H9 as defined in Table 1. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5738-13-R4A-H11 as defined in Table 1.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, said combination being as defined in Table 2.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-13-R2A-C1, 5738-13-R2A-D3, 5738-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-10-R3A-C6, 5738-10-R3A-D5, 5738-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-10-R4A-G12, 5738-13-R4A-D11, and .. 5738-13-R2A-H4.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2: 5738-13-R4A-D11, and 5738-13-R2A-H4.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R2A-C1 as defined in Table 2. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R2A-D3 as defined in Table 2. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5738-13-R4A-D11 as defined in Table 2. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R3A-F5 as defined in Table 2. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R4A-F11 as defined in Table 2. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5738-13-R2A-H3 as defined in Table 2.
In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R2A-H4 as defined in Table 2. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5738-13-R4A-H9 as defined in Table 2. In one embodiment, the extracellular binding domain of the anti-DEP1 chimeric antigen receptor (CAR) of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5738-13-R4A-H11 as defined in Table 2.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain, as described hereinabove.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 3.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 3.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-A10, 5826-13-R3A-B1, 5826-13-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13 -R4A-E6, 5826-13 -R4A-E9, 5826-13 -R4A-F10, 5826-13 -R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-8-R6A-E10, 5826-8-R5A-G8, 5826-8-R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-A10 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R3A-B1 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-B3 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R3A-D5 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the .. invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R3A-D6 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-E2 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-E6 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-E9 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-F10 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination .. being that of clone 5826-13-R4A-G11 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-G12 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H1 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H2 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H3 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H4 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H5 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H6 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H9 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H10 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 13-R4A-H11 as defined in Table 3. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of clone 5826-13-R4A-H12 as defined in Table 3.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, said combination being as defined in Table 4.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-13-R3A-A10, 5826-13-R3A-B1, 5826-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13-R4A-E6, 5826-13-R4A-E9, 5826-13-R4A-F10, 5826-13-R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-8-R6A-E10, 5826-8-R5A-G8, 5826-8-R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4: 5826-13-R3A-D5, 5826-13-R4A-H5, and 13-R4A-H12.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R3A-A10 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-B1 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the .. invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R3A-B3 as defined in Table 4.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R3A-D5 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R3A-D6 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-E2 as defined in Table 4.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-E6 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-E9 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-F10 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-G11 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-G12 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H1 as defined in Table 4.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-H2 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H3 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H4 as defined in Table 4.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-H5 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H6 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H9 as defined in Table 4.
In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone R4A-H10 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of clone 5826-13-R4A-H11 as defined in Table 4. In one embodiment, the extracellular binding domain of the anti-DPP4 chimeric antigen receptor (CAR) of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR
and (ii) a LCVR, combination being that of clone 5826-13-R4A-H12 as defined in Table 4.
In one embodiment, the extracellular binding domain of the CAR of the invention comprises or consists a single chain variable region (scFv) or a Fab fragment, preferably a scFv, comprising an one antigen-binding domain as defined hereinabove.
In one embodiment, the CAR of the invention comprises more than one extracellular binding domain, such as 2 extracellular binding domains, 3 extracellular binding domains or more. Such CARs are called "tandem CARs" or "multispecific CARs", such as bispecific, trispecific, etc.
In this embodiment, the CAR of the invention is multispecific and comprises extracellular binding domains, wherein at least one of the extracellular binding domains recognizes and is capable of binding to a senescent cell-associated antigen.
In one embodiment, the CAR of the invention is multispecific and comprises extracellular binding domains, each of which recognizes and is capable of binding to a different senescent cell-associated antigen.
In one embodiment, the CAR of the invention is multispecific and comprises extracellular binding domains, wherein one extracellular binding domain recognizes and is capable of binding to either of DEP1 or DPP4, and at least one other extracellular binding domain recognizes and is capable of binding to another senescent cell-associated antigen.
In one embodiment, the CAR of the invention is multispecific and comprises extracellular binding domains, wherein one extracellular binding domain recognizes and is capable of binding to DEP1, and at least one other extracellular binding domain recognizes and is capable of binding to DPP4.
In one embodiment, the CAR of the invention is bispecific and comprises two extracellular binding domains, wherein one extracellular binding domain recognizes and is capable of binding to DEP1, and the other extracellular binding domain recognizes and is capable of binding to DPP4.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 1; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) at least one, preferably at least two, more preferably three HCVR's CDRs and (ii) at least one, preferably at least two, more preferably three LCVR's CDRs, said combination being as defined in Table 3, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 1; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being as defined in Table 3, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-13-R2A-C1, 5738-13-R2A-D3, 5738-13-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-A10, 5826-13-R3A-B1, 5826-13-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13-R4A-E6, 5826-13-R4A-E9, 5826-13-R4A-F10, 5826-13-R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R3A-C6, 5738-10-R3A-D5, 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-8-R6A-E10, 5826-8-R5A-G8, 5826-8-R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 1: 5738-13-R4A-D11, and 5738-13-R2A-H4; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) three HCVR's CDRs and (ii) three LCVR's CDRs, said combination being that of any one of the following clones as defined in Table 3: 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, said combination being as defined in Table 2; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, said combination being as defined in Table 4, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2:
5738-13-R2A-C1, 5738-13-R2A-D3, 5738-13-R4A-D11, 5738-13-R3A-F5, 5738-13-R4A-F11, 5738-13-R2A-H3, 5738-13-R2A-H4, 5738-13-R4A-H9, and 5738-13-R4A-H11; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4:
5826-13-R3A-A10, 5826-13-R3A-B1, 5826-13-R3A-B3, 5826-13-R3A-D5, 5826-13-R3A-D6, 5826-13-R4A-E2, 5826-13-R4A-E6, 5826-13-R4A-E9, 5826-13-R4A-F10, 5826-13-R4A-G11, 5826-13-R4A-G12, 5826-13-R4A-H1, 5826-13-R4A-H2, 5826-13-R4A-H3, 5826-13-R4A-H4, 5826-13-R4A-H5, 5826-13-R4A-H6, 5826-13-R4A-H9, 5826-13-R4A-H10, 5826-13-R4A-H11, and 5826-13-R4A-H12, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2:
5738-10-R3A-C6, 5738-10-R3A-D5, 5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4:
5826-8-R6A-E10, 5826-8-R5A-G8, 5826-8-R6A-H11, 5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2:
5738-10-R4A-G12, 5738-13-R4A-D11, and 5738-13-R2A-H4; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4:
5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12, as described and defined hereinabove.
In this embodiment, a) one extracellular binding domain of the bispecific CAR of the invention comprises a DEP1-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 2:
5738-13-R4A-D11, and 5738-13-R2A-H4; and b) one extracellular binding domain of the bispecific CAR of the invention comprises a DPP4-binding domain comprising a combination of (i) a HCVR and (ii) a LCVR, combination being that of any one of the following clones as defined in Table 4:
5826-13-R3A-D5, 5826-13-R4A-H5, and 5826-13-R4A-H12, as described and defined hereinabove.
Additionally or alternatively, the CAR of the invention is multispecific and comprises extracellular binding domains, wherein at least two extracellular binding domains recognize and are capable of binding to the same senescent cell-associated antigen, but on different epitopes of said senescent cell-associated antigen.
Such multispecific CARs typically comprise:
(i) two of more extracellular binding domains, as defined hereinabove, (ii) one extracellular spacer domain, (iii) one transmembrane domain, (iv) optionally, at least one costimulatory domain, and (v) at least one intracellular signaling domain.
In a multispecific CAR, each extracellular binding domain comprises or consists of a single chain variable region (scFv) or a Fab fragment, preferably a scFv, comprising the antigen-binding domain as defined hereinabove.
In one embodiment, the extracellular binding domains in the multispecific CAR
of the invention are linked or fused together through a flexible peptidic linker, enabling each extracellular binding domain to form the desired structure for antigen binding (Pluckthun, 1994. "Antibodies from Escherichia coli". In Rosenberg & Moore (Eds.), The pharmacology of monoclonal antibodies. Handbook of Experimental Pharmacology, 113:269-315. Springer: Berlin, Heidelberg). Flexible peptidic linkers are generally composed of small, non-polar (e.g., glycine, Gly, G) or polar (e.g., serine, Ser, S; or threonine, Thr, T) amino acids, as suggested by Argos (1990. J Mol Biol.
211(4):943-958). The small size of these amino acids provides flexibility, and allows for mobility of the connecting functional domains, such as the extracellular binding domains.
In one embodiment, the flexible peptidic linker may be a short oligo- or polypeptide, preferably having a length ranging from 2 to 30 amino acids. In one embodiment, the flexible peptidic linker comprises glycine-serine repeats. In one embodiment, the flexible peptidic linker comprises one, or several repeats of, such as 2, 3, 4, 5 or more repeats of, GS
linker(s) (i.e., a sequence of one Gly and one Ser), G2S linker(s) (i.e., a sequence of two Gly and one Ser), G3S linker(s) (i.e., a sequence of three Gly and one Ser), G4S linker(s) (i.e., a sequence of four Gly and one Ser), or G5S linker(s) (i.e., a sequence of five Gly and one Ser).
In one embodiment, the CAR of the invention comprises an extracellular spacer domain (also called hinge domain).
In one embodiment, the at least one extracellular binding domain is connected to one transmembrane domain through one extracellular spacer domain.
The extracellular spacer domain typically facilitates proper protein folding, provides flexibility to the at least one extracellular binding domain and helps avoiding steric hindrance. It typically comprises a hydrophilic region linking the at least one extracellular binding domain and the transmembrane domain.
Extracellular spacer domains may include, but are not limited to, Fc fragments of antibodies or fragments or derivatives thereof, hinge regions of antibodies or fragments or derivatives thereof, CH2 regions of antibodies, CH3 regions antibodies, artificial spacer sequences or combinations thereof.
Examples of extracellular spacer domains include, but are not limited to, CD8a hinge;
CD28 hinge; flexible peptidic linkers (such as, e.g., Gly3); or hinge region, CH1, CH2 and/or CH3 domains of IgG' s (such as human IgG4).
In one embodiment, the extracellular spacer domain is selected from the group comprising or consisting of (i) a hinge region, CH2 domain and CH3 domain of IgG4, (ii) a hinge region of IgG4, (iii) a hinge region and CH2 domain of IgG4, (iv) a hinge region of CD8a, (v) a hinge region, CH2 domain and CH3 domain of IgGl, (vi) a hinge region of IgG1 (vii) a hinge region and CH2 domain of IgGl, and (viii) a hinge region of CD28;
and combinations thereof Additional extracellular spacer domains will be apparent to those skilled in the art and may be used in connection with alternate embodiments of the invention.
In one embodiment, the CAR of the invention comprises a transmembrane domain.
In one embodiment, the transmembrane domain comprises an amino acid sequence derived from the transmembrane domain of any protein which has such transmembrane domain, including any of the type I, type II or type III transmembrane proteins.
In one embodiment, the transmembrane domain may also comprise an artificial hydrophobic sequence.
Examples of transmembrane domains that are suitable in the CAR of the invention include, but are not limited to, transmembrane domains of an a, 0 or chain of a T cell receptor, or of CD28, CD3y, CD36, CD3c, CD3c CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, 0X40, CD2, CD27, LFA-1 (CD1 la, CD18), ICOS (CD278), 4-1BB (CD137), GITR (CD357), .. CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2Ry, IL7Ra, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD 1 1 a, LFA-1, ITGAM, CD1 lb, PD1, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM
(CD355), Ly9 (CD229), CD160 (BY55), PSGL1, CDIO0 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IP0-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG/Cbp, NKp44, NKp30, NKp46, NKG2D or NKG2C.
In one embodiment, the transmembrane domain comprises an amino acid sequence derived from the transmembrane domain of CD28 or CD3.
Additional transmembrane domains will be apparent to those skilled in the art and may be used in connection with alternate embodiments of the invention.
In one embodiment, the transmembrane domain may be recombinant, in which case it will comprise predominantly hydrophobic amino acids, such as, e.g., valine, Val, V or leucine, Leu, L.
In one embodiment, the CAR of the invention can optionally comprise one or several costimulatory domain(s).
Costimulatory domains enhance cell proliferation, cell survival and development of memory cells.
Examples of costimulatory domains that are suitable in the CAR of the invention include, but are not limited to, costimulatory domains of any of the members of the TNFR super family, CD28, CD137 (4-1BB), CD134 (0X40), Dap10, CD27, CD2, CD5, ICAM-1, Lck, TNFR-1, TNFR-II, Fas, CD30, CD40, CTLA-4, ICOS, PD-1, and combinations thereof.
Costimulatory domains from other proteins may also be used with the CARs of the invention. Additional costimulatory domains will be apparent to those skilled in the art and may be used in connection with alternate embodiments of the invention.
If the CAR of the invention comprises more than one costimulatory domain, these domains may be arranged in tandem, optionally separated by a linker, such as a flexible peptidic linker as has been described above.
In one embodiment, the costimulatory domain comprises a T cell costimulatory molecule, or a sequence derived therefrom.
In one embodiment, the CAR of the invention comprises at least one costimulatory domain selected from the group comprising or consisting of 4-1BB, ICOS, CD27, 0X40, CD28, CTLA4 and PD-1.
In one embodiment, the CAR of the invention comprises at least one intracellular signaling domain (also called endodomain).
The intracellular signaling domain is cytoplasmic, and allows to transduce the effector function signal and direct the cell to perform its specialized function upon binding of the extracellular binding domain to its antigen.
Examples of intracellular signaling domains that are suitable in the CAR of the invention include, but are not limited to, chain of the T cell receptor or any of its homologs (such as, e.g., q chain, FccRly and 0 chains, 1V1B1 (Iga) chain, B29 (Igf3) chain, etc.), CD3 polypeptides (such as, e.g., A, 6 and 6), syk family tyrosine kinases (such as, e.g., Syk, ZAP 70, etc.), src family tyrosine kinases (such as, e.g., Lck, Fyn, Lyn, etc.) and other molecules involved in T cell transduction, such as, e.g., CD2, CD5 and CD28.
In one embodiment, the intracellular signaling domain may be human CD3 chain, FcyRIII, FccRI, cytoplasmic tails of Fc receptors, immunoreceptor tyrosine-based activation motif (ITAM) bearing cytoplasmic receptors or combinations thereof Additional intracellular signaling domains will be apparent to those skilled in the art and may be used in connection with alternate embodiments of the invention.
In one embodiment, the at least one intracellular signaling domain may comprise the entire intracellular portion, or the entire native intracellular signaling domain, of the molecule from which it is derived, or a functional fragment or derivative thereof In one embodiment, the at least one intracellular signaling domain comprises or consists of a T cell primary signaling domain (or a sequence derived therefrom).
In one embodiment, the T cell primary signaling domain comprises or consists of a signaling domain of a protein selected in the group of CD3, CD3y, CD3, CD3c, common FcRy (FCER1G), FcRE (Fc Epsilon Rib), CD79a, CD79b, FcyRIIa, DAP10, DAP12, and sequences derived therefrom.
In one embodiment, the T cell primary signaling domain comprises or consists of a functional signaling domain of CD3.
T cell primary signaling domains that act in a stimulatory manner may comprise signaling motifs known as immunoreceptor tyrosine-based activation motifs (ITAMS).
Examples of ITAM containing T cell primary intracellular signaling domains that are of particular use in the invention include, but are not limited to, those of (or derived from) CD3c common FcRy (FCER1G), FcyRIIa, FcRf3 (FccR1b), CD3y, CD36, CD3c, CD5, CD22, CD66b, CD79a, CD79b, DAP10, and DAP12.
In one embodiment, the T cell primary signaling domain comprises a modified ITAM
domain (e.g., a mutated ITAM domain which has altered e.g., increased or decreased) activity as compared to the native ITAM domain. In one embodiment, a primary signaling domain comprises a modified ITAM-containing primary intracellular signaling domain, e.g., an optimized and/or truncated ITAM-containing primary intracellular signaling domain. In one embodiment, a primary signaling domain comprises one, two, three, four or more ITAM motifs.
In one embodiment, the at least one intracellular signaling domain and the at least one costimulatory domain, if present, may be linked to each other in tandem, in a random or in a specified order.
Optionally, a linker, such as a flexible peptidic linker as has been described above, may form the linkage between distinct intracellular signaling domains, and/or between a costimulatory domain and an intracellular signaling domain. Besides flexible peptidic linkers described above, a single amino acid (such as, e.g., alanine, Ala, A
or glycine, Gly, G) may also be a suitable linker.
In one embodiment, the CAR of the invention comprises more than one intracellular signaling domain, such as 2, 3, 4, 5, or more, intracellular signaling domains.
In one embodiment, the CAR of the invention may further comprise a tag, such as, e.g., a tag for quality control, enrichment, tracking in vivo and the like.
In one embodiment, said tag is localized N-terminally, C-terminally and/or internally.
Examples of tags that that are suitable in the CAR of the invention include, but are not limited to, hemagglutinin tag, poly-arginine tag, poly-histidine tag, Myc tag, strep tag, S-tag, HAT tag, 3xFlag tag, calmodulin-binding peptide (CBP) tag, SBP tag, chitin binding domain (CBD) tag, GST tag, maltose-binding protein (MBP) tag, fluorescent protein tag, T7 tag, V5 tag and Xpress tag.
The CAR of the invention may be a first-generation, second-generation or third-generation CAR.
The first generation of CARs was developed more than 30 years ago (Kuwana et al., 1987. Biochem Biophys Res Commun. 149(3):960-968; Gross et al., 1989.
Transplant Proc. 21(1 Pt 1):127-130; Gross et al., 1989. Proc Natl Acad Sci USA.
86(24):10024-10028).
In one embodiment, the CAR of the invention is a first-generation CAR and comprises:
(i) at least one extracellular binding domain, (ii) an extracellular spacer domain, (iii) a transmembrane domain, and (iv) one or more intracellular signaling domain(s).
A first-generation CAR can be, for example, a CAR in which signaling is provided by CD3c i.e., the intracellular signaling domain is CD3.
Second-generation CARs add a co-stimulatory domain, such as, e.g., CD28 or 4-1BB.
The involvement of these intracellular signaling domains improve T cell proliferation, cytokine secretion, resistance to apoptosis, and in vivo persistence.
In one embodiment, the CAR of the invention is a second-generation CAR and comprises:
(i) at least one extracellular binding domain, (ii) an extracellular spacer domain, (iii) a transmembrane domain, (iv) a costimulatory domain(s), and (v) one or more intracellular signaling domain(s).
Third-generation CARs combine multiple co-stimulatory domains, such as, e.g., 4-1BB or CD28-0X40, to increase T cell activity.
In one embodiment, the CAR of the invention is a third-generation CAR and comprises:
(i) at least one extracellular binding domain, (ii) an extracellular spacer domain, (iii) a transmembrane domain, (iv) at least two costimulatory domains, and (v) one or more intracellular signaling domain(s).
Another object of the present invention is a nucleic acid encoding the CAR of the invention.
Another object of the present invention is a vector comprising the nucleic acid encoding the CAR of the invention.
In one embodiment, the nucleic acid or vector of the invention comprises a nucleic acid sequence of the extracellular binding domain(s) operably linked to the nucleic acid sequence of an extracellular spacer domain, operably linked to the nucleic acid sequence of a transmembrane domain, operably linked to the nucleic acid sequence of a cytoplasmic domain (i.e., at least one intracellular signaling domain and optionally, at least one costimulatory domain).
The nucleic acid or the vector of the invention can be prepared in conventional ways (e.g., recombinant methods), where the genes and regulatory regions may be isolated, as appropriate, ligated, and cloned in an appropriate cloning host, analyzed by restriction or sequencing, or other convenient means. Particularly, using PCR, individual fragments including all or portions of a functional unit may be isolated, where one or more mutations may be introduced using "primer repair", ligation, in vitro mutagenesis, etc., as appropriate. Alternatively, the gene of interest can be produced synthetically, rather than cloned.
In one embodiment, the vector comprises a first nucleic acid encoding a CAR of the invention, and further comprises a second nucleic acid encoding an antibody or antigen-binding fragment thereof, a bispecific antibody (e.g., a BiTE), a cytokine or a costimulatory ligand. In one embodiment, the first nucleic acid and the second nucleic acid are each operably linked to a promoter. In one embodiment, the first nucleic acid is operably linked to a first promoter and the second nucleic acid is operably linked to a second promoter. The promoter can be a constitutively-expressed promoter (e.g., an EFla promoter) or an inducibly-expressed promoter (e.g., a NFAT promoter).
In one embodiment, expression of the CAR and expression of the antibody or antigen-binding fragment thereof, bispecific antibody (e.g., a BiTE), cytokine or costimulatory ligand are driven by the same promoter, e.g., a constitutively expressed promoter (e.g., an EF la promoter). In one embodiment, expression of the CAR and expression of the antibody or antigen-binding fragment thereof, bispecific antibody (e.g., a BiTE), cytokine or costimulatory ligand are driven by different promoters.
In one embodiment, the nucleic acid encoding the CAR can be located upstream or downstream of the second nucleic acid encoding the antibody or antigen-binding fragment thereof, the bispecific antibody (e.g., a BiTE), the cytokine or the costimulatory ligand.
Another object of the present invention is an immune cell, preferably an isolated immune cell engineered to express the chimeric antigen receptor (CAR) of the invention at its surface.
In one embodiment, the immune cell of the invention expresses at its cell surface a CAR
comprising an extracellular binding domain comprising or consisting of an antigen-binding domain directed to a senescent cell-associated antigen, which recognizes and is capable of binding to a senescent cell-associated antigen, as defined hereinabove.
In one embodiment, the immune cell of the invention expresses at its cell surface an anti-DEP1 chimeric antigen receptor (CAR), as defined hereinabove.
In one embodiment, the immune cell of the invention expresses at its cell surface an anti-DPP4 chimeric antigen receptor (CAR), as defined hereinabove.
In one embodiment, the immune cell of the invention expresses at its cell surface at least two CARs, wherein the first CAR and the second CAR recognize two different senescent cell-associated antigens.
In one embodiment, the immune cell of the invention expresses at its cell surface at least two CARs, wherein the first CAR is an anti-DEP1 chimeric antigen receptor, and the second CAR is an anti-DPP4 chimeric antigen receptor, as defined hereinabove.
In one embodiment, the immune cell of the invention expresses at its cell surface a multispecific CAR, as defined hereinabove.
In one embodiment, the immune cell of the invention expresses at its cell surface a bispecific CAR, comprising two extracellular binding domains, wherein one extracellular binding domain recognizes and is capable of binding to DEP1, and the other extracellular binding domain recognizes and is capable of binding to DPP4, as defined hereinabove.
In one embodiment, the immune cell of the invention further expresses at its cell surface a bispecific T cell engager (BiTE).
In one embodiment, the BiTE binds to at least one senescent cell-associated antigen and at least one non-senescent cell-associated antigen, as defined hereinabove.
In one embodiment, the immune cell of the invention is a T cell, preferably an isolated T cell. In one embodiment, the immune cell is a CDS+ T cell, a CD4+ T cells, a natural killer (NK) cell or an NKT cell.
In one embodiment, the immune cell of the invention is a cytotoxic T cell (also known as TC, cytotoxic T lymphocyte, CTL, T-killer cell, cytolytic T cell, CDS+ T cells or killer T cell). NK cells and NKT cells are also encompassed in the invention.
In one embodiment, the T cell is a CDS+ T cytotoxic lymphocyte cell selected from the group comprising or consisting of naive CDS+ T cells, CDS+ memory T cells, central memory CDS+ T cells, regulatory CDS+ T cells, IPS-derived CDS+ T cells, effector memory CDS+ T cells and bulk CDS+ T cells.
In one embodiment, the T cell is a CD4+ T helper lymphocyte cell selected from the group comprising or consisting of naive CD4+ T cells, CD4+ memory T cells, central memory CD4+ T cells, regulatory CD4+ T cells, IPS-derived CD4+ T cells, effector memory CD4+
T cells and bulk CD4+ T cells.
In one embodiment, the immune cell of the invention is cytotoxic for cells expressing at their surface the senescent cell-associated antigen recognized by the CAR
(such as, e.g., DEP1 and/or DPP4). In one embodiment, the immune cell of the invention is not cytotoxic for cells expressing at their surface the senescent cell-associated antigen recognized by the CAR (such as, e.g., DEP1 and/or DPP4).
In one embodiment, the immune cell of the invention is a phagocytic cell.
In one embodiment, the immune cell of the invention is a phagocytic cell selected from the group comprising or consisting of macrophages, monocytes, histiocytes, Kupffer cells, alveolar macrophages, microglial cells and dendritic cells.
In one embodiment, the immune cell of the invention is a mammal immune cell, preferably a human immune cell.
In one embodiment, the immune cells of the invention is an autologous cell, a syngeneic cell, an allogenic cell, or a xenogeneic cell.
Another object of the present invention is a population of immune cells, comprising a plurality of immune cells of the invention.
In one embodiment, the population of immune cells may be homogeneous, i.e., composed at more than 50%, such as more than 60%, 70%, 80%, 90%, 95% or more of the same immune cells, i.e., immune cells of same nature, origin, and/or expressing the same CAR
at their cell surface.
In one embodiment, the population of immune cells may be heterogeneous, i.e., composed of a mix of different immune cells, i.e., immune cells of different nature, origin, and/or expressing a different CAR at their cell surface.
Another object of the present invention is a method of obtaining an immune cell expressing the CAR of the invention at its surface, or a population of such immune cells.
Means and methods to obtain immune cells expressing the CAR of the invention at its surface, or a population of such immune cells, are well known in the art.
In one embodiment, the method for obtaining an immune cell expressing the CAR
of the invention at its surface, or a population of such immune cells, comprises one or several of:
- a step of isolating an immune cell or population of immune cells (e.g., T cells or phagocytic cells) from a sample obtained from a subject, - optionally, a step of selecting a specific subpopulation of immune cells, - a step of transducing the immune cell or population of immune cells with a nucleic acid encoding the CAR of the invention, - optionally, a step of expanding the transduced immune cell or population of immune cells, - optionally, a step of washing the immune cell or population of immune cells, - optionally, a step of cryopreserving the immune cell or population of immune cells.
Prior to transduction and expansion of the immune cell of the invention, a source of immune cells (e.g., T cells or phagocytic cells) is obtained from a subject.
Thus, in one embodiment, the immune cell or the population of immune cells of the invention is isolated and/or substantially purified.
T cells and/or phagocytic cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors.
In one embodiment, any number of T cell and/or phagocytic cells lines available in the art may be used.
In one embodiment, T cells and/or phagocytic cells can be obtained from a unit of blood collected from a subject using any number of techniques known to those skilled in the art, such as FicollTM separation.
In one embodiment, cells from the circulating blood of a subject are obtained by apheresis. The apheresis product typically contains lymphocytes, including T
cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets.
.. In one embodiment, cells from the circulating blood of a subject are obtained by leukapheresis. In one embodiment, cells collected by leukapheresis may be washed to remove the plasma fraction and to place the cells in an appropriate buffer or media for subsequent processing steps. In one embodiment of the invention, the cells are washed with phosphate buffered saline (PBS). In one embodiment, the wash solution lacks .. calcium, and may lack magnesium or many if not all divalent cations. After washing, the cells may be resuspended in a variety of biocompatible buffers, such as, e.g., Ca2+-free, Mg2+-free PBS, PlasmaLyte A, or other saline solution with or without buffer.
Alternatively, the undesirable components of the leukapheresis sample may be removed and the cells directly resuspended in culture media.
In one embodiment, T cells and/or phagocytic cells are isolated from peripheral blood lymphocytes by lysing the red blood cells and depleting the monocytes, e.g., by centrifugation through a PERCOLLTM gradient or by counterflow centrifugal elutriation.
A specific subpopulation of T cells can be further isolated by positive or negative selection techniques. Those skilled in the art would recognize that multiple rounds of selection can also be used in the context of this invention.
In one embodiment, it may be desirable to perform the selection procedure and use the "unselected" cells in the activation and expansion process. "Unselected" cells can also be subjected to further rounds of selection. Enrichment of a T cell population by negative selection can be accomplished with a combination of antibodies directed to surface markers unique to the negatively selected cells. One method is cell sorting and/or selection via negative magnetic immuno-adherence or flow cytometry that uses a cocktail of monoclonal antibodies directed to cell surface markers present on the cells negatively selected.
For example, to enrich CD4+ cells by negative selection, a monoclonal antibody cocktail typically includes antibodies directed to CD14, CD20, CD1 lb, CD16, HLA-DR, and CD8. To deplete T regulatory cells, anti-CD25 conjugated beads or other similar method of selection can be used. To enrich a population of monocytes, macrophages and/or dendritic cells by negative selection, a monoclonal antibody cocktail typically includes antibodies to CD34, CD3, CD4, CD8, CD14, CD19 or CD20. Those skilled in the art are familiar with such means and methods.
In one embodiment, the immune cell or population of immune cells of the invention is transduced with a nucleic acid encoding the CAR of the invention, or with a vector comprising the nucleic acid encoding the CAR of the invention, and optionally expanded.
Methods for transfecting eukaryotic cells and tissues removed from an organism in an ex vivo method are known to those skilled in the art. In one embodiment, the method is an ex vivo method. Thus, it is contemplated that cells or tissues may be removed and transfected ex vivo using nucleic acids or vectors of the invention. In one embodiment, the transplanted cells or tissues may be placed into an organism. In one embodiment, a nucleic acid is expressed in the transplanted immune cell population.
The nucleic acid encoding the CAR of the invention, once completed and demonstrated to have the appropriate sequences, may be introduced into the immune cell by any convenient means, including, but not limited to, by fusion, electroporation, biolistics, transfection, lipofection, or the like. Alternatively, the nucleic acid encoding the CAR of the invention may also be integrated and packaged into non-replicating, defective viral genomes like adenovirus, adeno-associated virus (AAV), or herpes simplex virus (HSV) or others, including retroviral vectors or lentiviral vectors, for infection or transduction into cells. The nucleic acid encoding the CAR of the invention may include viral sequences for transfection, if desired. The engineered cells may be grown and expanded in culture before introduction of the construct(s), followed by the appropriate treatment for introduction of the construct(s) and integration of the construct(s). The engineered cells are then expanded and screened by virtue of a marker present in the construct.
Various markers that may be used successfully include hprt, neomycin resistance, thymidine kinase, hygromycin resistance, etc.
In one embodiment, one may have a target site for homologous recombination, where it is desired that a nucleic acid be integrated at a particular locus. For example, one can knock-out an endogenous gene and replace it (at the same locus or elsewhere) with the gene encoded for by the construct using materials and methods as are known in the art for homologous recombination. For homologous recombination, one may use either OMEGA or 0-vectors. See, e.g., Thomas & Capecchi, 1987. Cell. 51(3):503-12;
Mansour et al., 1988. Nature. 336(6197):348-352; and Joyner et al., 1989. Nature.
338(6211):153-156.
The nucleic acid encoding the CAR of the invention may be introduced as a single DNA
molecule encoding at least the CAR of the invention and optionally another gene, or different DNA molecules having one or more genes. Other genes include genes that encode therapeutic molecules or suicide genes, for example. The constructs may be introduced simultaneously or consecutively, each with the same or different markers.
In one embodiment, suicide gene technology may be used. Different suicide gene technologies are described in the art depending on their mechanism of action (Jones et al, 2014. Front Pharmacol. 5:254). Examples of gene-directed enzyme prodrug therapy (GDEPT) converting a nontoxic drug to a toxic drug include herpes simplex virus thymidine kinase (HSV-TK) and cytosine deaminase (CD). Other examples are chimeric proteins composed of a drug binding domain linked to apoptotic components such as for example the inducible Fas (iFas) or the inducible Caspase 9 (iCasp9) systems.
Other examples include systems mediated by therapeutic antibodies such as inducing overexpression of c-myc at the surface of the engineered cell to induce their deletion by administration of an anti-c-myc antibody. The use of EGFR is described as a similar system compared to the c-myc system.
Vectors containing useful elements such as bacterial or yeast origins of replication, selectable and/or amplifiable markers, promoter/enhancer elements for expression in prokaryotes or eukaryotes, etc. that may be used to prepare stocks of construct DNAs and for carrying out transfections are well known in the art, and many are commercially available.
In one embodiment, the step of transducing the immune cell or population of immune cells corresponds to a gene disruption step, a gene correction step or a gene addition step, preferably a gene addition step.
The immune cells that have been transduced with the nucleic acid encoding the CAR of the invention are then grown in culture under selective conditions, to retain only those cells which were successfully transduced.
In one embodiment, the immune cell or the population of immune cells of the invention is or comprises or consists of a genetically modified immune cell.
In one embodiment, the genetically modified immune cell or the population of immune cells of the invention can be or comprise or consist of an allogeneic immune cell. For example, the allogeneic immune cell can be an immune cell lacking expression of a functional human leukocyte antigen (HLA), e.g., HLA class I and/or HLA class II or a T cell receptor (TCR).
In one embodiment, the immune cell or the population of immune cells of the invention can be engineered such that the immune cell does not express a functional HLA
and/or TCR on its surface. For example, an immune cell can be engineered such that cell surface expression HLA, e.g., HLA class 1 and/or HLA class II or non-classical HLA
molecules, is downregulated.
Modified immune cells that lack expression of a functional HLA and/or TCR can be obtained by any suitable means, including a knock-out or knock-down of one or more subunit of HLA. For example, the immune cell can include a knock-down of HLA
using siRNA, shRNA, clustered regularly interspaced short palindromic repeats (CRISPR) transcription-activator like effector nuclease (TALEN), zinc finger endonuclease (ZFN), meganuclease (mn, also known as homing endonuclease), or megaTAL (combining a TAL effector with a mn cleavage domain). Such systems are well known in the art.
In one embodiment, the nucleic acid encoding a CAR as described herein is inserted at a specific locus in the genome of an immune cell, such as, e.g., at the locus of a gene to be deleted. In one embodiment, the nucleic acid encoding a CAR as described herein is inserted within an HLA locus, thereby resulting in the inhibition of HLA
expression.
In one embodiment, the CAR of the invention, when expressed by a T cell or phagocytic cell, confers to the T cell or phagocytic cell the ability to bind to cells expressing DEP1 and/or DPP4 on their cell surface and be activated by DEP1 and/or DPP4, differently from the antigen that the T cells or phagocytic cell are or would have been specific or activated by.
The immune cell population of the invention may thus be defined as a redirected immune cell population. The term "redirected" refers to such immune cells, e.g., a T
cell or phagocytic cell, which carries a CAR as described herein, conferring to the immune cell the ability to bind to and be activated by a ligand that is different from the one the immune cell is or would have been specific or be activated by.
In one embodiment, the immune cell or population of immune cell of the invention can express certain gene products that can kill the modified cells under controlled conditions, such as inducible suicide genes.
In one embodiment, the immune cell or the population of immune cells of the invention is cultured for expansion. In one embodiment, the immune cell or the population of immune cells of the invention comprises or consists of progenitor cells, which are cultured for differentiation and expansion of the immune cells or population of immune cells as described herein.
Whether prior to or after transduction of the immune cells (i.e., T cells or phagocytic cells) to express a desirable CAR as described herein, the immune cells (i.e., T cells and/or phagocytic cells) can be activated and expanded generally using methods as described, e.g., in US6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466;
6,905,681;
7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874;
6,797,514; 6,867,041; and 7,572,631.
In one embodiment, immune cells may be cryopreserved, either after isolation and optionally, selection, and/or after transduction and expansion.
In one embodiment, cryopreserved cells are thawed and washed as described herein and allowed to rest for one hour at room temperature prior to activation.
Also contemplated in the context of the invention is the collection of blood samples or leukapheresis product from a subject at a time period prior to when the expanded cells as described herein might be needed. As such, the source of the cells to be expanded can be collected at any time point necessary, and desired cells, such as T cells and/or phagocytic cells, isolated and frozen for later use in cell therapy for any number of diseases or conditions that would benefit from cell therapy, such as those described herein.
In one embodiment, a blood sample or a leukapheresis product is taken from a generally healthy subject. In one embodiment, a blood sample or a leukapheresis product is taken from a healthy subject who is at risk of developing a disease, but who has not yet developed said disease, and the cells of interest are isolated and cryopreserved for later use. In one embodiment, the T cells and/or phagocytic cells may be expanded, frozen, and used at a later time.
Another object of the invention is a composition comprising, consisting of or consisting essentially of:
an antigen-binding domain, as described above;
an antibody or antigen-binding fragment thereof, as described above;
a nucleic acid encoding the antigen-binding domain, the antibody or the antigen-binding fragment thereof, as described above;
a vector comprising the nucleic acid encoding the antigen-binding domain, the antibody or the antigen-binding fragment thereof, as described above;
a CAR, as described above;
a nucleic acid encoding the CAR, as described above;
- a vector comprising the nucleic acid encoding the CAR, as described above;
an immune cell engineered to express the CAR at its cell surface, as described above;
a population of immune cells engineered to express the CAR at their cell surface, as described above.
In one embodiment, the composition comprises, consists of or consists essentially of:
a DEP1-binding domain, as described above;
an anti-DEP1 antibody or antigen-binding fragment thereof, as described above;
a nucleic acid encoding the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment thereof, as described above;
a vector comprising the nucleic acid encoding the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment thereof, as described above;
an anti-DEP1 CAR, as described above;
a nucleic acid encoding the anti-DEP1 CAR, as described above;
- a vector comprising the nucleic acid encoding the anti-DEP1 CAR, as described above;
an immune cell engineered to express the anti-DEP1 CAR at its cell surface, as described above;
a population of immune cells engineered to express the anti-DEP1 CAR at their cell surface, as described above.
In one embodiment, the composition comprises, consists of or consists essentially of:
a DPP4-binding domain, as described above;
an anti-DPP4 antibody or antigen-binding fragment thereof, as described above;
a nucleic acid encoding the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment thereof, as described above;
a vector comprising the nucleic acid encoding the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment thereof, as described above;
an anti-DPP4 CAR, as described above;
a nucleic acid encoding the anti-DPP4 CAR, as described above;
- a vector comprising the nucleic acid encoding the anti-DPP4 CAR, as described above;
an immune cell engineered to express the anti-DPP4 CAR at its cell surface, as described above;
a population of immune cells engineered to express the anti-DPP4 CAR at their cell surface, as described above.
In one embodiment, the composition comprises, consists of or consists essentially of:
a DEP1-binding domain and a DPP4-binding domain, as described above;
an anti-DEP1 antibody or antigen-binding fragment thereof and an anti-DPP4 antibody or antigen-binding fragment thereof, as described above;
- an anti-DEP1/anti-DPP4 bispecific antibody;
a nucleic acid encoding the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment thereof and a nucleic acid encoding the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment thereof, as described above;
- a nucleic acid encoding the anti-DEP1/anti-DPP4 bispecific antibody, as described above;
a vector comprising the nucleic acid encoding the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment thereof and a vector comprising the nucleic acid encoding the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment thereof, as described above;
a vector comprising the nucleic acid encoding the DEP1-binding domain, the anti-DEP1 antibody or the antigen-binding fragment thereof and the nucleic acid encoding the DPP4-binding domain, the anti-DPP4 antibody or the antigen-binding fragment thereof, as described above;
- a vector comprising the nucleic acid the anti-DEP1/anti-DPP4 bispecific antibody, as described above;
an anti-DEP1 CAR and an anti-DPP4 CAR, as described above;
an anti-DEP1/anti-DPP4 bispecific CAR, as described above;
a nucleic acid encoding the anti-DEP1 CAR and the anti-DPP4 CAR, as described above;
a nucleic acid encoding the anti-DEP1/anti-DPP4 bispecific CAR, as described above;
a vector comprising a nucleic acid encoding the anti-DEP1 CAR and a vector comprising the nucleic acid encoding the anti-DPP4 CAR, as described above;
- a vector comprising a nucleic acid encoding the anti-DEP1 CAR and the nucleic acid encoding the anti-DPP4 CAR, as described above;
a vector comprising a nucleic acid encoding the anti-DEP1/anti-DPP4 bispecific CAR, as described above;
an immune cell engineered to express the anti-DEP1 CAR and an immune cell engineered to express the anti-DPP4 CAR, as described above;
- an immune cell engineered to express the anti-DEP1 CAR and the anti-DPP4 CAR, as described above;
an immune cell engineered to express the anti-DEP1/anti-DPP4 bispecific CAR, as described above;
a population of immune cells engineered to express the anti-DEP1 CAR and a population of immune cells engineered to express the anti-DPP4 CAR, as described above;
a population of immune cells engineered to express the anti-DEP1 CAR and the anti-DPP4 CAR, as described above;
a population of immune cells engineered to express the anti-DEP1/anti-DPP4 bispecific CAR, as described above.
In one embodiment, the composition has been frozen and thawed. In one embodiment, the composition is lyophilized.
In one embodiment, the compositions of the invention are pharmaceutical compositions and further comprise at least one pharmaceutically acceptable excipient.
The term "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. Said excipient does not produce an adverse, allergic or other untoward reaction when administered to an animal, preferably a human. For human administration, preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by regulatory offices, such as, for example, FDA
Office or EMA.
Pharmaceutically acceptable excipients that may be used in the pharmaceutical composition of the invention include, without being not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances (for example sodium carboxymethylcellulose), polyethylene glycol, polyacrylates, waxes, polyethylene- polyoxypropylene- block polymers, polyethylene glycol and wool fat.
In one embodiment, the compositions according to the present invention are medicaments.
As used herein, the term "consisting essentially of', with reference to a composition, pharmaceutical composition or medicament, means that the antigen-binding domain, antibody or antigen-binding fragment thereof, nucleic acid, vector, CAR, immune cell or population of immune cells of the invention is/are the only therapeutic agent, or agent with a biologic activity, within said composition, pharmaceutical composition or medicament.
Such compositions and medicaments may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine;
antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives.
Since the present invention selectively target senescent cells, it is contemplated that the compositions according to the present invention may be cosmetic compositions, and further comprise at least one dermatologically acceptable excipient.
The term "dermatologically acceptable excipient" refers to excipient which are suitable for external topical application. Examples of dermatologically acceptable excipients include, but are not limited to, sebum-regulating agents, antibacterial agents, antifungal agents, keratolytic agents, keratoregulating agents, astringents, anti-inflammatory agents, anti-irritants, antioxidants, free-radical scavengers, cicatrizing agents, anti-aging agents and moisturizing agents.
The administration of the composition, pharmaceutical composition, medicament or cosmetic composition of the invention may be carried out in any convenient manner, including by injection, aerosol inhalation, topical delivery (such as, for example, by transdermal delivery), oral delivery, rectal delivery, nasal delivery, or vaginal delivery.
In one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition of the present invention is in a form adapted for injection, such as, e.g., for trans-arterial, intravenous (iv.), intramuscular, intraperitoneal (i.p.), intrapleural, intradermal, subcutaneous, transdermal injection or infusion.
Examples of forms suitable for injectable use include, but are not limited to, sterile solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The prevention against contamination by microorganisms can be brought about by adding in the composition preservatives such as, e.g., various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like). In one embodiment, it may be preferable to include isotonic agents, e.g., sugars or sodium chloride, to reduce pain during injection. In one embodiment, prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, e.g., aluminum monostearate and gelatin.
In one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition of the present invention is in an adapted form for a parenteral administration. Thus, in one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition of the invention is to be administered parenterally.
In one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition of the invention is in an adapted form for an intravenous administration. Thus, in one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition of the present invention is to be administered intravenously.
In one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition of the present invention may be injected directly into the site of the disease or disorder to be treated.
In one embodiment, a lyophilized composition, a lyophilized pharmaceutical composition, a lyophilized medicament or a lyophilized cosmetic composition of the invention is solubilized in water for injection and gently mixed, the mixture is gently mixed and charged into a suitable syringe. This invention thus also relates to a medical device, including a syringe filled or prefilled with a composition, pharmaceutical composition, medicament or cosmetic composition of the invention.
In one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition of the invention is formulated for topical administration. Thus, in one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition is to be administered topically.
Examples of forms adapted for topical administration include, without being limited to, liquid, paste or solid compositions, and more particularly aqueous solutions, drops, dispersions, sprays, microcapsules, micro- or nanoparticles, polymeric patch, or controlled-release patch, and the like.
In particular embodiments where the compositions of the invention comprise a CAR, an immune cell or a population of immune cells as described above, such compositions may be administered by intradermal or subcutaneous injection, such as by i.v.
injection.
In one embodiment, the compositions comprising a CAR, an immune cell or a population of immune cells may be injected directly into a lymph node, site of infection, site of inflammation or site of tissue or organ rejection. In one embodiment, the compositions comprising a CAR, an immune cell or a population of immune cells may be injected directly into the site of the autoimmune and/or inflammatory disease.
In one embodiment, the subject is administered, or is to be administered, with autologous cells. In some embodiments, the subject is administered, or is to be administered, with allogenic cells.
In one embodiment, the subject may be a mammal. In one embodiment, the subject may be a human.
Another object of the present invention is the use of the composition, pharmaceutical composition or medicament described herein, as a medicament.
Another object of the present invention is the use of the composition, pharmaceutical composition or medicament described herein, in treating, preventing or alleviating senescence-related diseases or disorders.
Another object of the present invention is a method of treating, preventing or alleviating senescence-related diseases or disorders in a subject in need thereof, comprising administering to said subject the composition, pharmaceutical composition or medicament described herein.
As used herein, the term "senescence-associated", "senescence-related" or "age-related" diseases, disorders, or conditions refers to a physiological condition that presents with one or more symptoms or signs, wherein a subject having the condition needs or would benefit from a lessening of such symptoms or signs. The condition is senescence-associated if it is caused or mediated in part by senescent cells, which may be induced by multiple etiologic factors including age, DNA damage, oxidative stress, genetic defects, etc. Lists of senescence-associated disorders that can potentially be treated or managed using the methods and products taught in this disclosure include those discussed in this disclosure and the previous disclosures to which this application claims priority.
Non-limiting examples of senescence-related diseases include : fibrotic diseases, chronic inflammatory diseases (e.g., arthritis or arthrosis), cancer, premalignant lesions, atherosclerosis, osteoarthritis, diabetes, diabetic ulcers, kyphosis, scoliosis, hepatic insufficiency, cirrhosis, Hutchinson-Gilford progeria syndrome (HGPS), laminopathies, osteoporosis, dementia, (cardio)vascular diseases (e.g., angina, arrhythmia, atherosclerosis, cardiomyopathy, congestive heart failure, coronary artery disease (CAD), carotid artery disease, endocarditis, heart attack, coronary thrombosis, myocardial infarction, high blood pressure/hypertension, hypercholesterolemia/hyperlipidemia, mitral valve prolapsed, peripheral artery disease (PAD) and stroke), obesity, metabolic syndrome, acute myocardial infarction, emphysema, insulin sensitivity, boutonneuse fever, sarcopenia, neurodegenerative diseases (e.g., Alzheimer's, Huntington's or Parkinson's disease), cataract, anemia, hypertension, age-related macular degeneration, COPD, asthma, renal insufficiency, incontinence, hearing loss such as deafness, vision loss such as blindness, sleeping disturbances, pain such as joint pain or leg pain, imbalance, fear, depression, breathlessness, weight loss, hair loss, muscle loss, loss of bone density, frailty and/or reduced fitness.
Another object of the present invention is the use of the composition, pharmaceutical composition or medicament described herein, in treating, preventing or alleviating fibrotic diseases, premalignant lesions, inflammatory diseases and cancers.
Another object of the present invention is a method of treating, preventing or alleviating fibrotic diseases, premalignant lesions, inflammatory diseases and cancers in a subject in need thereof, comprising administering to said subject the composition, pharmaceutical composition or medicament described herein.
Senescent cells are present in fibrosis of many tissues including, but not limited, to skin, liver, lung, pancreas and prostate.
Thus, in one embodiment, the senescence-related disease or disorder to be treated is a fibrotic disease. Exemplary fibrotic diseases which may be treated by the invention include but are not limited to eosinophilic esophagitis, hypereosinophilic syndromes (HES), Loeffler's endomyocarditis, endomyocardial fibrosis, idiopathic pulmonary fibrosis, and scleroderma.
In one embodiment, the pulmonary fibrotic disease to be treated, prevented or alleviated is selected from the group comprising idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) acute respiratory distress syndrome (ARDS), combined pulmonary fibrosis and emphysema (CPFR), pulmonary edema, Loffler's syndrome, eosinophilic pneumonia, respiratory hypersensitivity, allergic bronchopulmonary aspergillosis (ABPA), Hamman-Rich syndrome, sarcoidosis, pneumoconiosis, and hypersensitivity pneumonitis (HP).
In one embodiment, the pulmonary fibrotic disease to be treated, prevented or alleviated is chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis.
In one embodiment, the senescence-related disease or disorder to be treated is a premalignant lesion.
As used herein, the phrase "premalignant lesion" refers to a mass of cells and/or tissue having increased probability of transforming into a malignant tumor.
Examples of premalignant lesions include, but are not limited to, adenomatous polyps, Barrett's esophagus, pancreatic intraepithelial neoplasia (PanIN), IPMN
(intraductal papillary mucinus neoplasia), DCIS (ductal carcinoma in situ) in the breast, leukoplakia and erythroplakia. Thus, the premalignant lesion to be treated by the invention can transform into a malignant solid or non-solid (e.g., hematological malignancies) cancer (or tumor).
In one embodiment, the premalignant lesion which is to be treated is an adenomatous polyp of the colon, an adenomatous polyp of the rectum, an adenomatous polyp of the small bowel or Barrett's esophagus.
As used herein, the term "inflammatory diseases" refers to any abnormality associated with inflammation, such as, for example, chronic inflammatory diseases, acute inflammatory diseases.
Examples of inflammatory disorders include, but are not limited to, rheumatic diseases, neurological diseases, cardiovascular diseases, uro-gynecological diseases, eye and ear diseases, mucocutaneous diseases, infectious diseases, graft rejection diseases and allergic diseases.
Examples of rheumatic diseases include, but are not limited to, arthritis, osteoarthritis, rheumatoid arthritis, osteoporosis, fibromyalgia, lupus, systemic lupus erythematosus and scleroderma.
Examples of neurological diseases include, but are not limited to, multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury, spinal cord injury, dystonia, chronic regional pain syndrome, motor neuron disease/amyotrophic lateral sclerosis, Guillain-Barre syndrome, muscular dystrophy, cerebral palsy, neuropathy and myositis.
Examples of cardiovascular diseases include, but are not limited to, coronary heart disease, stroke, hypertensive heart disease, inflammatory heart disease, rheumatic heart disease, aortic aneurysm and dissection, congenital heart disease, deep vein thrombosis and pulmonary embolism and atherosclerosis.
Examples of uro-gynecological diseases include, but are not limited to, glomerulonephritis, urinary incontinence and prolapse.
Examples of eye and ear diseases include, but are not limited to, cataract, glaucoma, age-related macular degeneration (AMD), presbyopia, dry eyes, corneal diseases, diabetic retinopathy, vertigo, tinnitus and Meniere's disease.
Examples of mucocutaneous diseases include, but are not limited to, eczema, xeroderma pigmentosum, oral lichen planus, mucous membrane pemphigoid and pemphigus vulgaris.
Examples of infectious diseases include, but are not limited to, chronic infectious diseases, subacute infectious diseases, acute infectious diseases, viral diseases, bacterial diseases, protozoan diseases, parasitic diseases, fungal diseases, mycoplasma diseases and prion diseases.
Examples of diseases associated with transplantation of a graft include, but are not limited to, graft rejection, chronic graft rejection, subacute graft rejection, hyperacute graft rejection, acute graft rejection and graft versus host disease.
Examples of allergic diseases include, but are not limited to, asthma, hives, urticaria, pollen allergy, dust mite allergy, venom allergy, cosmetics allergy, latex allergy, chemical allergy, drug allergy, insect bite allergy, animal dander allergy, stinging plant allergy, poison ivy allergy and food allergy.
In one embodiment, the senescence-related disease or disorder to be treated is cancer.
Non-limiting examples of cancers which may be treated according to this aspect of the present invention include, but are not limited to, adenocarcinoma, adrenal gland tumor, ameloblastoma, anaplastic, anaplastic carcinoma of the thyroid, angiofibroma, angioma, angiosarcoma, apudoma, argentaffmoma, arrhenoblastoma, ascites tumor cell, ascitic tumor, astroblastoma, astrocytoma, ataxia-telangiectasia, atrial myxoma, a basal cell carcinoma cell, bone cancer, brainstem glioma, brain tumor, breast cancer, Burkitt's lymphoma, cerebellar astrocytoma, cervical cancer, cherry angioma, cholangiocarcinoma, cholangioma, chondroblastoma, chondroma, chondrosarcoma, chorioblastoma, choriocarcinoma, colon cancer, common acute lymphoblastic leukemia, craniopharyngioma, cystocarcinoma, cystofbroma, cystoma, ductal carcinoma in situ, ductal papilloma, dysgerminoma, encephaloma, endometrial carcinoma, endothelioma, ependymoma, epithelioma, erythroleukemia, Ewing's sarcoma, extra nodal lymphoma, feline sarcoma, fibro adenoma, fibro sarcoma, follicular cancer of the thyroid, ganglioglioma, gastrinoma cell, glioblastoma multiform, glioma, gonadoblastoma, haemangioblastoma, haemangioendothelioblastoma, haemangioendothelioma, haemangiopericytoma, haematolymphangioma, haemocytoblastoma, haemocytoma, hairy cell leukemia, hamartoma, hepatocarcinoma, hepatocellular carcinoma, hepatoma, histoma, Hodgkin's disease, hypernephroma, infiltrating cancer, infiltrating ductal cell carcinoma, insulinoma, juvenile angioforoma, Kaposi sarcoma, kidney tumor, large cell lymphoma, leukemia, a leukemia, acute leukemia, lipoma, liver cancer, liver metastases, Lucke carcinoma, lymphadenoma, lymphangioma, lymphocytic leukemia, lymphocytic lymphoma, lymphoeytoma, lymphoedema, lymphoma, lung cancer, malignant mesothelioma, malignant teratoma, mastocytoma, medulloblastome., melanoma, meningioma, mesothelioma, Morton's neuroma, multiple myeloma, myeloblastoma, myeloid leukemia, myelolipoma, myeloma, myoblastoma, myxoma, nasopharyngeal carcinoma, neoplastic, nephroblastoma, neuroblastoma, neurofibroma, neurofibromatosis, neuroglioma, neuroma, non-Hodgkin's lymphoma, oligodendroglioma, optic glioma, osteochondroma, osteogenic sarcoma, osteosarcoma, ovarian cancer, Paget's disease of the nipple, pancoast tumor, pancreatic cancer, phaeochromocytoma, pheoehromocytoma, plasmacytoma, primary brain tumor, progonoma, prolactinoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, rhabdo sarcoma, a solid tumor, sarcoma, a secondary tumor, seminoma, skin cancer, small cell carcinoma, squamous cell carcinoma, strawberry haemangioma, T cell lymphoma, teratoma, testicular cancer, thymoma, trophoblastic tumor, and Wilm's tumor.
In one embodiment, the composition, pharmaceutical composition or medicament described herein is used alone. In one embodiment, the composition , pharmaceutical composition, or medicament described herein is used in combination with at least one anti-cancer agent.
Indeed, many of existing and potential anti-cancer agents induce senescence of cancer cells, therefore the present invention can be used in combination with these agents to increase the efficacy of an anti-cancer treatment. Treatment by these agents can also reduce side effects of radiotherapy or chemotherapy with DNA-damaging agents.
Thus, the composition, pharmaceutical composition or medicament described herein can be used as an adjuvant therapy along with other treatment modalities for cancers, which are selected based on cancer type, location, the cell type and the grade of malignancy.
Conventional therapies include surgery, radiation therapy, and chemotherapy.
Exemplary anti-cancer drugs that can be co-administered with the composition, pharmaceutical composition or medicament described herein include, but are not limited to, acivicin, aclarubicin, acodazole hydrochloride, acronine, adriamycin, adozelesin, aldesleukin, altretamine, ambomycin, ametantrone acetate, aminoglutethimide, amsacrine, anastrozole, anthramycin, asparaginase, asperlin, azacytidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene hydrochloride, bisnafide dimesylate, bizelesin, bleomycin sulfate, brequinar sodium, bropirimine, busulfan, cactinomycin, calusterone, caracemide, carbetimer, carboplatin, carmustine, carubicin hydrochloride, carzelesin, cedefingol, chlorambucil, cirolemycin, cisplatin, cladribine, crisnatol mesylate, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, .. daunorubicin hydrochloride, decitabine, dexormaplatin, dezaguanine, dezaguanine mesylate, diaziquone, docetaxel, doxorubicin, doxorubicin hydrochloride, droloxifene, droloxifene citrate, dromostanolone propionate, duazomycin, edatrexate, eflornithine hydrochloride, elsamitrucin, enloplatin, enpromate, epipropidine, epirubicin hydrochloride, erbulozole, esorubicin hydrochloride, estramustine, estramustine phosphate sodium, etanidazole, etoposide, etoposide phosphate, etoprine, fadrozole hydrochloride, fazarabine, fenretinide, floxuridine, fludarabine phosphate, fluorouracil, fluorocitabine, fosquidone, fostriecin sodium, gemcitabine, gemcitabine hydrochloride, hydroxyurea, idarubicin hydrochloride, ifosfamide, ilmofosine, interferon alfa-2a, interferon alfa-2b, interferon alfa-nl, interferon alfa-n3, interferon beta-la, interferon gamma-lb, iproplatin, irinotecan hydrochloride, lanreotide acetate, letrozole, leuprolide acetate, liarozole hydrochloride, lometrexol sodium, lomustine, losoxantrone hydrochloride, masoprocol, maytansine, mechlorethamine hydrochloride, megestrol acetate, melengestrol acetate, melphalan, menogaril, mercaptopurine, methotrexate, methotrexate sodium, metoprine, meturedepa, mitindomide, mitocarcin, mitocromin, mitogillin, mitomalcin, mitomycin, mitosper, mitotane, mitoxantrone hydrochloride, mycophenolic acid, nocodazole, nogalamycin, ormaplatin, oxisuran, paclitaxel, pegaspargase, peliomycin, pentamustine, peplomycin sulfate, perfosfamide, pipobroman, piposulfan, piroxantrone hydrochloride, plicamycin, plomestane, porfimer sodium, porfiromycin, prednimustine, procarbazine hydrochloride, puromycin, puromycin hydrochloride, pyrazofurin, riboprine, rogletimide, safingol, safingol hydrochloride, semustine, simtrazene, sparfosate sodium, sparsomycin, spirogermanium hydrochloride, spiromustine, spiroplatin, streptonigrin, streptozocin, sulofenur, talisomycin, taxol, tecogalan sodium, tegafur, teloxantrone hydrochloride, temoporfin, teniposide, teroxirone, testolactone, thiamiprine, thioguanine, thiotepa, tiazofuirin, tirapazamine, topotecan hydrochloride, toremifene citrate, trestolone acetate, triciribine phosphate, trimetrexate, trimetrexate glucuronate, triptorelin, tubulozole hydrochloride, uracil mustard, uredepa, vapreotide, verteporfin, vinblastine sulfate, vincristine sulfate, vindesine, vindesine sulfate, vinepidine sulfate, vinglycinate sulfate, vinleurosine sulfate, vinorelbine tartrate, vinrosidine sulfate, vinzolidine sulfate, vorozole, zeniplatin, zinostatin, and zorubicin hydrochloride.
Additional antineoplastic agents include those disclosed in Chabner et al., 2001.
"Antineoplastic agents". In Goodman et al. (Eds.), Goodman & Gilman' s The pharmacological basis of therapeutics (le ed., pp. 1315-1404). New York, NY:
McGraw-Hill.
Another object of the present invention is the use of the cosmetic composition described herein, as cosmetics.
Indeed, since the present invention selectively target senescent cells, it is contemplated that the present invention can be used for skin care, skin anti-aging and/or skin rejuvenation.
Another object of the present invention is thus a method for rejuvenating the skin in a subject in need thereof, comprising administering to the subject the cosmetic composition described herein.
Because senescent cells drive age-related pathologies, a selective elimination of these cells can prevent or delay age-related deterioration. Thus, senescent cells may be therapeutic targets in the treatment of aging and age-related disease. As such, removal of senescent cells may delay tissue dysfunction and extend health span. Clearance of senescent cells is expected to improve tissue milieu, thereby improving the function of the remaining non-senescent cells.
Another object of the present invention is thus the use of the composition, pharmaceutical composition or medicament described herein, for depleting and/or killing senescent cells.
Another object of the present invention is thus a method for depleting and/or killing senescent cells in a subject, comprising administering to the subject the composition, pharmaceutical composition or medicament described herein.
In one embodiment, the composition, pharmaceutical composition, medicament or cosmetic composition described herein is to be administered to a subject in need thereof in a therapeutically effective amount.
It will be however understood that the total daily usage of the composition, pharmaceutical composition, medicament or cosmetic composition described herein will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disease being treated and the severity of the disease;
activity of the therapeutic agent in the composition, pharmaceutical composition, medicament or cosmetic composition (antigen-binding domain, antibody or antigen-binding fragment thereof, nucleic acid, vector, CAR, immune cell or population of immune cells of the invention) employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific composition, pharmaceutical composition, medicament or cosmetic composition employed; the duration of the treatment; drugs used in combination or coincidental with the composition, pharmaceutical composition, medicament or cosmetic composition employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. The total dose required for each treatment may be administered by multiple doses or in a single dose.
Disclosed herein is a chimeric antigen receptor (CAR) comprising:
(i) at least one extracellular binding domain, comprising at least one antigen-binding domain directed to a senescent cell-associated antigen, preferably to DEP1 and/or DPP4, (ii) an extracellular spacer domain, (iii) a transmembrane domain, (iv) optionally at least one costimulatory domain, and (v) at least one intracellular signaling domain.
In one embodiment, said at least one antigen-binding domain is directed to DEP1.
In one embodiment, said at least one antigen-binding domain is directed to DPP4.
In one embodiment, said CAR is a bispecific CAR comprising two antigen-binding domains.
In one embodiment, each of the at least two antigen-binding domains binds to a different antigen, preferably to DEP1 and DPP4.
Also disclosed herein is an isolated immune cell population expressing at least one CAR
according to the present disclosure, preferably the isolated immune cell population expresses:
at least one CAR directed to DEP1 and at least one CAR directed to DPP4; or - at least one bispecific CAR comprising two antigen-binding domains, preferably wherein each of the at least two antigen-binding domains binds to a different antigen, preferably to DEP1 and DPP4.
In one embodiment, the isolated immune cell population according to the present disclosure comprises immune cells selected from the group comprising T cells, natural killer (NK) cells, or a combination thereof.
Also disclosed herein is an isolated bispecific antibody or a fragment thereof, comprising at least two antigen binding domains directed to at least two senescent cell-associated antigens, preferably the at least two senescent cell-associated antigens are DEP1 and DPP4.
In one embodiment, the isolated bispecific antibody or fragment thereof according to the present disclosure comprises:
(i) an antigen-binding domain of an anti-human DEP1 antibody or a fragment thereof;
and (ii) an antigen-binding domain of an anti-human DPP4 antibody or a fragment thereof.
Also disclosed herein is a composition comprising:
the isolated immune cell population according to the present disclosure;
the isolated bispecific antibody or fragment thereof according to the present disclosure; or a mixture of an isolated anti-human DEP1 antibody or a fragment thereof and an isolated anti-human DPP4 antibody or a fragment thereof.
In one embodiment, the composition according to the present disclosure is a pharmaceutical composition and further comprises at least one pharmaceutically acceptable excipient.
In one embodiment, the composition or pharmaceutical composition according to the present disclosure is for use as a medicament.
In one embodiment, the composition or pharmaceutical composition according to the present disclosure is:
- for use in treating, preventing or alleviating senescence-related diseases or disorders; or for depleting and/or killing senescent cells.
In one embodiment, senescence-related diseases or disorders are selected from the group comprising fibrotic diseases, premalignant lesions, inflammatory diseases and cancers.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 ¨ 'The structure of CAR vector' ¨ is a schema illustrating the construction of the full-length CAR expression cassette, subcloned into Lenti-EFla-rhuMAB 41-VH-Linker-VL-CFPCART, pCDCAR1. The full length of chimeric antigen receptor was synthesized and subcloned into lentivirus vector. The insert was confirmed by Sanger sequencing and is schematically illustrated in the figure. This CAR vector was used in the CAR-T assays for the proof-of-concept experiments.
Figure 2 ¨ 'The assessment of senescent state and DPP4 levels in target cells' ¨ is a graph showing the senescent state of WI-38 and GM21808 cells, confirmed by senescence .. associated P-galactosidase activity. Representative results of control versus senescent fibroblasts are shown. DPP4 levels of the cells were monitored by quantitative RT-PCR.
Relative quantities of DPP4 in young WI-38 (low passage number: PDL < 20) or old WI-38 (high passage number: PDL > 50) and in GM21808 cells, untreated or cultured with DNA-damaging agent etoposide (adding etoposide every two days for fourteen days) were calculated. Fold-change, or relative quantity, of DPP4 in each sample was calculated relative to young WI-38 or untreated GM21808.
Figure 3 ¨ 'The ADCC Assay' ¨ is a graph showing the relative toxicity in young and old fibroblast cells (WI-38 cells), using 0.05 p.g/mL or 0.5 p.g/m1 of anti-DPP4 antibody.
Figure 4 ¨ 'The CAR-T assay' ¨ is a graph showing the results of selective elimination of senescent cells by engineered CAR-T against DPP4.
Figure 5¨ 'The quantification of experimental CAR-T assay results' ¨ is a graph showing the results of the CAR-T assay on control (WI-38/GM21808) versus senescent cells. Cells were incubated with increasing ratios of CAR-T to target cells (1:1, 5:1 and 10:1).
Figure 6 ¨ scEv library screening by phage display' ¨ is a graph showing the panning using hDEP1 Peptide #4/BSA as target and standard elution strategy. Four rounds were carried out in order to isolate specific binders. The reactivity of phages eluted after each round against the targeted peptide was assessed in phage-ELISA.
Figure 7 ¨ scEv library screening by phage display' ¨ is a graph showing the panning using hDEP1-ECD-His as target and standard elution strategy. Four rounds were carried out in order to isolate specific binders. The reactivity of phages eluted after each round against the targeted peptide was assessed in phage-ELISA.
Figure 8¨ 'DPP4 and DEP I mRNA levels in normal and diseased primary human lung fibroblasts' ¨ is a graph showing the relative quantity of DPP4 and DEP-1 in normal and diseased human lung fibroblasts. Expression levels in NHLF (normal human lung fibroblast), idiopathic pulmonary fibroblast (IPF) and chronic obstructive pulmonary disease (COPD) human fibroblast cells were calculated relative to NHLF.
Figure 9 ¨ 'DPP4 staining in fibroblasts' is a set of three graphs showing the staining of various primary human fibroblasts and different senescence-stressors in terms of DPP4 surface antigen presentation in target senescent cells versus normal/young cells. The data also include normal human cells versus human lung fibrosis disease cells. WI-(PDL < 20), GM21808 ( etoposide), normal human lung fibroblast (NHLF), idiopathic pulmonary fibroblast (IPF) and chronic obstructive pulmonary disease (COPD) human fibroblast cells were stained with anti-DPP4 antibodies or scFv. Control staining comprising secondary antibody only was included for all cell types, but only the control staining for NHLF cells is shown for illustration. Percentage of positive cells is indicated on the right side, with MFI indicated in parenthesis.
Figure 9A: staining with monoclonal antibody(Creative Biolabs);
Figure 9B: staining with 5826-13-R3A-D5;
Figure 9C: staining with 5826-13-R4A-H5.
Figure 10 ¨ 'DEP 1 staining in fibroblasts' is a set of three graphs showing the staining of various primary human fibroblasts and different senescence-stressors in terms of DEP1 surface antigen presentation in target senescent cells versus normal/young cells. The data also include normal human cells versus human lung fibrosis disease cells. WI-(PDL < 20), GM21808 ( etoposide), normal human lung fibroblast (NHLF), idiopathic pulmonary fibroblast (IPF) and chronic obstructive pulmonary disease (COPD) human fibroblast cells were stained with anti-DEP1 antibodies or scFv. Control staining comprising secondary antibody only was included for all cell types, but only the control staining for NHLF cells is shown for illustration. Percentage of positive cells is indicated on the right side, with MFI indicated in parenthesis.
Figure 10A: staining with monoclonal antibody(AbCam) Figure 10B: staining with 5738-10-R3A-D5;
Figure 10C: staining with 5738-13 -R4A-D 11;
Figure 10D: staining with 5738-13-R2A-H4.
EXAMPLES
The present invention is further illustrated by the following examples.
Example 1 ¨ DPP4 is expressed on the surface of senescent cells Materials and Methods Expression of DPP 4 (rhuMAB 41) antibody and antigen The full-length of the antigen was synthesized and subcloned into an expression vector.
The insert was confirmed by Sanger sequencing. After the vector was verified by sequencing, the vector was expressed in CHO-S cell line with chemically defined culture media. After 9 days cultivation, the protein was purified by Nickel columns, ultrafiltration and then subjected to 0.2-micron sterile filtration to get the bulk of high purity.
The heavy chain and light chain of the rhuMAB 41 antibody (Creative Biolabs) were synthesized and subcloned into Creative Biolabs property expression vector, respectively.
The insert was confirmed by Sanger sequencing. After the vectors were verified by sequencing, they were expressed in HEK293 cell line with chemically defined culture media. After 9 days of cultivation, the protein was purified by Protein A
affinity chromatography, ultrafiltration and then subjected to 0.2-micron sterile filtration to get the bulk of high purity.
Expression of DPP4 (rhuMAB 41) scFv The scFv consists of variable regions of heavy and light chains that are joined together .. by a flexible peptide linker. In the scFv, the order of the domains can be either VH-linker-VL or VL-linker-VH. The affinity of the two construction types to the target might be different. Hence, the two construction types can lead to secretory expression in different level.
The scFv(s) were expressed and tested by flow cytometry to evaluate the binding affinity to target cells. 5 x 105 WI-38 cells were co-cultured with rhuMAB 41 antibody (humanized antibody), VL-Linker-VH antibody and VH-Linker-VL antibody (1 [tg/tube), respectively, and then analyzed by using PE-anti-human IgG Fc as secondary antibody.
The results indicated that VH-linker-VL antibody has higher affinity for target cell WI-38 and was chosen for CAR development.
CAR-T cell preparation and construction Primary human T cells were used for CAR-T generation. Human primary T cells were isolated from PBMCs of healthy donors by magnetic beads and stimulated in growth medium supplemented with IL-2. Activated T cells were then transduced with lentivirus expressing customized chimeric antigen receptor. After CAR-T cell expansion, CAR-transduction efficiency was examined by FACS and qPCR.
The full-length of chimeric antigen receptor was synthesized and subcloned into lentivirus vector. The insert was confirmed by Sanger sequencing. The structure of CAR
vector is schematically illustrated in Figure 1.
Lentiviral vectors, which were derived from immunodeficiency viruses, were used for their relatively high efficiency for T cell transduction and their ability of infection of the non-proliferating cells. A second generation of the packaging system was utilized to generate transduction-ready pseudoviral particles in HEK293T cells. The titer of the lentivirus particle was determined by qPCR and cell-based titration assay. The results of lentivirus titration showed that prepared virus stock was at a high titer of 3.27 x 108 TU/mL.
Primary human T lymphocytes preparation and CAR-T preparation PBMC from a healthy human donor was stimulated with anti-CD3/CD28 magnetic beads and the T cells were isolated using magnetic cell separation system. To generate CAR-T
cells, the lentivirus particles with DPP4-CAR coding gene were incubated with the T cells in the presence of polybrene. After T cell expansion, the CAR-T cells were used for in vitro cytotoxicity assays.
Target cell preparation WI-38 target cells were obtained at population doubling 19 (PD19) and passaged until they stopped proliferating. They were further analyzed by FACS for the detection of their surface antigen DPP4 and by qRT-PCT for the detection of their relative DPP4 mRNA
expression level.
Cellular senescence induced by DNA damage was also induced in GM21808 fibroblasts by adding etoposide, as previously described (Robles et al., 1999. Biochem Pharmacol.
58(4):675-685; Gey & Seeger, 2013. Mech Ageing Dev. 134(3-4):130-138).
Untreated (control) and treated cells were further analyzed by qRT-PCT for the detection of their relative DPP4 mRNA expression level.
Natural killer (NK) cell preparation Effector cells (NK cells) were freshly prepared before the ADCC assay. By using EasySepTM Human NK Cell Isolation Kit (STEMCELL, Catalog:17955), NK cells were isolated from a healthy human donor and resuspended in RPMI 1640 medium at .. 5 x 106/mL.
ADCC assay The target cells (WI-38), i.e., the senescent cells and proliferating cells, were plated into a 24-well plate at 1 x 105 cell/well in 100 [tL RPMI-1640 supplied with 5% FBS
24 hour and cultured overnight. On the day of the assay, anti-DPP4 antibody (rhuMAB
41) was .. added into each well at a final concentration of 0 [tg/mL, 0.05 [tg/mL, and 0.5 [tg/mL.
After 30 minutes of incubation at 37 C with 5% CO2, 100 [tL NK cells (5 x 105 cell/well) were added to each well at E/T=5:1. After incubation for 6 hours at 37 C with 5% CO2, the cells were stained with eBioscienceTM Annexin V Apoptosis Detection Kit PE
(Invitrogen, Catalog: 88-8102-74) with 7-AAD and analyzed by flow cytometry.
In vitro CAR-T activity assay by FACS
In vitro analysis was used for evaluation of the targeting effect of DPP4-CAR-T. The target cells (WI-38 or GM21808), i.e., the senescent cells and proliferating cells, were plated into a 24-well plate at 1 x 105 cell/well in 100 [tL RPMI-1640 supplied with 5%
FBS and cultured overnight. On the day of the assay, effector cells (5 x 105 cell/well) .. were added to each well at E/T=5:1. After incubation for 6 hours at 37 C
with 5% CO2, the cells were stained with eBioscienceTM Annexin V Apoptosis Detection Kit PE
(Invitrogen, Catalog: 88-8102-74) with 7-AAD and analyzed by flow cytometry.
The relative percentage was quantified by normalizing the results to control CAR-T.
Results Assessment of senescent state and DPP4 levels in target cells The senescent state of the cells was confirmed by senescence associated fl-galactosidase activity. DPP4 levels were monitored by quantitative RT-PCR. Figure 2 shows that DPP4 is expressed selectively in senescent cells, but not in proliferating human diploid fibroblasts or healthy foreskin fibroblasts.
ADCC Assay In vitro Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) assays are common tools for immunotherapeutic drug discovery and biosimilar development. For this experiment, cytotoxicity is defined as apoptosis monitored by annexin-V
positive and 7-ADD negative cells counted.
Results of a standard ADCC assay are shown in Figure 3. This experiment depicts a difference between young and old fibroblast cells at indicated antibody concentration as listed 1.5 and 1.65-fold, respectively.
Our results show that high abundance of DPP4 on the surface of senescent cells lead to a 1.5-fold selective elimination of senescent cells using anti-DPP4 antibody under optimal conditions.
DPP4- CAR-T Assay When we used the same cells with control and DPP4-CAR-T cells, we observe a 3-fold selective elimination of old senescent cells with respect to the young ones.
CAR-T cells engineered against DPP4 show high specificity against DPP4-bearing senescent cells (Figure 4). The quantification of experimental results also shows that increasing CAR-T
levels are only cytotoxic to senescent cells, but not to control cells (Figure 5). This indicates that the CAR-T assay selectively eliminates target cells, i.e., senescent cells.
Conclusion DPP4 is a novel senescent surface marker identified in human fibroblasts both in replicative and oncogene-induced (RAS) senescence. DPP4 is robustly upregulated on the plasma membrane of senescent cells.
DPP4 is expressed selectively in senescent cells, but not proliferating human diploid fibroblasts, making it a suitable target for senolytic therapy (Figure 2). We showed that, upon two different senescent-inducing stimuli in two different types of fibroblasts, CAR-T cell therapy against DPP4 selectively eliminates DPP4-positive senescent cells (Figure 5).
Example 2 ¨ Development of scFv against human DEP1 Materials Rat immunization and splenectomy - "hDEP1 Peptide #1": amino acid residues 36-48 of SEQ ID NO: 1, conjugated to BSA
- "hDEP1 Peptide #2": amino acid residues 436-452 of SEQ ID NO: 1, conjugated to BSA
- "hDEP1 Peptide #3": amino acid residues 728-741 of SEQ ID NO: 1, conjugated to BSA
- "hDEP1 Peptide #4": amino acid residues 864-881 of SEQ ID NO: 1, conjugated to BSA
- "hDEP1-ECD-Fc": amino acid residues 621-969 of SEQ ID NO: 1 conjugated to an IgG1 Fc domain (SEQ ID NO: 2), produced recombinantly in CHO cells and purified on protein A resin - "hDEP1-ECD-His": amino acid residues 621-969 of SEQ ID NO: 1 conjugated to a 6xHis tag through a linker (SEQ ID NO: 3), produced recombinantly in CHO
cells and purified on Ni-NTA resin - B SA (NEB) - Freund's complete and incomplete adjuvants (Sigma, F5881 and F5506) - Standard ELISA material - Fc-specific polyclonal anti-rat immunoglobulin G (IgG) (Jackson 112-036-071;
1/5000) RNA extraction - RNAse AWAY (Molecular Bio-products, Cat. n 7002) - Tri reagent (Molecular research center Inc, Cat. n TR118) - BCP (Molecular research center Inc, Cat. n 13P-ISI) - Isopropanol, ethanol 75% (molecular grade) RT-PCR, library pre-cloning - SuperScript Reverse Transcriptase (Invitrogen, Cat. n 18064-014) - Murine Primers set - Taq DNA polymerase, recombinant (Invitrogen, Cat. 10342-020) - pGemT Vector System (Promega, Cat. A3600) - Electroporation device and material - Electrocompetent Sure bacteria (E. coli) (Stratagene, Cat. 200227) - Nucleobond AX (Macherey-Nagel, Cat. 740 573-100) Ampli6;ingVH and VL
- Red Taq (Sigma, Hamburg) + 10x buffer - dNTP mix (10 mM each) - Oligonucleotide primer - Agarose (Serva, Heidelberg) - TAE-buffer 50x (2 M TrisHC1, 1 M acetic acid, 0.05 M EDTA pH 8) - Nucleospin Extract 2 Kit (Macherey-Nagel, DUren) Cloning VH and VL
- NotI, MluI, NcoI, HindIII (NEB) - Buffer 2, Buffer 3 (NEB) - BSA (NEB) - Calf intestine phosphatase (CIP) (MBI Fermentas, St. Leon-Rot) - T4 ligase (Promega, Mannheim) - 3 M sodium acetate pH 5.2 - E. coli XL1-Blue MRF (Stratagene, Amsterdam), genotype: A(mcrA)183 A(mcrCB-hsdSMR-mrr)173 endAl supE44 thi-1 recAl gyrA96 relAl lac [F' proAB lacIqZAM15 Tn10 (Tetr)]
- Electroporator MicroPulser (BIO-RAD, Munchen) - 2 M glucose (sterile filtered) - 2 M magnesium solution (1 M MgCl, 1 M MgSO4) - SOC medium pH 7.0 (2 w/v tryptone, 0.5 % w/v yeast extract, 0.05 %
w/v NaCl, 20 mM Mg solution, 20 mM glucose) - 2xYT-medium pH 7.0 (1.6 % w/v tryptone, 1 % w/v yeast extract, 0.5 % w/v NaCl) - 2xYT-GAT (2xYT + 100 mM glucose + 100 p.g/mL ampiciline + 20 p.g/mL
tetracycline) - Ampiciline (100 mg/mL stock) - Tetracycline (10 mg/mL stock) - 9 cm-Petrie dishes - 25 cm-square Petri dishes ("pizza plates") - 2xYT-GAT agar plates (2xYT-GAT, 1.5 % w/v agar-agar) - Nucleobond Plasmid Midi Kit (Macherey-Nagel) - Glycerol 99.5 % (Roth, Karlsruhe) Library packaging - 2xYT-medium pH 7.0 (1.6 % w/v tryptone, 1 % w/v yeast extract, 0.5 %
w/v NaCl) - 2xTY-GA (2xTY, 100 mM glucose, 100 p.g/mL ampicillin) - M13K07 Helperphage for monovalent display (Stratagene) - 2x TY-AK (2x TY + 100 p.g/mL ampicillin + 50 p.g/mL kanamycin) - Sorval Centrifuge RC5B Plus, rotor G53 and SS34 (Thermo Scientific, Waltham) - Polyethylenglycol (PEG) solution (20 % w/v PEG 6000, 2.5 M NaCl) - Phage dilution buffer (10 mM Tris-HC1 pH 7.5, 20 mM NaCl, 2 mM EDTA) Library screening - Microtiter plate (Nunc Maxisorp) - 3 % BSA in TBS (50 mM Tris; 137 mM NaCl; 2.7 mM KCl; pH adjusted to 8.0) - TBS supplemented with 0.1 % Tween20 - E. coli (SURE strain, Stratagene) - SB (super broth) supplemented with tetracycline (10 p.g/mL) and carbenicillin (50 lig/mL).
SB supplemented with tetracycline (10 ug/mL), carbenicillin (50 ug/mL) and kanamycin (70 ug/mL) Polyethylenglycol (PEG) solution (20 % w/v PEG 6000, 2.5 M NaCl) Sorval Centrifuge RC5B Plus, rotor G53 and SS34 (Thermo Scientific, Waltham) scFv production and purification E. coli strain HB2151 SB (super broth) supplemented with carbenicillin (50 ug/mL) and 1 % glucose 1 mM IPTG
Polymyxin B sulfate - His-Trap column (GE Healthcare, Buckinghamshire, UK) Methods Rat immunization 12 rats were immunized with i.p. injections of 50 ug of hDEP1 Peptide #1, Peptide #2, Peptide #3 or Peptide #4 (3 rats/peptide). In parallel, 5 rats were immunized with i.p.
injections of 50 ug of hDEP1-ECD-Fc.
The three first injections were administered at 14 days intervals (DO, D14 and D28). A
fourth injection was administered after animal selection according to the titer reached.
The first injection at DO was mixed with complete Freund's adjuvant. The remaining injections were carried out with incomplete Freund's adjuvant.
The rat immune response was evaluated by ELISA performed in 96-well microtiter plates using hDEP1 Peptide #1, Peptide #2, Peptide #3, Peptide #4, hDEP1-ECD-His, or BSA.
Pre-immune serum was used as a negative control. For detection, Fc-specific polyclonal anti-rat IgG was used and the titer was measured as the reciprocal of the highest dilution of immune serum giving a signal at 50 % of the highest OD.
RNA extraction, RT-PCR, library pre-cloning After the fourth injection, RNA was isolated with Tri Reagent/BCP method from the spleen of the immunized rats and used for reverse transcription.
Oligonucleotides sets were used for amplification of the DNA encoding the lc and k light chain and to amplify the DNA encoding Fd fragments of the heavy y chain. To obtain two sub-libraries encoding the Fd fragment and light chain, the corresponding PCR products were pooled and sub-cloned into the pGEMT vector.
Library construction The final library was constructed starting from these two sub-libraries. The DNA
encoding the Fd fragment and the light chain was re-amplified with two individual oligonucleotide sets introducing the required restrictions sites for library-cloning using the pTH1 vector. First the pTH1 vector and the VL-amplified repertoire were digested with MluI and NotI. Afterwards, the enzyme reaction was terminated and the vector was dephosphorylated with calf intestinal phosphatase. The vector and the VL-repertoire were purified using NucleoSpinII Gel and PCR Clean-up Kit (Macherey-Nagel) and 270 ng of the VL-repertoire was cloned into 1 lig of dephosphorylated vector using T4 DNA-ligase.
The pellet was washed twice with 70 % ethanol and resuspended in 30 tL H20 before it was used for electroporation (1.7 kV) with 25 tL of XL1-BlueMRF'. The transformed bacteria were cultured on 2x YT agar plates supplemented with 100 [tg/mL
ampicillin, 20 [tg/mL tetracycline and 100 mM glucose. The colonies were harvested by resuspension in 40 mL of 2x YT medium with a Drigalsky spatula and plasmids were isolated with the Nucleobond Plasmid Midi Kit. Following this, the VL-library and the VH-repertoire were digested with SfiI and HindIII, ligated and electroporated as described for VL, but this time 250 ng of the digested and purified VH-repertoire was inserted into 1 lig of the VL-library. The harvested bacteria of the final scFv antibody gene library were pooled, aliquoted and stored at -80 C. The library was packaged with M13K07.
Library packaging To package the library, inoculate 400 mL 2 x TY-GA in a 1 L Erlenmeyer flask with 1 mL
antibody gene library stock and then infect 25 mL bacteria culture (¨ 1.25 x 1010 cells) with 2.5 x 1011 colony forming units (cfu) of the helper phage M13K07.
Produce scFv-phage overnight at 250 rpm and 30 C. Pellet the bacteria by centrifugation for 10 minutes at 10000 g. Precipitate the phage from the supernatant by adding 1/5 volume PEG solution. Incubate for 1 hour at 4 C with gentle shaking, followed by centrifugation for 1 hour at 10000g. Discard the supernatant, resolve each pellet in 10 mL
phage dilution buffer and add 1/5 volume PEG solution. Incubate on ice for 20 minutes and pellet the phage by centrifugation for 30 minutes at 10000 g. Discard the supernatant and put the open tubes upside down on tissue paper. Let the viscous PEG
solution move out completely. Resuspend the phage pellet in 1 mL phage dilution buffer.
Library screening For isolation of anti-DEP I specific scFv, microtiter plates were coated overnight with hDEP1-ECD-His or Peptide #4 at 10 1.tg/mL in PBS at 4 C. The plates were then blocked with 3% BSA in TBS for 2 hours at 37 C. After a washing step, the antibody phage display library was added and incubated for an additional 2 hours at 37 C.
During the first round of panning, the plates were washed 5 times with TBS
supplemented with 0.1 % Tween20. The plates were finally rinsed with sterile PBS and phage were eluted with trypsin (1 mg/mL in TBS) for 30 minutes at 37 C. The eluted phages were used to infect E. coli cultured in SB supplemented with tetracycline and carbenicillin.
For the production of new phage particles, infected E. coli were co-infected with M13K07 and cultured overnight at 37 C in SB supplemented with tetracycline, carbenicillin and kanamycin. Phage particles were precipitated in PEG/NaCl (4 % w/v PEG8000, 3 %
w/v NaCl) and used for the next round of panning. This was performed as described above, with the exception that the plates were washed with increasing stringency.
The infected E. coli of the last round of panning were grown on SB media in petri dishes and used for screening by ELISA using hDEP1-ECD-His or Peptide #4.
scFv production and purification For expression of soluble scFv, the DNA encoding the selected scFv was used to transform the non-suppressor E. coil strain HB2151. Transformed E. coil were then used to inoculate 500 mL of SB medium and cultivated at 30 C until OD600 1.5. Then, 1 mM
IPTG was added to induce the expression of scFv and the culture was incubated overnight at 22 C. After harvesting by centrifugation at 2500 g for 15 minutes at 4 C, scFv were extracted with polymyxin B sulfate and purified using a His-Trap column according to the manufacturer's instructions. Purified scFv were quantified by Dm and controlled by SDS-PAGE analysis.
Confirmation of selected scFv by ELISA against screening peptide The soluble anti-DEP1 scFv were tested in indirect ELISA for reactivities against the 4 peptides (Peptide #1, Peptide #2, Peptide #3, and Peptide #4), against hDEP1-ECD-His and its murine counterpart with SEQ ID NO: 4; and against BSA as negative control.
Reactivity was assessed by OD450, in serial dilutions.
Results Serum of the 17 rats was collected on D38 (after the third immunization, on D28) and Fc-specific polyclonal anti-rat IgG was used to measure the titer at 50 % of maximum signal.
Results are given in Table 5.
Table 5 hDEP1 hDEP1 hDEP1 hDEP1 hDEP1-Peptide Peptide Peptide Peptide BSA
ECD-His #1 #2 #3 #4 hDEP1 Rat 1 380000 ND ND ND ND ND
Peptide Rat 2 55000 ND ND ND ND ND
#1 Rat 3 11000 ND ND ND ND ND
hDEP1 Rat 4 ND 27000 ND ND ND
ND
Peptide Rat 5 ND 23000 ND ND ND ND
#2 Rat 6 A7) 1'0000 Ni) :\7) NI) (demi) hDEP1 Rat 7 ND ND 12000 ND 500 ND
Peptide Rat 8 ND ND 18000 ND 500 ND
#3 Rat 9 ND ND 22000 ND 500 ND
hDEP1 Rat 10 ND ND ND 113000 6000 ND
Peptide Rat 11 ND ND ND 110000 4500 ND
#4 Rat 12 ND ND ND
Rat 13 500 500 500 ND 321000 ND
Rat 14 ND ND 500 ND 64000 500 hDEP1-Rat 15 ND ND 500 ND 180000 500 ECD-Fc Rat 16 500 500 500 500 82000 ND
Rat 17 ND ND 500 ND 40000 ND
High titers were harvested against each immunogenic peptide.
Peptides #1 and #4 appeared to be more immunogenic than Peptides #2 and #3, allowing better immune responses. Rats immunized with Peptide #4 also presented a positive immune response for the recombinant hDEP1-ECD-His protein, while rats immunized with Peptides #1 and #2 did not present such positive immune response.
Overall, rat 10 seemed to be the best candidate among rats 1 to 12.
High titers were also harvested against the recombinant protein hDEP1-ECD-His, ranging from 1/40000 to 1/321000. Overall, rat 13 seemed to be the best candidate among rats 13 to 17.
A splenectomy was carried out on rats 10 and 13. RNA were extracted from the spleens, and total RNA was quantified (Table 6) and controlled on agarose gel (not shown).
Table 6 Sample Concentration (pg/mL) A260nm A280nm A260nmi A280nm A260nmi A230nm Rat 10 2108.9 52.7 29.5 1.78 1.55 Rat 13 2370.77 59.3 33.4 1.77 1.42 The first step of the library construction consisted of the VL fragments cloning in a phagemid vector, and then the VH fragments were inserted into the vector containing the VL repertoire. The vector format VH/VL-6xHis-Flag was selected for constructions.
Rat 10 The final scFv library consisted of 1 x 107 independent clones with a full-size insert rate of 92 % (by colony-PCR) and was finally packaged in M13K07 phage.
The panning was performed using hDEP1 Peptide #4/BSA as target and standard elution strategy. Four rounds were carried out in order to isolate specific binders.
After each round, only the phages having interacted with hDEP1 Peptide #4/BSA were eluted.
Between the first and the last round of panning, the number of eluted phages increased, indicating that amplification/selection of reactive phages was expected from this panning.
The reactivity of the phages eluted after each round against the targeted peptide was assessed in phage-ELISA and confirmed that potential binders were eluted in rounds 3 and 4 (Figure 6).
96 isolated clones from the second, third and fourth rounds of panning were hand-picked and used to produce the respective soluble scFv in microtiter plate. Each clone was then tested in ELISA against hDEP1 Peptide #4/BSA.
48 isolated clones showing a specific signal against hDEP1 Peptide #4/BSA
compared to negative control (BSA) were selected. Their DNA was extracted and sequenced.
Sequences with an early stop codon or with an incorrect size were considered as recombined. The non-recombined sequences were aligned for redundancy analysis in order to identify the identical sequences (referred to as "redundant"
sequences).
Twelve sequences corresponding to non-recombined and non-redundant scFv sequences were identified, grouped into two clusters (Table 7).
Table 7. HCVR and LCVR column indicate the amino acid sequence of the heavy chain and light chain variable regions, respectively.
Cluster Clone's name Redundancy HCVR LC VR
Cluster 1 Cluster 2 According to sequence and redundancy analysis, the following clones were selected:
- 5738-10-R3A-C6 (cluster 1) - 5738-10-R3A-D5 (cluster 2) - 5738-10-R4A-G12 (cluster 2) After transformation of the 3 selected clones DNA in an E. coli strain dedicated to production, the clones were expressed as soluble scFv and purified using the His tag on an Ni-NTA column. These soluble anti-hDEP1 scFv were tested in indirect ELISA
for reactivities against the 4 peptides and DEP1 proteins (human and murine) and against the negative control (BSA only).
All three scFv were reactive against hDEP1 Peptide #4, as expected, especially the two scFv of cluster 2. No reactivity could be observed against the 3 other peptides. Only clone 5738-10-R4A-G12 showed a reactivity against hDEP1, with no response for the mDEP1 or the negative control.
Rat /3 The final scFy library consisted of 1 x 107 independent clones with a full-size insert rate of 88 % (by colony-PCR) and was finally packaged in M13K07 phage.
The panning was performed using hDEP1-ECD-His as target and standard elution strategy. Four rounds were carried out in order to isolate specific binders.
After each round, only the phages having interacted with hDEP1-ECD-His were eluted.
Between the first and the last round of panning, the number of eluted phages increased, indicating that amplification/selection of reactive phages was expected from this panning. The reactivity of the phages eluted after each round against the targeted peptide was assessed in phage-ELISA and confirmed that potential binders were eluted in rounds 2, 3 and 4 (Figure 7).
96 isolated clones from the second, third and fourth rounds of panning were hand-picked and used to produce the respective soluble scFy in microtiter plate. Each clone was then tested in ELISA against hDEP1-ECD-His.
48 isolated clones showing a specific signal against hDEP1-ECD-His compared to negative control (BSA) were selected. Their DNA was extracted and sequenced.
Sequences with an early stop codon or with an incorrect size were considered as recombined. The non-recombined sequences were aligned for redundancy analysis in order to identify the identical sequences (referred to as "redundant"
sequences).
Nine sequences corresponding to non-recombined and non-redundant scFy sequences were identified, grouped into two clusters (Table 8).
Table 8. HCVR and LCVR column indicate the amino acid sequence of the heavy chain and light chain variable regions, respectively.
Cluster Clone's name Redundancy HCVR LCVR
Cluster 1 Cluster 2 573 8-13 -R3A-F5 1 69 90 According to sequence and redundancy analysis, the following clones were selected:
- 5738-13-R4A-D11 (cluster 1) - 5738-13-R2A-H4 (cluster 2) After transformation of the 2 selected clones DNA in an E. coli strain dedicated to production, the clones were expressed as soluble scFv and purified using the His tag on an Ni-NTA column. These soluble anti-hDEP1 scFv were tested in indirect ELISA
for reactivities against the 4 peptides and DEP1 proteins (human and murine) and against the negative control (BSA only).
The two scFv were reactive against hDEP1, as expected. No reactivity could be observed against any of the 4 peptides, the mDEP1 or the negative control.
Example 3 ¨ Development of scFv against human DPP4 Materials Rat immunization and splenectomy - "hDPP4 Peptide P2": amino acid residues 170-191 of SEQ ID NO: 101, conjugated to BSA
- "hDPP4 Peptide P3": amino acid residues 235-254 of SEQ ID NO: 101, conjugated to BSA
- "hDPP4 Peptide P5": amino acid residues 492-517 of SEQ ID NO: 101, conjugated to BSA
- "hDPP4 Peptide P6": amino acid residues 533-551 of SEQ ID NO: 101, conjugated to BSA
- "hDPP4-ECD-His": SEQ ID NO: 102 - "mDPP4": murine DDP with SEQ ID NO: 103 - BSA (NEB) - Freund's complete and incomplete adjuvants (Sigma, F5881 and F5506) - Standard ELISA material - Fc-specific polyclonal anti-rat immunoglobulin G (IgG) (Jackson 112-036-071;
1/5000) RNA extraction - RNAse AWAY (Molecular Bio-products, Cat. n 7002) - Tri reagent (Molecular research center Inc, Cat. n TR118) - BCP (Molecular research center Inc, Cat. n'BP-ISI) - Isopropanol, ethanol 75% (molecular grade) RT-PCR, library pre-cloning - SuperScript Reverse Transcriptase (Invitrogen, Cat. n 18064-014) - Murine Primers set - Tag DNA polymerase, recombinant (Invitrogen, Cat. 10342-020) - pGemT Vector System (Promega, Cat. A3600) - Electroporation device and material - Electrocompetent Sure bacteria (E. coli) (Stratagene, Cat. 200227) - Nucleobond AX (Macherey-Nagel, Cat. 740 573-100) Amplifying VH and VL
- Red Tag (Sigma, Hamburg) + 10x buffer - dNTP mix (10 mM each) - Oligonucleotide primer - Agarose (Serva, Heidelberg) - TAE-buffer 50x (2 M TrisHC1, 1 M acetic acid, 0.05 M EDTA pH 8) - Nucleospin Extract 2 Kit (Macherey-Nagel, Diiren) CloningVH and VL
- NotI, MluI, NcoI, HindIII (NEB) - Buffer 2, Buffer 3 (NEB) - BSA (NEB) - Calf intestine phosphatase (CIP) (MBI Fermentas, St. Leon-Rot) - T4 ligase (Promega, Mannheim) - 3 M sodium acetate pH 5.2 - E. coli XL1-Blue MRF (Stratagene, Amsterdam), genotype: A(mcrA)183 A(mcrCB-hsdSMR-mrr)173 endAl supE44 thi-1 recAl gyrA96 relAl lac [F' proAB lacIqZAM15 Tn10 (Tetr)]
- Electroporator MicroPulser (BIO-RAD, Munchen) - 2 M glucose (sterile filtered) - 2 M magnesium solution (1 M MgCl, 1 M MgSO4) - SOC medium pH 7.0 (2 w/v tryptone, 0.5 % w/v yeast extract, 0.05 %
w/v NaCl, mM Mg solution, 20 mM glucose) - 2 xYT-medium pH 7.0 (1.6 % w/v tryptone, 1 % w/v yeast extract, 0.5 %
w/v NaCl) 15 - 2xYT-GAT (2xYT + 100 mM glucose + 100 ug/mL ampiciline + 20 ug/mL
tetracycline) - Ampiciline (100 mg/mL stock) - Tetracycline (10 mg/mL stock) - 9 cm-Petrie dishes 20 - 25 cm-square Petri dishes ("pizza plates") - 2 xYT-GAT agar plates (2 xYT-GAT, 1.5 % w/v agar-agar) - Nucleobond Plasmid Midi Kit (Macherey-Nagel) - Glycerol 99.5 % (Roth, Karlsruhe) Library packaging - 2 xYT-medium pH 7.0 (1.6 % w/v tryptone, 1 % w/v yeast extract, 0.5 % w/v NaCl) - 2xTY-GA (2xTY, 100 mM glucose, 100 ug/mL ampicillin) - M13K07 Helperphage for monovalent display (Stratagene) - 2x TY-AK (2x TY + 100 ug/mL ampicillin + 50 ug/mL kanamycin) - Sorval Centrifuge RC5B Plus, rotor G53 and SS34 (Thermo Scientific, Waltham) - Polyethylenglycol (PEG) solution (20 % w/v PEG 6000, 2.5 M NaCl) - Phage dilution buffer (10 mM Tris-HC1 pH 7.5, 20 mM NaCl, 2 mM EDTA) Library screening - Microtiter plate (Nunc Maxisorp) - 3 % BSA in TBS (50 mM Tris; 137 mM NaCl; 2.7 mM KC1; pH adjusted to 8.0) - TBS supplemented with 0.1 % Tween20 - E. coli (SURE strain, Stratagene) - SB (super broth) supplemented with tetracycline (10 p.g/mL) and carbenicillin (50 lig/mL).
- SB supplemented with tetracycline (10 pg/mL), carbenicillin (50 p.g/mL) and kanamycin (70 lig/mL) - Polyethylenglycol (PEG) solution (20 % w/v PEG 6000, 2.5 M NaCl) - Sorval Centrifuge RC5B Plus, rotor G53 and SS34 (Thermo Scientific, Waltham) scFv production and purification - E. coli strain HB2151 - SB (super broth) supplemented with carbenicillin (50 lig/mL) and 1 %
glucose - 1 mM IPTG
- Polymyxin B sulfate - His-Trap column (GE Healthcare, Buckinghamshire, UK) Methods Rat immunization 12 rats were immunized with i.p. injections of 50 lig of hDDP4 Peptide P1, Peptide P3, Peptide P5 or Peptide P6 (3 rats/peptide). In parallel, 5 rats were immunized with i.p.
injections of 50 lig of hDDP4-ECD-His.
The three first injections were administered at 14 days intervals (DO, D14 and D28). A
fourth injection was administered after animal selection according to the titer reached.
The first injection at DO was mixed with complete Freund' s adjuvant. The remaining injections were carried out with incomplete Freund's adjuvant.
The rat immune response was evaluated by ELISA performed in 96-well microtiter plates using hDDP4 Peptide P1, Peptide P3, Peptide P5, Peptide P6, hDPP4-ECD-His, mDPP4, or B SA.
Pre-immune serum was used as a negative control. For detection, Fc-specific polyclonal anti-rat IgG was used and the titer was measured as the reciprocal of the highest dilution of immune serum giving a signal at 50 % of the highest OD.
RNA extraction, RT-PCR, library pre-cloning After the fourth injection, RNA was isolated with Tri Reagent/BCP method from the spleen of the immunized rats and used for reverse transcription.
Oligonucleotides sets were used for amplification of the DNA encoding the lc and k light chain and to amplify the DNA encoding Fd fragments of the heavy y chain. To obtain two sub-libraries encoding the Fd fragment and light chain, the corresponding PCR products were pooled and sub-cloned into the pGEMT vector.
Library construction The final library was constructed starting from these two sub-libraries. The DNA
encoding the Fd fragment and the light chain was re-amplified with two individual oligonucleotide sets introducing the required restrictions sites for library-cloning using the pTH1 vector. First the pTH1 vector and the VL-amplified repertoire were digested with MluI and NotI. Afterwards, the enzyme reaction was terminated and the vector was dephosphorylated with calf intestinal phosphatase. The vector and the VL-repertoire were purified using NucleoSpinII Gel and PCR Clean-up Kit (Macherey-Nagel) and 270 ng of the VL-repertoire was cloned into 1 lig of dephosphorylated vector using T4 DNA-ligase.
The pellet was washed twice with 70 % ethanol and resuspended in 30 tL H20 before it was used for electroporation (1.7 kV) with 25 tL of XL1-BlueMRF'. The transformed bacteria were cultured on 2x YT agar plates supplemented with 10011g/mL
ampicillin, 20 1.tg/mL tetracycline and 100 mM glucose. The colonies were harvested by DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
Claims (20)
1. A DPP4-binding domain, comprising a combination of three heavy chain variable region (HCVR)'s complementary-determining regions (CDRs) and three light chain variable region (LCVR)'s CDRs, said combination being as defined in Table 3.
2. The DPP4-binding domain according to claim 1, comprising:
a) a HCVR which comprises the following three CDRs:
VH-CDR1 selected from the group consisting of SEQ ID NO: 109 and 108;
VH-CDR2 selected from the group consisting of SEQ ID NO: 122 and 127;
VH-CDR3 selected from the group consisting of SEQ ID NO: 139 and 138;
b) a LCVR which comprises the following three CDRs:
VL-CDR1 selected from the group consisting of SEQ ID NO: 148 and 147;
VL-CDR2 selected from the group consisting of SEQ ID NO: 160 and 159;
VL-CDR3 selected from the group consisting of SEQ ID NO: 172 and 171.
a) a HCVR which comprises the following three CDRs:
VH-CDR1 selected from the group consisting of SEQ ID NO: 109 and 108;
VH-CDR2 selected from the group consisting of SEQ ID NO: 122 and 127;
VH-CDR3 selected from the group consisting of SEQ ID NO: 139 and 138;
b) a LCVR which comprises the following three CDRs:
VL-CDR1 selected from the group consisting of SEQ ID NO: 148 and 147;
VL-CDR2 selected from the group consisting of SEQ ID NO: 160 and 159;
VL-CDR3 selected from the group consisting of SEQ ID NO: 172 and 171.
3. The DPP4-binding domain according to claim 1 or 2, being selected from the group consisting of:
i. a DPP4-binding domain comprising a VH-CDR1 with SEQ ID NO: 109, a VH-CDR2 with SEQ ID NO: 122, a VH-CDR3 with SEQ ID NO: 139, a VL-CDR1 with SEQ ID NO: 148, a VL-CDR2 with SEQ ID NO: 160 and a VL-CDR3 with SEQ ID NO: 172; and ii. a DPP4-binding domain comprising a VH-CDR1 with SEQ ID NO: 108, a VH-CDR2 with SEQ ID NO: 127, a VH-CDR3 with SEQ ID NO: 138, a VL-CDR1 with SEQ ID NO: 147, a VL-CDR2 with SEQ ID NO: 159 and a VL-CDR3 with SEQ ID NO: 171.
i. a DPP4-binding domain comprising a VH-CDR1 with SEQ ID NO: 109, a VH-CDR2 with SEQ ID NO: 122, a VH-CDR3 with SEQ ID NO: 139, a VL-CDR1 with SEQ ID NO: 148, a VL-CDR2 with SEQ ID NO: 160 and a VL-CDR3 with SEQ ID NO: 172; and ii. a DPP4-binding domain comprising a VH-CDR1 with SEQ ID NO: 108, a VH-CDR2 with SEQ ID NO: 127, a VH-CDR3 with SEQ ID NO: 138, a VL-CDR1 with SEQ ID NO: 147, a VL-CDR2 with SEQ ID NO: 159 and a VL-CDR3 with SEQ ID NO: 171.
4. The DPP4-binding domain according to any one of claims 1 to 3, being selected from the group consisting of:
i. a DPP4-binding domain comprising a HCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 185 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 213; and ii. a DPP4-binding domain comprising a HCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 197 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 212.
i. a DPP4-binding domain comprising a HCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 185 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 213; and ii. a DPP4-binding domain comprising a HCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 197 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 212.
5. A DEP1-binding domain, comprising a combination of three heavy chain variable region (HCVR)'s complementary-determining regions (CDRs) and three light chain variable region (LCVR)'s CDRs, said combination being as defined in Table 1.
6. The DEP1-binding domain according to claim 5, comprising:
a) a HCVR which comprises the following three CDRs:
VH-CDR1 selected from the group consisting of SEQ ID NO: 10, 11 and 5;
VH-CDR2 selected from the group consisting of SEQ ID NO: 21, 25 and 12;
VH-CDR3 selected from the group consisting of SEQ ID NO: 30, 32 and 29;
b) a LCVR which comprises the following three CDRs:
VL-CDR1 selected from the group consisting of SEQ ID NO: 37, 38 and 33;
VL-CDR2 selected from the group consisting of SEQ ID NO: 44, 46 and 40;
VL-CDR3 selected from the group consisting of SEQ ID NO: 53, 52 and 49.
a) a HCVR which comprises the following three CDRs:
VH-CDR1 selected from the group consisting of SEQ ID NO: 10, 11 and 5;
VH-CDR2 selected from the group consisting of SEQ ID NO: 21, 25 and 12;
VH-CDR3 selected from the group consisting of SEQ ID NO: 30, 32 and 29;
b) a LCVR which comprises the following three CDRs:
VL-CDR1 selected from the group consisting of SEQ ID NO: 37, 38 and 33;
VL-CDR2 selected from the group consisting of SEQ ID NO: 44, 46 and 40;
VL-CDR3 selected from the group consisting of SEQ ID NO: 53, 52 and 49.
7. The DEP1-binding domain according to claim 5 or 6, being selected from the group consisting of:
i. a DEP1-binding domain comprising a VH-CDR1 with SEQ ID NO: 10, a VH-CDR2 with SEQ ID NO: 21, a VH-CDR3 with SEQ ID NO: 30, a VL-CDR1 with SEQ ID NO: 37, a VL-CDR.2 with SEQ ID NO: 44 and a VL-CDR3 with SEQ ID NO: 53;
ii. a DEP1-binding domain comprising a VH-CDR1 with SEQ ID NO: 11, a VH-CDR2 with SEQ ID NO: 25, a VH-CDR3 with SEQ ID NO: 32, a VL-CDR1 with SEQ ID NO: 38, a VL-CDR.2 with SEQ ID NO: 46 and a VL-CDR3 with SEQ ID NO: 52; and iii. a DEP1-binding domain comprising a VH-CDR1 with SEQ ID NO: 5, a VH-CDR2 with SEQ ID NO: 12, a VH-CDR3 with SEQ ID NO: 29, a VL-CDR1 with SEQ ID NO: 33, a VL-CDR2 with SEQ ID NO: 40 and a VL-CDR3 with SEQ ID NO: 49.
i. a DEP1-binding domain comprising a VH-CDR1 with SEQ ID NO: 10, a VH-CDR2 with SEQ ID NO: 21, a VH-CDR3 with SEQ ID NO: 30, a VL-CDR1 with SEQ ID NO: 37, a VL-CDR.2 with SEQ ID NO: 44 and a VL-CDR3 with SEQ ID NO: 53;
ii. a DEP1-binding domain comprising a VH-CDR1 with SEQ ID NO: 11, a VH-CDR2 with SEQ ID NO: 25, a VH-CDR3 with SEQ ID NO: 32, a VL-CDR1 with SEQ ID NO: 38, a VL-CDR.2 with SEQ ID NO: 46 and a VL-CDR3 with SEQ ID NO: 52; and iii. a DEP1-binding domain comprising a VH-CDR1 with SEQ ID NO: 5, a VH-CDR2 with SEQ ID NO: 12, a VH-CDR3 with SEQ ID NO: 29, a VL-CDR1 with SEQ ID NO: 33, a VL-CDR2 with SEQ ID NO: 40 and a VL-CDR3 with SEQ ID NO: 49.
8. The DEP1-binding domain according to claims 5 to 7, being selected from the group consisting of:
i. a DEP1-binding domain comprising a HCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 68 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 89;
ii. a DEP1-binding domain comprising a HCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 72 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 93; and iii. a DEP1-binding domain comprising a HCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 58 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 78.
i. a DEP1-binding domain comprising a HCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 68 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 89;
ii. a DEP1-binding domain comprising a HCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 72 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 93; and iii. a DEP1-binding domain comprising a HCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 58 and a LCVR with a sequence sharing at least 80% of sequence identity with the non-CDR regions of SEQ ID NO: 78.
9. An isolated antibody or antigen-binding fragment thereof comprising the DPP4-binding domain according to any one of claims 1 to 4 or the DEP1-binding domain according to any one of claims 5 to 8.
10. The isolated antibody or antigen-binding fragment thereof according to claim 9, being a bispecific antibody comprising the DPP4-binding domain according to any one of claims 1 to 4 and the DEP1-binding domain according to any one of claims 5 to 8.
11. A chimeric antigen receptor (CAR) comprising:
a. at least one extracellular binding domain, comprising at least one DPP4-binding domain according to any one of claims 1 to 4 and/or at least one DEP1-binding domain according to any one of claims 5 to 8, b. an extracellular spacer domain, c. a transmembrane domain, d. optionally, at least one costimulatory domain, and e. at least one intracellular signaling domain.
a. at least one extracellular binding domain, comprising at least one DPP4-binding domain according to any one of claims 1 to 4 and/or at least one DEP1-binding domain according to any one of claims 5 to 8, b. an extracellular spacer domain, c. a transmembrane domain, d. optionally, at least one costimulatory domain, and e. at least one intracellular signaling domain.
12. An immune cell engineered to express the CAR of claim 11 at its surface.
13. A population of immune cells, comprising a plurality of immune cells according to claim 12.
14. The population of immune cells according to claim 13, comprising:
a) a plurality of immune cells according to claim 12 engineered to express a CAR comprising at least one DPP4-binding domain according to any one of claims 1 to 4 at its surface, and a plurality of immune cells according to claim 12 engineered to express a CAR comprising at least one DEP1-binding domain according to any one of claims 5 to 8 at its surface; or b) a plurality of immune cells according to claim 12 engineered to express a CAR comprising at least one DPP4-binding domain according to any one of claims 1 to 4 and a CAR comprising at least one DEP1-binding domain according to any one of claims 5 to 8 at its surface; or c) a plurality of immune cells according to claim 12 engineered to express a CAR comprising at least one DPP4-binding domain according to any one of claims 1 to 4 and at least one DEP1-binding domain according to any one of claims 5 to 8 at its surface.
a) a plurality of immune cells according to claim 12 engineered to express a CAR comprising at least one DPP4-binding domain according to any one of claims 1 to 4 at its surface, and a plurality of immune cells according to claim 12 engineered to express a CAR comprising at least one DEP1-binding domain according to any one of claims 5 to 8 at its surface; or b) a plurality of immune cells according to claim 12 engineered to express a CAR comprising at least one DPP4-binding domain according to any one of claims 1 to 4 and a CAR comprising at least one DEP1-binding domain according to any one of claims 5 to 8 at its surface; or c) a plurality of immune cells according to claim 12 engineered to express a CAR comprising at least one DPP4-binding domain according to any one of claims 1 to 4 and at least one DEP1-binding domain according to any one of claims 5 to 8 at its surface.
15. A composition comprising:
- the isolated antibody or antigen-binding fragment thereof according to claim 9 or 10, - the immune cell according to claim 12, and/or - the population of immune cells according to claim 13 or 14.
- the isolated antibody or antigen-binding fragment thereof according to claim 9 or 10, - the immune cell according to claim 12, and/or - the population of immune cells according to claim 13 or 14.
16. The composition according to claim 15, being a pharmaceutical composition and further comprising at least one pharmaceutically acceptable excipient.
17. The composition according to claim 15 or 16, for use as a drug.
18. The composition according to claim 15 or 16, for use in treating, preventing or alleviating a senescence-related disease or disorder, preferably selected from the group consisting of fibrotic diseases, premalignant disorders, inflammatory diseases and cancers.
19. The composition for use according to claim 18, wherein the senescence-related disease or disorder is a fibrotic disease, preferably a pulmonary fibrotic disease.
20. The composition according to claim 15 or 16, for use in depleting and/or killing senescent cells.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19200182 | 2019-09-27 | ||
US16/585,256 US20210093665A1 (en) | 2019-09-27 | 2019-09-27 | Chimeric antigen receptors against senescent cells and uses thereof |
PCT/EP2020/076995 WO2021058795A2 (en) | 2019-09-27 | 2020-09-25 | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3155930A1 true CA3155930A1 (en) | 2021-04-01 |
Family
ID=72811789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3155930A Pending CA3155930A1 (en) | 2019-09-27 | 2020-09-25 | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4034561A2 (en) |
CA (1) | CA3155930A1 (en) |
WO (1) | WO2021058795A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114805587B (en) * | 2022-06-10 | 2023-11-28 | 清华大学 | CAR-NK cells and their use in the treatment of organ and tissue aging and fibrosis |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ES2241710T3 (en) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | PROCEDURE TO PRODUCE MULTIVALENT PROTEINS FROM UNION TO ANTIGEN. |
SE9400088D0 (en) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
JP2004500095A (en) | 2000-02-24 | 2004-01-08 | エクサイト セラピーズ, インコーポレイテッド | Simultaneous stimulation and enrichment of cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
EP1261644A2 (en) * | 2000-03-01 | 2002-12-04 | Vanderbilt University | Modulation of the activity of the endothelial cell surface receptor ecrtp/dep-1 in the regulation of angiogenesis |
AU3942202A (en) | 2000-11-30 | 2002-06-11 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
EP1392361A4 (en) * | 2001-05-11 | 2009-08-05 | Univ Texas | Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 |
AU2005250341A1 (en) * | 2004-04-23 | 2005-12-15 | Amgen Inc. | Antibodies to angiogenesis inhibiting domains of CD148 |
JP4997239B2 (en) * | 2005-07-22 | 2012-08-08 | ワイズ・エー・シー株式会社 | Anti-CD26 antibody and method of use thereof |
DK2602323T3 (en) | 2007-06-01 | 2018-04-16 | Open Monoclonal Tech Inc | Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies |
JP2015030666A (en) * | 2013-07-31 | 2015-02-16 | 学校法人順天堂 | Anti-human cd26 monoclonal antibodies and antigen-binding fragments thereof |
AU2017307610B2 (en) * | 2016-08-04 | 2023-10-05 | Memorial Sloan-Kettering Cancer Center | Cancer antigen targets and uses thereof |
KR20190141657A (en) * | 2017-02-28 | 2019-12-24 | 보르 바이오파마, 인크. | Compositions and Methods for Inhibition of Lineage Specific Proteins |
-
2020
- 2020-09-25 CA CA3155930A patent/CA3155930A1/en active Pending
- 2020-09-25 WO PCT/EP2020/076995 patent/WO2021058795A2/en active Application Filing
- 2020-09-25 EP EP20789003.9A patent/EP4034561A2/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4034561A2 (en) | 2022-08-03 |
WO2021058795A3 (en) | 2021-05-27 |
WO2021058795A2 (en) | 2021-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10889652B2 (en) | Antibodies and chimeric antigen receptors specific for ROR1 | |
CN111526888B (en) | Anti-TIGIT antibodies and their use as therapeutics and diagnostics | |
CA2960650C (en) | Cytotoxicity-inducing therapeutic agent | |
US20190077872A1 (en) | Method for enhancing humoral immune response | |
KR20180072820A (en) | A bispecific antigen binding molecule that binds to an anti-IL1RAP antibody, IL1RAP and CD3, | |
TW201735947A (en) | Cell injury inducing therapeutic drug for use in cancer therapy | |
AU2017205900B2 (en) | Therapeutic anti-CD9 antibody | |
WO2020135559A1 (en) | Cd30-binding moieties, chimeric antigen receptors, and uses thereof | |
US20240009242A1 (en) | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof | |
KR20220147631A (en) | Materials and methods for modulating an immune response | |
EP4245855A1 (en) | Anti-tspan8-anti-cd3 bispecific antibody and anti-tspan8 antibody | |
WO2021170100A1 (en) | Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof | |
CA3155930A1 (en) | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof | |
US20210093665A1 (en) | Chimeric antigen receptors against senescent cells and uses thereof | |
JP2024506682A (en) | Anti-TCR δ chain variable region 1 antibody | |
US20240033356A1 (en) | Chimeric antigen receptor t cell and method | |
WO2024046468A1 (en) | Fusion proteins targeting lysosomal degradation pathway | |
WO2024026471A1 (en) | Cd98hc antigen-binding domains and uses therefor |